[
{"protocolSection":{"identificationModule":{"nctId":"NCT03196180","orgStudyIdInfo":{"id":"NCI-2017-01079"},"secondaryIdInfos":[{"id":"NCI-2017-01079","type":"REGISTRY","domain":"CTRP (Clinical Trial Reporting Program)"},{"id":"N01-CN-2012-00031"},{"id":"1712088061","type":"OTHER","domain":"University of Arizona Cancer Center - Prevention Research Clinic"},{"id":"UAZ2016-08-02","type":"OTHER","domain":"DCP"},{"id":"N01CN00031","type":"NIH","link":"https://reporter.nih.gov/quickSearch/N01CN00031"},{"id":"P30CA023074","type":"NIH","link":"https://reporter.nih.gov/quickSearch/P30CA023074"}],"organization":{"fullName":"National Cancer Institute (NCI)","class":"NIH"},"briefTitle":"Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia","officialTitle":"A Feasibility Trial of Alternating Intravaginal Application of 5-Fluorouracil and Imiquimod for Treatment of High-Grade Cervical Squamous Intraepithelial Lesions"},"statusModule":{"statusVerifiedDate":"2025-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-10-15","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-11-04","type":"ACTUAL"},"completionDateStruct":{"date":"2024-08-02","type":"ACTUAL"},"studyFirstSubmitDate":"2017-06-21","studyFirstSubmitQcDate":"2017-06-21","studyFirstPostDateStruct":{"date":"2017-06-22","type":"ACTUAL"},"resultsFirstSubmitDate":"2022-01-28","resultsFirstSubmitQcDate":"2022-01-28","resultsFirstPostDateStruct":{"date":"2022-02-23","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-03-20","lastUpdatePostDateStruct":{"date":"2025-04-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"National Cancer Institute (NCI)","class":"NIH"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This early phase I clinical trial studies the side effects of topical fluorouracil and imiquimod ointment in treating patients with high-grade cervical intraepithelial neoplasia. Topical fluorouracil may kill precancerous cells. Imiquimod ointment may stimulate the immune system. Applying topical fluorouracil and imiquimod ointment may cause fewer side effects and may be a better way to treat patients with precancerous cervical lesions.","detailedDescription":"PRIMARY OBJECTIVE:\n\nI. Assess feasibility, evaluated based on safety and tolerability, of a combination agent intervention (once-weekly self-administered intravaginal application of 5-fluorouracil alternating with once-weekly provider-applied imiquimod) for treatment of high-grade cervical squamous intraepithelial lesions.\n\nSECONDARY OBJECTIVES:\n\nI. Assess efficacy of the combination agent intervention on cervical disease regression (endpoint based on histologic regression from high-grade lesions to low-grade or no lesions and clearance of high risk-human papillomavirus \\[HPV\\] detection) between baseline and study exit visits.\n\nII. Assess efficacy of the combination agent intervention on genotype-specific HPV clearance between baseline and study exit visits.\n\nIII. Assess efficacy of the combination agent intervention on biomarkers of local immune activation (measurement of changes in expression of Toll-like receptors (TLR) and T-regulatory cells and the levels of innate, immune mediating and proinflammatory cytokines with intravaginal 5-fluorouracil \\[FU\\] and imiquimod) between baseline and study exit visits.\n\nOUTLINE: This is a phase I, dose escalation study of imiquimod.\n\nPatients receive topical fluorouracil intravaginally via applicator at weeks 1, 3, 5, 7, 9, 11, 13, and 15 and imiquimod intravaginally via applicator at weeks 2, 4, 6, 8, 10, 12, 14, and 16. Patients who are menstruating will delay application until the end of the menstrual cycle.\n\nAfter completion of study treatment, patients are followed up within 8 months."},"conditionsModule":{"conditions":["Cervical Intraepithelial Neoplasia Grade 2/3","Cervical Squamous Cell Carcinoma In Situ","Cervical Squamous Intraepithelial Neoplasia 2","High Grade Cervical Intraepithelial Neoplasia"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":13,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment (topical fluorouracil, imiquimod)","type":"EXPERIMENTAL","description":"Patients receive topical fluorouracil intravaginally via applicator at weeks 1, 3, 5, 7, 9, 11, 13, and 15 and imiquimod intravaginally via applicator at weeks 2, 4, 6, 8, 10, 12, 14, and 16. Patients who are menstruating will delay application until the end of the menstrual cycle.","interventionNames":["Drug: Imiquimod","Drug: Topical Fluorouracil"]}],"interventions":[{"type":"DRUG","name":"Imiquimod","description":"Given intravaginally","armGroupLabels":["Treatment (topical fluorouracil, imiquimod)"],"otherNames":["Aldara","R 837","S 26308","Zyclara"]},{"type":"DRUG","name":"Topical Fluorouracil","description":"Given intravaginally","armGroupLabels":["Treatment (topical fluorouracil, imiquimod)"],"otherNames":["Actino-Hermal","Arumel","Carac","Cytosafe","Efudex","Efurix","Fiverocil","Fluoroplex","Flurox","Timazin","Tolak"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Feasibility of Intravaginal Use 5-FU and Imiquimod on Alternating Weeks in Women With Biopsy Confirmed High Grade Cervical Squamous Intraepithelial Lesions.","description":"Feasibility is evaluated based on safety and tolerability of the study intervention. For safety, the study assessed the number of participants experiencing the specified adverse events defined as Grade 2 or greater toxicity (or Grade 1 toxicity of any genital lesion (blisters, ulcerations, or pustules)) that is possibly, probably, or definitely related and lasts for more than 5 days. For tolerability, the study assessed the number of participants who were not able to apply at least 50% of the treatment due to the specified adverse events.","timeFrame":"Up to 22 weeks"}],"secondaryOutcomes":[{"measure":"Response to Intravaginal 5-FU and Imiquimod Defined as Histologic Regression and Clearance of High-risk Human Papilloma Virus (HR-HPV)","description":"The response will be reported along with their 95% confidence intervals. Response is defined as histologic regression from high-grade lesions to low-grade- or no lesions and clearance of HR-HPV detection between baseline and end of study.","timeFrame":"At end of study visit (4-6 weeks after the last agent application)"},{"measure":"Type Specific Human Papillomavirus (HPV) Clearance","description":"The type-specific HR-HPV clearance will be reported along with their 95% confidence intervals.","timeFrame":"At end of study visit (4-6 weeks after the last agent application)"},{"measure":"Change in Expression of Biomarkers of Local Immune Activation (Cytokines) After Treatment With Self-administered Intravaginal Topical Fluorouracil and Imiquimod","description":"For each biomarker, the mean change of log transformed data and the associated standard deviation will be reported. Will measure the innate (IFN-alpha2), immune mediating (IFN-gamma, IL-10, IL-12), and pro-inflammatory (IL-1alpha, -1beta, -6, -8, MIP-1alpha, TNF) cytokine.","timeFrame":"Baseline to up to end of study visit (4-6 weeks after last agent application)"},{"measure":"Change in Expression of Biomarkers of Local Immune Activation (Toll Like Receptors (TLRs)) After Treatment With Self-administered Intravaginal Topical Fluorouracil and Imiquimod","description":"For each biomarker, the mean change of log transformed data and the associated standard deviation will be reported. TLR messenger ribonucleic acid expression is normalized by the housekeeping genes and does not have a unit of measure.","timeFrame":"Baseline to up to end of study visit (4-6 weeks after last agent application)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Women with biopsy confirmed high grade cervical squamous intraepithelial lesions (i.e., cervical squamous intraepithelial neoplasia 3 \\[CIN3\\] lesions, and cervical squamous epithelial neoplasia 2 \\[CIN2\\] lesions with diagnosis confirmed by positive p16 immunohistochemistry staining) within 12 weeks of baseline visit\n* Karnofsky \\>= 70%\n* Leukocytes \\>= 3,000/microliter\n* Absolute neutrophil count \\>= 1,500/microliter\n* Platelets \\>= 100,000/microliter\n* Serum creatinine =\\< the upper institutional limits\n* Participants must have a negative human immunodeficiency virus (HIV) antibody/antigen test and negative Chlamydia (C.) trachomatis/Neisseria (N.) gonorrhea nucleic acid amplification test (NAAT)\n* Agree to use an effective form of contraception; the effects of intravaginal 5-fluorocuracil and imiquimod on the developing human fetus at the recommended therapeutic dose are unknown; for this reason and because 5- fluorouracil is known to be teratogenic, women of child-bearing potential must agree to use adequate dual methods of contraception (hormonal method of birth control, intrauterine device, or tubal ligation - plus condoms) or abstinence prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Women treated previously with 5-fluorouracil or imiquimod or other medications for high-grade squamous intraepithelial lesions will be excluded from the study\n* Concurrent vaginal, vulvar, anal lesions or symptomatic infections\n* Pregnant or planning pregnancy within the next 6 months, or breastfeeding; pregnant women are excluded from this study because 5-fluorouracil is an antimetabolite with the potential for teratogenic effects; because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with 5-fluorouracil, breastfeeding should be discontinued if the mother is treated with 5-fluorouracil\n* Inability to speak or read English or Spanish\n* Prior hysterectomy\n* Use of anticoagulant medications\n* Subjects who have a known immunocompromised condition (HIV positive \\[+\\], use of immunosuppressive medications or systemic steroids, organ transplant recipients) or autoimmune conditions (e.g. psoriasis, rheumatoid arthritis or other known autoimmune conditions)\n* Evidence of invasive anal, vulva, vaginal, or cervical carcinoma; prior loop electrosurgical excision procedure (LEEP) or ablative treatment within 6 months prior to study entry; other invasive malignancies, with the exception of non-melanoma skin cancer, within the last 5 years\n* Pathologic findings consistent with\n\n  * Atypical endometrial cells or serious glandular-cell atypia (atypical glandular cells, favor neoplasia cytology diagnosis)\n  * Evidence of cervical carcinoma on Pap smear or biopsy\n  * More than two cervical quadrants of CIN 3 as visualized by colposcopy\n  * Nonvisual squamous columnar junction on colposcopy with no concurrent endocervical sampling performed\n* Use of other investigational agents within 6 months prior to enrollment\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to 5-fluorouracil or imiquimod\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (other than human papilloma virus \\[HPV\\]), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Subjects with known partial or complete dihydropyrimidine dehydrogenase (DPD) enzyme deficiency","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Lisa Rahangdale","affiliation":"UNC Lineberger Comprehensive Cancer Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"UNC Lineberger Comprehensive Cancer Center","city":"Chapel Hill","state":"North Carolina","zip":"27599","country":"United States","geoPoint":{"lat":35.9132,"lon":-79.05584}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page","url":"https://grants.nih.gov/policy/sharing.htm"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Treatment (Topical Fluorouracil, Imiquimod)","description":"Patients receive once-weekly intravaginal application of 5-fluorouracil and imiquimod used on alternating weeks for 8 to 16 weeks.\n\nImiquimod: Given intravaginally\n\nTopical Fluorouracil: Given intravaginally"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"13"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"11"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Treatment (Topical Fluorouracil, Imiquimod)","description":"Patients receive once-weekly intravaginal application of 5-fluorouracil and imiquimod used on alternating weeks for 8 to 16 weeks.\n\nImiquimod: Given intravaginally\n\nTopical Fluorouracil: Given intravaginally"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"13"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27","spread":"4"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"13"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"2"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"11"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"3"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"7"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"2"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Feasibility of Intravaginal Use 5-FU and Imiquimod on Alternating Weeks in Women With Biopsy Confirmed High Grade Cervical Squamous Intraepithelial Lesions.","description":"Feasibility is evaluated based on safety and tolerability of the study intervention. For safety, the study assessed the number of participants experiencing the specified adverse events defined as Grade 2 or greater toxicity (or Grade 1 toxicity of any genital lesion (blisters, ulcerations, or pustules)) that is possibly, probably, or definitely related and lasts for more than 5 days. For tolerability, the study assessed the number of participants who were not able to apply at least 50% of the treatment due to the specified adverse events.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 22 weeks","groups":[{"id":"OG000","title":"Treatment (Topical Fluorouracil, Imiquimod)","description":"Patients receive topical fluorouracil intravaginally via applicator at weeks 1, 3, 5, 7, 9, 11, 13, and 15 and imiquimod intravaginally via applicator at weeks 2, 4, 6, 8, 10, 12, 14, and 16. Patients who are menstruating will delay application until the end of the menstrual cycle.\n\nImiquimod: Given intravaginally\n\nTopical Fluorouracil: Given intravaginally"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"classes":[{"title":"Safety","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Tolerability","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}]},{"type":"SECONDARY","title":"Response to Intravaginal 5-FU and Imiquimod Defined as Histologic Regression and Clearance of High-risk Human Papilloma Virus (HR-HPV)","description":"The response will be reported along with their 95% confidence intervals. Response is defined as histologic regression from high-grade lesions to low-grade- or no lesions and clearance of HR-HPV detection between baseline and end of study.","populationDescription":"Participants who were HR-HPV negative at baseline were excluded from the analysis","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"At end of study visit (4-6 weeks after the last agent application)","groups":[{"id":"OG000","title":"Treatment (Topical Fluorouracil, Imiquimod)","description":"Patients receive once-weekly intravaginal application of 5-fluorouracil and imiquimod used on alternating weeks for 8 to 16 weeks.\n\nImiquimod: Given intravaginally\n\nTopical Fluorouracil: Given intravaginally"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","lowerLimit":"12","upperLimit":"74"}]}]}]},{"type":"SECONDARY","title":"Type Specific Human Papillomavirus (HPV) Clearance","description":"The type-specific HR-HPV clearance will be reported along with their 95% confidence intervals.","populationDescription":"Participants positive for a given HPV genotype at baseline were assessed for the clearance of this genotype at the end of study.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"At end of study visit (4-6 weeks after the last agent application)","groups":[{"id":"OG000","title":"Treatment (Topical Fluorouracil, Imiquimod)","description":"Patients receive once-weekly intravaginal application of 5-fluorouracil and imiquimod used on alternating weeks for 8 to 16 weeks.\n\nImiquimod: Given intravaginally\n\nTopical Fluorouracil: Given intravaginally"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"title":"HPV16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75","lowerLimit":"19","upperLimit":"99"}]}]},{"title":"HPV31","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50","lowerLimit":"1","upperLimit":"99"}]}]},{"title":"HPV35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"3","upperLimit":"100"}]}]},{"title":"HPV39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"98"}]}]},{"title":"HPV51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"84"}]}]},{"title":"HPV52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75","lowerLimit":"19","upperLimit":"99"}]}]},{"title":"HPV56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"98"}]}]},{"title":"HPV66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50","lowerLimit":"1","upperLimit":"99"}]}]},{"title":"HPV68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"16","upperLimit":"100"}]}]}]},{"type":"SECONDARY","title":"Change in Expression of Biomarkers of Local Immune Activation (Cytokines) After Treatment With Self-administered Intravaginal Topical Fluorouracil and Imiquimod","description":"For each biomarker, the mean change of log transformed data and the associated standard deviation will be reported. Will measure the innate (IFN-alpha2), immune mediating (IFN-gamma, IL-10, IL-12), and pro-inflammatory (IL-1alpha, -1beta, -6, -8, MIP-1alpha, TNF) cytokine.","populationDescription":"Participants with data at both baseline and end of study for a given biomarker were included in the analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"log pg/ml","timeFrame":"Baseline to up to end of study visit (4-6 weeks after last agent application)","groups":[{"id":"OG000","title":"Treatment (Topical Fluorouracil, Imiquimod)","description":"Patients receive once-weekly intravaginal application of 5-fluorouracil and imiquimod used on alternating weeks for 8 to 16 weeks.\n\nImiquimod: Given intravaginally\n\nTopical Fluorouracil: Given intravaginally"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"title":"IFN-alpha 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":"1.49"}]}]},{"title":"IFN-gamma","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"0.81"}]}]},{"title":"IL-1 alpha","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.55","spread":"1.01"}]}]},{"title":"IL-1 beta","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"1.84"}]}]},{"title":"IL-6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.84","spread":"1.94"}]}]},{"title":"IL-8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.16","spread":"2.63"}]}]},{"title":"IL-12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"0.95"}]}]},{"title":"IL-13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.53","spread":"1.11"}]}]},{"title":"MIP-1 alpha","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.66","spread":"0.77"}]}]},{"title":"TNF alpha","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"1.99"}]}]}]},{"type":"SECONDARY","title":"Change in Expression of Biomarkers of Local Immune Activation (Toll Like Receptors (TLRs)) After Treatment With Self-administered Intravaginal Topical Fluorouracil and Imiquimod","description":"For each biomarker, the mean change of log transformed data and the associated standard deviation will be reported. TLR messenger ribonucleic acid expression is normalized by the housekeeping genes and does not have a unit of measure.","populationDescription":"Participants with data at both baseline and end of study for a given biomarker were included in the analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"gene expression level","timeFrame":"Baseline to up to end of study visit (4-6 weeks after last agent application)","groups":[{"id":"OG000","title":"Treatment (Topical Fluorouracil, Imiquimod)","description":"Patients receive once-weekly intravaginal application of 5-fluorouracil and imiquimod used on alternating weeks for 8 to 16 weeks.\n\nImiquimod: Given intravaginally\n\nTopical Fluorouracil: Given intravaginally"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"title":"TLR2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.90","spread":"2.16"}]}]},{"title":"TLR3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"4.26"}]}]},{"title":"TLR4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":"1.84"}]}]},{"title":"TLR7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.20","spread":"1.36"}]}]},{"title":"TLR9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","spread":"4.43"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"14-22 weeks","eventGroups":[{"id":"EG000","title":"Treatment (Topical Fluorouracil, Imiquimod)","description":"Patients receive once-weekly intravaginal application of 5-fluorouracil and imiquimod used on alternating weeks for 8 to 16 weeks.\n\nImiquimod: Given intravaginally\n\nTopical Fluorouracil: Given intravaginally","deathsNumAffected":0,"deathsNumAtRisk":13,"seriousNumAffected":0,"seriousNumAtRisk":13,"otherNumAffected":13,"otherNumAtRisk":13}],"otherEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Pain - Lower abdominal","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Fever","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Flu like symptoms","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Other","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Bacterial vaginosis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Candida","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Upper respiratory infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":13}]},{"term":"Weight gain","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}]},{"term":"Weight loss","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Headache","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":13}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Cervical erythema","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Cervical friability","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Dysmenorrhea/cramping with menses","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Dyspareunia","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Metrorrhagia","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Pain - Pelvic","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":13}]},{"term":"Pain - Vagina","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":13}]},{"term":"Postcoital bleeding","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Unexplained infrequent bleeding","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":13}]},{"term":"Vaginal abrasions","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Vaginal discharge as observed by clinician","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Vaginal erythema","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Vaginal discharge by participant report","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":13}]},{"term":"Vaginal lesions","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}]},{"term":"Vulvar/vaginal itching","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":13}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Hypertension","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":13}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"pointOfContact":{"title":"Sherry Chow, PhD","organization":"University of Arizona","email":"schow@azcc.arizona.edu","phone":"520-626-3358"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2019-04-04","uploadDate":"2022-01-28T15:55","filename":"Prot_SAP_000.pdf","size":2887428}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D002578","term":"Uterine Cervical Dysplasia"}],"ancestors":[{"id":"D011230","term":"Precancerous Conditions"},{"id":"D009369","term":"Neoplasms"},{"id":"D002577","term":"Uterine Cervical Diseases"},{"id":"D014591","term":"Uterine Diseases"},{"id":"D005831","term":"Genital Diseases, Female"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D000091662","term":"Genital Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077271","term":"Imiquimod"},{"id":"D005472","term":"Fluorouracil"}],"ancestors":[{"id":"D000634","term":"Aminoquinolines"},{"id":"D011804","term":"Quinolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D014498","term":"Uracil"},{"id":"D011744","term":"Pyrimidinones"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT02774291","orgStudyIdInfo":{"id":"2015-5254"},"secondaryIdInfos":[{"id":"NCI-2015-01781","type":"REGISTRY","domain":"CTRP (Clinical Trial Reporting Program)"},{"id":"2015-5254","type":"OTHER","domain":"Albert Einstein College of Medicine"},{"id":"P30CA013330","type":"NIH","link":"https://reporter.nih.gov/quickSearch/P30CA013330"}],"organization":{"fullName":"Albert Einstein College of Medicine","class":"OTHER"},"briefTitle":"Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes","officialTitle":"Pilot Study of Adoptive Cell Transfer for the Treatment of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes"},"statusModule":{"statusVerifiedDate":"2023-07","overallStatus":"TERMINATED","whyStopped":"Due to lack of accrual the study was formally terminated on 01-JUL-2020. Primary Completion and Study Completion Dates have been revised based accordingly based on respective definitions","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-04-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-07-01","type":"ACTUAL"},"completionDateStruct":{"date":"2020-08-04","type":"ACTUAL"},"studyFirstSubmitDate":"2016-05-13","studyFirstSubmitQcDate":"2016-05-16","studyFirstPostDateStruct":{"date":"2016-05-17","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-08-06","resultsFirstSubmitQcDate":"2023-07-17","resultsFirstPostDateStruct":{"date":"2023-08-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-07-17","lastUpdatePostDateStruct":{"date":"2023-08-04","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Albert Einstein College of Medicine","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This pilot clinical trial studies the side effects of anti-ESO (cancer/test antigen) murine T-cell receptor (mTCR)-transduced autologous peripheral blood lymphocytes and combination chemotherapy with cyclophosphamide and fludarabine phosphate in treating patients with cancer that has spread to other places in the body (metastatic) and expresses the gene NY-ESO-1. Donor white blood cells that are treated in the laboratory with anti-cluster of differentiation (CD)3 may help treat metastatic cancer. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine phosphate, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Aldesleukin may stimulate white blood cells, including natural killer cells, to kill metastatic cancer cells. Giving anti-ESO (cancer/test antigen) mTCR-transduced autologous peripheral blood lymphocytes together with combination chemotherapy and aldesleukin may kill more cancer cells.","detailedDescription":"PRIMARY OBJECTIVES:\n\nI. To determine the safety and tolerability of the administration of anti-ESO (cancer/test antigen) mTCR (T cell receptor)-engineered peripheral blood lymphocytes (anti-thyroglobulin mTCR-transduced autologous peripheral blood lymphocytes) plus high-dose aldesleukin following a nonmyeloablative lymphoid depleting preparative regimen in human leukocyte antigen (HLA)-A2 positive patients with metastatic cancer expressing the ESO antigen.\n\nSECONDARY OBJECTIVES:\n\nI. Determine the in vivo survival of T-cell receptor (TCR) gene-engineered cells.\n\nII. Determine the objective response rate by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.\n\nOUTLINE:\n\nPatients receive standard cyclophosphamide intravenously (IV) over 1 hour on days -7 to -6 and fludarabine phosphate via intravenous piggy back (IVPB) over 30 minutes on days -5 to -1 followed by anti-ESO (cancer/test antigen) mTCR-transduced autologous peripheral blood lymphocytes IV over 20-30 minutes on day 0 and aldesleukin IV over 15 minutes approximately every 8 hours on days 0-4. Patients also receive filgrastim subcutaneously (SC) on days 1-4.\n\nAfter completion of study treatment, patients are followed up at 6 weeks, annually for 5 years, and then periodically for 10 years thereafter."},"conditionsModule":{"conditions":["HLA-A2 Positive Cells Present","Metastatic Malignant Neoplasm","Metastatic Malignant Neoplasm in the Brain"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":3,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment (mTCR, aldesleukin)","type":"EXPERIMENTAL","description":"Patients receive standard cyclophosphamide IV over 1 hour on days -7 to -6 and fludarabine phosphate via IVPB over 30 minutes on days -5 to -1 followed by anti-ESO (cancer/test antigen) mTCR-transduced autologous peripheral blood lymphocytes IV over 20-30 minutes on day 0 and aldesleukin IV over 15 minutes approximately every 8 hours on days 0-4. Patients also receive filgrastim SC on days 1-4.","interventionNames":["Biological: Aldesleukin","Biological: Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes","Drug: Cyclophosphamide","Biological: Filgrastim","Drug: Fludarabine Phosphate","Other: Laboratory Biomarker Analysis"]}],"interventions":[{"type":"BIOLOGICAL","name":"Aldesleukin","description":"Given IV","armGroupLabels":["Treatment (mTCR, aldesleukin)"],"otherNames":["125-L-Serine-2-133-interleukin 2","Proleukin","r-serHuIL-2","Recombinant Human IL-2","Recombinant Human Interleukin-2"]},{"type":"BIOLOGICAL","name":"Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes","description":"Given IV","armGroupLabels":["Treatment (mTCR, aldesleukin)"],"otherNames":["Anti-thyroglobulin mTCR-transduced Autologous PBL"]},{"type":"DRUG","name":"Cyclophosphamide","description":"Given IV","armGroupLabels":["Treatment (mTCR, aldesleukin)"],"otherNames":["(-)-Cyclophosphamide","2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate","Carloxan","Ciclofosfamida","Ciclofosfamide","Cicloxal","Clafen","Claphene","CP monohydrate","CTX","CYCLO-cell","Cycloblastin","Cycloblastine","Cyclophospham","Cyclophosphamid monohydrate","Cyclophosphamidum","Cyclophosphan","Cyclophosphane","Cyclophosphanum","Cyclostin","Cyclostine","Cytophosphan","Cytophosphane","Cytoxan","Fosfaseron","Genoxal","Genuxal","Ledoxina","Mitoxan","Neosar","Revimmune","Syklofosfamid","WR- 138719"]},{"type":"BIOLOGICAL","name":"Filgrastim","description":"Given SC","armGroupLabels":["Treatment (mTCR, aldesleukin)"],"otherNames":["Filgrastim XM02","G-CSF","Neupogen","r-metHuG-CSF","Recombinant Methionyl Human Granulocyte Colony Stimulating Factor","rG-CSF","Tbo-filgrastim","Tevagrastim"]},{"type":"DRUG","name":"Fludarabine Phosphate","description":"Given IVPB","armGroupLabels":["Treatment (mTCR, aldesleukin)"],"otherNames":["2-F-ara-AMP","9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-","Beneflur","Fludara","Oforta","SH T 586"]},{"type":"OTHER","name":"Laboratory Biomarker Analysis","description":"Correlative studies","armGroupLabels":["Treatment (mTCR, aldesleukin)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Toxicity Graded According to NCI-CTCAE Version 4.0","description":"Toxicity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.0.","timeFrame":"Up to 15 years"}],"secondaryOutcomes":[{"measure":"Number of Participants Demonstrating in Vivo Survival of TCR Gene-engineered Cells","description":"TCR and vector presence will be quantitated in PBMC samples (5-10mL) using established PCR techniques. This will provide data to estimate the in vivo survival of lymphocytes derived from the infused cells. In addition, measurement of CD4+ and CD8+ T-cells will be conducted and studies of these T-cell subsets in the circulation will be determined by using specific PCR assays capable of detecting the unique DNA sequence for each retroviral vector engineered T-cell. Descriptive statistics will be used to determine the in vivo survival of TCR gene-engineered cells.","timeFrame":"6 weeks post evaluations scan and at 3, 6, and 12 months and annually thereafter"},{"measure":"Number of Participants Demonstrating Objective Response Rate (Complete Response + Partial Response) Using RECIST Criteria","description":"Objective Response Rate will be graded based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria.\n\nComplete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.\n\nProgressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.\n\nStable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study\n\nDescriptive statistics will be used to determine the objective response rate.","timeFrame":"Up to 15 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Measurable metastatic cancer that expresses NY ESO-1 as assessed by one of the following methods: reverse transcriptase-polymerase chain reaction (RT-PCR) on tumor tissue, or by immunohistochemistry of resected tissue, or serum antibody reactive with ESO\n* Confirmation of diagnosis of metastatic cancer by the Laboratory of Pathology at the Montefiore Medical Center\n* Patients must have previously received systemic standard care (or effective salvage chemotherapy regimens) for metastatic disease, if known to be effective for that disease, and have been either non-responders (progressive disease) or have recurred\n* 3 or fewer brain metastases; Note: if lesions are symptomatic or greater than or equal to 1 cm each, these lesions must have been treated and stable for 3 months for the patient to be eligible\n* More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients' toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo); Note: patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less or as specified in the eligibility criteria\n* Eight weeks must have elapsed from the time of any antibody therapy that could affect an anti-cancer immune response, including anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA 4) therapy, at the time the patient receives the preparative regimen to allow antibody levels to decline; Note: patients who have previously received ipilimumab and have documented gastrointestinal (GI) toxicity must have a normal colonoscopy with normal colonic biopsies\n* Willing to sign a durable power of attorney\n* Able to understand and sign the informed consent document\n* Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1\n* Life expectancy of greater than three months\n* Patients must be HLA-A\\*0201 positive\n* Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after cells are no longer detected in the blood\n* Serology:\n\n  * Seronegative for human immunodeficiency virus (HIV) antibody; (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive can have decreased immune-competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities)\n  * Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody; if hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be hepatitis C virus (HCV) ribonucleic acid (RNA) negative\n* Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus\n* Absolute neutrophil count greater than 1000/mm\\^3 without the support of filgrastim\n* White blood cell (WBC) \\>= 3000/mm\\^3\n* Platelet count \\>= 100,000/mm\\^3\n* Hemoglobin \\> 8.0 g/dl\n* Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =\\< to 2.5 times the upper limit of normal\n* Serum creatinine =\\< to 1.6 mg/dl\n* Total bilirubin =\\< to 1.5 mg/dl, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl\n\nExclusion Criteria:\n\n* Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant\n* Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)\n* Active systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease\n* Concurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities)\n* Concurrent systemic steroid therapy\n* History of severe immediate hypersensitivity reaction to any of the agents used in this study\n* History of coronary revascularization or ischemic symptoms\n* History of or active central nervous system (CNS) or peripheral nerve stimulation (PNS) involvement\n* Documented left ventricular ejection fraction (LVEF) of less than or equal to 45%; testing is required in patients with:\n\n  * Clinically significant atrial and/or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second or third degree heart block\n  * Age \\>= 60 years old\n* Pulmonary function testing in patients with:\n\n  * A prolonged history of cigarette smoking (20 pk/yr of smoking within the past two years)\n  * Symptoms of respiratory dysfunction","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"66 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Ira Braunschweig","affiliation":"Albert Einstein College of Medicine","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Albert Einstein College of Medicine","city":"The Bronx","state":"New York","zip":"10461","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Treatment (mTCR, Aldesleukin)","description":"Patients receive standard cyclophosphamide IV over 1 hour on days -7 to -6 and fludarabine phosphate via IVPB over 30 minutes on days -5 to -1 followed by anti-ESO (cancer/test antigen) mTCR-transduced autologous peripheral blood lymphocytes IV over 20-30 minutes on day 0 and aldesleukin IV over 15 minutes approximately every 8 hours on days 0-4. Patients also receive filgrastim SC on days 1-4.\n\nAldesleukin: Given IV\n\nAnti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes: Given IV\n\nCyclophosphamide: Given IV\n\nFilgrastim: Given SC\n\nFludarabine Phosphate: Given IVPB\n\nLaboratory Biomarker Analysis: Correlative studies"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"3"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Treatment (mTCR, Aldesleukin)","description":"Patients receive standard cyclophosphamide IV over 1 hour on days -7 to -6 and fludarabine phosphate via IVPB over 30 minutes on days -5 to -1 followed by anti-ESO (cancer/test antigen) mTCR-transduced autologous peripheral blood lymphocytes IV over 20-30 minutes on day 0 and aldesleukin IV over 15 minutes approximately every 8 hours on days 0-4. Patients also receive filgrastim SC on days 1-4.\n\nAldesleukin: Given IV\n\nAnti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes: Given IV\n\nCyclophosphamide: Given IV\n\nFilgrastim: Given SC\n\nFludarabine Phosphate: Given IVPB\n\nLaboratory Biomarker Analysis: Correlative studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"3"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"3"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"2"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"3"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Toxicity Graded According to NCI-CTCAE Version 4.0","description":"Toxicity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.0.","populationDescription":"The study was officially closed on 7/1/2020 as documented on the final progress report dated 8/4/2020. Data for this Outcome Measure limited to 3 participants","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 15 years","groups":[{"id":"OG000","title":"Treatment (mTCR, Aldesleukin)","description":"Patients receive standard cyclophosphamide IV over 1 hour on days -7 to -6 and fludarabine phosphate via IVPB over 30 minutes on days -5 to -1 followed by anti-ESO (cancer/test antigen) mTCR-transduced autologous peripheral blood lymphocytes IV over 20-30 minutes on day 0 and aldesleukin IV over 15 minutes approximately every 8 hours on days 0-4. Patients also receive filgrastim SC on days 1-4.\n\nAldesleukin: Given IV\n\nAnti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes: Given IV\n\nCyclophosphamide: Given IV\n\nFilgrastim: Given SC\n\nFludarabine Phosphate: Given IVPB\n\nLaboratory Biomarker Analysis: Correlative studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Demonstrating in Vivo Survival of TCR Gene-engineered Cells","description":"TCR and vector presence will be quantitated in PBMC samples (5-10mL) using established PCR techniques. This will provide data to estimate the in vivo survival of lymphocytes derived from the infused cells. In addition, measurement of CD4+ and CD8+ T-cells will be conducted and studies of these T-cell subsets in the circulation will be determined by using specific PCR assays capable of detecting the unique DNA sequence for each retroviral vector engineered T-cell. Descriptive statistics will be used to determine the in vivo survival of TCR gene-engineered cells.","populationDescription":"Data was never collected/aggregated and in vivo survival of TCR gene-engineered cells outcome measure was never analyzed due to the limited number of participants and early termination. The study was officially closed on 7/1/2020 as documented on the final IRB progress report dated 8/4/2020.","reportingStatus":"POSTED","timeFrame":"6 weeks post evaluations scan and at 3, 6, and 12 months and annually thereafter","groups":[{"id":"OG000","title":"Treatment (mTCR, Aldesleukin)","description":"Patients receive standard cyclophosphamide IV over 1 hour on days -7 to -6 and fludarabine phosphate via IVPB over 30 minutes on days -5 to -1 followed by anti-ESO (cancer/test antigen) mTCR-transduced autologous peripheral blood lymphocytes IV over 20-30 minutes on day 0 and aldesleukin IV over 15 minutes approximately every 8 hours on days 0-4. Patients also receive filgrastim SC on days 1-4.\n\nAldesleukin: Given IV\n\nAnti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes: Given IV\n\nCyclophosphamide: Given IV\n\nFilgrastim: Given SC\n\nFludarabine Phosphate: Given IVPB\n\nLaboratory Biomarker Analysis: Correlative studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"SECONDARY","title":"Number of Participants Demonstrating Objective Response Rate (Complete Response + Partial Response) Using RECIST Criteria","description":"Objective Response Rate will be graded based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria.\n\nComplete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.\n\nProgressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.\n\nStable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study\n\nDescriptive statistics will be used to determine the objective response rate.","populationDescription":"Data to support the Objective Response Rate outcome measure was never collected and analyzed due to the limited number of participants enrolled and early termination. The study was officially closed on 7/1/2020 as documented on the final progress report dated 8/4/2020.","reportingStatus":"POSTED","timeFrame":"Up to 15 years","groups":[{"id":"OG000","title":"Treatment (mTCR, Aldesleukin)","description":"Patients receive standard cyclophosphamide IV over 1 hour on days -7 to -6 and fludarabine phosphate via IVPB over 30 minutes on days -5 to -1 followed by anti-ESO (cancer/test antigen) mTCR-transduced autologous peripheral blood lymphocytes IV over 20-30 minutes on day 0 and aldesleukin IV over 15 minutes approximately every 8 hours on days 0-4. Patients also receive filgrastim SC on days 1-4.\n\nAldesleukin: Given IV\n\nAnti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes: Given IV\n\nCyclophosphamide: Given IV\n\nThe study was closed via final progress report on 08/03/2020, no new data are available.\n\nFilgrastim: Given SC\n\nFludarabine Phosphate: Given IVPB\n\nLaboratory Biomarker Analysis: Correlative studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"9 months","description":"The study was closed via final progress report on 08/03/2020 and no further AE data were collected.","eventGroups":[{"id":"EG000","title":"Treatment (mTCR, Aldesleukin)","description":"Patients receive standard cyclophosphamide IV over 1 hour on days -7 to -6 and fludarabine phosphate via IVPB over 30 minutes on days -5 to -1 followed by anti-ESO (cancer/test antigen) mTCR-transduced autologous peripheral blood lymphocytes IV over 20-30 minutes on day 0 and aldesleukin IV over 15 minutes approximately every 8 hours on days 0-4. Patients also receive filgrastim SC on days 1-4.\n\nAldesleukin: Given IV\n\nAnti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes: Given IV\n\nCyclophosphamide: Given IV\n\nFilgrastim: Given SC\n\nFludarabine Phosphate: Given IVPB\n\nLaboratory Biomarker Analysis: Correlative studies","deathsNumAffected":2,"deathsNumAtRisk":3,"seriousNumAffected":0,"seriousNumAtRisk":3,"otherNumAffected":2,"otherNumAtRisk":3}],"otherEvents":[{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Intermittent, Grades 1-2","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3}]},{"term":"Edema limbs","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Bilateral legs, right\\>left. Grade 2","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":3}]},{"term":"Weight Gain","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":3}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Intermittent, highest severity Grade 2","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Intermittent, Grades 1-2","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Intermittent, highest severity Grade 2","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Right Lower Extremity, Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":3}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Intermittent, highest severity Grade 2","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3}]},{"term":"Sinus Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Intermittent, highest severity Grade 2","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3}]},{"term":"Hypomagnesemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Intermittent, highest severity Grade 2","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3}]},{"term":"Neutrophil Count Decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Intermittent, Grades 2-4","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3}]},{"term":"Hypokalemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Intermittent,, Grades 1-2","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":3}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"At rest, Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Hypoglycemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Intermittent, highest severity Grade 1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Generalized, abdomen-back. Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Confusion","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"'generalized weakness', Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Fever","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Hypophosphatemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Intermittent, Grades 1-3","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3}]},{"term":"Creatinine Increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Platelet Count Decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 4","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Chest Pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Nonspecific. Grade 2","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Flushing","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Bone Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Jaw, Grade 2","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Loss of appetite. Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Sleep apnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Intermittent, positional desaturation (lying down). Grade 2","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3}]},{"term":"Acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 2","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 4","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Blood Bilirubin Increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 2","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 2","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Urinary Frequency","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Nonspecified, Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Intermittent, Grade 1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"'hair loss.' Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Mucositis oral","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Braunschweig, Ira","organization":"Albert Einstein College of Medicine/Montefiore medical center","email":"ibraunsc@montefiore.org","phone":"718-798-7474"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2018-11-30","uploadDate":"2021-05-20T08:38","filename":"Prot_SAP_000.pdf","size":2936380}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D009362","term":"Neoplasm Metastasis"},{"id":"D001932","term":"Brain Neoplasms"}],"ancestors":[{"id":"D009385","term":"Neoplastic Processes"},{"id":"D009369","term":"Neoplasms"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"},{"id":"D016543","term":"Central Nervous System Neoplasms"},{"id":"D009423","term":"Nervous System Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D001927","term":"Brain Diseases"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C082598","term":"aldesleukin"},{"id":"D003520","term":"Cyclophosphamide"},{"id":"D000069585","term":"Filgrastim"},{"id":"D016179","term":"Granulocyte Colony-Stimulating Factor"},{"id":"C042382","term":"fludarabine phosphate"}],"ancestors":[{"id":"D010752","term":"Phosphoramide Mustards"},{"id":"D009588","term":"Nitrogen Mustard Compounds"},{"id":"D009150","term":"Mustard Compounds"},{"id":"D006846","term":"Hydrocarbons, Halogenated"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D063088","term":"Phosphoramides"},{"id":"D009943","term":"Organophosphorus Compounds"},{"id":"D003115","term":"Colony-Stimulating Factors"},{"id":"D006023","term":"Glycoproteins"},{"id":"D006001","term":"Glycoconjugates"},{"id":"D002241","term":"Carbohydrates"},{"id":"D016298","term":"Hematopoietic Cell Growth Factors"},{"id":"D016207","term":"Cytokines"},{"id":"D036341","term":"Intercellular Signaling Peptides and Proteins"},{"id":"D010455","term":"Peptides"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D001685","term":"Biological Factors"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT01479348","orgStudyIdInfo":{"id":"120014"},"secondaryIdInfos":[{"id":"12-C-0014"}],"organization":{"fullName":"National Institutes of Health Clinical Center (CC)","class":"NIH"},"briefTitle":"Imaging Study for FdCyd and THU Cancer Treatment","officialTitle":"Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine"},"statusModule":{"statusVerifiedDate":"2020-05","overallStatus":"TERMINATED","whyStopped":"Slow, insufficient accrual.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-11-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-08-04","type":"ACTUAL"},"completionDateStruct":{"date":"2019-01-11","type":"ACTUAL"},"studyFirstSubmitDate":"2011-11-22","studyFirstSubmitQcDate":"2011-11-22","studyFirstPostDateStruct":{"date":"2011-11-24","type":"ESTIMATED"},"resultsFirstSubmitDate":"2020-04-27","resultsFirstSubmitQcDate":"2020-05-06","resultsFirstPostDateStruct":{"date":"2020-05-22","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-05-21","lastUpdatePostDateStruct":{"date":"2020-06-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Peter Choyke, M.D.","investigatorTitle":"Principal Investigator","investigatorAffiliation":"National Cancer Institute (NCI)"},"leadSponsor":{"name":"National Cancer Institute (NCI)","class":"NIH"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"Background:\n\n\\- The drugs FdCyd (also called 5-fluoro-2'-deoxycytidine) and THU (also called tetrahydrouridine) are being used in a cancer treatment study. Not a lot is known about how FdCyd works in the body. Researchers want to look at a modified form of FdCyd using imaging studies to see how the drug reacts with the cancer. This study is not a treatment study. It is open only to people who are already on the FdCyd and THU cancer treatment study.\n\nObjectives:\n\n\\- To study how FdCyd affects advanced cancer cells.\n\nEligibility:\n\n\\- Participants in National Cancer Institute study 09-C-0214.\n\nDesign:\n\n* Participants will have two imaging studies, one before starting FdCyd and THU treatment and one after starting treatment.\n* Participants will have the modified FdCyd, known as F-18 FdCyd, with a dose of THU. The doses will be followed by two imaging study scans and frequent blood samples.\n* This procedure will be repeated at a later date, during the FdCyd and THU treatment period.\n* Treatment will not be provided as part of this study. This is an imaging study protocol only....","detailedDescription":"BACKGROUND:\n\n\\- In pre-clinical models, 5-fluoro-2-deoxycytidine (FdCyd), administered along with\n\ntetrahydrouridine (THU; an inhibitor of cytidine/deoxycytidine deaminase), has shown superior anti-tumor activity as compared with 5-fluorouracil.\n\n\\- FdCyd can be phosphorylated to 5-fluoro-2-deoxycytidylate (FdCMP) by deoxycytidine\n\nkinase and the nucleotide deaminated to FdUMP by deoxycytidylate (dCMP) deaminase.\n\nThe activity of dCMP deaminase is reported to be higher in human malignancies than in normal tissues, which may result in selective cytotoxicity.\n\n* FdCyd is an inhibitor of deoxyribonucleic acid (DNA) methyltransferase and DNA methylation, resulting in reexpression of genes silenced by DNA hypermethylation. It is being evaluated in a phase II multihistology clinical trial at the Developmental Therapeutics Clinic, National Cancer Institute (NCI), Clinical Center, National Institutes of Health (NIH).\n* While FdCyd + THU has shown preliminary evidence of activity in early phase trials not all patients show clinical response. The establishment of a radiolabeled form to image the biodistribution in vivo at baseline and during therapy may provide insight into the distribution of the therapeutic drug.\n* The first step in the development of such an in vivo marker is to determine the\n\nbiodistribution and safety of the radiolabeled form.\n\nOBJECTIVES:\n\n* Determine the safety of \\[F-18\\]-5-fluoro-2'-deoxycytidine (FdCyd) administered intravenously with administration of tetrahydrouridine (THU).\n* Estimate the radiation dosimetry of \\[F-18\\]-FdCyd in humans.\n\nELIGIBILITY:\n\n* Only patients enrolled in NCI Phase II Study evaluating FdCyd with THU (NCI Protocol # 09-C-0214 (CTEP# 8351) or NCI Protocol #12-C-0066 (CTEP# 9127)) at the NIH Clinical Center will be eligible to participate in this study).\n* Patients must have a target lesion greater than or equal to 10mm\n* May not be pregnant or lactating; must be less than or equal to 350 lbs; and may not have known allergy to FdCyd or contraindications to positron emission tomography (PET)/computed tomography (CT) imaging.\n\nDESIGN:\n\n* There are two arms to this study\n* The first arm will be patients enrolling in the therapeutic Phase II 5-FdCyd/THU study (NCI Protocol # 09-C-0214 (CTEP# 8351) in the NCI Developmental Therapeutics Clinic\n* The second arm will be patients enrolling in the Phase I 5-FdCyd/THU study (NCI Protocol #12-C-0066 (CTEP# 9127)) in the NCI Developmental Therapeutics Clinic.\n* Patients will undergo an initial \\[F-18\\]-FdCyd + THU PET/CT imaging prior to therapeutic dosing on study NCI Protocol # 09-C-0214 (CTEP# 8351) or NCI Protocol #12-C-0066 (CTEP# 9127). Repeat imaging will be performed while the patient is receiving FdCyd + THU therapy under the parent therapeutic protocol. This imaging must be completed 2-5 days after cycle start and at least 2 hours after a dose. Upon completion of repeat imaging, patients will be taken off this imaging study 24 hours after the last imaging session."},"conditionsModule":{"conditions":["Head and Neck Neoplasms","Lung Neoplasms","Urinary Bladder Neoplasms","Breast Neoplasms"],"keywords":["Imaging","Radiopharmaceutical","Safety","Dosimetry","Drug Distribution","Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"DIAGNOSTIC","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":5,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1/Intravenous (IV) Tetrahydrouridine (THU)","type":"EXPERIMENTAL","description":"\\[F-18\\]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine","interventionNames":["Drug: [F-18]-5-FLUORO-2'-DEOXYCYTIDINE","Drug: Tetrahydrouridine intravenous (IV)","Drug: Tetrahydrouridine (oral)","Diagnostic Test: Positron emission tomography (PET)/Computed tomography (CT)"]},{"label":"2/Oral Tetrahydrouridine (THU)","type":"EXPERIMENTAL","description":"\\[F-18\\]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine","interventionNames":["Drug: [F-18]-5-FLUORO-2'-DEOXYCYTIDINE","Drug: Tetrahydrouridine intravenous (IV)","Drug: Tetrahydrouridine (oral)","Diagnostic Test: Positron emission tomography (PET)/Computed tomography (CT)"]}],"interventions":[{"type":"DRUG","name":"[F-18]-5-FLUORO-2'-DEOXYCYTIDINE","description":"18FdCyd radiotracer","armGroupLabels":["1/Intravenous (IV) Tetrahydrouridine (THU)","2/Oral Tetrahydrouridine (THU)"],"otherNames":["18FdCyd"]},{"type":"DRUG","name":"Tetrahydrouridine intravenous (IV)","description":"Total dose of THU = 350 mg/m\\^2, IV","armGroupLabels":["1/Intravenous (IV) Tetrahydrouridine (THU)","2/Oral Tetrahydrouridine (THU)"],"otherNames":["THU"]},{"type":"DRUG","name":"Tetrahydrouridine (oral)","description":"Total dose of THU is 3000 mg, oral","armGroupLabels":["1/Intravenous (IV) Tetrahydrouridine (THU)","2/Oral Tetrahydrouridine (THU)"],"otherNames":["THU"]},{"type":"DIAGNOSTIC_TEST","name":"Positron emission tomography (PET)/Computed tomography (CT)","description":"One prior CT and 3 sequential whole body PET","armGroupLabels":["1/Intravenous (IV) Tetrahydrouridine (THU)","2/Oral Tetrahydrouridine (THU)"],"otherNames":["PET scan/CT scan"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Frequency and Severity of Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0","description":"\\[F-18\\]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event.","timeFrame":"Within 5 days after interventions"},{"measure":"Radiation Dosimetry Estimates of 5-fluoro-2'-Deoxycytidine (FdCyd) in Humans","description":"Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data.","timeFrame":"1 year"}],"secondaryOutcomes":[{"measure":"Tumor to Background Ratios (TBRs) of Target Lesions at 4 Time Points After Injection","description":"Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection.","timeFrame":"9 minutes, 32 minutes, 56 minutes and 2 hours after injection"},{"measure":"Number of Participants With Serious and Non-Serious Adverse Events","description":"Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.","timeFrame":"Date treatment consent signed to date off study, approximately 20 months and 12 days."}]},"eligibilityModule":{"eligibilityCriteria":"* INCLUSION CRITERIA:\n* Enrolled in the National Institutes of Health (NIH) Phase II Clinical protocol evaluating 5-fluro-2'-deoxycytidine (FdCyd) with Tetrahydrouridine (THU) (09-C-0214) with target lesion measured as greater than or equal to 10mm with spiral computed tomography (CT) scan.\n* Written, voluntary, informed consent of the patient must be obtained in compliance with institutional, state and federal guidelines\n* For females: Negative serum pregnancy test OR post-menopausal for at least 2 years OR patient has had a hysterectomy\n\nEXCLUSION CRITERIA:\n\n* Participants with severe claustrophobia unresponsive to oral anxiolytics\n* Subjects weighing \\> 400 lbs (weight limit for scanner table), or unable to fit within the imaging gantry\n* Known allergy to FdCyd\n* The subject is unable to lie still for 75 minutes\n* 5 Pregnant or lactating women. Pregnant women are excluded from this study because the effects of 18F-FdCyd in pregnancy are not known. Because there is an unknown but potential risk for adverse events in nursing infants secondary to administration of 18F-FdCyd in the mother, breastfeeding should be discontinued if the mother receives 18F-FdCyd\n* Participants with any co-existing medical or psychiatric condition that is likely to interfere with study procedures and/or results","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Karen A Kurdziel, M.D.","affiliation":"National Cancer Institute (NCI)","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"National Institutes of Health Clinical Center, 9000 Rockville Pike","city":"Bethesda","state":"Maryland","zip":"20892","country":"United States","geoPoint":{"lat":38.98067,"lon":-77.10026}}]},"referencesModule":{"references":[{"pmid":"1255749","type":"BACKGROUND","citation":"Carter SK. Editorial: Large-bowel cancer-The current status of treatment. J Natl Cancer Inst. 1976 Jan;56(1):3-10. doi: 10.1093/jnci/56.1.3. No abstract available."},{"pmid":"2407810","type":"BACKGROUND","citation":"Doroshow JH, Multhauf P, Leong L, Margolin K, Litchfield T, Akman S, Carr B, Bertrand M, Goldberg D, Blayney D, et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol. 1990 Mar;8(3):491-501. doi: 10.1200/JCO.1990.8.3.491."},{"pmid":"14116219","type":"BACKGROUND","citation":"HARTMANN JR, ORIGENES ML Jr, MURPHY ML, SITARZ A, ERLANDSON M. EFFECTS OF 2'-DEOXY-5-FLUOROURIDINE (NSC-27640) AND 5-FLUOROURACIL (NSC-19893) ON CHILDHOOD LEUKEMIA. Cancer Chemother Rep. 1964 Jan;34:51-4. No abstract available."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"No participants were enrolled in the 2/Oral Tetrahydrouridine (THU) Group.","groups":[{"id":"FG000","title":"1/Intravenous (IV) Tetrahydrouridine (THU)","description":"\\[F-18\\]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine\n\n\\[F-18\\]-5-FLUORO-2'-DEOXYCYTIDINE: 18FdCyd radiotracer\n\nTetrahydrouridine intravenous (IV): Total dose of THU = 350 mg/m\\^2, IV\n\nTetrahydrouridine (oral): Total dose of THU is 3000 mg, oral\n\nPositron emission tomography (PET)/Computed tomography (CT): One prior CT and 3 sequential whole body PET"},{"id":"FG001","title":"2/Oral Tetrahydrouridine (THU)","description":"\\[F-18\\]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine\n\n\\[F-18\\]-5-FLUORO-2'-DEOXYCYTIDINE: 18FdCyd radiotracer\n\nTetrahydrouridine intravenous (IV): Total dose of THU = 350 mg/m\\^2, IV\n\nTetrahydrouridine (oral): Total dose of THU is 3000 mg, oral\n\nPositron emission tomography (PET)/Computed tomography (CT): One prior CT and 3 sequential whole body PET"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"1/Intravenous (IV) Tetrahydrouridine (THU)","description":"\\[F-18\\]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine\n\n\\[F-18\\]-5-FLUORO-2'-DEOXYCYTIDINE: 18FdCyd radiotracer\n\nTetrahydrouridine intravenous (IV): Total dose of Tetrahydrouridine (THU) = 350 mg/m\\^2, IV\n\nTetrahydrouridine (oral): Total dose of THU is 3000 mg, oral\n\nPositron emission tomography (PET)/Computed tomography (CT): One prior CT and 3 sequential whole body PET"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"5"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"3"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"2"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"55.46","spread":"15.19"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"2"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"3"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"4"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"3"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}]}]},{"title":"Baseline Tumor Types","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Head & Neck Carcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}]},{"title":"Non-Small Cell Lung Carcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}]},{"title":"Hepatocellular Carcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Frequency and Severity of Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0","description":"\\[F-18\\]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"adverse events","timeFrame":"Within 5 days after interventions","groups":[{"id":"OG000","title":"1/Intravenous (IV) Tetrahydrouridine (THU)","description":"\\[F-18\\]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine\n\n\\[F-18\\]-5-FLUORO-2'-DEOXYCYTIDINE: 18FdCyd radiotracer\n\nTetrahydrouridine intravenous (IV): Total dose of Tetrahydrouridine (THU) = 350 mg/m\\^2, IV\n\nTetrahydrouridine (oral): Total dose of THU is 3000 mg, oral\n\nPositron emission tomography (PET)/Computed tomography (CT): One prior CT and 3 sequential whole body PET"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"classes":[{"title":"Day 1 Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Day 2, Grade 2 Hypoalbuminemia","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Day 2, Grade 3 Anemia","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Day 3 Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Day 4 Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Day 5 Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Radiation Dosimetry Estimates of 5-fluoro-2'-Deoxycytidine (FdCyd) in Humans","description":"Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mSv/MBq","timeFrame":"1 year","groups":[{"id":"OG000","title":"1/Intravenous (IV) Tetrahydrouridine (THU)","description":"\\[F-18\\]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine\n\n\\[F-18\\]-5-FLUORO-2'-DEOXYCYTIDINE: 18FdCyd radiotracer\n\nTetrahydrouridine intravenous (IV): Total dose of Tetrahydrouridine (THU) = 350 mg/m\\^2, IV\n\nTetrahydrouridine (oral): Total dose of THU is 3000 mg, oral\n\nPositron emission tomography (PET)/Computed tomography (CT): One prior CT and 3 sequential whole body PET"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"classes":[{"title":"Adrenals","categories":[{"measurements":[{"groupId":"OG000","value":"1.83","spread":"9.3"}]}]},{"title":"Brain","categories":[{"measurements":[{"groupId":"OG000","value":"8.17","spread":"2.04"}]}]},{"title":"Breasts","categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":"1.01"}]}]},{"title":"Gallbladder wall","categories":[{"measurements":[{"groupId":"OG000","value":"4.05","spread":"7.55"}]}]},{"title":"Lower large intestine wall","categories":[{"measurements":[{"groupId":"OG000","value":"2.52","spread":"7.82"}]}]},{"title":"Small intestine","categories":[{"measurements":[{"groupId":"OG000","value":"2.13","spread":"4.57"}]}]},{"title":"Stomach wall","categories":[{"measurements":[{"groupId":"OG000","value":"1.90","spread":"3.27"}]}]},{"title":"Upper large intestine wall","categories":[{"measurements":[{"groupId":"OG000","value":"2.04","spread":"6.43"}]}]},{"title":"Heart wall","categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":"1.82"}]}]},{"title":"Kidneys","categories":[{"measurements":[{"groupId":"OG000","value":"5.26","spread":"2.23"}]}]},{"title":"Liver","categories":[{"measurements":[{"groupId":"OG000","value":"6.02","spread":"2.74"}]}]},{"title":"Lungs","categories":[{"measurements":[{"groupId":"OG000","value":"1.82","spread":"7.10"}]}]},{"title":"Muscle","categories":[{"measurements":[{"groupId":"OG000","value":"1.16","spread":"1.35"}]}]},{"title":"Ovaries","categories":[{"measurements":[{"groupId":"OG000","value":"1.57","spread":"2.22"}]}]},{"title":"Pancreas","categories":[{"measurements":[{"groupId":"OG000","value":"1.63","spread":"4.27"}]}]},{"title":"Red marrow","categories":[{"measurements":[{"groupId":"OG000","value":"1.14","spread":"2.19"}]}]},{"title":"Osteogenic cells","categories":[{"measurements":[{"groupId":"OG000","value":"1.71","spread":"6.41"}]}]},{"title":"Skin","categories":[{"measurements":[{"groupId":"OG000","value":"8.65","spread":"1.19"}]}]},{"title":"Spleen","categories":[{"measurements":[{"groupId":"OG000","value":"1.69","spread":"5.55"}]}]},{"title":"Testes","categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":"2.38"}]}]},{"title":"Thymus","categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":"3.01"}]}]},{"title":"Thyroid","categories":[{"measurements":[{"groupId":"OG000","value":"8.23","spread":"4.39"}]}]},{"title":"Urinary bladder wall","categories":[{"measurements":[{"groupId":"OG000","value":"7.96","spread":"5.24"}]}]},{"title":"Uterus","categories":[{"measurements":[{"groupId":"OG000","value":"1.63","spread":"4.99"}]}]}]},{"type":"SECONDARY","title":"Tumor to Background Ratios (TBRs) of Target Lesions at 4 Time Points After Injection","description":"Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection.","populationDescription":"One participant contributed to data in each row.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"TBR ratio","timeFrame":"9 minutes, 32 minutes, 56 minutes and 2 hours after injection","groups":[{"id":"OG000","title":"1/Intravenous (IV) Tetrahydrouridine (THU)","description":"\\[F-18\\]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine\n\n\\[F-18\\]-5-FLUORO-2'-DEOXYCYTIDINE: 18FdCyd radiotracer\n\nTetrahydrouridine intravenous (IV): Total dose of Tetrahydrouridine (THU) = 350 mg/m\\^2, IV\n\nTetrahydrouridine (oral): Total dose of THU is 3000 mg, oral\n\nPositron emission tomography (PET)/Computed tomography (CT): One prior CT and 3 sequential whole body PET"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"classes":[{"title":"Pt 1 L. Parotid adenosquam. cell ca at 9 min","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4"}]}]},{"title":"Pt 1 L. Parotid adenosquam. cell ca at 32 min","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5"}]}]},{"title":"Pt 1 L. Parotid adenosquam. cell ca at 56 min","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5"}]}]},{"title":"Pt 1 L. Parotid adenosquam. cell ca at 2 hrs","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6"}]}]},{"title":"Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"}]}]},{"title":"Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7"}]}]},{"title":"Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7"}]}]},{"title":"Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6"}]}]},{"title":"Pt 3 Non-small Cell Lung Ca at 9 min","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4"}]}]},{"title":"Pt 3 Non-small Cell Lung Ca at 32 min","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4"}]}]},{"title":"Pt 3 Non-small Cell Lung Ca at 56 min","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5"}]}]},{"title":"Pt 3 Non-small Cell Lung Ca at 2 hrs","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7"}]}]},{"title":"Pt 4 Non-small Cell Lung Ca at 9 min","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.4"}]}]},{"title":"Pt 4 Non-small Cell Lung Ca at 32 min","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1"}]}]},{"title":"Pt 4 Non-small Cell Lung Ca at 56 min","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6"}]}]},{"title":"Pt 4 Non-small Cell Lung Ca at 2 hrs","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"}]}]},{"title":"Pt 5 Hepatocellular Ca at 9 min","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Activity within the tumor was not clearly discernable from remainder of liver parenchyma, thus TBRs are not included for Pt. 5 because of concern about reporting misleading values in setting of high background/surrounding liver uptake."}]}]},{"title":"Pt 5 Hepatocellular Ca at 32 min","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Activity within the tumor was not clearly discernable from remainder of liver parenchyma, thus TBRs are not included for Pt. 5 because of concern about reporting misleading values in setting of high background/surrounding liver uptake."}]}]},{"title":"Pt 5 Hepatocellular Ca at 56 min","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Activity within the tumor was not clearly discernable from remainder of liver parenchyma, thus TBRs are not included for Pt. 5 because of concern about reporting misleading values in setting of high background/surrounding liver uptake."}]}]},{"title":"Pt 5 Hepatocellular Ca at 2 hrs","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Activity within the tumor was not clearly discernable from remainder of liver parenchyma, thus TBRs are not included for Pt. 5 because of concern about reporting misleading values in setting of high background/surrounding liver uptake."}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious and Non-Serious Adverse Events","description":"Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Date treatment consent signed to date off study, approximately 20 months and 12 days.","groups":[{"id":"OG000","title":"1/Intravenous (IV) Tetrahydrouridine (THU)","description":"\\[F-18\\]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine\n\n\\[F-18\\]-5-FLUORO-2'-DEOXYCYTIDINE: 18FdCyd radiotracer\n\nTetrahydrouridine intravenous (IV): Total dose of Tetrahydrouridine (THU) = 350 mg/m\\^2, IV\n\nTetrahydrouridine (oral): Total dose of THU is 3000 mg, oral\n\nPositron emission tomography (PET)/Computed tomography (CT): One prior CT and 3 sequential whole body PET"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Date treatment consent signed to date off study, approximately 20 months and 12 days.","eventGroups":[{"id":"EG000","title":"1/Intravenous (IV) Tetrahydrouridine (THU)","description":"\\[F-18\\]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine\n\n\\[F-18\\]-5-FLUORO-2'-DEOXYCYTIDINE: 18FdCyd radiotracer\n\nTetrahydrouridine intravenous (IV): Total dose of Tetrahydrouridine (THU) = 350 mg/m\\^2, IV\n\nTetrahydrouridine (oral): Total dose of THU is 3000 mg, oral\n\nPositron emission tomography (PET)/Computed tomography (CT): One prior CT and 3 sequential whole body PET","deathsNumAffected":2,"deathsNumAtRisk":5,"seriousNumAffected":2,"seriousNumAtRisk":5,"otherNumAffected":2,"otherNumAtRisk":5}],"seriousEvents":[{"term":"Death NOS","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":5}]}],"otherEvents":[{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5}]},{"term":"Hypoalbuminemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":5}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Dr. Karen Kurdziel","organization":"National Cancer Institute","email":"kurdziek@nih.gov","phone":"804-897-1207"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2015-03-09","uploadDate":"2020-04-13T08:23","filename":"Prot_SAP_000.pdf","size":1021003},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form: IV FdCyd + THU","date":"2015-03-18","uploadDate":"2020-04-13T08:23","filename":"ICF_001.pdf","size":272466},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form: Oral FdCyd + THU","date":"2015-03-18","uploadDate":"2020-04-13T08:25","filename":"ICF_002.pdf","size":250194}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D006258","term":"Head and Neck Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D001749","term":"Urinary Bladder Neoplasms"},{"id":"D001943","term":"Breast Neoplasms"},{"id":"D009369","term":"Neoplasms"}],"ancestors":[{"id":"D009371","term":"Neoplasms by Site"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D014571","term":"Urologic Neoplasms"},{"id":"D014565","term":"Urogenital Neoplasms"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D001745","term":"Urinary Bladder Diseases"},{"id":"D014570","term":"Urologic Diseases"},{"id":"D052801","term":"Male Urogenital Diseases"},{"id":"D001941","term":"Breast Diseases"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D013767","term":"Tetrahydrouridine"},{"id":"D049268","term":"Positron-Emission Tomography"},{"id":"D000072078","term":"Positron Emission Tomography Computed Tomography"}],"ancestors":[{"id":"D014529","term":"Uridine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D009705","term":"Nucleosides"},{"id":"D009706","term":"Nucleic Acids, Nucleotides, and Nucleosides"},{"id":"D012263","term":"Ribonucleosides"},{"id":"D014055","term":"Tomography, Emission-Computed"},{"id":"D007090","term":"Image Interpretation, Computer-Assisted"},{"id":"D003952","term":"Diagnostic Imaging"},{"id":"D019937","term":"Diagnostic Techniques and Procedures"},{"id":"D003933","term":"Diagnosis"},{"id":"D007089","term":"Image Enhancement"},{"id":"D010781","term":"Photography"},{"id":"D011877","term":"Radionuclide Imaging"},{"id":"D014054","term":"Tomography"},{"id":"D003947","term":"Diagnostic Techniques, Radioisotope"},{"id":"D014057","term":"Tomography, X-Ray Computed"},{"id":"D064847","term":"Multimodal Imaging"},{"id":"D011856","term":"Radiographic Image Enhancement"},{"id":"D011859","term":"Radiography"},{"id":"D014056","term":"Tomography, X-Ray"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT04476251","orgStudyIdInfo":{"id":"200116"},"secondaryIdInfos":[{"id":"20-C-0116"}],"organization":{"fullName":"National Institutes of Health Clinical Center (CC)","class":"NIH"},"briefTitle":"E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical Cancer","officialTitle":"A Pilot Study of E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical Cancer"},"statusModule":{"statusVerifiedDate":"2021-12","overallStatus":"TERMINATED","whyStopped":"Multiple logistical challenges","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-01-14","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-09-15","type":"ACTUAL"},"completionDateStruct":{"date":"2021-09-15","type":"ACTUAL"},"studyFirstSubmitDate":"2020-07-16","studyFirstSubmitQcDate":"2020-07-16","studyFirstPostDateStruct":{"date":"2020-07-20","type":"ACTUAL"},"resultsFirstSubmitDate":"2021-11-09","resultsFirstSubmitQcDate":"2021-11-09","resultsFirstPostDateStruct":{"date":"2021-12-08","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-12-07","lastUpdatePostDateStruct":{"date":"2021-12-15","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Scott Norberg, D.O.","investigatorTitle":"Principal Investigator","investigatorAffiliation":"National Cancer Institute (NCI)"},"leadSponsor":{"name":"National Cancer Institute (NCI)","class":"NIH"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Background:\n\nMore than 12,000 cases of cervical cancer are diagnosed in the United States each year. A new therapy has been developed that involves taking white blood cells from a person, genetically modifying the cells in a lab so they recognize cancer, and then giving the cells back to the person. Researchers want to see if this therapy can help people with cervical cancer.\n\nObjective:\n\nTo find out if people with Stage IIB-IVA cervical cancer can safely be given E7 T-cell receptor (TCR) T cells before they get standard treatment.\n\nEligibility:\n\nPeople age 18 and older who have Stage IIB-IVA cervical cancer\n\nDesign:\n\nParticipants will be screened under a separate protocol. Tests will include:\n\n* Physical exam\n* Medicine review\n* Blood tests\n* Pregnancy test (if needed)\n* Vein assessment\n* Tumor sample or biopsy\n* Electrocardiogram (to record the hearts electrical activity)\n* Imaging scans, x-rays, and/or endoscopy\n* Heart and/or lung tests.\n\nSome screening tests will be repeated during the study.\n\nParticipants will undergo leukapheresis. For this, blood is removed through a needle in the arm. A machine removes the white blood cells. The rest of the blood is returned through a needle in the other arm. Participants may need to have a large catheter inserted into a vein.\n\nParticipants will stay at the hospital for 2-3 weeks. They will get chemotherapy drugs. They will get the E7 TCR T cells as an intravenous infusion. They will get the drug aldesleukin.\n\nParticipants will visit the National Institutes of Health (NIH) 3 and 6 weeks after treatment. They will be contacted yearly for 5 years. They will be asked to participate in long-term follow-up for 15 years....","detailedDescription":"Background:\n\n* Cervical cancer is the third most common cause of death among women with gynecologic cancers in the United States. Worldwide, cervical cancer accounts for nearly 300,000 deaths annually.\n* Virtually all cases of cervical cancer result from chronic infection with high-risk human papillomavirus (HPV), the most common type being HPV16.\n* The treatment of locally advanced cervical cancer consists of chemoradiation +/- extended field radiation therapy. Participants with International Federation of Gynecology and Obstetrics (FIGO) (revised 2018) stage III-IVA have the worse prognosis with approximately 50% of the participants dying from their disease within 5 years.\n* Induction chemotherapy is an active area of study in this type of cancer. The aim of induction therapy is to reduce the risk of disease recurrence and improve overall survival.\n* E7 T-cell receptor (TCR) T cells, administered as a single infusion, have demonstrated safety and clinical activity in advanced, treatment-refractory metastatic HPV+ cancers.\n\nObjectives:\n\n-To determine the feasibility of induction E7 TCR T cell therapy for FIGO (2018) stage IIB-IVA, HPV16+ cervical cancer\n\nEligibility:\n\n* Participants greater than or equal to 18 years old with FIGO (2018) stage IIB-IVA cervical cancer.\n* The cancer must be human papillomavirus 16 (HPV16+) and participant must be HLA-A\\*02:01+.\n* Participants must be treatment-naive (i.e., no prior local or systemic treatment, including radiation; prior loop electrosurgical excision procedure (LEEP) procedure or cone biopsy is allowed).\n\nDesign:\n\n* This is a single arm, pilot study, testing the feasibility of induction E7 TCR T cell therapy.\n* Participants will receive a conditioning regimen of cyclophosphamide and fludarabine, a single infusion of E7 TCR T cells, and systemic aldesleukin.\n* Participants will be referred for standard of care definitive therapy (i.e., chemoradiation +/- extended field radiation therapy) within 6 weeks after infusion of E7 TCR T cells."},"conditionsModule":{"conditions":["Uterine Cervical Neoplasms"],"keywords":["T Cell Receptor","Immunotherapy","Aldesleukin","Cyclophosphamide","Fludarabine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":1,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm 1/E7 T-Cell Receptor (TCR) T Cell Therapy","type":"EXPERIMENTAL","description":"E7 TCR T Cell Therapy","interventionNames":["Biological: E7 T-Cell Receptor (TCR)"]}],"interventions":[{"type":"BIOLOGICAL","name":"E7 T-Cell Receptor (TCR)","description":"Patients will receive up to 3x10\\^10 E7 T-Cell Receptor (TCR) T cells (i.e. TCR+ cells).","armGroupLabels":["Arm 1/E7 T-Cell Receptor (TCR) T Cell Therapy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The Fraction of Participants for Whom E7 T-Cell Receptor (TCR) Induction Therapy is Feasible in Participants With Cervical Cancer","description":"The Fraction of participants for whom E7 T-Cell Receptor (TCR) induction therapy is feasible in participants with cervical cancer","timeFrame":"6 months"}],"secondaryOutcomes":[{"measure":"Fraction of Participants With Relapse-free Survival at 2 Years and 5 Years Following Definitive Standard of Care Therapy","description":"Fraction of participants with relapse-free survival at 2 years and 5 years estimated from a Kaplan-Meier curve of relapsed free survival following definitive standard of care therapy who achieve a success. Relapsed free survival is defined as the time from date on study to date of relapse of disease.","timeFrame":"2 yrs and 5 yrs"},{"measure":"Fraction of Participants With Grade 1-5 Adverse Events","description":"To evaluate the safety of E7 induction therapy, the types and grades of toxicity obtained will be reported. Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, Grade 4 is life-threatening, and Grade 5 is death related to adverse event.","timeFrame":"1 year"},{"measure":"Percentage of E7 T-Cell Receptor (TCR)T Cells Following Completion of Chemoradiation","description":"Percentage of E7 T-Cell Receptor (TCR)T cells following completion of chemoradiation","timeFrame":"1 year"},{"measure":"Fraction of Participants Who Achieve an Objective Response (Partial Response + Complete Response) Following E7 T-Cell Receptor (TCR) T Cell Induction Therapy","description":"Fraction of participants who achieve an objective response (Partial Response + Complete Response) following E7 induction therapy will be reported. Response may be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete Response is disappearance of all target lesions. Partial Response is at least a 30% decrease in the sum of the diameters of target lesion; and/or Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST). Complete Metabolic Response is complete resolution of F-fluorodeoxyglucose (FDG) uptake in all lesions, and Partial Metabolic Response is  30% reduction of the SUL (lean body mass corrected standard uptake value) peak and an absolute drop of 0.8 SULpeak units.","timeFrame":"1 year"}],"otherOutcomes":[{"measure":"Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)","description":"Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.","timeFrame":"Date treatment consent signed to date off study, approximately 20 days."}]},"eligibilityModule":{"eligibilityCriteria":"-INCLUSION CRITERIA:\n\n1. Participants with histologically or cytologically confirmed carcinoma of the cervix that has not been treated, with clinical staging as follows:\n\n   * Lead-in safety cohort: FIGO (International Federation of Gynecology and Obstetrics) stage IIIC-IVA (2018 International FIGO Staging System)\n   * After lead-in safety cohort: FIGO stage IIB-IVA (2018 International FIGO Staging System)\n2. Human papillomavirus 16 (HPV16+) tumor and HLA-A\\*02:01+ Human leukocyte antigen (HLA) type. Note: HLA-A\\*02 is also acceptable for enrollment but not for treatment.\n3. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria or Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) (if not eligible by RECIST 1.1).\n4. Age 18 years. Because no dosing or adverse event data are currently available on the use of E7 TCR T cells in participants \\<18 years of age, children are excluded from this study. Note: This age range is consistent with the age of participants with the disease being studied.\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n6. Women of child-bearing potential must have a negative pregnancy test because E7 TCR T cells have unknown potential for teratogenic or abortifacient effects. Women of child- bearing potential are defined as all women who are not post-menopausal or who have not had a hysterectomy. Note: Postmenopausal will be defined in this study as women over the age of 55 who have not had a menstrual period in at least 1 year.\n7. The effects of E7 TCR T cells on the developing human fetus are unknown. For this reason and because the chemotherapy agents used in this trial are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (e.g., intrauterine device, hormonal or barrier method of birth control; abstinence; tubal ligation or vasectomy) prior to study entry and for four months after treatment. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.\n8. Seronegative for HIV (human immunodeficiency virus) antibody. The experimental treatment being evaluated in this protocol depends on an intact immune system. Participants who are HIV seropositive can have decreased immune-competence and thus be less responsive to the experimental treatment.\n9. Seronegative for hepatitis B antigen and hepatitis C antibody. If hepatitis C antibody test is positive, then the participant must be tested for the presence of antigen by Reverse transcription polymerase chain reaction (RT-PCR) and be hepatitis C Virus (HCV) ribonucleic acid (RNA) negative.\n10. Must be willing to participate in Gene Therapy Long Term Follow up Protocol (20C0051), which will follow participants for up to 15 years per Food and Drug Administration (FDA) requirements.\n11. Participants must have organ and marrow function as defined below:\n\n    * leukocytes \\>=3,000/mcL\n    * absolute neutrophil count \\>=1,500/mcL\n    * platelets \\>=100,000/mcL\n    * hemoglobin \\>=9.0 g/dL\n    * total bilirubin within normal institutional limits except in participants with Gilbert's Syndrome who must have a total bilirubin \\< 3.0 mg/dL\n    * Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT)/alanine aminotransferase (ALT) serum glutamate-pyruvate transaminase (SGPT) Serum ALT/AST \\< 2.5X ULN\n    * creatinine clearance Calculated creatinine clearance (CrCl) \\>=50 mL/min/1.73 m\\^2 for participants with creatinine levels above institutional normal (by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation)\n12. Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n1. Previous treatment for invasive cervical cancer including:\n\n   * Chemotherapy or other systemic treatments\n   * Radiation therapy\n   * Hysterectomy (prior LEEP procedure or cone biopsy is allowed)\n2. Participants who are receiving any other investigational agents.\n3. History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in study.\n4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations at the time of treatment that would limit compliance with study requirements.\n5. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with E7 TCR T cells, breastfeeding should be discontinued if the mother is treated with E7 TCR T cells. These potential risks may also apply to other agents used in this study.\n6. Participants with any form of systemic immunodeficiency, including acquired deficiency such as HIV or primary immunodeficiency such as Severe Combined Immunodeficiency Disease, are ineligible. The experimental treatment being evaluated in this protocol depends on an intact immune system. Participants who have decreased immune competence may be less responsive to the treatment.\n7. Participants on immunosuppressive drugs including corticosteroids.\n8. Participants with autoimmune diseases such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, autoimmune hepatitis, autoimmune pancreatitis, or systemic lupus erythematosus. Hypothyroidism, vitiligo and other minor autoimmune disorders are not exclusionary.\n9. Participants with a second invasive malignancy requiring treatment within the last 2 years are not eligible with the following exceptions:\n\n   * Ductal carcinoma in situ (DCIS) of the breast\n   * Cutaneous skin cancers requiring only local excision","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Scott M Norberg, D.O.","affiliation":"National Cancer Institute (NCI)","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"National Institutes of Health Clinical Center","city":"Bethesda","state":"Maryland","zip":"20892","country":"United States","geoPoint":{"lat":38.98067,"lon":-77.10026}}]},"referencesModule":{"seeAlsoLinks":[{"label":"NIH Clinical Center Detailed Web Page","url":"https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2020-C-0116.html"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Arm 1/E7 T-Cell Receptor (TCR) T Cell Therapy","description":"E7 TCR T Cell Therapy\n\nE7 TCR: Patients will receive up to 3x10\\^10 E7 T-Cell Receptor (TCR) T cells (i.e. TCR+ cells)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Not treated","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Arm 1/E7 T-Cell Receptor (TCR) T Cell Therapy","description":"E7 TCR T Cell Therapy\n\nE7 TCR: Patients will receive up to 3x10\\^10 E7 T-Cell Receptor (TCR) T cells (i.e. TCR+ cells)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"1"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"18","spread":"0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"The Fraction of Participants for Whom E7 T-Cell Receptor (TCR) Induction Therapy is Feasible in Participants With Cervical Cancer","description":"The Fraction of participants for whom E7 T-Cell Receptor (TCR) induction therapy is feasible in participants with cervical cancer","populationDescription":"This outcome measure was not done due to multiple logistical challenges. One participant was enrolled but not treated.","reportingStatus":"POSTED","timeFrame":"6 months","groups":[{"id":"OG000","title":"Arm 1/E7 T-Cell Receptor (TCR) T Cell Therapy","description":"E7 TCR T Cell Therapy\n\nE7 TCR: Patients will receive up to 3x10\\^10 E7 T-Cell Receptor (TCR) T cells (i.e. TCR+ cells)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"SECONDARY","title":"Fraction of Participants With Relapse-free Survival at 2 Years and 5 Years Following Definitive Standard of Care Therapy","description":"Fraction of participants with relapse-free survival at 2 years and 5 years estimated from a Kaplan-Meier curve of relapsed free survival following definitive standard of care therapy who achieve a success. Relapsed free survival is defined as the time from date on study to date of relapse of disease.","populationDescription":"This outcome measure was not done due to multiple logistical challenges. One participant was enrolled but not treated.","reportingStatus":"POSTED","timeFrame":"2 yrs and 5 yrs","groups":[{"id":"OG000","title":"Arm 1/E7 T-Cell Receptor (TCR) T Cell Therapy","description":"E7 TCR T Cell Therapy\n\nE7 TCR: Patients will receive up to 3x10\\^10 E7 T-Cell Receptor (TCR) T cells (i.e. TCR+ cells)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"SECONDARY","title":"Fraction of Participants With Grade 1-5 Adverse Events","description":"To evaluate the safety of E7 induction therapy, the types and grades of toxicity obtained will be reported. Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, Grade 4 is life-threatening, and Grade 5 is death related to adverse event.","populationDescription":"This outcome measure was not done due to multiple logistical challenges. One participant was enrolled but not treated.","reportingStatus":"POSTED","timeFrame":"1 year","groups":[{"id":"OG000","title":"Arm 1/E7 T-Cell Receptor (TCR) T Cell Therapy","description":"E7 TCR T Cell Therapy\n\nE7 TCR: Patients will receive up to 3x10\\^10 E7 T-Cell Receptor (TCR) T cells (i.e. TCR+ cells)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"SECONDARY","title":"Percentage of E7 T-Cell Receptor (TCR)T Cells Following Completion of Chemoradiation","description":"Percentage of E7 T-Cell Receptor (TCR)T cells following completion of chemoradiation","populationDescription":"This outcome measure was not done due to multiple logistical challenges. One participant was enrolled but not treated.","reportingStatus":"POSTED","timeFrame":"1 year","groups":[{"id":"OG000","title":"Arm 1/E7 T-Cell Receptor (TCR) T Cell Therapy","description":"E7 TCR T Cell Therapy\n\nE7 TCR: Patients will receive up to 3x10\\^10 E7 T-Cell Receptor (TCR) T cells (i.e. TCR+ cells)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"SECONDARY","title":"Fraction of Participants Who Achieve an Objective Response (Partial Response + Complete Response) Following E7 T-Cell Receptor (TCR) T Cell Induction Therapy","description":"Fraction of participants who achieve an objective response (Partial Response + Complete Response) following E7 induction therapy will be reported. Response may be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete Response is disappearance of all target lesions. Partial Response is at least a 30% decrease in the sum of the diameters of target lesion; and/or Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST). Complete Metabolic Response is complete resolution of F-fluorodeoxyglucose (FDG) uptake in all lesions, and Partial Metabolic Response is  30% reduction of the SUL (lean body mass corrected standard uptake value) peak and an absolute drop of 0.8 SULpeak units.","populationDescription":"This outcome measure was not done due to multiple logistical challenges. One participant was enrolled but not treated.","reportingStatus":"POSTED","timeFrame":"1 year","groups":[{"id":"OG000","title":"Arm 1/E7 T-Cell Receptor (TCR) T Cell Therapy","description":"E7 TCR T Cell Therapy\n\nE7 TCR: Patients will receive up to 3x10\\^10 E7 T-Cell Receptor (TCR) T cells (i.e. TCR+ cells)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)","description":"Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.","populationDescription":"This outcome measure was not done due to multiple logistical challenges. One participant was enrolled but not treated.","reportingStatus":"POSTED","timeFrame":"Date treatment consent signed to date off study, approximately 20 days.","groups":[{"id":"OG000","title":"Arm 1/E7 T-Cell Receptor (TCR) T Cell Therapy","description":"E7 TCR T Cell Therapy\n\nE7 TCR: Patients will receive up to 3x10\\^10 E7 T-Cell Receptor (TCR) T cells (i.e. TCR+ cells)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Date treatment consent signed to date off study, approximately 20 days.","eventGroups":[{"id":"EG000","title":"Arm 1/E7 T-Cell Receptor (TCR) T Cell Therapy","description":"E7 TCR T Cell Therapy\n\nE7 TCR: Patients will receive up to 3x10\\^10 E7 T-Cell Receptor (TCR) T cells (i.e. TCR+ cells).","deathsNumAffected":0,"deathsNumAtRisk":1,"seriousNumAffected":0,"seriousNumAtRisk":1,"otherNumAffected":0,"otherNumAtRisk":1}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Scott M. Norberg D.O.","organization":"National Cancer Institute","email":"scott.norberg@nih.gov","phone":"301-275-9668"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2020-11-04","uploadDate":"2021-11-09T09:39","filename":"Prot_SAP_000.pdf","size":939916},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form: Screening Consent","date":"2021-01-02","uploadDate":"2021-11-09T09:40","filename":"ICF_001.pdf","size":1008545},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form: Affected Patient Consent","date":"2021-01-02","uploadDate":"2021-11-09T09:40","filename":"ICF_002.pdf","size":1654798}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D002583","term":"Uterine Cervical Neoplasms"}],"ancestors":[{"id":"D014594","term":"Uterine Neoplasms"},{"id":"D005833","term":"Genital Neoplasms, Female"},{"id":"D014565","term":"Urogenital Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D002577","term":"Uterine Cervical Diseases"},{"id":"D014591","term":"Uterine Diseases"},{"id":"D005831","term":"Genital Diseases, Female"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D000091662","term":"Genital Diseases"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT02190279","orgStudyIdInfo":{"id":"140140"},"secondaryIdInfos":[{"id":"14-C-0140"}],"organization":{"fullName":"National Institutes of Health Clinical Center (CC)","class":"NIH"},"briefTitle":"18F-DCFBC PET/CT in Prostate Cancer","officialTitle":"A Pilot Study of 18F-DCFBC PET/CT in Prostate Cancer"},"statusModule":{"statusVerifiedDate":"2019-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-07-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-12-31","type":"ACTUAL"},"completionDateStruct":{"date":"2018-01-11","type":"ACTUAL"},"studyFirstSubmitDate":"2014-07-12","studyFirstSubmitQcDate":"2014-07-12","studyFirstPostDateStruct":{"date":"2014-07-15","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-12-21","resultsFirstSubmitQcDate":"2019-04-17","resultsFirstPostDateStruct":{"date":"2019-04-23","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-04-17","lastUpdatePostDateStruct":{"date":"2019-04-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Maria Liza Lindenberg, M.D.","investigatorTitle":"Principal Investigator","investigatorAffiliation":"National Cancer Institute (NCI)"},"leadSponsor":{"name":"National Cancer Institute (NCI)","class":"NIH"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Background:\n\n\\- Prostate cancer is the second leading cause of cancer deaths in American men. A chemical called a radiotracer helps doctors get images of this type of cancer. Researchers want to test a radiotracer called N-\\[N-\\[(S)-1,3-dicarboxypropyl\\]carbamoyl\\]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) (18F-DCFBC).\n\nObjective:\n\n\\- To see if the radiotracer 18F-DCFBC can identify sites of prostate cancer in the body.\n\nEligibility:\n\n\\- Men ages 18 and over with prostate cancer. The cancer must be newly diagnosed, have relapsed, or has spread outside the prostate.\n\nDesign:\n\n* Participants will be screened with physical exam and medical history. They will give a blood sample.\n* Participants will be divided into three groups.\n\nGroup 1: people with cancer only in the prostate scheduled for surgical prostate removal or biopsy at National Institutes of Health (NIH).\n\nGroup 2: people who had their prostate removed or had radiation therapy and now have a rising prostate-specific antigen (PSA) without other signs of disease.\n\nGroup 3: people whose cancer has spread to other areas of the body.\n\n* Participants will have 18F-DCFBC injected into a vein then imaged in a positron emission tomography (PET)/computed tomography (CT) camera. During the scans, they will lie on their back on the scanner table.\n* Group 1 will have a magnetic resonance imaging (MRI) scan. A tube will be placed in the rectum. Coils may be wrapped around the outside of the pelvis. Participants will have a contrast agent injected through an intravenous line.\n* Group 3 will have another PET/CT scan with a different radiotracer, 18F NaF, within 21 days of the 18F-DCFBC scan to look for prostate cancer in the bone.\n* Group 3 will repeat the two PET/CT scans 4-6 months after the initial scans.\n* A few days after each scan, participants will be contacted for follow-up.","detailedDescription":"Background\n\n* Prostate cancer is the second leading cause of cancer deaths in American men.\n* Current methods of imaging advanced prostate cancer (computed tomography ((CT) and bone scan) are non specific and new, more specific molecular imaging probes are sought.\n* Many prostate cancers express the prostate specific membrane antigen (PSMA) a transmembrane protein with N-acetylated alpha-linked acidic dipeptidase (NAALADase) enzymatic activity. PSMA is also expressed in angiogenesis but otherwise has limited expression in normal tissue.\n* N-\\[N-\\[(S)-1,3-dicarboxypropyl\\]carbamoyl\\]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) (18F-DCFBC) is a radiolabeled positron emission tomography (PET) agent which binds with high affinity to PSMA and through whole-body non-invasive functional imaging, may provide new information on the expression of PSMA.\n\nPrimary Objective\n\n\\- To assess the ability of 18F-DCFBC to differentiate between tumorous and nontumorous tissues in localized, recurrent (based on rising prostatic-specific antigen ((PSA) post treatment) and metastatic prostate cancer\n\nEligibility\n\n* Subject is greater than or equal to 18 years old\n* Eastern Cooperative Oncology Group (ECOG) 0-2 with adenocarcinoma of the prostate and fits criteria for one of the following:\n* ARM 1\n\n  \\-- Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.\n\n  ---A multiparametric magnetic resonance imaging (MRI) (standard of care at the National Institutes of Health ((NIH) Clinical Center) must be performed within 4 months of18F-DCFBC injection with findings suggestive for prostate cancer and confirmed with histopathology.\n* ARM 2\n\n  * Patients with biochemical prostate cancer relapse after definitive treatment\n\n    * For patients status post radiation therapy for prostate cancer, a PSA increase from post radiation therapy nadir\n    * OR\n    * For patients status post prostatectomy, any PSA \\>/=0.2 ng/ml\n  * Nonspecific or no evidence for disease on standard imaging modality\n* ARM 3\n\n  * Patients with identifiable metastatic disease on a conventional imaging modality. If only soft tissue metastasis, one lesion must measure 6mm or greater. Patients must have confirmation of prostate cancer prior to 18F-DCFBC imaging.\n\nDesign\n\nThis is a single site 3-arm study enrolling a total of 110 evaluable patients: Arm 1 will include 12 patients with presumed localized prostate cancer scheduled to undergo prostatectomy or biopsy within 4 months of enrollment; Arm 2 will include 78 patients with biochemical recurrence without evidence of metastasis on conventional imaging; and Arm 3 will include 20 patients with known metastatic disease who may or may not be on or/scheduled to begin therapeutic intervention. Patients with presumed localized disease will undergo a standard of care, clinical multiparametric endorectal coil MRI in the National Cancer Institute (NCI) Molecular Imaging Clinic within 4 months of screening. Patients in Arm 3 will undergo 2 imaging sessions: baseline and 4-6 month follow-up. Clinical records (including PSA) and treatment (if any) that occurred in the imaging interval must be available. All patients in Arm 3 will also undergo Na18F PET/CT for evaluation of bone metastases as part of this protocol. In order to allow for a small number of nonevaluable patients, the accrual ceiling will be set at 125."},"conditionsModule":{"conditions":["Prostatic Neoplasms","Prostate Cancer"],"keywords":["Prostate Specific Membrane Antigen","Radiolabeled PET Agent","Imaging","NaF"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"DIAGNOSTIC","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":116,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Suspected Localized Prostate Cancer","type":"EXPERIMENTAL","description":"Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.","interventionNames":["Drug: 18F DCFBC"]},{"label":"Biochemical Recurrence","type":"EXPERIMENTAL","description":"Patients with biochemical prostate cancer relapse after definitive treatment","interventionNames":["Drug: 18F DCFBC"]},{"label":"Known Metastatic Disease","type":"EXPERIMENTAL","description":"Patients with identifiable metastatic disease on a conventional imaging modality. If only soft tissue metastasis, one lesion must measure 6mm or greater. Patients must have confirmation of prostate cancer prior to investigational imaging.","interventionNames":["Drug: 18F DCFBC","Drug: Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)"]}],"interventions":[{"type":"DRUG","name":"18F DCFBC","description":"Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec.","armGroupLabels":["Biochemical Recurrence","Known Metastatic Disease","Suspected Localized Prostate Cancer"]},{"type":"DRUG","name":"Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)","armGroupLabels":["Known Metastatic Disease"],"otherNames":["Na 18F PET/CT"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Local Recurrence, Lymph Node Metastases or Distant Metastatic Sites Detected by N-[N-[(S)-1,3-dicarboxypropyl]Carbamoyl]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) Imaging","description":"Any abnormal focus of 18F-DCFBC uptake higher than the surrounding background and not associated with physiological uptake was considered positive for prostate cancer, and each was classified as local recurrence, lymph node metastases or distant metastatic sites.","timeFrame":"1 hour and 2 hour timepoints at baseline"},{"measure":"Number of Lesions Detected by N-[N-[(S)-1,3-dicarboxypropyl]Carbamoyl]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC)","description":"Any abnormal focus of 18F-DCFBC uptake higher than the surrounding background and not associated with physiological uptake was considered a positive lesion for prostate cancer.The measure would be compared with other imaging or pathology.","timeFrame":"1 hour and 2 hour timepoints at baseline"}],"secondaryOutcomes":[{"measure":"Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)","description":"Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.","timeFrame":"Date treatment consent signed to date off study, approximately 42 months and 21 days"},{"measure":"Number of Detectable Lesions in Bone With Respect to 18F-DCFBC Imaging and/or Na18F Positron Emission Tomography (PET)/Computed Tomography (CT) in Patients With Known Metastatic Disease","description":"18F-DFBC and conventional imaging was used to identify positive lesions in bone.","timeFrame":"3 months"},{"measure":"Average Standardized Uptake Value (SUVmax) for Primary Prostate Cancer Patients Compared to Benign Prostatic Hyperplasia (BPH)","description":"Primary prostate cancer was compared to BPH nodules and normal prostate tissue using a one-way analysis of variance (Anova). Negative uptake is defined as tumor uptake less than adjacent background soft tissue, or blood pool for lymph nodes.","timeFrame":"1 hour and 2 hour post injection (p.i.)"},{"measure":"Median Tumor Foci Size in Suspected Localized Prostate Cancer Patients Undergoing Prostatectomy","description":"Tissue was obtained and stained with hematoxylin-eosin. The resulting whole mount specimens were correlated with MRI and PET/CT imaging. For each dominant/index tumor (largest tumor with highest Gleason score) was determined.","timeFrame":"1 month"},{"measure":"Detectability of Suspicious Prostate Cancer Lesions in Suspected Localized Prostate Cancer Patients With Prostate Gland","description":"Visualizing positive lesions with DCFBC and mpMRI.","timeFrame":"3 months"},{"measure":"Detectability of Suspicious Tumors Based on Prostate Specific-Antigen (PSA) Levels in the Biochemical Recurrence Group","description":"Visualizing positive lesions as a function of PSA value. Undetectable PSA is normal in this population.","timeFrame":"3 months"}]},"eligibilityModule":{"eligibilityCriteria":"* INCLUSION CRITERIA:\n* Subject is greater than or equal to18 years old\n* Platelet count \\> 50,000/mm\\^3\n* Eastern Cooperative Oncology Group (ECOG) Performance score of 0 to 2.\n* Ability to provide informed consent. All subjects must sign an informed consent form indicating their understanding of the investigational nature and risks of the study before any protocol-related studies are performed.\n* Categories\n\n  * ARM 1 only\n\n    ---For patients with presumed localized disease (any tumor (T), nodes 0 (N0), metastasized 0 (M0)), a multiparametric magnetic resonance imaging (MRI) (standard of care at the National Institutes of Health ((NIH) Clinical Center) must be performed within 4 months of the N-\\[N-\\[(S)-1,3-dicarboxypropyl\\]carbamoyl\\]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) (18F-DCFBC) injection with findings suggestive for prostate cancer and a prostate lesion at least 6mm or greater. Must have histopathologic confirmation of prostate cancer prior to 18F-DCFBC imaging.\n  * ARM 2 only:\n\n    * For patients status post radiation therapy for prostate cancer, any prostatic-specific antigen (PSA) increase from post radiation therapy nadir\n    * OR\n    * For patients status post prostatectomy, a PSA \\>/=0.2 ng/ml\n    * Nonspecific or no evidence for disease on standard imaging modality\n  * ARM 3 only:\n\n    * Patients must have identifiable metastatic disease on at least 1 clinically indicated imaging modality. If only soft tissue metastasis, one lesion must measure at least 6mm or greater. Patients must have confirmation of prostate cancer prior to 18FDCFBC imaging\n\nNote: A patient who is eligible for one arm, subsequently may cross-over into a different arm.\n\nEXCLUSION CRITERIA:\n\n* Subjects for whom participating would significantly delay the scheduled standard of care therapy\n* Subjects with any coexisting medical or psychiatric condition that is likely to interfere with study procedures and/or results.\n* Subjects with severe claustrophobia unresponsive to oral anxiolytics\n* Other medical conditions deemed by the principal investigator (or associates) to make the subject unsafe/ineligible for protocol procedures.\n* Subjects weighing \\> 350 lbs. (weight limit for scanner table), or unable to fit within the imaging gantry\n* Serum creatinine \\> 2 times the upper limit of normal\n* Total bilirubin \\> 2 times the upper limit of normal\n* Liver transaminases (alanine aminotransferase (ALT), aspartate aminotransferase (AST)) greater than 3 times the upper limit of normal","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Maria Liza Lindenberg, M.D.","affiliation":"National Cancer Institute (NCI)","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"National Institutes of Health Clinical Center, 9000 Rockville Pike","city":"Bethesda","state":"Maryland","zip":"20892","country":"United States","geoPoint":{"lat":38.98067,"lon":-77.10026}}]},"referencesModule":{"references":[{"pmid":"28894899","type":"RESULT","citation":"Mena E, Lindenberg ML, Shih JH, Adler S, Harmon S, Bergvall E, Citrin D, Dahut W, Ton AT, McKinney Y, Weaver J, Eclarinal P, Forest A, Afari G, Bhattacharyya S, Mease RC, Merino MJ, Pinto P, Wood BJ, Jacobs P, Pomper MG, Choyke PL, Turkbey B. Clinical impact of PSMA-based 18F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):4-11. doi: 10.1007/s00259-017-3818-x. Epub 2017 Sep 11."},{"pmid":"28806263","type":"RESULT","citation":"Turkbey B, Mena E, Lindenberg L, Adler S, Bednarova S, Berman R, Ton AT, McKinney Y, Eclarinal P, Hill C, Afari G, Bhattacharyya S, Mease RC, Merino MJ, Jacobs PM, Wood BJ, Pinto PA, Pomper MG, Choyke PL. 18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology. Clin Nucl Med. 2017 Oct;42(10):735-740. doi: 10.1097/RLU.0000000000001804."},{"pmid":"29602821","type":"RESULT","citation":"Harmon SA, Bergvall E, Mena E, Shih JH, Adler S, McKinney Y, Mehralivand S, Citrin DE, Couvillon A, Madan RA, Gulley JL, Mease RC, Jacobs PM, Pomper MG, Turkbey B, Choyke PL, Lindenberg ML. A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer. J Nucl Med. 2018 Nov;59(11):1665-1671. doi: 10.2967/jnumed.117.207373. Epub 2018 Mar 30."},{"pmid":"33568190","type":"DERIVED","citation":"Rowe LS, Harmon S, Horn A, Shankavaram U, Roy S, Ning H, Lindenberg L, Mena E, Citrin DE, Choyke P, Turkbey B. Pattern of failure in prostate cancer previously treated with radical prostatectomy and post-operative radiotherapy: a secondary analysis of two prospective studies using novel molecular imaging techniques. Radiat Oncol. 2021 Feb 10;16(1):32. doi: 10.1186/s13014-020-01733-x."}],"seeAlsoLinks":[{"label":"NIH Clinical Center Detailed Web Page","url":"https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2014-C-0140.html"}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Suspected Localized Prostate Cancer","description":"Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.\n\nN-\\[N-\\[(S)-1,3-dicarboxypropyl\\]carbamoyl\\]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) (18F DCFBC): Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."},{"id":"FG001","title":"Biochemical Recurrence","description":"Patients with biochemical prostate cancer relapse after definitive treatment\n\n18F DCFBC: Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."},{"id":"FG002","title":"Known Metastatic Disease","description":"Patients with identifiable metastatic disease on a conventional imaging modality. If only soft tissue metastasis, one lesion must measure 6mm or greater. Patients must have confirmation of prostate cancer prior to investigational imaging.\n\n18F DCFBC: Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"69"},{"groupId":"FG002","numSubjects":"31"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"69"},{"groupId":"FG002","numSubjects":"28"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"}]}],"dropWithdraws":[{"type":"Withdrawal consent","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Refused further treatment","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Screening failure","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Suspected Localized Prostate Cancer","description":"Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.\n\nN-\\[N-\\[(S)-1,3-dicarboxypropyl\\]carbamoyl\\]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) (18F DCFBC): Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."},{"id":"BG001","title":"Biochemical Recurrence","description":"Patients with biochemical prostate cancer relapse after definitive treatment\n\n18F DCFBC: Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."},{"id":"BG002","title":"Known Metastatic Disease","description":"Patients with identifiable metastatic disease on a conventional imaging modality. If only soft tissue metastasis, one lesion must measure 6mm or greater. Patients must have confirmation of prostate cancer prior to investigational imaging.\n\n18F DCFBC: Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"31"},{"groupId":"BG003","value":"116"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"54"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"62"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"64.58","spread":"8.53"},{"groupId":"BG001","value":"65.33","spread":"6.67"},{"groupId":"BG002","value":"63.93","spread":"11.41"},{"groupId":"BG003","value":"64.85","spread":"8.38"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"31"},{"groupId":"BG003","value":"116"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"31"},{"groupId":"BG003","value":"116"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"4"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"14"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"27"},{"groupId":"BG003","value":"98"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"31"},{"groupId":"BG003","value":"116"}]}]}]},{"title":"Gleason Grade at Diagnosis","description":"Gleason grades help determine a good or bad prognosis for a with prostate cancer. Grade 5-6 are low on the scale and can indicate a less aggressive cancer. A higher number such as Grade 7-10 means a more aggressive cancer.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Gleason Grade 5","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}]},{"title":"Gleason Grade 6","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"17"}]}]},{"title":"Gleason Grade 7-8","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"68"}]}]},{"title":"Gleason Grade 9-10","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"24"}]}]},{"title":"Not available","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"}]}]}]},{"title":"Prior Prostate Cancer Therapy","description":"Androgen deprivation therapy (ADT). Radium 223 (Ra223).","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"None","categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"19"}]}]},{"title":"Radical Prostatectomy","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"50"}]}]},{"title":"Brachytherapy/Radiation","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"11"}]}]},{"title":"ADT + Surgery or Radiation","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"7"}]}]},{"title":"ADT + Chemotherapy","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"7"}]}]},{"title":"ADT","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]}]},{"title":"Combo radical prostectomy and radiation therapy","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"17"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}]}]},{"title":"Baseline Imaging","description":"N-\\[N-\\[(S)-1,3-dicarboxypropyl\\]carbamoyl\\]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) Positron emission tomography (PET) Computed tomography (CT)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"NaF PET/CT","categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"41"}]}]},{"title":"DCFBC(1h) PET/CT","categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"109"}]}]},{"title":"DCFBC(2h) PET/CT","categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"27"},{"groupId":"BG003","value":"108"}]}]}]},{"title":"Prostatic-Specific Antigen (PSA) at Baseline","description":"Normal PSA is defined as less than 4.0 ng/ml.","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"ng/ml","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"37.5","lowerLimit":"3.26","upperLimit":"216"},{"groupId":"BG001","value":"1.63","lowerLimit":"0.2","upperLimit":"37.4"},{"groupId":"BG002","value":"1.90","lowerLimit":"0.01","upperLimit":"4379"},{"groupId":"BG003","value":"13.67","lowerLimit":"1.15","upperLimit":"1544"}]}]}]},{"title":"Castration Status","description":"Castrate sensitive is defined as cancer that is outside the boundary of the prostate. Castrate resistant is defined as cancer of the prostate that no longer responds to one of the most common types of prostate treatment known as androgen deprivation therapy (ADT) (i.e. lowers testosterone levels).","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Untreated","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"}]}]},{"title":"Castrate-sensitive","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"14"}]}]},{"title":"Castrate-resistant","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"11"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Local Recurrence, Lymph Node Metastases or Distant Metastatic Sites Detected by N-[N-[(S)-1,3-dicarboxypropyl]Carbamoyl]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) Imaging","description":"Any abnormal focus of 18F-DCFBC uptake higher than the surrounding background and not associated with physiological uptake was considered positive for prostate cancer, and each was classified as local recurrence, lymph node metastases or distant metastatic sites.","populationDescription":"In Arm 1: 3 patients were excluded from analysis due to prior focal ablation therapy (1), prior brachytherapy (1), and lack of histopathologic confirmation tissue.\n\nArm 2: 1 patient had technical issues and was not included in the final analysis Arm 3: 2 patients were not imaged and 1 patient withdrew consent","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"1 hour and 2 hour timepoints at baseline","groups":[{"id":"OG000","title":"Suspected Localized Prostate Cancer","description":"Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.\n\nN-\\[N-\\[(S)-1,3-dicarboxypropyl\\]carbamoyl\\]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) (18F DCFBC): Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."},{"id":"OG001","title":"Biochemical Recurrence","description":"Patients with biochemical prostate cancer relapse after definitive treatment\n\n18F DCFBC: Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."},{"id":"OG002","title":"Known Metastatic Disease","description":"Patients with identifiable metastatic disease on a conventional imaging modality. If only soft tissue metastasis, one lesion must measure 6mm or greater. Patients must have confirmation of prostate cancer prior to investigational imaging.\n\n18F DCFBC: Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"28"}]}],"classes":[{"title":"Lymph nodes","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"28"}]}]},{"title":"Distant sites","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"}]}]},{"title":"Prostate bed/anastomosis","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"28"}]}]}]},{"type":"PRIMARY","title":"Number of Lesions Detected by N-[N-[(S)-1,3-dicarboxypropyl]Carbamoyl]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC)","description":"Any abnormal focus of 18F-DCFBC uptake higher than the surrounding background and not associated with physiological uptake was considered a positive lesion for prostate cancer.The measure would be compared with other imaging or pathology.","populationDescription":"In Arm 1: 3 patients were excluded from analysis due to prior focal ablation therapy (1), prior brachytherapy (1), and lack of histopathologic confirmation tissue.\n\nArm 2: 1 patient had technical issues and was not included in the final analysis Arm 3: 2 patients were not imaged and 1 patient withdrew consent","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"lesions","timeFrame":"1 hour and 2 hour timepoints at baseline","groups":[{"id":"OG000","title":"Suspected Localized Prostate Cancer","description":"Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.\n\nN-\\[N-\\[(S)-1,3-dicarboxypropyl\\]carbamoyl\\]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) (18F DCFBC): Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."},{"id":"OG001","title":"Biochemical Recurrence","description":"Patients with biochemical prostate cancer relapse after definitive treatment\n\n18F DCFBC: Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."},{"id":"OG002","title":"Known Metastatic Disease","description":"Patients with identifiable metastatic disease on a conventional imaging modality. If only soft tissue metastasis, one lesion must measure 6mm or greater. Patients must have confirmation of prostate cancer prior to investigational imaging.\n\n18F DCFBC: Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"28"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"140"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)","description":"Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Date treatment consent signed to date off study, approximately 42 months and 21 days","groups":[{"id":"OG000","title":"Suspected Localized Prostate Cancer","description":"Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.\n\nN-\\[N-\\[(S)-1,3-dicarboxypropyl\\]carbamoyl\\]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) (18F DCFBC): Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."},{"id":"OG001","title":"Biochemical Recurrence","description":"Patients with biochemical prostate cancer relapse after definitive treatment\n\n18F DCFBC: Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."},{"id":"OG002","title":"Known Metastatic Disease","description":"Patients with identifiable metastatic disease on a conventional imaging modality. If only soft tissue metastasis, one lesion must measure 6mm or greater. Patients must have confirmation of prostate cancer prior to investigational imaging.\n\n18F DCFBC: Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"8"}]}]}]},{"type":"SECONDARY","title":"Number of Detectable Lesions in Bone With Respect to 18F-DCFBC Imaging and/or Na18F Positron Emission Tomography (PET)/Computed Tomography (CT) in Patients With Known Metastatic Disease","description":"18F-DFBC and conventional imaging was used to identify positive lesions in bone.","populationDescription":"The Suspected Localized Prostate Cancer and Biochemical Recurrence Arms/Groups are not applicable for this outcome measure, thus are not represented here. Data was collected for 31 participants but only 28 had data evaluable for final analysis in the Known Metastatic Group.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of bone lesions","timeFrame":"3 months","typeUnitsAnalyzed":"lesions","denomUnitsSelected":"lesions","groups":[{"id":"OG000","title":"Known Metastatic Disease","description":"Patients with identifiable metastatic disease on a conventional imaging modality. If only soft tissue metastasis, one lesion must measure 6mm or greater. Patients must have confirmation of prostate cancer prior to investigational imaging.\n\n18F DCFBC: Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"}]},{"units":"lesions","counts":[{"groupId":"OG000","value":"241"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"185"}]}]}]},{"type":"SECONDARY","title":"Average Standardized Uptake Value (SUVmax) for Primary Prostate Cancer Patients Compared to Benign Prostatic Hyperplasia (BPH)","description":"Primary prostate cancer was compared to BPH nodules and normal prostate tissue using a one-way analysis of variance (Anova). Negative uptake is defined as tumor uptake less than adjacent background soft tissue, or blood pool for lymph nodes.","populationDescription":"3 patients were excluded from analysis due to prior focal ablation therapy (1), prior brachytherapy (1), and lack of histopathologic confirmation tissue. The Biochemical Recurrence and Known Metastatic Disease Arms/Groups are not applicable for this outcome measure, thus are not represented here.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"standardized uptake value (SUV)","timeFrame":"1 hour and 2 hour post injection (p.i.)","groups":[{"id":"OG000","title":"Suspected Localized Prostate Cancer","description":"Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.\n\nN-\\[N-\\[(S)-1,3-dicarboxypropyl\\]carbamoyl\\]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) (18F DCFBC): Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"classes":[{"title":"Primary prostate tumor - 1 hour post injection","categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"4.4"}]}]},{"title":"BPH nodules - 1 hour post injection","categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"0.3"}]}]},{"title":"Normal prostate - 1 hour post injection","categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"0.4"}]}]},{"title":"Primary prostate tumor - 2 hour post injection","categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"5.3"}]}]},{"title":"BPH nodules - 2 hour post injection","categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"0.36"}]}]},{"title":"Normal prostate tumor - 2 hour post injection","categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"0.28"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"At 1 hour post injection.","nonInferiorityType":"OTHER","pValue":"0.0033","statisticalMethod":"ANOVA"},{"groupIds":["OG000"],"groupDescription":"At 2 hour post injection.","nonInferiorityType":"OTHER","pValue":"0.012","statisticalMethod":"ANOVA"}]},{"type":"SECONDARY","title":"Median Tumor Foci Size in Suspected Localized Prostate Cancer Patients Undergoing Prostatectomy","description":"Tissue was obtained and stained with hematoxylin-eosin. The resulting whole mount specimens were correlated with MRI and PET/CT imaging. For each dominant/index tumor (largest tumor with highest Gleason score) was determined.","populationDescription":"3 patients were excluded from analysis, because of prior focal laser ablation therapy (n=1), prior brachytherapy (n=1), and lack of histopathology confirmation tissue (n=1). The Biochemical Recurrence and Known Metastatic Disease Arms/Groups are not applicable for this outcome measure, thus are not represented here.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"cm","timeFrame":"1 month","typeUnitsAnalyzed":"Tumor foci","denomUnitsSelected":"Tumor foci","groups":[{"id":"OG000","title":"Suspected Localized Prostate Cancer","description":"Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.\n\nN-\\[N-\\[(S)-1,3-dicarboxypropyl\\]carbamoyl\\]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) (18F DCFBC): Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]},{"units":"Tumor foci","counts":[{"groupId":"OG000","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"0.6","upperLimit":"4.7"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"One way analysis variance.","pValue":"<0.05","statisticalMethod":"variance"}]},{"type":"SECONDARY","title":"Detectability of Suspicious Prostate Cancer Lesions in Suspected Localized Prostate Cancer Patients With Prostate Gland","description":"Visualizing positive lesions with DCFBC and mpMRI.","populationDescription":"3 patients were excluded from analysis, because of prior focal laser ablation therapy (n=1), prior brachytherapy (n=1), and lack of histopathology confirmation tissue (n=1). The Biochemical Recurrence and Known Metastatic Disease Arms/Groups are not applicable for this outcome measure, thus are not represented here.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percent of lesions identified","timeFrame":"3 months","typeUnitsAnalyzed":"lesions","denomUnitsSelected":"lesions","groups":[{"id":"OG000","title":"Suspected Localized Prostate Cancer","description":"Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.\n\nN-\\[N-\\[(S)-1,3-dicarboxypropyl\\]carbamoyl\\]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) (18F DCFBC): Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]},{"units":"lesions","counts":[{"groupId":"OG000","value":"25"}]}],"classes":[{"title":"18F-DCFBC","categories":[{"measurements":[{"groupId":"OG000","value":"36"}]}]},{"title":"mpMRI","categories":[{"measurements":[{"groupId":"OG000","value":"96"}]}]}]},{"type":"SECONDARY","title":"Detectability of Suspicious Tumors Based on Prostate Specific-Antigen (PSA) Levels in the Biochemical Recurrence Group","description":"Visualizing positive lesions as a function of PSA value. Undetectable PSA is normal in this population.","populationDescription":"1 patient had technical issues and was not included in the final analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percent of tumors identified","timeFrame":"3 months","groups":[{"id":"OG000","title":"Biochemical Recurrence","description":"Patients with biochemical prostate cancer relapse after definitive treatment\n\n18F DCFBC: Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"}]}],"classes":[{"title":"<0.5 ng/mL","categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}]},{"title":"0.5 to <1.0 ng/mL","categories":[{"measurements":[{"groupId":"OG000","value":"46"}]}]},{"title":"1.0 to 2.0 ng/mL","categories":[{"measurements":[{"groupId":"OG000","value":"83"}]}]},{"title":"2.0 ng/mL","categories":[{"measurements":[{"groupId":"OG000","value":"77"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Date treatment consent signed to date off study, approximately 42 months and 21 days.","eventGroups":[{"id":"EG000","title":"Suspected Localized Prostate Cancer","description":"Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.\n\nN-\\[N-\\[(S)-1,3-dicarboxypropyl\\]carbamoyl\\]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) (18F DCFBC: Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec.","deathsNumAffected":0,"deathsNumAtRisk":16,"seriousNumAffected":0,"seriousNumAtRisk":16,"otherNumAffected":1,"otherNumAtRisk":16},{"id":"EG001","title":"Biochemical Recurrence","description":"Patients with biochemical prostate cancer relapse after definitive treatment\n\n18F DCFBC: Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec.","deathsNumAffected":0,"deathsNumAtRisk":69,"seriousNumAffected":1,"seriousNumAtRisk":69,"otherNumAffected":3,"otherNumAtRisk":69},{"id":"EG002","title":"Known Metastatic Disease","description":"Patients with identifiable metastatic disease on a conventional imaging modality. If only soft tissue metastasis, one lesion must measure 6mm or greater. Patients must have confirmation of prostate cancer prior to investigational imaging.\n\n18F DCFBC: Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec.","deathsNumAffected":2,"deathsNumAtRisk":31,"seriousNumAffected":4,"seriousNumAtRisk":31,"otherNumAffected":8,"otherNumAtRisk":31}],"seriousEvents":[{"term":"Gastrointestinal disorders - Other, nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Thromboembolic event","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Death NOS","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, death","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Death due to progressive disease","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":31}]}],"otherEvents":[{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Fever","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Urinary tract pain","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Urinary urgency","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Hyperkalemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Hypernatremia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Hypophosphatemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Investigations - Other, near syncope","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Lymphocyte count increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":31}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Dr. Maria Liza Lindenberg","organization":"National Cancer Institute","email":"liza.lindenberg@nih.gov","phone":"240-760-6109"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2015-12-27","uploadDate":"2018-10-30T14:25","filename":"Prot_SAP_000.pdf","size":1097493},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2015-12-14","uploadDate":"2018-10-30T14:25","filename":"ICF_001.pdf","size":453694}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D011471","term":"Prostatic Neoplasms"}],"ancestors":[{"id":"D005834","term":"Genital Neoplasms, Male"},{"id":"D014565","term":"Urogenital Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D005832","term":"Genital Diseases, Male"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D011469","term":"Prostatic Diseases"},{"id":"D052801","term":"Male Urogenital Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C530683","term":"N-(N-((S)-1,3-Dicarboxypropyl)carbamoyl)-4-(18F)fluorobenzyl-L-cysteine"},{"id":"D012964","term":"Sodium"}],"ancestors":[{"id":"D008672","term":"Metals, Alkali"},{"id":"D004602","term":"Elements"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D019565","term":"Metals, Light"},{"id":"D008670","term":"Metals"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT05105087","orgStudyIdInfo":{"id":"21F.624"},"secondaryIdInfos":[{"id":"R21CA249870","type":"NIH","link":"https://reporter.nih.gov/quickSearch/R21CA249870"},{"id":"JT 16886","type":"OTHER","domain":"JeffTrial Number"}],"organization":{"fullName":"Thomas Jefferson University","class":"OTHER"},"briefTitle":"Gynecological Sentinel Lymph Nodes CEUS","officialTitle":"Detection of Sentinel Lymph Nodes in Female Lower Genital Tract Cancer Patients With Contrast-Enhanced Ultrasound Imaging"},"statusModule":{"statusVerifiedDate":"2025-08","overallStatus":"COMPLETED","startDateStruct":{"date":"2022-04-28","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-11-15","type":"ACTUAL"},"completionDateStruct":{"date":"2025-01-29","type":"ACTUAL"},"studyFirstSubmitDate":"2021-08-13","studyFirstSubmitQcDate":"2021-10-25","studyFirstPostDateStruct":{"date":"2021-11-03","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-06-27","resultsFirstSubmitQcDate":"2025-08-05","resultsFirstPostDateStruct":{"date":"2025-08-22","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-08-05","lastUpdatePostDateStruct":{"date":"2025-08-22","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Thomas Jefferson University","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This clinical trial compares the use of ultrasound for the detection of sentinel lymph nodes (SLNs) to the standard of care (which varies depending on cancer treatment). The ultrasound contrast agent is called Sonazoid and it consists of tiny gas-filled bubbles about the side of red blood cells. Diagnostic procedures, such as ultrasound with Sonazoid, may help identify more SLNs than standard of care in patients with cervical, vaginal, or vulvar cancer.","detailedDescription":"PRIMARY OBJECTIVES:\n\nI. To determine the concordance between lymphosonography and the standard of care in the identification sentinel lymph nodes (SLNs) in patients with cervical, vaginal or vulvar cancer.\n\nII. To determine if lymphosonography can identify more SLNs with metastatic deposits in patients with cervical, vaginal or vulvar cancer when compared to the standard of care.\n\nOUTLINE:\n\nPatients receive perflubutane microbubble (Sonazoid) injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment.\n\nAfter completion of study intervention, patients are followed up for 30 days."},"conditionsModule":{"conditions":["Cervical Carcinoma","Malignant Female Reproductive System Neoplasm","Vaginal Carcinoma","Vulvar Carcinoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"DIAGNOSTIC","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":9,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Diagnostic (perflubutane microbubble, ultrasound)","type":"EXPERIMENTAL","description":"Patients receive perflubutane microbubble injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment.","interventionNames":["Drug: Perflubutane Microbubble","Procedure: Contrast-Enhanced Ultrasound"]}],"interventions":[{"type":"DRUG","name":"Perflubutane Microbubble","description":"Given subdermally","armGroupLabels":["Diagnostic (perflubutane microbubble, ultrasound)"],"otherNames":["Sonazoid","gas-filled microbubbles"]},{"type":"PROCEDURE","name":"Contrast-Enhanced Ultrasound","description":"Undergo ultrasound","armGroupLabels":["Diagnostic (perflubutane microbubble, ultrasound)"],"otherNames":["CEUS"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Sentinel Lymph Nodes (SLNs) Identified by Lymphosonography as Well as Blue Dye or Positron Emission Tomography (PET)-Computed Tomography (CT)","description":"The number of SLN detected by contrast enhanced ultrasound will be compared to the number of SLN detected by the standard of care (i.e., by blue dye or by PET-CT).","timeFrame":"up to 30 minutes during CEUS procedure"}],"secondaryOutcomes":[{"measure":"Location of Sentinel Lymph Nodes (SLNs) Identified by Contrast-enhanced Ultrasound (CEUS)","timeFrame":"up to 30 minutes during CEUS procedure"},{"measure":"Size of Sentinel Lymph Nodes (SLNs) Identified","description":"The locations, depth beneath the skin surface and size (measured in three orthogonal dimensions) of each SLN will be recorded.","timeFrame":"up to 30 minutes during CEUS procedure"},{"measure":"Depth Beneath the Skin Surface of Each SLN","description":"The locations, depth beneath the skin surface and size (measured in three orthogonal dimensions) of each SLN will be recorded - \\[this verbiage comes directly from the protocol\\]","timeFrame":"up to 30 minutes during CEUS procedure"},{"measure":"Presence of Metastatic Deposits in the Sentinel Lymph Node (SLNs)","description":"The presence or absence of metastatic deposits in SLNs will be obtained by pathology (when available).","timeFrame":"Within 7 days post-surgery"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Be female\n* Be diagnosed with cervical, vaginal or vulvar cancer\n* Be at least 18 years of age\n* If of child-bearing potential, must have a negative pregnancy test\n* Be able to comply with study procedures\n* Have read and signed the Institutional Review Board (IRB)-approved informed consent form for participating in the study\n\nExclusion Criteria:\n\n* Females who are pregnant or nursing\n* Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 hours afterwards\n* Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example:\n\n  * Patients on life support or in a critical care unit\n  * Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia\n  * Patients with recent cerebral hemorrhage\n  * Patients who have undergone surgery within 24 hours prior to the study sonographic examination\n* Patients with congenital heart defects\n* Patient with a known allergy to Sonazoid (including an anaphylactic allergy to eggs or egg products)","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Ji-Bin Liu, MD","affiliation":"Thomas Jefferson University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Sidney Kimmel Cancer Center at Thomas Jefferson University","city":"Philadelphia","state":"Pennsylvania","zip":"19107","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Screening assessments were performed within 4 weeks prior to the administration of Sonazoid. A full demographic profile, known drug allergies or intolerances, and a review of the subject's medical/surgical history were recorded.\n\n9 participants received CEUS. 5 completed both CEUS and surgery with pathology and were analyzed. 2 were ineligible for surgery (advanced disease), and 2 withdrew consent prior to surgery; thus no outcome data were available for these 4 participants.","recruitmentDetails":"This was a single-site, open-label, non-randomized pilot study conducted at Thomas Jefferson University (TJU), Sidney Kimmel Cancer Center, Philadelphia, PA. Subject recruitment was expected to last 24 months, beginning in April 2022 and ending in November 2023. Recruitment was conducted from the patient population of the Department of Gynecology Oncology at TJU. Eligible participants were identified by surgical co-investigators from their existing patient population.","groups":[{"id":"FG000","title":"Diagnostic (Perflubutane Microbubble, Ultrasound)","description":"Patients receive perflubutane microbubble injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment.\n\nPerflubutane Microbubble: Given subdermally\n\nContrast-Enhanced Ultrasound: Undergo ultrasound"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"9"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"Ineligible for surgery due to advanced disease","reasons":[{"groupId":"FG000","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Diagnostic (Perflubutane Microbubble, Ultrasound)","description":"Patients receive perflubutane microbubble injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment.\n\nPerflubutane Microbubble: Given subdermally\n\nContrast-Enhanced Ultrasound: Undergo ultrasound"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"5"}]}],"measures":[{"title":"Age, Categorical","populationDescription":"Only patients who completed both CEUS and surgery with SLN excision and pathology evaluation (N=5) were included for analysis.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"4"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"1"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"55","lowerLimit":"36","upperLimit":"75"}]}]}]},{"title":"Sex: Female, Male","populationDescription":"Only patients who completed both CEUS and surgery with SLN excision and pathology evaluation (N=5) were included for analysis.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"5"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","populationDescription":"Only patients who completed both CEUS and surgery with SLN excision and pathology evaluation (N=5) were included for analysis.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"3"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Sentinel Lymph Nodes (SLNs) Identified by Lymphosonography as Well as Blue Dye or Positron Emission Tomography (PET)-Computed Tomography (CT)","description":"The number of SLN detected by contrast enhanced ultrasound will be compared to the number of SLN detected by the standard of care (i.e., by blue dye or by PET-CT).","populationDescription":"Only participants who completed CEUS and surgery (N=5) were analyzed.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"sentinel lymph nodes (SLNs)","timeFrame":"up to 30 minutes during CEUS procedure","typeUnitsAnalyzed":"sentinel lymph nodes (SLNs)","denomUnitsSelected":"sentinel lymph nodes (SLNs)","groups":[{"id":"OG000","title":"Diagnostic (Perflubutane Microbubble, Ultrasound)","description":"Patients receive perflubutane microbubble injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment.\n\nPerflubutane Microbubble: Given subdermally\n\nContrast-Enhanced Ultrasound: Undergo ultrasound"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]},{"units":"sentinel lymph nodes (SLNs)","counts":[{"groupId":"OG000","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}]}]},{"type":"SECONDARY","title":"Location of Sentinel Lymph Nodes (SLNs) Identified by Contrast-enhanced Ultrasound (CEUS)","populationDescription":"Only participants who completed CEUS and surgery (N=5) were analyzed.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"sentinel lymph nodes (SLNs)","timeFrame":"up to 30 minutes during CEUS procedure","typeUnitsAnalyzed":"sentinel lymph nodes (SLNs)","denomUnitsSelected":"sentinel lymph nodes (SLNs)","groups":[{"id":"OG000","title":"Diagnostic (Perflubutane Microbubble, Ultrasound)","description":"Patients receive perflubutane microbubble injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment.\n\nPerflubutane Microbubble: Given subdermally\n\nContrast-Enhanced Ultrasound: Undergo ultrasound"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]},{"units":"sentinel lymph nodes (SLNs)","counts":[{"groupId":"OG000","value":"17"}]}],"classes":[{"title":"Left Inguinal Region","categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]},{"title":"Left Iliac Region","categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]},{"title":"Right Iliac Region","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}]},{"type":"SECONDARY","title":"Size of Sentinel Lymph Nodes (SLNs) Identified","description":"The locations, depth beneath the skin surface and size (measured in three orthogonal dimensions) of each SLN will be recorded.","populationDescription":"Only participants who completed CEUS and surgery (N=5) were analyzed.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Full Range","unitOfMeasure":"centimeters (cm)","timeFrame":"up to 30 minutes during CEUS procedure","typeUnitsAnalyzed":"sentinel lymph nodes (SLNs)","denomUnitsSelected":"sentinel lymph nodes (SLNs)","groups":[{"id":"OG000","title":"Diagnostic (Perflubutane Microbubble, Ultrasound)","description":"Patients receive perflubutane microbubble injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment.\n\nPerflubutane Microbubble: Given subdermally\n\nContrast-Enhanced Ultrasound: Undergo ultrasound"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]},{"units":"sentinel lymph nodes (SLNs)","counts":[{"groupId":"OG000","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"0.7","upperLimit":"2.4"}]}]}]},{"type":"SECONDARY","title":"Depth Beneath the Skin Surface of Each SLN","description":"The locations, depth beneath the skin surface and size (measured in three orthogonal dimensions) of each SLN will be recorded - \\[this verbiage comes directly from the protocol\\]","populationDescription":"Only participants who completed CEUS and surgery (N=5) were analyzed.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Full Range","unitOfMeasure":"centimeters (cm)","timeFrame":"up to 30 minutes during CEUS procedure","typeUnitsAnalyzed":"sentinel lymph nodes (SLNs)","denomUnitsSelected":"sentinel lymph nodes (SLNs)","groups":[{"id":"OG000","title":"Diagnostic (Perflubutane Microbubble, Ultrasound)","description":"Patients receive perflubutane microbubble injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment.\n\nPerflubutane Microbubble: Given subdermally\n\nContrast-Enhanced Ultrasound: Undergo ultrasound"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]},{"units":"sentinel lymph nodes (SLNs)","counts":[{"groupId":"OG000","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.71","lowerLimit":"0.5","upperLimit":"6.0"}]}]}]},{"type":"SECONDARY","title":"Presence of Metastatic Deposits in the Sentinel Lymph Node (SLNs)","description":"The presence or absence of metastatic deposits in SLNs will be obtained by pathology (when available).","populationDescription":"Only participants who completed CEUS and surgery (N=5) were analyzed.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Metastatic sentinel lymph nodes (SLNs)","timeFrame":"Within 7 days post-surgery","typeUnitsAnalyzed":"sentinel lymph nodes (SLNs)","denomUnitsSelected":"sentinel lymph nodes (SLNs)","groups":[{"id":"OG000","title":"Diagnostic (Perflubutane Microbubble, Ultrasound)","description":"Patients receive perflubutane microbubble injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment.\n\nPerflubutane Microbubble: Given subdermally\n\nContrast-Enhanced Ultrasound: Undergo ultrasound"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]},{"units":"sentinel lymph nodes (SLNs)","counts":[{"groupId":"OG000","value":"11"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"The PI will follow AEs with start dates occurring any time after informed consent is obtained until 7 (for non-serious AEs) or 30 days (for SAEs) after the last day of study participation. Events will be followed for outcome information until resolution or stabilization.","eventGroups":[{"id":"EG000","title":"Diagnostic (Perflubutane Microbubble, Ultrasound)","description":"Patients receive perflubutane microbubble injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment.\n\nPerflubutane Microbubble: Given subdermally\n\nContrast-Enhanced Ultrasound: Undergo ultrasound","deathsNumAffected":0,"deathsNumAtRisk":9,"seriousNumAffected":0,"seriousNumAtRisk":9,"otherNumAffected":0,"otherNumAtRisk":9}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Ji-Bin Liu, MD","organization":"Thomas Jefferson University","email":"jxl120@jefferson.edu","phone":"215-955-4862"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2023-11-29","uploadDate":"2025-06-19T10:06","filename":"Prot_SAP_000.pdf","size":847168}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D002583","term":"Uterine Cervical Neoplasms"},{"id":"D014625","term":"Vaginal Neoplasms"},{"id":"D014846","term":"Vulvar Neoplasms"}],"ancestors":[{"id":"D014594","term":"Uterine Neoplasms"},{"id":"D005833","term":"Genital Neoplasms, Female"},{"id":"D014565","term":"Urogenital Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D002577","term":"Uterine Cervical Diseases"},{"id":"D014591","term":"Uterine Diseases"},{"id":"D005831","term":"Genital Diseases, Female"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D014623","term":"Vaginal Diseases"},{"id":"D014845","term":"Vulvar Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C069727","term":"Sonazoid"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT03891654","orgStudyIdInfo":{"id":"18-2874.cc"},"secondaryIdInfos":[{"id":"P30CA046934","type":"NIH","link":"https://reporter.nih.gov/quickSearch/P30CA046934"}],"organization":{"fullName":"University of Colorado, Denver","class":"OTHER"},"briefTitle":"Dynamic Contrast Enhanced Computed Tomography to Assess Radiation Therapy in Liver Cancer Patients","officialTitle":"Pilot Study of Dynamic Contrast Enhanced Computed Tomography (DCE-CT) Imaging for the Assessment of Radiation Therapy Outcome for Liver Cancer Patients"},"statusModule":{"statusVerifiedDate":"2022-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-08-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-12-20","type":"ACTUAL"},"completionDateStruct":{"date":"2022-04-28","type":"ACTUAL"},"studyFirstSubmitDate":"2019-03-25","studyFirstSubmitQcDate":"2019-03-25","studyFirstPostDateStruct":{"date":"2019-03-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-04-28","lastUpdatePostDateStruct":{"date":"2022-05-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"University of Colorado, Denver","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":true},"descriptionModule":{"briefSummary":"This is a pilot study that uses a standard of care technique, Stereotactic Body Radiation Therapy (SBRT), in combination with Dynamic Contrast Enhanced Computed Tomography (DCE-CT) to determine if perfusion changes from SBRT of liver cancer may be used for outcome assessment and prediction of prognosis.","detailedDescription":"Patients will undergo standard of care SBRT while also receiving DCE-CT, also known as perfusion CT, pre-treatment, 6 hours post-treatment and 6 weeks post-treatment."},"conditionsModule":{"conditions":["Liver Cancer"],"keywords":["Radiation","Metastases","Dynamic Contrast Enhanced Computed Tomography","Pilot"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","interventionModelDescription":"Each patient will receive the standard of care, with the intervention, DCE-CT perfusion, occurring pre-treatment and post-treatment","primaryPurpose":"DIAGNOSTIC","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":3,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Dynamic Contrast Enhanced Computed Tomography","type":"EXPERIMENTAL","description":"DCE-CT, also known as perfusion CT, is a functional imaging modality that uses repeated computed tomography imaging after injection of an iodine based contrast agent.","interventionNames":["Diagnostic Test: Dynamic Contrast Enhanced Computed Tomography"]}],"interventions":[{"type":"DIAGNOSTIC_TEST","name":"Dynamic Contrast Enhanced Computed Tomography","description":"Patients will receive DCE-CT prior to the start of standard of care, Stereotactic Body Radiation Therapy (SBRT), as well as 6 hours post administration of SBRT and 6 weeks post administration of SBRT.","armGroupLabels":["Dynamic Contrast Enhanced Computed Tomography"],"otherNames":["DCE-CT","Perfusion CT"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"DCE-CT Perfusion Metrics: K-Trans","description":"Determine the association between the delivered radiation therapy dose distribution and the change in perfusion measurement through K-Trans (extraction-flow product) as shown through DCE-CT imaging.","timeFrame":"Baseline to end of follow-up, up to 12 weeks"},{"measure":"DCE-CT Perfusion Metrics: Blood Volume","description":"Determine the association between the delivered radiation therapy dose distribution and the change in perfusion measurement through blood volume as shown through DCE-CT imaging.","timeFrame":"Baseline to end of follow-up, up to 12 weeks"},{"measure":"DCE-CT Perfusion Metrics: Blood Flow","description":"Determine the association between the delivered radiation therapy dose distribution and the change in perfusion measurement through blood flow as shown through DCE-CT imaging.","timeFrame":"Baseline to end of follow-up, up to 12 weeks"}],"secondaryOutcomes":[{"measure":"Correlation Between Patient Demographics and K-Trans: Age","description":"Stratify K-Trans results by age to determine correlation of DCE-CT imaging results compared to patient demographics","timeFrame":"Post follow-up to end of study, up to 12 months"},{"measure":"Correlation Between Patient Demographics and K-Trans: Sex","description":"Stratify K-Trans results by sex to determine correlation of DCE-CT imaging results compared to patient demographics","timeFrame":"Post follow-up to end of study, up to 12 months"},{"measure":"Correlation Between Patient Demographics and K-Trans: Race","description":"Stratify K-Trans results by race to determine correlation of DCE-CT imaging results compared to patient demographics","timeFrame":"Post follow-up to end of study, up to 12 months"},{"measure":"Correlation Between Patient Demographics and K-Trans: Clinical Stage of Disease","description":"Stratify K-Trans results by clinical stage at diagnosis to determine correlation of DCE-CT imaging results compared to patient demographics","timeFrame":"Post follow-up to end of study, up to 12 months"},{"measure":"Correlation Between Patient Demographics and Blood Volume: Age","description":"Stratify blood volume results age to determine correlation of DCE-CT imaging results compared to patient demographics","timeFrame":"Post follow-up to end of study, up to 12 months"},{"measure":"Correlation Between Patient Demographics and Blood Volume: Sex","description":"Stratify blood volume results sex to determine correlation of DCE-CT imaging results compared to patient demographics","timeFrame":"Post follow-up to end of study, up to 12 months"},{"measure":"Correlation Between Patient Demographics and Blood Volume: Race","description":"Stratify blood volume results race to determine correlation of DCE-CT imaging results compared to patient demographics","timeFrame":"Post follow-up to end of study, up to 12 months"},{"measure":"Correlation Between Patient Demographics and Blood Volume: Clinical Stage of Disease","description":"Stratify blood volume results by clinical stage at diagnosis to determine correlation of DCE-CT imaging results compared to patient demographics","timeFrame":"Post follow-up to end of study, up to 12 months"},{"measure":"Correlation Between Patient Demographics and Blood Flow: Age","description":"Stratify blood flow results age to determine correlation of DCE-CT imaging results compared to patient demographics","timeFrame":"Post follow-up to end of study, up to 12 months"},{"measure":"Correlation Between Patient Demographics and Blood Flow: Sex","description":"Stratify blood flow results sex to determine correlation of DCE-CT imaging results compared to patient demographics","timeFrame":"Post follow-up to end of study, up to 12 months"},{"measure":"Correlation Between Patient Demographics and Blood Flow: Race","description":"Stratify blood flow results race to determine correlation of DCE-CT imaging results compared to patient demographics","timeFrame":"Post follow-up to end of study, up to 12 months"},{"measure":"Correlation Between Patient Demographics and Blood Flow: Clinical Stage of Disease","description":"Stratify blood flow results by clinical stage at diagnosis to determine correlation of DCE-CT imaging results compared to patient demographics","timeFrame":"Post follow-up to end of study, up to 12 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Provision to sign and date the consent form\n2. Stated willingness to comply with all study procedures and be available for the duration of the study\n3. Be a Male or Female aged 18-100\n4. Diagnosed with Liver HCC or metastases\n5. Must be receiving or will plan to receive SBRT for Liver HCC or metastases\n\nExclusion Criteria:\n\n1. Allergy to iodine contrast\n2. CT with contrast not offered as a Standard of Care\n3. Pregnant women","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Moyed Miften, PhD","affiliation":"University of Colorado, Denver","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"University of Colorado Denver","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP_ICF","hasProtocol":true,"hasSap":true,"hasIcf":true,"label":"Study Protocol, Statistical Analysis Plan, and Informed Consent Form","date":"2020-01-16","uploadDate":"2022-01-25T11:52","filename":"Prot_SAP_ICF_000.pdf","size":1002070}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D008113","term":"Liver Neoplasms"},{"id":"D009362","term":"Neoplasm Metastasis"}],"ancestors":[{"id":"D004067","term":"Digestive System Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D008107","term":"Liver Diseases"},{"id":"D009385","term":"Neoplastic Processes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT05859971","orgStudyIdInfo":{"id":"2023-0030"},"secondaryIdInfos":[{"id":"5R44CA206754","type":"NIH","link":"https://reporter.nih.gov/quickSearch/5R44CA206754"},{"id":"UW22145","type":"OTHER","domain":"UW Madison"},{"id":"SMPH/SURGERY/SURG ONC","type":"OTHER","domain":"UW Madison"},{"id":"Protocol Version 11/29/2022","type":"OTHER","domain":"UW Madison"}],"organization":{"fullName":"University of Wisconsin, Madison","class":"OTHER"},"briefTitle":"ICG and SLN Mapping","officialTitle":"Use of ICG-fluorescent Imaging for Sentinel Lymph Node Mapping in Patients With Breast Cancer"},"statusModule":{"statusVerifiedDate":"2024-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-04-13","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-06-01","type":"ACTUAL"},"completionDateStruct":{"date":"2023-06-01","type":"ACTUAL"},"studyFirstSubmitDate":"2023-04-06","studyFirstSubmitQcDate":"2023-05-05","studyFirstPostDateStruct":{"date":"2023-05-16","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-07-22","resultsFirstSubmitQcDate":"2024-07-22","resultsFirstPostDateStruct":{"date":"2024-08-15","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-07-14","lastUpdatePostDateStruct":{"date":"2025-07-29","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"University of Wisconsin, Madison","class":"OTHER"},"collaborators":[{"name":"OnLume Inc.","class":"INDUSTRY"},{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":true,"isUsExport":false},"descriptionModule":{"briefSummary":"The purpose of this research study is to assess the feasibility of using a different dye and imaging device, indocyanine green (ICG)-fluorescent imaging through the Asimov Imaging Platform, to perform sentinel lymph node biopsy.\n\nParticipants in this research study will be undergoing a sentinel lymph node biopsy as part of surgical treatment for breast cancer. Active participation will last through the post-operative visit.","detailedDescription":"In this study, the sentinel lymph node biopsy will be performed with radioactive tracer (technetium-99 sulfur colloid) and blue dye, which is standard of care. Decisions will be made during surgery about which lymph nodes to remove using information from the radioactive tracer and blue dye alone.\n\nFor this research, ICG fluorescence dye during participant's surgery will also be used. After anesthesia has started, the ICG fluorescence dye will be injected in the breast along at the edge of the areola in the same location as the radioactive tracer and blue dye injections. The breast and axilla will then be imaged with the Asimov Imaging Platform to look for the sentinel lymph nodes."},"conditionsModule":{"conditions":["Breast Cancer"],"keywords":["breast cancer","sentinel lymph node","ICG fluorescence"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"DIAGNOSTIC","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":10,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Sentinel Lymph Node (SLN) mapping","type":"EXPERIMENTAL","description":"SLN mapping and biopsy will be performed using technetium-99m sulfur colloid and isosulfan blue dye, as well as ICG-fluorescent imaging.","interventionNames":["Drug: SLN mapping using technetium-99m +/- isosulfan blue dye","Device: SLN mapping with ICG fluorescence using the Asimov Platform"]}],"interventions":[{"type":"DRUG","name":"SLN mapping using technetium-99m +/- isosulfan blue dye","description":"The isosulfan blue dye injection will be performed by the participating surgeon in the operating room; as per standard of care, injection will be subareolar. Incisions will be planned based on the technetium-99m activity or at the lateral aspect of the pectoralis muscle, per usual care.","armGroupLabels":["Sentinel Lymph Node (SLN) mapping"]},{"type":"DEVICE","name":"SLN mapping with ICG fluorescence using the Asimov Platform","description":"2 ml (5 mg) of ICG solution will be injected intradermally in 1-4 injection sites in the lateral areolar region. After injection, gentle manual massage will be performed for 5 minutes. ICG imaging will be obtained prior to incision. After incision is made (following standard of care procedures), the axilla will be visualized using the Asimov Platform to assess for ICG-fluorescence in sentinel lymph nodes.","armGroupLabels":["Sentinel Lymph Node (SLN) mapping"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Concordance Between Detection of Sentinel Lymph Nodes by ICG Versus Technetium-99, at the Lymph Node Level","description":"The study team will describe concordance rates between technetium-99 and ICG-fluorescence for each sentinel lymph node removed.","timeFrame":"Day of operation"},{"measure":"Concordance Between Detection of Sentinel Lymph Nodes by ICG Versus Technetium-99, at the Patient Level","description":"The study team will assess concordance rates at the patient level rates between technetium-99 and ICG-fluorescence.","timeFrame":"Day of operation"}],"secondaryOutcomes":[{"measure":"Accuracy of the ICG Mapping","description":"Using the technetium-99as the gold standard, the study team will describe the number of lymph nodes that would have been missed (i.e. technetium-99 + but ICG- in removed SLN) or would have been excised unnecessarily (i.e. residual ICG-fluorescence in axilla but no residual technetium-99) if ICG-fluorescent imaging had guided the SLN.","timeFrame":"Day of operation"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n*  18 years of age\n* Diagnosis of clinical T1 or T2 breast cancer clinically node negative breast cancer requiring surgical lymph node evaluation\n* Surgery at University of Wisconsin Hospital and Clinic\n\nExclusion Criteria:\n\n* Pregnant: It is not known whether indocyanine green can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Women of child-bearing age will undergo a urine pregnancy test on the day of surgery, which is standard of care prior to anesthesia.\n* Breastfeeding: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when indocyanine green is administered to a nursing woman. Study team will exclude women who are breastfeeding.\n* Unable to provide informed consent\n* Allergy to indocyanine green\n* History of ipsilateral breast or axillary surgery","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Heather Neuman, MD","affiliation":"University of Wisconsin, Madison","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"University of Wisconsin","city":"Madison","state":"Wisconsin","zip":"53705","country":"United States","geoPoint":{"lat":43.07305,"lon":-89.40123}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Participants were recruited in April and May of 2023.","groups":[{"id":"FG000","title":"Sentinel Lymph Node (SLN) Mapping","description":"SLN mapping and biopsy will be performed using technetium-99m sulfur colloid and isosulfan blue dye, as well as ICG-fluorescent imaging.\n\nSLN mapping using technetium-99m +/- isosulfan blue dye: The isosulfan blue dye injection will be performed by the participating surgeon in the operating room; as per standard of care, injection will be subareolar. Incisions will be planned based on the technetium-99m activity or at the lateral aspect of the pectoralis muscle, per usual care.\n\nSLN mapping with ICG fluorescence using the Asimov Platform: 2 ml (5 mg) of ICG solution will be injected intradermally in 1-4 injection sites in the lateral areolar region. After injection, gentle manual massage will be performed for 5 minutes. ICG imaging will be obtained prior to incision. After incision is made (following standard of care procedures), the axilla will be visualized using the Asimov Platform to assess for ICG-fluorescence in sentinel lymph nodes."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"10"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"10"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Sentinel Lymph Node (SLN) Mapping","description":"SLN mapping and biopsy will be performed using technetium-99m sulfur colloid and isosulfan blue dye, as well as ICG-fluorescent imaging."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"10"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60.8","lowerLimit":"45","upperLimit":"78"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"10"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"10"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"9"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Concordance Between Detection of Sentinel Lymph Nodes by ICG Versus Technetium-99, at the Lymph Node Level","description":"The study team will describe concordance rates between technetium-99 and ICG-fluorescence for each sentinel lymph node removed.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percent concordance","timeFrame":"Day of operation","groups":[{"id":"OG000","title":"Sentinel Lymph Node (SLN) Mapping","description":"SLN mapping and biopsy will be performed using technetium-99m sulfur colloid and isosulfan blue dye, as well as ICG-fluorescent imaging."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]}]},{"type":"PRIMARY","title":"Concordance Between Detection of Sentinel Lymph Nodes by ICG Versus Technetium-99, at the Patient Level","description":"The study team will assess concordance rates at the patient level rates between technetium-99 and ICG-fluorescence.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percent concordance","timeFrame":"Day of operation","groups":[{"id":"OG000","title":"Sentinel Lymph Node (SLN) Mapping","description":"SLN mapping and biopsy will be performed using technetium-99m sulfur colloid and isosulfan blue dye, as well as ICG-fluorescent imaging."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]}]},{"type":"SECONDARY","title":"Accuracy of the ICG Mapping","description":"Using the technetium-99as the gold standard, the study team will describe the number of lymph nodes that would have been missed (i.e. technetium-99 + but ICG- in removed SLN) or would have been excised unnecessarily (i.e. residual ICG-fluorescence in axilla but no residual technetium-99) if ICG-fluorescent imaging had guided the SLN.","populationDescription":"unable to assess, see post-hoc measures for data available and limitations and caveats for relevant detail","reportingStatus":"POSTED","timeFrame":"Day of operation","groups":[{"id":"OG000","title":"Sentinel Lymph Node (SLN) Mapping","description":"SLN mapping and biopsy will be performed using technetium-99m sulfur colloid and isosulfan blue dye, as well as ICG-fluorescent imaging."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"POST_HOC","title":"Number of Participants With Residual Radioactivity","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day of operation","groups":[{"id":"OG000","title":"Sentinel Lymph Node (SLN) Mapping","description":"SLN mapping and biopsy will be performed using technetium-99m sulfur colloid and isosulfan blue dye, as well as ICG-fluorescent imaging."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}]},{"type":"POST_HOC","title":"Number of Participants With Visible Fluorescence in the Axilla","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"day of operation","groups":[{"id":"OG000","title":"Sentinel Lymph Node (SLN) Mapping","description":"SLN mapping and biopsy will be performed using technetium-99m sulfur colloid and isosulfan blue dye, as well as ICG-fluorescent imaging."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Through post-operative visit, up to 3 weeks","eventGroups":[{"id":"EG000","title":"Sentinel Lymph Node (SLN) Mapping","description":"SLN mapping and biopsy will be performed using technetium-99m sulfur colloid and isosulfan blue dye, as well as ICG-fluorescent imaging.\n\nSLN mapping using technetium-99m +/- isosulfan blue dye: The isosulfan blue dye injection will be performed by the participating surgeon in the operating room; as per standard of care, injection will be subareolar. Incisions will be planned based on the technetium-99m activity or at the lateral aspect of the pectoralis muscle, per usual care.\n\nSLN mapping with ICG fluorescence using the Asimov Platform: 2 ml (5 mg) of ICG solution will be injected intradermally in 1-4 injection sites in the lateral areolar region. After injection, gentle manual massage will be performed for 5 minutes. ICG imaging will be obtained prior to incision. After incision is made (following standard of care procedures), the axilla will be visualized using the Asimov Platform to assess for ICG-fluorescence in sentinel lymph nodes.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":0,"otherNumAtRisk":10}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Difficult to differentiate general staining of the tissue from the ICG versus true residual fluorescence in a lymph node."},"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Heather Neuman, MD, MS, FACS","organization":"University of Wisconsin School of Medicine and Public Health","email":"neuman@surgery.wisc.edu","phone":"(608) 262-9060"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2023-02-23","uploadDate":"2024-07-03T12:29","filename":"Prot_SAP_000.pdf","size":544599}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D001943","term":"Breast Neoplasms"}],"ancestors":[{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D001941","term":"Breast Diseases"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT00214422","nctIdAliases":["NCT00278356"],"orgStudyIdInfo":{"id":"050241"},"secondaryIdInfos":[{"id":"05-C-0241"}],"organization":{"fullName":"National Institutes of Health Clinical Center (CC)","class":"NIH"},"briefTitle":"Intensity Modulated Radiation Therapy for Prostate Cancer","officialTitle":"A Pilot Study of Image Guided Prostate and Pelvic Nodal Irradiation With Intensity Modulated Radiation Therapy (IMRT) in Prostate Cancer"},"statusModule":{"statusVerifiedDate":"2019-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2005-09-19","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2014-05-27","type":"ACTUAL"},"completionDateStruct":{"date":"2018-04-18","type":"ACTUAL"},"studyFirstSubmitDate":"2006-06-19","studyFirstSubmitQcDate":"2005-09-20","studyFirstPostDateStruct":{"date":"2005-09-21","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-10-30","resultsFirstSubmitQcDate":"2019-02-04","resultsFirstPostDateStruct":{"date":"2019-03-01","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-07-17","lastUpdatePostDateStruct":{"date":"2019-07-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Kevin Camphausen, M.D.","investigatorTitle":"Principal Investigator","investigatorAffiliation":"National Cancer Institute (NCI)"},"leadSponsor":{"name":"National Cancer Institute (NCI)","class":"NIH"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"BACKGROUND:\n\n-This study represents a progression from findings in four previous National Cancer Institute (NCI) Radiation Oncology Branch (ROB) protocols (02-C-0167A, 02-C-0207E, 03-C-0190B, 04-C-0171). In these previous works we have begun to develop techniques to obtain Magnetic Resonance (MR) biological images and co-register tissue in prostate cancer patients.\n\nOBJECTIVES:\n\n-The primary objective of the first portion of this study is to assess the feasibility of using Intensity-modulated radiation therapy (IMRT) to treat the at-risk lymph nodes in prostate cancer. Also, if feasible, we hope optimize this technique with experience.\n\nELIGIBILITY:\n\n-This is a study of image guided, targeted radiation therapy in patients with high risk of nodal metastases from prostate cancer. Patients with prostate cancer who have more than 15% risk of lymph node (as defined by the Partin tables) metastasis will be eligible for this study.\n\nDESIGN:\n\n* On the first 10 patients, we will perform approximately 5 computed tomography (CT) simulations throughout the course of their therapy. On each simulation, the initial treatment plan will be re-run. The dose-volume data from target and normal tissues will then be re-analyzed. From this analysis we will be better able to determine the size of margins needed to account for organ motion and changes such as varying amounts of gas in the bowel and fluid in the bladder. To the best of our knowledge, no such analyses have been published.\n* If the initial part of this trial is feasible, we will proceed to a phase I dose escalation trial of radiation to the at-risk lymph nodes. The primary statistical objective of the phase I portion of this study is to estimate the Maximum Tolerated Dose (MTD) of external beam radiation based on evaluating acute toxicity. The study will be conducted with a dose-escalation design with 3 patients in each dose cohort. If fewer than 2 of 3 patients experience an acute dose limiting toxicity (DLT) than patients will be accrued to the next dose cohort. If 2 or more of 3 patients experience a DLT then the MTD will be exceeded and the prior, lower dose cohort will be considered the MTD. Secondary objectives of this study are to relate patterns in gene and protein expression to response and toxicity and to evaluate the frequency of late term toxicity.\n* Specific procedures and risks will be described in a separate consent to be obtained at the time of biopsy. Tissue samples will be processed for complementary deoxyribonucleic acid (cDNA) microarray testing and stored for future analysis in the Radiation Oncology Branch, NCI.\n* Anatomic Magnetic Resonance Imaging (MRI) and magnetic resonance (MR) biological images of the prostate and pelvis will be obtained and tissue will be acquired with biopsy locations precisely translated (co-registered) to an MR image of reference. A fiducial marker (gold seed) will be left at the biopsy site as a fiducial marker to direct future radiation therapy to the prostate. If necessary, additional fiducial markers will be placed for prostate localization during treatment.","detailedDescription":"BACKGROUND:\n\n-This study represents a progression from findings in four previous National Cancer Institute (NCI) Radiation Oncology Branch (ROB) protocols (02-C-0167A, 02-C-0207E, 03-C-0190B, 04-C-0171). In these previous works we have begun to develop techniques to obtain Magnetic Resonance (MR) biological images and co-register tissue in prostate cancer patients.\n\nOBJECTIVES:\n\n-The primary objective of the first portion of this study is to assess the feasibility of using Intensity-modulated radiation therapy (IMRT) to treat the at-risk lymph nodes in prostate cancer. Also, if feasible, we hope optimize this technique with experience.\n\nELIGIBILITY:\n\n* This is a study of image guided, targeted radiation therapy in patients with high risk of nodal metastases from prostate cancer.\n* Patients with prostate cancer who have more than 15% risk of lymph node (as defined by the Partin tables) metastasis will be eligible for this study.\n\nDESIGN:\n\n* On the first 10 patients, we will perform approximately 5 computed tomography (CT) simulations throughout the course of their therapy. On each simulation, the initial treatment plan will be re-run. The dose-volume data from target and normal tissues will then be re-analyzed. From this analysis we will be better able to determine the size of margins needed to account for organ motion and changes such as varying amounts of gas in the bowel and fluid in the bladder. To the best of our knowledge, no such analyses have been published.\n* If the initial part of this trial is feasible, we will proceed to a phase I dose escalation trial of radiation to the at-risk lymph nodes. The primary statistical objective of the phase I portion of this study is to estimate the Maximum Tolerated Dose (MTD) of external beam radiation based on evaluating acute toxicity. The study will be conducted with a dose-escalation design with 3 patients in each dose cohort. If fewer than 2 of 3 patients experience an acute dose limiting toxicity (DLT) than patients will be accrued to the next dose cohort. If 2 or more of 3 patients experience a DLT then the MTD will be exceeded and the prior, lower dose cohort will be considered the MTD. Secondary objectives of this study are to relate patterns in gene and protein expression to response and toxicity and to evaluate the frequency of late term toxicity.\n* Specific procedures and risks will be described in a separate consent to be obtained at the time of biopsy. Tissue samples will be processed for complementary deoxyribonucleic acid (cDNA) microarray testing and stored for future analysis in the Radiation Oncology Branch, NCI.\n* Anatomic Magnetic Resonance Imaging (MRI) and magnetic resonance (MR) biological images of the prostate and pelvis will be obtained and tissue will be acquired with biopsy locations precisely translated (co-registered) to an MR image of reference. A fiducial marker (gold seed) will be left at the biopsy site as a fiducial marker to direct future radiation therapy to the prostate. If necessary, additional fiducial markers will be placed for prostate localization during treatment."},"conditionsModule":{"conditions":["Prostate Cancer"],"keywords":["Prostate","Radiation","Cancer","Prostate Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":19,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm 1- 5040cGy to the lymph nodes","type":"EXPERIMENTAL","description":"5040Gray (cGy) to the lymph nodes","interventionNames":["Radiation: Radiation"]},{"label":"Arm 2 - 5400cGy to the lymph nodes","type":"EXPERIMENTAL","description":"5400Gray (cGy) to the lymph nodes","interventionNames":["Radiation: Radiation"]},{"label":"Arm 3 - 5900cGy to the lymph nodes","type":"EXPERIMENTAL","description":"5900Gray (cGy) to the lymph nodes","interventionNames":["Radiation: Radiation"]}],"interventions":[{"type":"RADIATION","name":"Radiation","description":"Radiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes.","armGroupLabels":["Arm 1- 5040cGy to the lymph nodes","Arm 2 - 5400cGy to the lymph nodes","Arm 3 - 5900cGy to the lymph nodes"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Any Grade 2 Toxicity Using Intensity Modulated Radiation Therapy (IMRT) to Treat the At-risk Lymph Nodes in Prostate Cancer ( up to First 10 Patients)","description":"Radiation side effects were assessed by the Radiation Oncology Group (RTOG) Acute/Late Toxicity Grading Gastrointestinal and Genitourinary criteria. Acute Grade 0 - no symptoms, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, Grade 4 is life threatening, and Grade 5 is death directly related to radiation side effects. Late toxicity is defined as occurring after 90 days.","timeFrame":"At one week, one month, 2 months, 3 months, 6 months, 9 months, 1 year, 18 months, 2 years, 30 months, and 3 years after radiation therapy"},{"measure":"Maximum Tolerated Dose (MTD) of External Beam Radiation to Pelvic Lymph Nodes of Interest in Patients Receiving Radiation Therapy for Prostate Cancer (After the First 10 Patients) In Arm 1, Arm 2, and Arm 3","description":"Maximum tolerated dose (MTD) is defined as the dose level immediately below the dose level at which 2 or more in a cohort of either 3 or 6 patients experiences a dose limiting toxicity (DLT) attributed to radiation therapy. An acute DLT will be defined as Radiation Therapy Oncology Group (RTOG) grade 3 or greater, acute gastrointestinal or genitourinary toxicity within 3 months after the completion of radiation.","timeFrame":"Completion of Treatment, an average of 8.5 weeks"}],"secondaryOutcomes":[{"measure":"Number of Participants With Grade 2 Late Gastrointestinal or Genitourinary Toxicity Assessed by the Radiation Oncology Group (RTOG) Criteria","description":"Long-term effects and toxicity following intensity modulated radiation therapy (IMRT) dose escalation to the pelvic nodes were measured by the Radiation Oncology Group (RTOG) Criteria. Lower GI/Pelvis grade 2 toxicity Diarrhea requiring parasympatholytic drugs (e.g. Lomotil)/mucous discharge not necessitating sanitary pads/rectal or abdominal pain requiring analgesics and Genitourinary grade 2 defined as Frequency of urination or nocturia that is less frequent than every hour. Dysuria, urgency, bladder spasm requiring local anesthetic (e.g. Pyridium).","timeFrame":"At median follow-up, approximately 28 months following radiation"},{"measure":"Number of Participants With a Dose Limiting Toxicity (DLT)","description":"An acute Dose Limiting Toxicity (DLT) will be defined as Radiation Therapy Oncology Group (RTOG) grade 3 or greater, acute gastrointestinal or genitourinary toxicity within 3 months after the completion of radiation.","timeFrame":"Within 3 months after completion of radiation"},{"measure":"Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)","description":"Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.","timeFrame":"Date treatment consent signed to date off study, approximately 8 years and 3.5 months."},{"measure":"Number of Participants With Grade 3 or 4 Acute and/or Late Gastrointestinal or Genitourinary Toxicity Assessed by the Radiation Oncology Group (RTOG) Criteria","description":"Long-term effects and toxicity following intensity modulated radiation therapy (IMRT) dose escalation to the pelvic nodes were measured by the Radiation Oncology Group (RTOG) Criteria. Grade 3 toxicity Lower GI/Pelvis is Diarrhea requiring parenteral support/severe mucous or blood discharge necessitating sanitary pads/abdominal distention (flat plate radiograph demonstrates distended bowel loops), Grade 3 toxicity Genitourinary Frequency with urgency and nocturia hourly or more frequently/dysuria, pelvis pain or bladder spasm requiring regular, frequent narcotic/gross hematuria with/without clot passage.","timeFrame":"At median follow-up, approximately 28 months following radiation"}]},"eligibilityModule":{"eligibilityCriteria":"* INCLUSION CRITERIA:\n\nEastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\n\nPathology report confirming adenocarcinoma of the prostate\n\nRisk of lymph node metastasis greater than or equal to15% as defined by the Partin tables or biopsy proven positive lymph nodes\n\nTumor visible on magnetic resonance imaging (MRI)\n\nNo prior surgery, radiation, or chemotherapy for prostate cancer, with the exception of hormone therapy which may be given neoadjuvantly for up to four (4) months.\n\nAge greater than 18 years old and less than 90 years old.\n\nEXCLUSION CRITERIA:\n\nCognitively impaired patients who cannot give informed consent.\n\nPatients with metastatic disease beyond the pelvis\n\nContraindication to biopsy\n\n* Bleeding disorder\n* Prothrombin time (PT)/partial thromboplastin time (PTT) greater than or equal to 1.5 times the upper limit of normal\n* Platelets less than or equal to 50K\n* Artificial heart valve\n\nContraindication to MRI\n\n* Patients weighing greater than136 kgs (weight limit for the scanner tables)\n* Allergy to magnetic resonance (MR) contrast agent\n* Patients with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable electronic devices.\n\nPre-existing and active prostatitis or proctitis\n\nOther medical conditions deemed by the principal investigator (PI) or associates to make the patient ineligible for protocol investigations, procedures, and high-dose external beam radiotherapy.","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Kevin A Camphausen, M.D.","affiliation":"National Cancer Institute (NCI)","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"National Institutes of Health Clinical Center, 9000 Rockville Pike","city":"Bethesda","state":"Maryland","zip":"20892","country":"United States","geoPoint":{"lat":38.98067,"lon":-77.10026}}]},"referencesModule":{"references":[{"pmid":"12128107","type":"BACKGROUND","citation":"Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105. doi: 10.1016/s0360-3016(02)02829-8."},{"pmid":"12743142","type":"BACKGROUND","citation":"Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS; Radiation Therapy Oncology Group 9413. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003 May 15;21(10):1904-11. doi: 10.1200/JCO.2003.05.004."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"6 participants in Arm 1 participated in a feasibility phase prior to the dose escalation phase of the study.","groups":[{"id":"FG000","title":"Arm 1- 5040cGy to the Lymph Nodes","description":"5040 Gray (cGy) to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes."},{"id":"FG001","title":"Arm 2 - 5400cGy to the Lymph Nodes","description":"5400cGy to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes."},{"id":"FG002","title":"Arm 3 - 5900cGy to the Lymph Nodes","description":"5900cGy to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Developed esophageal ca","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Pt taken off study","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Disease progression on study","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Unable to make a radiation treatment","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Arm 1- 5040cGy to the Lymph Nodes","description":"5040 Gray (cGy) to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes."},{"id":"BG001","title":"Arm 2 - 5400cGy to the Lymph Nodes","description":"5400cGy to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes."},{"id":"BG002","title":"Arm 3 - 5900cGy to the Lymph Nodes","description":"5900cGy to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"19"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"9"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"10"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"64.14","spread":"7.41"},{"groupId":"BG001","value":"59.37","spread":"20.36"},{"groupId":"BG002","value":"67.68","spread":"2.78"},{"groupId":"BG003","value":"64.13","spread":"9.35"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"19"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"19"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"4"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"14"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"19"}]}]}]},{"title":"Median Prostatic Specific Antigen (PSA) at Diagnosis","description":"Normal PSA is less than 2.5 ng/ml.","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"ng/ml","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16.65","lowerLimit":"5.5","upperLimit":"103"},{"groupId":"BG001","value":"33.4","lowerLimit":"5.7","upperLimit":"42.9"},{"groupId":"BG002","value":"8.95","lowerLimit":"4.75","upperLimit":"27.3"},{"groupId":"BG003","value":"19.67","lowerLimit":"4.75","upperLimit":"103"}]}]}]},{"title":"Median Gleason Score at Diagnosis","description":"Gleason grading scale helps to evaluate the severity of prostate cancer. A score \\>8 is a low-grade cancer (less aggressive). A score \\<8 is a high grade cancer (more aggressive, poor prognosis).","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"scores on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8","lowerLimit":"7","upperLimit":"9"},{"groupId":"BG001","value":"7","lowerLimit":"6","upperLimit":"9"},{"groupId":"BG002","value":"8","lowerLimit":"7","upperLimit":"8"},{"groupId":"BG003","value":"7.6","lowerLimit":"6","upperLimit":"9"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Any Grade 2 Toxicity Using Intensity Modulated Radiation Therapy (IMRT) to Treat the At-risk Lymph Nodes in Prostate Cancer ( up to First 10 Patients)","description":"Radiation side effects were assessed by the Radiation Oncology Group (RTOG) Acute/Late Toxicity Grading Gastrointestinal and Genitourinary criteria. Acute Grade 0 - no symptoms, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, Grade 4 is life threatening, and Grade 5 is death directly related to radiation side effects. Late toxicity is defined as occurring after 90 days.","populationDescription":"6 participants in Arm 1 participated in a feasibility phase prior to the dose escalation phase of the study.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At one week, one month, 2 months, 3 months, 6 months, 9 months, 1 year, 18 months, 2 years, 30 months, and 3 years after radiation therapy","groups":[{"id":"OG000","title":"Arm 1- 5040cGy to the Lymph Nodes","description":"5040 Gray (cGy) to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"classes":[{"title":"Week 1","categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"1 month","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"2 months","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"3 months","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"6 months","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"9 months","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"1 year","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"18 months","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"2 years","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"30 months","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"3 years","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}]},{"type":"PRIMARY","title":"Maximum Tolerated Dose (MTD) of External Beam Radiation to Pelvic Lymph Nodes of Interest in Patients Receiving Radiation Therapy for Prostate Cancer (After the First 10 Patients) In Arm 1, Arm 2, and Arm 3","description":"Maximum tolerated dose (MTD) is defined as the dose level immediately below the dose level at which 2 or more in a cohort of either 3 or 6 patients experiences a dose limiting toxicity (DLT) attributed to radiation therapy. An acute DLT will be defined as Radiation Therapy Oncology Group (RTOG) grade 3 or greater, acute gastrointestinal or genitourinary toxicity within 3 months after the completion of radiation.","populationDescription":"The MTD of this study was not reached. The original principal investigator left the National Institutes of Health and we are unable to determine why the outcome was not met.","reportingStatus":"POSTED","timeFrame":"Completion of Treatment, an average of 8.5 weeks","groups":[{"id":"OG000","title":"Arm 1- 5040cGy to the Lymph Nodes","description":"5040 Gray (cGy) to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes."},{"id":"OG001","title":"Arm 2 - 5400cGy to the Lymph Nodes","description":"Radiation will be given in dose escalations from 5040 Gray (cGY) to a maximum of 5900 cGy to lymph nodes."},{"id":"OG002","title":"Arm 3 - 5900cGY to the Lymph Nodes","description":"Radiation will be given in dose escalations from 5040 Gray (cGY) to a maximum of 5900 cGy to lymph nodes."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"type":"SECONDARY","title":"Number of Participants With Grade 2 Late Gastrointestinal or Genitourinary Toxicity Assessed by the Radiation Oncology Group (RTOG) Criteria","description":"Long-term effects and toxicity following intensity modulated radiation therapy (IMRT) dose escalation to the pelvic nodes were measured by the Radiation Oncology Group (RTOG) Criteria. Lower GI/Pelvis grade 2 toxicity Diarrhea requiring parasympatholytic drugs (e.g. Lomotil)/mucous discharge not necessitating sanitary pads/rectal or abdominal pain requiring analgesics and Genitourinary grade 2 defined as Frequency of urination or nocturia that is less frequent than every hour. Dysuria, urgency, bladder spasm requiring local anesthetic (e.g. Pyridium).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At median follow-up, approximately 28 months following radiation","groups":[{"id":"OG000","title":"Arm 1- 5040cGy to the Lymph Nodes","description":"5040 Gray (cGy) to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes."},{"id":"OG001","title":"Arm 2 - 5400cGy to the Lymph Nodes","description":"5400cGy to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes."},{"id":"OG002","title":"Arm 3 - 5900cGy to the Lymph Nodes","description":"5900cGy to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}]}],"classes":[{"title":"Gastrointestinal","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Genitourinary","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Dose Limiting Toxicity (DLT)","description":"An acute Dose Limiting Toxicity (DLT) will be defined as Radiation Therapy Oncology Group (RTOG) grade 3 or greater, acute gastrointestinal or genitourinary toxicity within 3 months after the completion of radiation.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within 3 months after completion of radiation","groups":[{"id":"OG000","title":"Arm 1- 5040cGy to the Lymph Nodes","description":"5040 Gray (cGy) to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes."},{"id":"OG001","title":"Arm 2 - 5400cGy to the Lymph Nodes","description":"5400cGy to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes."},{"id":"OG002","title":"Arm 3 - 5900cGy to the Lymph Nodes","description":"5900cGy to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}]}],"classes":[{"title":"Gastrointestinal","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Genitourinary","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)","description":"Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Date treatment consent signed to date off study, approximately 8 years and 3.5 months.","groups":[{"id":"OG000","title":"Arm 1- 5040cGy to the Lymph Nodes","description":"5040 Gray (cGy) to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes."},{"id":"OG001","title":"Arm 2 - 5400cGy to the Lymph Nodes","description":"5400cGy to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes."},{"id":"OG002","title":"Arm 3 - 5900cGy to the Lymph Nodes","description":"5900cGy to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Grade 3 or 4 Acute and/or Late Gastrointestinal or Genitourinary Toxicity Assessed by the Radiation Oncology Group (RTOG) Criteria","description":"Long-term effects and toxicity following intensity modulated radiation therapy (IMRT) dose escalation to the pelvic nodes were measured by the Radiation Oncology Group (RTOG) Criteria. Grade 3 toxicity Lower GI/Pelvis is Diarrhea requiring parenteral support/severe mucous or blood discharge necessitating sanitary pads/abdominal distention (flat plate radiograph demonstrates distended bowel loops), Grade 3 toxicity Genitourinary Frequency with urgency and nocturia hourly or more frequently/dysuria, pelvis pain or bladder spasm requiring regular, frequent narcotic/gross hematuria with/without clot passage.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At median follow-up, approximately 28 months following radiation","groups":[{"id":"OG000","title":"Arm 1- 5040cGy to the Lymph Nodes","description":"5040 Gray (cGy) to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes."},{"id":"OG001","title":"Arm 2 - 5400cGy to the Lymph Nodes","description":"5400cGy to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGY) to a maximum of 5900 cGy to lymph nodes."},{"id":"OG002","title":"Arm 3 - 5900cGY to the Lymph Nodes","description":"5900cGy to the lymph nodes\n\nRadiation will be given in dose escalations from 5040 Gray (cGY) to a maximum of 5900 cGy to lymph nodes."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}]}],"classes":[{"title":"Gastrointestinal","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Genitourinary","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Date treatment consent signed to date off study, approximately 8 years and 3.5 months.","eventGroups":[{"id":"EG000","title":"Arm 1- 5040cGy to the Lymph Nodes","description":"5040 Gray (cGy) to the lymph nodes\n\nExternal Beam Radiation: Radiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":1,"seriousNumAtRisk":12,"otherNumAffected":12,"otherNumAtRisk":12},{"id":"EG001","title":"Arm 2 - 5400cGy to the Lymph Nodes","description":"5400cGy to the lymph nodes\n\nExternal Beam Radiation: Radiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes.","deathsNumAffected":0,"deathsNumAtRisk":3,"seriousNumAffected":1,"seriousNumAtRisk":3,"otherNumAffected":3,"otherNumAtRisk":3},{"id":"EG002","title":"Arm 3 - 5900cGy to the Lymph Nodes","description":"5900cGy to the lymph nodes\n\nExternal Beam Radiation: Radiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes.","deathsNumAffected":0,"deathsNumAtRisk":4,"seriousNumAffected":0,"seriousNumAtRisk":4,"otherNumAffected":4,"otherNumAtRisk":4}],"seriousEvents":[{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Infection with normal ANC or Grade 1 or 2 neutrophils::Liver","organSystem":"Infections and infestations","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]}],"otherEvents":[{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Cystitis","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Dermatology/Skin - Other (Penis mass)","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":4}]},{"term":"Dysphagia (difficulty swallowing)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Erectile dysfunction","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Fatigue (asthenia, lethargy, malaise)","organSystem":"General disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":10,"numAtRisk":12},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":4}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (Anal lesion - HPV virus (Bx on 1/28/18))","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (Diarrhea)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (Diarrhea, mucous discharge, abdo pain)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (Esophageal cancer)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (Urgency, abdominal pain)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (dysuria)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (frequency)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (increased bowel frequency)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (loose stools; frequency)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (mild BRBPR (hemorrhoids stable))","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (moderate diarrhea)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (moderate diarrhea, frequency, mucous)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (moderate frequency, urgency)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (rectal bleeding; urgency, frequent watery stools)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Gynecomastia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Hair loss/alopecia (scalp or body)","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Hemorrhage, GI::Rectum","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":4}]},{"term":"Hemorrhage, GU::Urinary NOS","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Hot flashes/flushes","organSystem":"Endocrine disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":9,"numAtRisk":12},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":4}]},{"term":"Hyperpigmentation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Hypertension","organSystem":"Cardiac disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Hypotension","organSystem":"Cardiac disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Incontinence, anal","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Incontinence, urinary","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":4}]},{"term":"Insomnia","organSystem":"General disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Leukocytes (total WBC)","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":4}]},{"term":"Libido","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":12},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":3},{"groupId":"EG002","numEvents":12,"numAffected":4,"numAtRisk":4}]},{"term":"Mood alteration::Depression","organSystem":"Nervous system disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":3,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Orgasmic dysfunction","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"PTT (Partial Thromboplastin Time)","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Pain - Other (L shoulder)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Pain - Other (R hip)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Pain - Other (Thoracic back pain)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Pain::Abdomen NOS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":4}]},{"term":"Pain::Breast","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Pain::Pelvis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Platelets","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":4}]},{"term":"Rash/desquamation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Rash: acne/acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Rash: erythema multiforme (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis)","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Renal/Genitourinary - Other (Dribbling)","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Renal/Genitourinary - Other (Dysuria)","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Urinary frequency/urgency","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":3},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":4}]},{"term":"Urinary retention (including neurogenic bladder)","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":12},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Weight gain","organSystem":"General disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":10,"numAtRisk":12},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Weight loss","organSystem":"General disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Cardiac General - Other (heart murmur)","organSystem":"Cardiac disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Dyspnea (shortness of breath)","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Edema: limb","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Endocrine - Other (breast tenderness)","organSystem":"Endocrine disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (Incontinence)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (blood streaked stool)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (loose stool, urgency)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (loose stools)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (small amount blood in stools)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (urgency)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Hemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Infection with normal ANC or Grade 1 or 2 neutrophils::Urinary tract NOS","organSystem":"Infections and infestations","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Joint-function","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Pain::Back","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Pain::Joint","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Proctitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Renal/Genitourinary - Other (Dysuria, Hematuria)","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Renal/Genitourinary - Other (nocturia)","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)","organSystem":"Immune system disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Edema: limb","organSystem":"General disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Endocrine - Other ( thyroid size increased)","organSystem":"Endocrine disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Gastrointestinal - Other (frequency, soft BM's; mild abdo cramping)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Hemoglobin","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":4}]},{"term":"Hemorrhage, GU::Urethra","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Neutrophils/granulocytes (ANC/AGC)","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Pain::Extremity-limb","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Renal/Genitourinary - Other (Weak stream)","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":6,"numAtRisk":12},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Renal/Genitourinary - Other (dysuria, nocturia)","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"CTC (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Dr. Kevin Camphausen","organization":"National Cancer Institute","email":"camphausen@nih.gov","phone":"240-760-6205"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2011-07-22","uploadDate":"2018-10-03T10:57","filename":"ICF_000.pdf","size":241710},{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2017-05-16","uploadDate":"2018-12-26T08:34","filename":"Prot_SAP_001.pdf","size":1145905}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D011471","term":"Prostatic Neoplasms"},{"id":"D009369","term":"Neoplasms"}],"ancestors":[{"id":"D005834","term":"Genital Neoplasms, Male"},{"id":"D014565","term":"Urogenital Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D005832","term":"Genital Diseases, Male"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D011469","term":"Prostatic Diseases"},{"id":"D052801","term":"Male Urogenital Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D011827","term":"Radiation"}],"ancestors":[{"id":"D055585","term":"Physical Phenomena"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT03272633","orgStudyIdInfo":{"id":"011702"},"secondaryIdInfos":[{"id":"NCI-2017-01537","type":"REGISTRY","domain":"CTRP (Clinical Trial Reporting Program)"},{"id":"Pro20170000537"},{"id":"011702","type":"OTHER","domain":"Rutgers Cancer Institute of New Jersey"},{"id":"P30CA072720","type":"NIH","link":"https://reporter.nih.gov/quickSearch/P30CA072720"}],"organization":{"fullName":"Rutgers, The State University of New Jersey","class":"OTHER"},"briefTitle":"Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies","officialTitle":"Post-Transplant Use of Irradiated Haplo-Allogeneic Cells"},"statusModule":{"statusVerifiedDate":"2023-06","overallStatus":"TERMINATED","whyStopped":"Lack of enrollment","startDateStruct":{"date":"2020-10-26","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-06-30","type":"ACTUAL"},"completionDateStruct":{"date":"2022-09-22","type":"ACTUAL"},"studyFirstSubmitDate":"2017-08-24","studyFirstSubmitQcDate":"2017-09-01","studyFirstPostDateStruct":{"date":"2017-09-05","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-03-20","resultsFirstSubmitQcDate":"2023-06-23","resultsFirstPostDateStruct":{"date":"2023-06-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-06-23","lastUpdatePostDateStruct":{"date":"2023-06-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Roger Strair, MD, PhD","investigatorTitle":"Professor of Medicine, RWJMS","investigatorAffiliation":"Rutgers Cancer Institute of New Jersey"},"leadSponsor":{"name":"Rutgers, The State University of New Jersey","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies. Transfusion of irradiated donor cells (immune cells) from relatives may cause the patient's cancer to decrease in size and may help control cancer in patients receiving a stem cell transplant.","detailedDescription":"PRIMARY OBJECTIVES:\n\nI. To determine the toxicity associated with the administration of irradiated haploidentical cells (IHC) to patients with high-risk hematologic malignancies.\n\nSECONDARY OBJECTIVES:\n\nI. To determine if there is evidence of disease response associated with IHC.\n\nTERTIARY OBJECTIVES:\n\nI. To determine if treatment with the irradiated cells induces an immune response targeting tumor associated epitopes.\n\nOUTLINE: Patients are assigned to 1 of 2 cohorts.\n\nCOHORT I: Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous hematopoietic stem cell transplantation (HSCT), patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nCOHORT II: Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAfter completion of study treatment, patients will be followed up within 8 weeks."},"conditionsModule":{"conditions":["Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia in Remission","Hematopoietic Cell Transplantation Recipient","JAK2 Gene Mutation","Loss of Chromosome 17p","Mantle Cell Lymphoma","Minimal Residual Disease","Myelodysplastic Syndrome","Non-Hodgkin Lymphoma","Plasma Cell Myeloma","RAS Family Gene Mutation","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Hematologic Malignancy","Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Therapy-Related Acute Myeloid Leukemia","Therapy-Related Myelodysplastic Syndrome","TP53 Gene Mutation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":2,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort I (initial IHC within 42 days)","type":"EXPERIMENTAL","description":"Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous HSCT, patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.","interventionNames":["Procedure: Allogeneic Hematopoietic Stem Cell Transplantation","Biological: Irradiated Allogeneic Cells"]},{"label":"Cohort II (initial IHC within 70 days or after relapse)","type":"EXPERIMENTAL","description":"Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.","interventionNames":["Procedure: Allogeneic Hematopoietic Stem Cell Transplantation","Biological: Irradiated Allogeneic Cells"]}],"interventions":[{"type":"PROCEDURE","name":"Allogeneic Hematopoietic Stem Cell Transplantation","description":"Receive IHC","armGroupLabels":["Cohort I (initial IHC within 42 days)","Cohort II (initial IHC within 70 days or after relapse)"],"otherNames":["Allogeneic Hematopoietic Cell Transplantation","allogeneic stem cell transplantation","HSC","HSCT"]},{"type":"BIOLOGICAL","name":"Irradiated Allogeneic Cells","description":"Correlative studies","armGroupLabels":["Cohort I (initial IHC within 42 days)","Cohort II (initial IHC within 70 days or after relapse)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants Who Received Irradiated Haploidentical Cells (IHC) With Disease Response","description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR","timeFrame":"Up to 8 weeks after last protocol treatment"},{"measure":"the Number of Participants With Toxicities Associated With Administration of Irradiated Haploidentical Cells (IHC) Evaluated According to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0","description":"The anticipated/projected IHC-associated toxicities of greatest concern include: short-term toxicities- constitutional/systemic adverse events including fevers, hypotension, pulmonary infiltrates; long-term toxicities: autoimmune effects, graft-versus-host disease (GVHD), graft rejection. Toxicity will be measured by occurrence of any experimental treatment-related adverse events (AE) up to 12 weeks of completion of therapy. The CTCAE version 4.0 will be utilized for the description and grading of the AE. All symptoms, signs, or diseases assessed as experimental treatment-related will be captu","timeFrame":"Up to 12 weeks of completion of therapy"}],"secondaryOutcomes":[{"measure":"Induction of Host T Cells Reactive With Tumor Associated Epitopes","description":"It will be determined if treatment with the irradiated cells induces an immune response targeting tumor associated epitopes.","timeFrame":"Up to 8 weeks after last protocol treatment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient with disease (stage) eligible per cohort\n* COHORT 1: patients undergoing high dose chemotherapy with autologous stem cell rescue and ?high-risk? disease as defined below:\n\n  * Diffuse large cell lymphoma or peripheral T cell lymphoma (including specified World Health Organization \\[WHO\\] subtypes) not in computed tomography (CT)-positron emission tomography (PET) complete remission at time of high dose therapy\n  * Diffuse large cell lymphoma with ?double hit? or ?double expressor? features\n  * Diffuse large cell lymphoma or peripheral T cell lymphoma (including WHO specified subtypes) refractory to standard induction therapy OR relapsing within 1 year of treatment OR in greater that second complete remission (CR)\n  * Mantle cell lymphoma not in CR1\n  * Multiple myeloma with ONE (or more) of the following high risk features:\n\n    * Less than very good partial remission at time of high dose therapy\n    * High Revised-International Staging System (R-ISS) (stage III ? 2 microglobulin \\>= 5.5 plus lactate dehydrogenase \\[LDH\\] \\> upper limit of normal \\[ULN\\] and/or del17p, t(4;14), t(14;16)) at time of diagnosis\n    * Cytogenetics or fluorescent in situ hybridization (FISH) del17p\n* COHORT 2: patients with high risk disease having undergone an allogeneic hematopoietic stem cell transplant from a 10/10 human leukocyte antigen (HLA) matched donor with one of the following disease subtypes:\n\n  * Acute myeloid leukemia (AML) in CR1 with high risk features (European Leukemia Network \\[ELN\\]) at presentation\n\n    * Diagnostic sample with either t(6;9), t(9;22), 11q23, inv 3, -5, -7, del17p, complex cytogenetics, NPMwt-flt3ITD+, OR p53 mutation (mut); patients whose samples have mutations in RUNX1 or ASXL1 are also eligible (unless the patient has favorable cytogenetics)\n  * AML in CR1 with measurable minimal residual disease (MRD) by molecular (e.g., myeloid mutation profile, polymerase chain reaction \\[PCR\\] for NPM1, core-binding factor \\[CBF\\], mixed lineage leukemia \\[MLL\\]) or flow cytometry\n  * AML not in CR1 (including patients with morphologic CR but with incomplete recovery, CRi)\n  * Myelodysplastic syndrome (MDS) with complex cytogenetics, 17p deletion or p53 mutation, or JAK2 or RAS mutation\n  * Treatment-related MDS or AML\n  * Acute lymphoblastic leukemia (ALL) not in CR1\n  * ALL with MRD\n  * Any hematologic malignancy relapsed or with persistent disease after allogeneic hematopoietic stem cell transplant\n  * Multiple myeloma\n  * Non-Hodgkin lymphoma (NHL) with chemoresistant disease at time of transplant\n  * Any patient undergoing allogeneic hematopoietic stem cell transplant and an anticipated rate of relapse \\> 80% based upon published data and for which there is consensus amongst the Hematologic Malignancies Tumor Study Group that enrollment is appropriate\n* Availability of a genetic child, genetic parent or sibling as a potential HLA haploidentical donor\n* Meets standard eligibility requirements for high dose chemotherapy with autologous stem cell rescue (COHORT 1) or allogeneic hematopoietic stem cell transplant (COHORT 2) and has signed consent for those procedures\n* DONOR: Donor must be related to patient and be partially (\\>= 3/6 antigen) HLA-matched\n* DONOR: Donor must meet all Robert Wood Johnson (RWJ) Blood Services requirements for hematopoietic stem cell donation including:\n\n  * Age \\>= 18 years old;\n  * Normal hemogram (white blood cells \\[WBC\\] 4.0-10.0 x 10\\^3/mm\\^3; platelet count 150,000 to 440,000/mm\\^3 ; hemoglobin/hematocrit; 12.5-18 g/dl, 38 to 54%\n  * Not pregnant or lactating;\n  * Not human immunodeficiency virus (HIV)-1, HIV-2, hepatitis C virus (HCV), hepatitis B core or human T-cell lymphotropic virus (HTLV)-I/II seropositive; hepatitis B surface antigen (HB S ag) (-); meet other infectious disease screening criteria utilized by RWJ Blood Services;\n  * No uncontrolled infections, other medical or psychological/social conditions, or medications that might increase the likelihood of patient or donor adverse effects or poor outcomes;\n  * Meet other blood bank criteria for blood product donation (as determined by RWJ Blood Center screening history and laboratory studies)\n\nExclusion Criteria:\n\n* Non-English speaking person\n* Patients undergoing haploidentical allogeneic hematopoietic stem cell transplants are not eligible; patients undergoing \\< 10/10 HLA allele matched allogeneic transplant are not eligible\n* Pregnant women\n* DONOR: Non-English speaking person\n* DONOR: Pregnant women","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Roger Strair","affiliation":"Rutgers Cancer Institute of New Jersey","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Rutgers Cancer Institute of New Jersey","city":"New Brunswick","state":"New Jersey","zip":"08903","country":"United States","geoPoint":{"lat":40.48622,"lon":-74.45182}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Cohort I (Initial IHC Within 42 Days)","description":"Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous HSCT, patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies"},{"id":"FG001","title":"Cohort II (Initial IHC Within 70 Days or After Relapse)","description":"Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"No participants qualified for cohort I","groups":[{"id":"BG000","title":"Cohort I (Initial IHC Within 42 Days)","description":"Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous HSCT, patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies"},{"id":"BG001","title":"Cohort II (Initial IHC Within 70 Days or After Relapse)","description":"Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Received Irradiated Haploidentical Cells (IHC) With Disease Response","description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR","populationDescription":"no data was collected. Refers to the Cohort 1 Arm","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 8 weeks after last protocol treatment","groups":[{"id":"OG000","title":"Cohort I (Initial IHC Within 42 Days)","description":"Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous HSCT, patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies"},{"id":"OG001","title":"Cohort II (Initial IHC Within 70 Days or After Relapse)","description":"Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"2"}]}]}]},{"type":"PRIMARY","title":"the Number of Participants With Toxicities Associated With Administration of Irradiated Haploidentical Cells (IHC) Evaluated According to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0","description":"The anticipated/projected IHC-associated toxicities of greatest concern include: short-term toxicities- constitutional/systemic adverse events including fevers, hypotension, pulmonary infiltrates; long-term toxicities: autoimmune effects, graft-versus-host disease (GVHD), graft rejection. Toxicity will be measured by occurrence of any experimental treatment-related adverse events (AE) up to 12 weeks of completion of therapy. The CTCAE version 4.0 will be utilized for the description and grading of the AE. All symptoms, signs, or diseases assessed as experimental treatment-related will be captu","populationDescription":"no data was collected. Refers to the Cohort 1 Arm","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 12 weeks of completion of therapy","groups":[{"id":"OG000","title":"Cohort I (Initial IHC Within 42 Days)","description":"Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous HSCT, patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies"},{"id":"OG001","title":"Cohort II (Initial IHC Within 70 Days or After Relapse)","description":"Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Induction of Host T Cells Reactive With Tumor Associated Epitopes","description":"It will be determined if treatment with the irradiated cells induces an immune response targeting tumor associated epitopes.","populationDescription":"no data was collected","reportingStatus":"POSTED","timeFrame":"Up to 8 weeks after last protocol treatment","groups":[{"id":"OG000","title":"Cohort I (Initial IHC Within 42 Days)","description":"Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous HSCT, patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies"},{"id":"OG001","title":"Cohort II (Initial IHC Within 70 Days or After Relapse)","description":"Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to 8 weeks after last protocol treatment","description":"no data was collected. Adverse Events Description text only refers to the Cohort II No participants were enrolled in Cohort I, so no adverse events were monitored/assessed for Cohort I","eventGroups":[{"id":"EG000","title":"Cohort I (Initial IHC Within 42 Days)","description":"Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous HSCT, patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies","deathsNumAffected":0,"deathsNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"otherNumAffected":0,"otherNumAtRisk":0},{"id":"EG001","title":"Cohort II (Initial IHC Within 70 Days or After Relapse)","description":"Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Receive IHC\n\nIrradiated Allogeneic Cells: Correlative studies","deathsNumAffected":0,"deathsNumAtRisk":2,"seriousNumAffected":0,"seriousNumAtRisk":2,"otherNumAffected":2,"otherNumAtRisk":2}],"seriousEvents":[{"term":"Musculoskeletal and connective tissue disorders","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":0},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":2}]}],"otherEvents":[{"term":"General disorders and administration site conditions","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":0},{"groupId":"EG001","numAffected":2,"numAtRisk":2}]},{"term":"Investigations","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":0},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":2}]},{"term":"Eye disorders","organSystem":"Eye disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":0},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":2}]},{"term":"Metabolism and nutrition disorders","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":0},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":2}]},{"term":"Nervous system disorders","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":0},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":2}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Roger K. Strair, MD","organization":"Cancer Institute of New Jersey Rutgers","email":"strairrk@cinj.rutgers.edu","phone":"732-235-4523"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2021-04-23","uploadDate":"2023-02-28T17:04","filename":"Prot_SAP_000.pdf","size":11605725},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2021-04-23","uploadDate":"2023-02-22T14:18","filename":"ICF_001.pdf","size":1281809}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D054198","term":"Precursor Cell Lymphoblastic Leukemia-Lymphoma"},{"id":"C538045","term":"Chromosome 17 deletion"},{"id":"D020522","term":"Lymphoma, Mantle-Cell"},{"id":"D018365","term":"Neoplasm, Residual"},{"id":"D009190","term":"Myelodysplastic Syndromes"},{"id":"D008228","term":"Lymphoma, Non-Hodgkin"},{"id":"D009101","term":"Multiple Myeloma"},{"id":"D016403","term":"Lymphoma, Large B-Cell, Diffuse"},{"id":"D019337","term":"Hematologic Neoplasms"},{"id":"D016399","term":"Lymphoma, T-Cell"}],"ancestors":[{"id":"D007945","term":"Leukemia, Lymphoid"},{"id":"D007938","term":"Leukemia"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D006402","term":"Hematologic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D008232","term":"Lymphoproliferative Disorders"},{"id":"D008206","term":"Lymphatic Diseases"},{"id":"D007160","term":"Immunoproliferative Disorders"},{"id":"D007154","term":"Immune System Diseases"},{"id":"D008223","term":"Lymphoma"},{"id":"D009385","term":"Neoplastic Processes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"},{"id":"D001855","term":"Bone Marrow Diseases"},{"id":"D054219","term":"Neoplasms, Plasma Cell"},{"id":"D020141","term":"Hemostatic Disorders"},{"id":"D014652","term":"Vascular Diseases"},{"id":"D002318","term":"Cardiovascular Diseases"},{"id":"D010265","term":"Paraproteinemias"},{"id":"D001796","term":"Blood Protein Disorders"},{"id":"D006474","term":"Hemorrhagic Disorders"},{"id":"D016393","term":"Lymphoma, B-Cell"},{"id":"D009371","term":"Neoplasms by Site"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT02065609","orgStudyIdInfo":{"id":"201307037"},"secondaryIdInfos":[{"id":"R21CA182945","type":"NIH","link":"https://reporter.nih.gov/quickSearch/R21CA182945"}],"organization":{"fullName":"Washington University School of Medicine","class":"OTHER"},"briefTitle":"89ZrTrastuzumab Breast Imaging With Positron Emission Tomography","officialTitle":"Assessment of HER2 Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using 89 Zr-Trastuzumab"},"statusModule":{"statusVerifiedDate":"2022-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-02"},"primaryCompletionDateStruct":{"date":"2017-12-31","type":"ACTUAL"},"completionDateStruct":{"date":"2018-02-13","type":"ACTUAL"},"studyFirstSubmitDate":"2014-02-05","studyFirstSubmitQcDate":"2014-02-14","studyFirstPostDateStruct":{"date":"2014-02-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2022-07-20","resultsFirstSubmitQcDate":"2022-10-03","resultsFirstPostDateStruct":{"date":"2022-10-06","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-10-05","lastUpdatePostDateStruct":{"date":"2022-10-13","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Farrokh Dehdashti","investigatorTitle":"Professor of Radiology","investigatorAffiliation":"Washington University School of Medicine"},"leadSponsor":{"name":"Washington University School of Medicine","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The main purpose of this study is to see if Positron Emission Tomography (PET-Imaging) with 89Zr labeled trastuzumab can detect trastuzumab (HER2) positive breast cancer."},"conditionsModule":{"conditions":["Breast Cancer"],"keywords":["Trastuzumab"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"DIAGNOSTIC","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":52,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort 1","type":"EXPERIMENTAL","description":"89Zr-Trastuzumab Human Dosimetry and Safety","interventionNames":["Drug: 89Zr-Trastuzumab Human Dosimetry and Safety","Drug: HER2 Positive Lesion Detection and Safety"]},{"label":"Cohort 2: Lesion Detection and Safety","type":"EXPERIMENTAL","description":"HER2 Positive Lesion Detection and Safety","interventionNames":["Drug: 89Zr-Trastuzumab Human Dosimetry and Safety","Drug: HER2 Positive Lesion Detection and Safety"]}],"interventions":[{"type":"DRUG","name":"89Zr-Trastuzumab Human Dosimetry and Safety","description":"PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety","armGroupLabels":["Cohort 1","Cohort 2: Lesion Detection and Safety"]},{"type":"DRUG","name":"HER2 Positive Lesion Detection and Safety","description":"Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging","armGroupLabels":["Cohort 1","Cohort 2: Lesion Detection and Safety"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Adverse Events as a Measure of Safety and Tolerability After 89Zr-Trastuzumab Administration","description":"Subjects medical record was followed for 30 days following 89Zr-Trastuzumab Administration for AE Assessment with AE being defined as Any unfavorable medical occurrence in a human subject who receives 89Zr-Trastuzumab and PET/CT imaging, including any abnormal sign, symptom, or disease. The event does not necessarily have to be causally related to injection of 89Zr-Trastuzumab or PET/CT imaging to qualify as an adverse event, just temporally related.","timeFrame":"30 Days following 89Zr-Trastuzumab Administration"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female patients 18 years of age or older\n* Cohort 1: Her2-positive (defined as 3+) or FISH HER2:CEP17 ratio \\> 2 biopsy proven breast cancer\n* Cohort 2: Her2-positive (defined as 3+) or FISH HER2:CEP17 ratio \\> 2 OR HER2negative (0 or 1+, 2+ and FISH negative) biopsy-proven breast cancer\n* Primary or recurrent/metastatic lesion size  1.5 cm as determined by imaging studies (ultrasonography, mammography, CT or MRI) or physical examination\n* Able to give informed consent\n* Not currently pregnant or nursing: Subject must be surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (cessation of menses for more than 1 year), non-lactating, or of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of 89Zr-trastuzumab) is negative\n* Patients currently receiving trastuzumab therapy with or without other types of systemic therapy can participate if their disease progresses (development of new lesion(s) or worsening of known lesion(s) based on imaging modalities or physical examination.\n\nExclusion Criteria:\n\n* Patients with other invasive malignancies, with the exception of non- melanoma skin cancer, who had (or have) any evidence of the other cancer present within the last 5 years\n* Unable to tolerate 60 min of PET imaging per imaging session","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Farrokh Dehdashti, MD","affiliation":"Washington University School of Medicine","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Washington University School of Medicine @ Barnes-Jewish Hospital","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Study first enrollment occurred in February 2014 and closed to enrollment 31 December 2017. Subjects were recruited from those patients being seen by medical oncology at Siteman Cancer Center. Planned enrollment was 67 participants with a total of 52 subjects enrolled with evaluable data at the end of the grant period.","groups":[{"id":"FG000","title":"Cohort 1","description":"89Zr-Trastuzumab Human Dosimetry and Safety\n\n89Zr-Trastuzumab Human Dosimetry and Safety: PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety\n\nHER2 Positive Lesion Detection and Safety: Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging"},{"id":"FG001","title":"Cohort 2: Lesion Detection and Safety","description":"HER2 Positive Lesion Detection and Safety\n\n89Zr-Trastuzumab Human Dosimetry and Safety: PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety\n\nHER2 Positive Lesion Detection and Safety: Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"40"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"40"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Cohort 1","description":"89Zr-Trastuzumab Human Dosimetry and Safety\n\n89Zr-Trastuzumab Human Dosimetry and Safety: PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety\n\nHER2 Positive Lesion Detection and Safety: Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging"},{"id":"BG001","title":"Cohort 2: Lesion Detection and Safety","description":"HER2 Positive Lesion Detection and Safety\n\n89Zr-Trastuzumab Human Dosimetry and Safety: PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety\n\nHER2 Positive Lesion Detection and Safety: Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"52"}]}],"measures":[{"title":"Age, Customized","paramType":"MEAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56.9","lowerLimit":"29","upperLimit":"74"},{"groupId":"BG001","value":"56","lowerLimit":"37","upperLimit":"78"},{"groupId":"BG002","value":"56.5","lowerLimit":"29","upperLimit":"78"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"52"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"51"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"52"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events as a Measure of Safety and Tolerability After 89Zr-Trastuzumab Administration","description":"Subjects medical record was followed for 30 days following 89Zr-Trastuzumab Administration for AE Assessment with AE being defined as Any unfavorable medical occurrence in a human subject who receives 89Zr-Trastuzumab and PET/CT imaging, including any abnormal sign, symptom, or disease. The event does not necessarily have to be causally related to injection of 89Zr-Trastuzumab or PET/CT imaging to qualify as an adverse event, just temporally related.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"30 Days following 89Zr-Trastuzumab Administration","groups":[{"id":"OG000","title":"Cohort 1","description":"89Zr-Trastuzumab Human Dosimetry and Safety\n\n89Zr-Trastuzumab Human Dosimetry and Safety: PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety\n\nHER2 Positive Lesion Detection and Safety: Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging"},{"id":"OG001","title":"Cohort 2: Lesion Detection and Safety","description":"HER2 Positive Lesion Detection and Safety\n\n89Zr-Trastuzumab Human Dosimetry and Safety: PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety\n\nHER2 Positive Lesion Detection and Safety: Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Subjects were monitored for adverse events for the 30 days following 89Zr-Trastuzumab administration","description":"AE assessment was based on the following: Any unfavorable medical occurrence in a human subject who receives 89Zr-Trastuzumab and PET/CT imaging, including any abnormal sign, symptom, or disease. The event does not necessarily have to be causally related to injection of 89Zr-Trastuzumab or PET/CT imaging to qualify as an adverse event, just temporally related. The event of kidney injury and sepsis noted at 30 day follow up was directly related to SOC therapy and not considered study related AE","eventGroups":[{"id":"EG000","title":"Cohort 1","description":"89Zr-Trastuzumab Human Dosimetry and Safety\n\n89Zr-Trastuzumab Human Dosimetry and Safety: PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety\n\nHER2 Positive Lesion Detection and Safety: Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":1,"otherNumAtRisk":12},{"id":"EG001","title":"Cohort 2: Lesion Detection and Safety","description":"HER2 Positive Lesion Detection and Safety\n\n89Zr-Trastuzumab Human Dosimetry and Safety: PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety\n\nHER2 Positive Lesion Detection and Safety: Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging","deathsNumAffected":0,"deathsNumAtRisk":40,"seriousNumAffected":0,"seriousNumAtRisk":40,"otherNumAffected":1,"otherNumAtRisk":40}],"otherEvents":[{"term":"non-neutropenic fever","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"One Cohort 1 subject presented with non-neutropenic fever and flu like symptoms 1 day after administration of 89Zr-Trastuzumab and 2 days after receiving standard of care chemotherapy. Subject had similar presentation with prior cycle of SOC therapy","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":40}]},{"term":"Flu Like Symptoms","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"One Cohort 1 subject presented with non-neutropenic fever and flu like symptoms 1 day after administration of 89Zr-Trastuzumab and 2 days after receiving standard of care chemotherapy. Subject had similar presentation with prior cycle of SOC therapy","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":40}]},{"term":"Acute Kidney Injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Cohort 2 subject presented 26 days post administration of 89Zr-Trastuzumab with sepsis and renal injury","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":40}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Cohort 2 subject presented 26 days post administration of 89Zr-Trastuzumab with sepsis and renal injury","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":40}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Dr. Farrokh Dehdashti","organization":"Washington University School of Medicine in St. Louis","email":"dehdashtif@wustl.edu","phone":"314-362-1474"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP_ICF","hasProtocol":true,"hasSap":true,"hasIcf":true,"label":"Study Protocol, Statistical Analysis Plan, and Informed Consent Form","date":"2018-03-14","uploadDate":"2021-10-21T14:54","filename":"Prot_SAP_ICF_000.pdf","size":1607031}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D001943","term":"Breast Neoplasms"}],"ancestors":[{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D001941","term":"Breast Diseases"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D012449","term":"Safety"}],"ancestors":[{"id":"D000056","term":"Accident Prevention"},{"id":"D000059","term":"Accidents"},{"id":"D011634","term":"Public Health"},{"id":"D004778","term":"Environment and Public Health"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT03132467","orgStudyIdInfo":{"id":"2016-0902"},"secondaryIdInfos":[{"id":"NCI-2018-01189","type":"REGISTRY","domain":"CTRP (Clinical Trial Reporting Program)"},{"id":"2016-0902","type":"OTHER","domain":"M D Anderson Cancer Center"}],"organization":{"fullName":"M.D. Anderson Cancer Center","class":"OTHER"},"briefTitle":"Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer","officialTitle":"A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab [MEDI4736]) Plus Anti-CTLA-4 Antibody (Tremelimumab) in Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer"},"statusModule":{"statusVerifiedDate":"2024-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-06-13","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-01-31","type":"ACTUAL"},"completionDateStruct":{"date":"2024-05-20","type":"ACTUAL"},"studyFirstSubmitDate":"2017-04-25","studyFirstSubmitQcDate":"2017-04-26","studyFirstPostDateStruct":{"date":"2017-04-27","type":"ACTUAL"},"resultsFirstSubmitDate":"2021-12-28","resultsFirstSubmitQcDate":"2022-01-26","resultsFirstPostDateStruct":{"date":"2022-02-17","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-05-21","lastUpdatePostDateStruct":{"date":"2024-06-05","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"M.D. Anderson Cancer Center","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This early phase I trial studies the side effects of durvalumab and tremelimumab before surgery in treating patients with hormone receptor positive, HER2 negative stage II-III breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.","detailedDescription":"PRIMARY OBJECTIVES:\n\nI. To evaluate the feasibility of enrolling patients with hormone receptor positive (HR+)/human epidermal growth factor receptor negative (HER2-) breast cancer onto a trial evaluating investigational agents prior to initiating standard neoadjuvant chemotherapy.\n\nII. To evaluate the safety and tolerability of tremelimumab plus durvalumab in patients with HR+/HER2- breast cancer.\n\nSECONDARY OBJECTIVES:\n\nI. To assess immunologic/molecular responses to tremelimumab and durvalumab in patients with HR+/HER2- breast cancer who receive the combination therapy.\n\nEXPLORATORY OBJECTIVES:\n\nI. To evaluate the pathologic response in patients with HR+/HER2- breast cancer receiving tremelimumab plus durvalumab prior to initiating standard neoadjuvant chemotherapy.\n\nOUTLINE:\n\nPatients receive tremelimumab intravenously (IV) over 1 hour and durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo a biopsy and receive standard of care neoadjuvant chemotherapy before undergoing surgery.\n\nAfter completion of study treatment, patients are followed up until the time of surgery."},"conditionsModule":{"conditions":["Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Estrogen Receptor Positive","HER2/Neu Negative","Progesterone Receptor Positive","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":16,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment (tremelimumab, durvalumab)","type":"EXPERIMENTAL","description":"Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo a biopsy and receive standard of care neoadjuvant chemotherapy before undergoing surgery.","interventionNames":["Biological: Durvalumab","Biological: Tremelimumab"]}],"interventions":[{"type":"BIOLOGICAL","name":"Durvalumab","description":"Given IV","armGroupLabels":["Treatment (tremelimumab, durvalumab)"],"otherNames":["Imfinzi","Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer","MEDI-4736","MEDI4736"]},{"type":"BIOLOGICAL","name":"Tremelimumab","description":"Given IV","armGroupLabels":["Treatment (tremelimumab, durvalumab)"],"otherNames":["Anti-CTLA4 Human Monoclonal Antibody CP-675,206","CP-675","CP-675,206","CP-675206","Ticilimumab"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Feasibility of Enrolling 15 Patients Within 2 Years","description":"Feasibility established if all 15 patients enroll within 12 months of starting the study. The start date for measuring feasibility will be the date the first patient is screened.","timeFrame":"Up to 2 years"},{"measure":"Safety and Tolerability of Tremelimumab Plus Durvalumab in Participants With HR+/HER2 Neg Breast Cancer.","description":"To evaluate the safety and tolerability of tremelimumab plus durvalumab in patients with HR+/HER2 neg breast cancer. Adverse events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event \\[CTCAE\\] v4.03.","timeFrame":"2 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent and any locally-required authorization (e.g., Health Insurance Portability and Accountability Act \\[HIPAA\\]) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Hormone receptor positive (defined as estrogen receptor \\[ER\\] and/or progesterone receptor \\[PR\\] positive), HER2 negative breast cancer that is clinically staged II-III with no known metastatic disease. ER and/or PR defined as positive if expression \\> 10% by immunohistochemistry (IHC). HER2 negative or non-amplified as determined by the current American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) criteria which are as follows: HER2 testing by immunohistochemistry (IHC) as 0 or 1+. If HER2 is 2+, ISH (in situ hybridization) must be performed. HER2 is positive if: IHC 3+ based on circumferential membrane staining that is complete, intense ISH positive based on: 1) Single-probe average HER2 copy number \\>= 6.0 signals/cell, 2) Dual-probe HER2/CEP17 ratio \\>= 2.0; c,e with an average HER2 copy number \\>= 4.0 signals/cell, 3) Dual-probe HER2/CEP17 ratio \\>= 2.0; c,e with an average HER2 copy number \\< 4.0 signals/cell, 4) Dual-probe HER2/CEP17 ratio \\< 2.0; c,e with an average HER2 copy number \\>= 6.0 signals/cell\n* Chemotherapy is planned for the patient in the neoadjuvant setting\n* Hemoglobin \\>= 9.0 g/dL\n* Absolute neutrophil count (ANC) \\>=1.5 x 10\\^9/L (\\>= 1500 per mm\\^3)\n* Platelet count \\>= 100 x 10\\^9/L (\\>= 100,000 per mm\\^3)\n* Serum bilirubin =\\< 1.5 x institutional upper limit of normal (ULN). This will not apply to subjects with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only upon treating physician, principal investigators (PI) or co-PIs approval\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\< 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be =\\< 5 x ULN\n* Creatinine clearance (CL) \\> 40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance\n* Female subjects must either be of non-reproductive potential (i.e., post-menopausal by history: \\>= 60 years old and no menses for \\>= 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative urine pregnancy test upon study entry\n* Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up\n\nExclusion Criteria:\n\n* Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)\n* Participation in another clinical study with an investigational product during the last 1 month prior to initiation of therapy\n* Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab or an anti-CTLA4, including tremelimumab\n* History of another primary malignancy except for:\n\n  * Malignancy treated with curative intent and with no known active disease \\>= 5 years before the first dose of study drug and of low potential risk for recurrence\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n  * Adequately treated carcinoma in situ without evidence of disease e.g., cervical cancer in situ\n* Has received therapy for this current diagnosis of breast cancer including endocrine therapy or chemotherapy\n* A single QT interval corrected for heart rate (QTc) \\>= 470 ms. If an electrocardiogram (ECG) is interpreted to be a prolonged QT interval, 2 additional ECGs will be obtained and the PI will then evaluate all three ECGs and determine whether the patient should be excluded. Mean QT interval corrected for heart rate (QTc) \\>= 470 ms calculated from 3 electrocardiograms (ECGs) using Fridericia's correction\n* Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid\n* Active or prior documented autoimmune disease within the past 2 years\n\n  * NOTE: Subjects with vitiligo, Graves disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded\n* Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)\n* History of primary immunodeficiency\n* History of allogeneic organ transplant\n* History of hypersensitivity to durvalumab or tremelimumab or any excipient\n* History of hypersensitivity to the combination or comparator agent (if applicable)\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent\n* Known history of previous clinical diagnosis of tuberculosis\n* History of leptomeningeal carcinomatosis\n* Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab\n* Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control\n* Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results\n* Subjects with uncontrolled seizures","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Jennifer K Litton","affiliation":"M.D. Anderson Cancer Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"M D Anderson Cancer Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}}]},"referencesModule":{"seeAlsoLinks":[{"label":"University of Texas MD Anderson Cancer Center Website","url":"http://www.mdanderson.org"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"16 participants enrolled, 8 participants were inevaluable.","recruitmentDetails":"This was a feasibility trial of combined checkpoint blockade in patients with HR+/HER2 neg primary breast cancer to determine whether the strategy of combined checkpoint blockade therapy prior to chemotherapy could be an effective frontline therapy. Patients were eligible if they had hormone receptor positive, HER2 negative breast cancer and had neoadjuvant chemotherapy planned.","groups":[{"id":"FG000","title":"Treatment (Tremelimumab, Durvalumab)","description":"Patients were treated with durvalumab at a dose of 1500 mg and tremelimumab at a dose of 75 mg, both administered IV, for 2 cycles on days 1 and 28 Patients then received standard neoadjuvant chemotherapy prior to breast surgery Pre- and post-treatment tumor biopsies and blood samples were available for 5 out of 8 patients and were analyzed by CyTOF, IHC, and NanoString\""}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"8"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Treatment (Tremelimumab, Durvalumab)","description":"Patients were treated with durvalumab at a dose of 1500 mg and tremelimumab at a dose of 75 mg, both administered IV, for 2 cycles on days 1 and 28 Patients then received standard neoadjuvant chemotherapy prior to breast surgery Pre- and post-treatment tumor biopsies and blood samples were available for 5 out of 8 patients and were analyzed by CyTOF, IHC, and NanoString\""}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"8"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"55","lowerLimit":"47","upperLimit":"66"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"8"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"8"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"7"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Feasibility of Enrolling 15 Patients Within 2 Years","description":"Feasibility established if all 15 patients enroll within 12 months of starting the study. The start date for measuring feasibility will be the date the first patient is screened.","populationDescription":"The trials primary endpoint of 15 participants enrollment feasibility within 2 years was NOT met due to early termination of the study.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 2 years","groups":[{"id":"OG000","title":"Treatment (Tremelimumab, Durvalumab)","description":"Patients were treated with durvalumab at a dose of 1500 mg and tremelimumab at a dose of 75 mg, both administered IV, for 2 cycles on days 1 and 28 Patients then received standard neoadjuvant chemotherapy prior to breast surgery Pre- and post-treatment tumor biopsies and blood samples were available for 5 out of 8 patients and were analyzed by CyTOF, IHC, and NanoString\""}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]}]},{"type":"PRIMARY","title":"Safety and Tolerability of Tremelimumab Plus Durvalumab in Participants With HR+/HER2 Neg Breast Cancer.","description":"To evaluate the safety and tolerability of tremelimumab plus durvalumab in patients with HR+/HER2 neg breast cancer. Adverse events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event \\[CTCAE\\] v4.03.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"adverse events","timeFrame":"2 months","groups":[{"id":"OG000","title":"Treatment (Tremelimumab, Durvalumab)","description":"Participants with stage II or III HR+/HER2 negative breast cancer who were to receive neoadjuvant chemotherapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"classes":[{"title":"Serious Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"2 months","eventGroups":[{"id":"EG000","title":"Treatment (Tremelimumab, Durvalumab)","description":"Patients were treated with durvalumab at a dose of 1500 mg and tremelimumab at a dose of 75 mg, both administered IV, for 2 cycles on days 1 and 28 Patients then received standard neoadjuvant chemotherapy prior to breast surgery Pre- and post-treatment tumor biopsies and blood samples were available for 5 out of 8 patients and were analyzed by CyTOF, IHC, and NanoString\"","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":3,"seriousNumAtRisk":8,"otherNumAffected":8,"otherNumAtRisk":8}],"seriousEvents":[{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]}],"otherEvents":[{"term":"Conjunctivits","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Dysgeusia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Hot flashes","organSystem":"Endocrine disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Mucositis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":8}]},{"term":"Pruritis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":8}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"The trial was stopped early after 2 of 8 patients experienced G3 immunerelated adverse events."},"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Dr. Jennifer Litton, MD- VP, Clinical Research, Clinical Research","organization":"UT MD Anderson Cancer Center","email":"jlitton@mdanderson.org","phone":"(713) 792-2817"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2018-10-05","uploadDate":"2021-12-28T17:37","filename":"Prot_SAP_000.pdf","size":782902}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"interventionBrowseModule":{"meshes":[{"id":"C000613593","term":"durvalumab"},{"id":"D007074","term":"Immunoglobulin G"},{"id":"D004220","term":"Disulfides"},{"id":"C520704","term":"tremelimumab"}],"ancestors":[{"id":"D007132","term":"Immunoglobulin Isotypes"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D013440","term":"Sulfides"},{"id":"D000838","term":"Anions"},{"id":"D007477","term":"Ions"},{"id":"D004573","term":"Electrolytes"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D006862","term":"Hydrogen Sulfide"},{"id":"D013457","term":"Sulfur Compounds"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT01957709","orgStudyIdInfo":{"id":"2705.00"},"secondaryIdInfos":[{"id":"NCI-2013-01779","type":"REGISTRY","domain":"CTRP (Clinical Trial Reporting Program)"},{"id":"2705","type":"OTHER","domain":"Fred Hutchinson Cancer Research Center"},{"id":"2705.00","type":"OTHER","domain":"Fred Hutch/University of Washington Cancer Consortium"},{"id":"K12CA076930","type":"NIH","link":"https://reporter.nih.gov/quickSearch/K12CA076930"},{"id":"K23CA175167","type":"NIH","link":"https://reporter.nih.gov/quickSearch/K23CA175167"},{"id":"P30CA015704","type":"NIH","link":"https://reporter.nih.gov/quickSearch/P30CA015704"}],"organization":{"fullName":"Fred Hutchinson Cancer Center","class":"OTHER"},"briefTitle":"Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma","officialTitle":"A Pilot Study to Test Whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients With Synovial Sarcoma and Myxoid/Round Cell Liposarcoma"},"statusModule":{"statusVerifiedDate":"2019-06","overallStatus":"TERMINATED","whyStopped":"Enough samples were collected for data analysis.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-09-25","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-06-01","type":"ACTUAL"},"completionDateStruct":{"date":"2018-06-01","type":"ACTUAL"},"studyFirstSubmitDate":"2013-10-04","studyFirstSubmitQcDate":"2013-10-04","studyFirstPostDateStruct":{"date":"2013-10-08","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-05-28","resultsFirstSubmitQcDate":"2019-06-19","resultsFirstPostDateStruct":{"date":"2019-07-10","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-06-19","lastUpdatePostDateStruct":{"date":"2019-07-10","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Fred Hutchinson Cancer Center","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"},{"name":"Horizon Pharma USA, Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This pilot clinical trial studies the effect of recombinant interferon gamma on tissue in treating patients with soft tissue sarcoma. Interferon gamma may interfere with the growth of tumor cells.","detailedDescription":"PRIMARY OBJECTIVES:\n\nI. To determine whether systemic administration of interferon (IFN) gamma (recombinant interferon gamma) will increase class I major histocompatibility complex (MHC) expression in synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) tumors.\n\nSECONDARY OBJECTIVES:\n\nI. To determine whether systemic administration of IFN gamma will increase class II MHC expression in SS and MRCL tumors.\n\nII. To examine changes in the immune response to MRCL and SS by examining changes in the immune infiltrates, antibody response and antigen specific T cell response before and after IFN gamma treatment.\n\nOUTLINE:\n\nPatients receive recombinant interferon gamma subcutaneously (SC) every 7 days for 4 weeks before surgery.\n\nAfter completion of study, patients are followed up at 2 weeks post-surgery."},"conditionsModule":{"conditions":["Myxoid Liposarcoma","Round Cell Liposarcoma","Synovial Sarcoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","interventionModelDescription":"100 mcg/m2 weekly injection for four weeks","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":8,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Basic science (interferon gamma and MHC expression)","type":"EXPERIMENTAL","description":"Patients receive recombinant interferon gamma subcutaneously weekly for 4 weeks before surgery.","interventionNames":["Other: Laboratory Biomarker Analysis","Biological: Recombinant Interferon Gamma"]}],"interventions":[{"type":"OTHER","name":"Laboratory Biomarker Analysis","description":"Correlative studies","armGroupLabels":["Basic science (interferon gamma and MHC expression)"]},{"type":"BIOLOGICAL","name":"Recombinant Interferon Gamma","description":"Given subcutaneously weekly for four weeks prior to surgery.","armGroupLabels":["Basic science (interferon gamma and MHC expression)"],"otherNames":["Gamma Interferon (GEN)","Gamma Interferon-SCH","Gamma-Interferon","Ginterferon","IFN-g","Interferon Gamma","Interferon Gamma (BIO)","Interferon, Gamma"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in Class I Major Histocompatibility Complex (MHC) Expression After Treatment With IFN Gamma","description":"It would be highly relevant to observe marked increase macrophages (effect size \\> 2.5). Four patients gives over 90% power to detect such a large increase with a two-tailed alpha of 0.05.","timeFrame":"Baseline to up to 2 weeks post-surgery"}],"secondaryOutcomes":[{"measure":"MHC Class II Expression","description":"To determine whether systemic administration of IFNg will increase class II MHC expression in SS and MRCL tumors.","timeFrame":"Baseline to 2 weeks post biopsy."},{"measure":"Changes in Immune Response","description":"To examine changes in the immune response to MRCL and SS by examining changes in the immune infiltrates, antibody response and antigen specific T cell response before and after IFNg treatment.","timeFrame":"Baseline to 2 weeks post biopsy"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. A diagnosis of synovial sarcoma and myxoid/round cell liposarcoma\n2. Male or female subject, 18 or older\n3. A superficial tumor easily and safely accessible for a research biopsy or are being considered for resection or biopsy of their tumor as part of standard of care and have recent pathology.\n4. Zubrod performance status of '0-2' or Karnofsky score \\> 60%\n5. No treatment with systemic anti-cancer treatment (chemotherapy or biologics) within 2 weeks of starting interferon gamma\n6. Patients with a history of coronary artery disease must have had a normal stress test within 180 days of starting IFN gamma\n7. Must have been off metformin for at least 2 weeks prior to starting IFN gamma\n8. No use of full dose, therapeutic anti-coagulation. However, low dose warfarin for catheter prophylaxis or acetylsalicylic acid are acceptable.\n9. No thrombotic event within 6 months (deep vein thrombosis, pulmonary embolism) of starting IFN gamma\n\nExclusion Criteria:\n\n1. Active infection requiring oral or intravenous antibiotics\n2. Pregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence. Women of childbearing potential must have a negative pregnancy test within two weeks prior to entry.\n3. Serum creatinine \\> 1.5 mg/dL or Glomerular Filtration Rate \\< 50\n4. Significant hepatic dysfunction (SGOT \\> 150 IU or \\> 3x upper limit of normal; bilirubin \\> 1.6 mg/dL; prothrombin time \\> 1.5x control).\n5. Known central nervous system (CNS) metastasis. Once CNS metastasis have been treated these patients may participate if they are otherwise good trial candidates.\n6. Current treatment with steroids (must be discontinued 1 week before starting IFN gamma)\n7. Hemoglobin A1C \\> 8.5%\n8. Uncontrolled hypertension, blood pressure (BP) \\> 150/100 mmHg; patients with elevated BP may enroll once BP is corrected\n9. Cancer/testis antigen 1B (NY-ESO-1) specific T cell therapy within 1 year of starting on the trial\n10. New (\\< 6 months) cardiac arrhythmia (electrocardiogram \\[EKG\\] should be performed within 2 weeks of starting IFN gamma).\n11. History of clinically significant congestive heart failure.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Seth Pollack","affiliation":"Fred Hutch/University of Washington Cancer Consortium","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Fred Hutch/University of Washington Cancer Consortium","city":"Seattle","state":"Washington","zip":"98109","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}}]},"referencesModule":{"references":[{"pmid":"32269142","type":"DERIVED","citation":"Schroeder BA, Black RG, Spadinger S, Zhang S, Kohli K, Cao J, Mantilla JG, Conrad EU, Riddell SR, Jones RL, Yee C, Pollack SM. Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy. J Immunother Cancer. 2020 Apr;8(1):e000247. doi: 10.1136/jitc-2019-000247."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Recruitment was done in the Seattle Cancer Care Alliance medical clinic, or by patient referral.","groups":[{"id":"FG000","title":"Basic Science (Interferon Gamma and MHC Expression)","description":"Patients receive recombinant interferon gamma SC weekly for 4 weeks before surgery.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRecombinant Interferon Gamma: Given Subcutaneously"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"8"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"7"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Patient refused to complete post-tx bx","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Basic Science (Interferon Gamma and MHC Expression)","description":"Patients receive recombinant interferon gamma SC every 7 days for 4 weeks before surgery or thrice weekly for 2 weeks before surgery.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRecombinant Interferon Gamma: Given SC"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"8"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"6"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"2"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"3"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"5"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"7"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"2"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"6"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Class I Major Histocompatibility Complex (MHC) Expression After Treatment With IFN Gamma","description":"It would be highly relevant to observe marked increase macrophages (effect size \\> 2.5). Four patients gives over 90% power to detect such a large increase with a two-tailed alpha of 0.05.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"percentage of MHC Class I+ on tumor cell","timeFrame":"Baseline to up to 2 weeks post-surgery","groups":[{"id":"OG000","title":"Basic Science (Interferon Gamma and MHC Expression)","description":"Patients receive recombinant interferon gamma SC every 7 days for 4 weeks before surgery or thrice weekly for 2 weeks before surgery.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRecombinant Interferon Gamma: Given SC"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"classes":[{"title":"Pre-treatment","categories":[{"measurements":[{"groupId":"OG000","value":"8.91","lowerLimit":".131","upperLimit":"51.6"}]}]},{"title":"Post-treatment","categories":[{"measurements":[{"groupId":"OG000","value":"26.6","lowerLimit":"1.39","upperLimit":"92.2"}]}]}]},{"type":"SECONDARY","title":"MHC Class II Expression","description":"To determine whether systemic administration of IFNg will increase class II MHC expression in SS and MRCL tumors.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"percentage of MHC Class II on tumor cell","timeFrame":"Baseline to 2 weeks post biopsy.","groups":[{"id":"OG000","title":"Basic Science (Interferon Gamma and MHC Expression)","description":"Patients receive recombinant interferon gamma SC every 7 days for 4 weeks before surgery or thrice weekly for 2 weeks before surgery.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRecombinant Interferon Gamma: Given SC"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"classes":[{"title":"Pre-treatment","categories":[{"measurements":[{"groupId":"OG000","value":"2.556","lowerLimit":"0.0","upperLimit":"6.10"}]}]},{"title":"Post-treatment","categories":[{"measurements":[{"groupId":"OG000","value":"6.125","lowerLimit":"0.0","upperLimit":"10.5"}]}]}]},{"type":"SECONDARY","title":"Changes in Immune Response","description":"To examine changes in the immune response to MRCL and SS by examining changes in the immune infiltrates, antibody response and antigen specific T cell response before and after IFNg treatment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"percentage of T cells","timeFrame":"Baseline to 2 weeks post biopsy","groups":[{"id":"OG000","title":"Basic Science (Interferon Gamma and MHC Expression)","description":"Patients receive recombinant interferon gamma SC every 7 days for 4 weeks before surgery or thrice weekly for 2 weeks before surgery.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRecombinant Interferon Gamma: Given SC"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"classes":[{"title":"Pre-treatment","categories":[{"measurements":[{"groupId":"OG000","value":"0.14","lowerLimit":"0.015","upperLimit":"1.05"}]}]},{"title":"Post-treatment","categories":[{"measurements":[{"groupId":"OG000","value":"0.82","lowerLimit":"0.074","upperLimit":"3.39"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Patients will be evaluated at their baseline visit prior to administration of the IFNg through two weeks following their surgery. Ideally this will be a period of 6-10 weeks, depending on the number of times a patient received IFNg subcutaneously and when their surgery was scheduled.","eventGroups":[{"id":"EG000","title":"Basic Science (Interferon Gamma and MHC Expression)","description":"Patients receive recombinant interferon gamma SC every 7 days for 4 weeks before surgery or thrice weekly for 2 weeks before surgery.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRecombinant Interferon Gamma: Given SC","deathsNumAffected":7,"deathsNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":8,"otherNumAtRisk":8}],"otherEvents":[{"term":"Flu-like symptoms","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1: all events","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":8}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1: 4 events Grade 2: 1 event","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":8}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1: all events","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":8}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1: all events","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":8}]},{"term":"Fever","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1: all events","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":8}]},{"term":"Body Aches","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1: all events","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":8}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1: all events","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":8}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Night Sweats","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Paresthesia","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Upper Respiratory Infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 2","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 3","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Biopsy site pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 2","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Early termination of trial due to collection of enough data necessary to complete analysis."},"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Seth Pollack, MD","organization":"Fred Hutchinson Cancer Research Center","email":"spollack@fredhutch.org","phone":"206-667-6629"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2018-09-12","uploadDate":"2019-05-17T15:41","filename":"Prot_SAP_000.pdf","size":537721}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D018208","term":"Liposarcoma, Myxoid"},{"id":"D013584","term":"Sarcoma, Synovial"}],"ancestors":[{"id":"D008080","term":"Liposarcoma"},{"id":"D018205","term":"Neoplasms, Adipose Tissue"},{"id":"D018204","term":"Neoplasms, Connective and Soft Tissue"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D012509","term":"Sarcoma"},{"id":"D009372","term":"Neoplasms, Connective Tissue"}]},"interventionBrowseModule":{"meshes":[{"id":"D007371","term":"Interferon-gamma"}],"ancestors":[{"id":"D007372","term":"Interferons"},{"id":"D016207","term":"Cytokines"},{"id":"D036341","term":"Intercellular Signaling Peptides and Proteins"},{"id":"D010455","term":"Peptides"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D016215","term":"Macrophage-Activating Factors"},{"id":"D008222","term":"Lymphokines"},{"id":"D011506","term":"Proteins"},{"id":"D001685","term":"Biological Factors"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT02827838","orgStudyIdInfo":{"id":"IRB00038877"},"secondaryIdInfos":[{"id":"NCI-2016-00639","type":"REGISTRY","domain":"CTRP (Clinical Trial Reporting Program)"},{"id":"CCCWFU 60116","type":"OTHER","domain":"Comprehensive Cancer Center of Wake Forest University"},{"id":"P30CA012197","type":"NIH","link":"https://reporter.nih.gov/quickSearch/P30CA012197"}],"organization":{"fullName":"Wake Forest University Health Sciences","class":"OTHER"},"briefTitle":"Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer","officialTitle":"Pilot Study to Evaluate the Anti-Tumor Effect of Durvalumab (Medi4736) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN), Human Papilloma Virus (HPV) Positive Versus Negative, When Treated Before Surgery"},"statusModule":{"statusVerifiedDate":"2025-02","overallStatus":"TERMINATED","whyStopped":"Study closed prior to meeting enrollment goal and funding issues","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-04-22","type":"ACTUAL"},"completionDateStruct":{"date":"2022-04-22","type":"ACTUAL"},"studyFirstSubmitDate":"2016-05-20","studyFirstSubmitQcDate":"2016-07-06","studyFirstPostDateStruct":{"date":"2016-07-11","type":"ESTIMATED"},"resultsFirstSubmitDate":"2024-06-18","resultsFirstSubmitQcDate":"2025-02-26","resultsFirstPostDateStruct":{"date":"2025-03-17","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-02-26","lastUpdatePostDateStruct":{"date":"2025-03-17","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Wake Forest University Health Sciences","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This pilot clinical trial studies how well durvalumab before surgery works in treating patients with oral cavity or oropharynx cancer. Monoclonal antibodies, such as durvalumab, may interfere with the ability of tumor cells to grow and spread.","detailedDescription":"PRIMARY OBJECTIVES:\n\nI. To investigate the effect of durvalumab on local and systemic immune activation by HPV status in patients with oral cavity and oropharynx head and neck squamous cell carcinoma (HNSCC).\n\nII. To examine the effects of durvalumab on systemic immune response to HPV and tumor associated antigens.\n\nIII. To examine the effects of durvalumab on immune regulatory mechanisms. IV. To explore the association between levels of immune-regulatory micro-ribonucleic acid (miR) in plasma and saliva and immune response.\n\nSECONDARY OBJECTIVES:\n\nI. Investigate the effect of the treatment with durvalumab on the computed tomography (CT) scan and positron emission tomography (PET) scan response.\n\nII. Evaluate the safety of a short induction treatment with durvalumab.\n\nOUTLINE:\n\nPatients receive durvalumab intravenously (IV) over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nAfter completion of study treatment, patients are followed up for 90 days."},"conditionsModule":{"conditions":["Human Papillomavirus Infection","Stage I Oral Cavity Squamous Cell Carcinoma","Stage I Oropharyngeal Squamous Cell Carcinoma","Stage II Oral Cavity Squamous Cell Carcinoma","Stage II Oropharyngeal Squamous Cell Carcinoma","Stage III Oral Cavity Squamous Cell Carcinoma","Stage III Oropharyngeal Squamous Cell Carcinoma","Stage IVA Oral Cavity Squamous Cell Carcinoma","Stage IVA Oropharyngeal Squamous Cell Carcinoma","Stage IVB Oral Cavity Squamous Cell Carcinoma","Stage IVB Oropharyngeal Squamous Cell Carcinoma","Stage IVC Oropharyngeal Squamous Cell Carcinoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":17,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment (durvalumab, surgery)","type":"EXPERIMENTAL","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.","interventionNames":["Biological: Durvalumab","Other: Laboratory Biomarker Analysis","Procedure: Therapeutic Conventional Surgery"]}],"interventions":[{"type":"BIOLOGICAL","name":"Durvalumab","description":"Given IV","armGroupLabels":["Treatment (durvalumab, surgery)"],"otherNames":["Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer","MEDI-4736","MEDI4736"]},{"type":"OTHER","name":"Laboratory Biomarker Analysis","description":"Correlative studies","armGroupLabels":["Treatment (durvalumab, surgery)"]},{"type":"PROCEDURE","name":"Therapeutic Conventional Surgery","description":"Undergo surgery","armGroupLabels":["Treatment (durvalumab, surgery)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Immune Effector Assessed in Blood by Flow Cytometry and in Tissue by Immunohistochemistry","description":"Concentration of certain immune effector will be assessed in blood pre- and post- treatment. Descriptive statistics, confidence intervals will be calculated and 2-sample t-tests will be performed. Tumor-infiltrating immune-regulator and effector cells will be quantified (0 to 3+) using standing immunofluorescence techniques. Counts and percents will be calculated for these measures overall and by HPV (+/-) groups pre- and post-treatment. Fisher exact tests will be used to compare groups at pre- and post- treatment. Stuart-Maxwell tests (generalizations of the McNemar's Test","timeFrame":"Up to 18 months"},{"measure":"Immune-regulatory miR Responses as Measured in Plasma Assessed by Quantitative Reverse Transcriptase PCR (qRT-PCR)","description":"Percent change of levels of immune-regulatory miRs assessed in plasma assessed pre-treatment and one week post-treatment.","timeFrame":"At baseline and at one week post treatment start"},{"measure":"Systemic Immune Response to HPV Assessed by Enzyme-linked Immunosorbent Assay (ELISA)","description":"Lab results will be compared between patients who are HPV+ and HPV- using 2 sample t-tests. These measures will be compared in several ways. First, baseline, pre-treatment levels will be examined using descriptive statistics (n, mean, standard deviations, range). These measures will be examined overall and by HPV (+/-) groups. For each measure, and time point, 95% confidence intervals will be estimated. Next, two sample t-tests will be performed to compare levels of the measures at baseline. Next, measures taken post-treatment will be examined in a similar manner (descriptive statistics and 2-","timeFrame":"Up to 18 months"},{"measure":"Regulatory Responses Assessed in Blood by Flow Cytometry and in Tissue by Immunohistochemistry","description":"Concentration of certain regulatory cells will be assessed in blood pre- and post- treatment. Descriptive statistics, confidence intervals will be calculated and 2-sample t-tests will be performed. Tumor-infiltrating immune-regulator and effector cells will be quantified (0 to 3+) using standing immunofluorescence techniques. Counts and percents will be calculated for these measures overall and by HPV (+/-) groups pre- and post-treatment. Fisher exact tests will be used to compare groups at pre- and post- treatment. Stuart-Maxwell tests (generalizations of the McNemar's Tes","timeFrame":"Up to 18 months"},{"measure":"Immune-regulatory miR Responses as Measured in Saliva Assessed by Quantitative Reverse Transcriptase PCR (qRT-PCR)","description":"Percent change of levels of immune-regulatory miRs assessed in saliva assessed pre-treatment and one week post-treatment.","timeFrame":"Baseline and one week post treatment start"},{"measure":"Immune-regulatory miR Responses as Measured in Tumor Tissue Assessed by Quantitative Reverse Transcriptase PCR (qRT-PCR)","description":"Levels of immune-regulatory miRs assessed in blood, saliva and tumor tissue will be assessed pre- and post- treatments. Descriptive statistics, confidence intervals will be calculated and 2-sample t-tests will be performed. In addition, correlations between the different methods will be examined (i.e., correlation between saliva and blood measures, saliva and tumor measures, and blood and tumor measures).","timeFrame":"Up to 18 months"},{"measure":"Systemic Immune Response to Tumor Associated Antigens Assessed by Enzyme-linked Immunosorbent Assay (ELISA)","description":"Lab results will be compared between patients who are HPV+ and HPV- using 2 sample t-tests. These measures will be compared in several ways. First, baseline, pre-treatment levels will be examined using descriptive statistics (n, mean, standard deviations, range). These measures will be examined overall and by HPV (+/-) groups. For each measure, and time point, 95% confidence intervals will be estimated. Next, two sample t-tests will be performed to compare levels of the measures at baseline. Next, measures taken post-treatment will be examined in a similar manner (descriptive statistics and 2-","timeFrame":"Up to 18 months"}],"secondaryOutcomes":[{"measure":"Incidence of Adverse Events (AEs) as Measured by CTCAE Version 4.03","description":"AEs will be coded using the Medical Dictionary for Regulatory Activities to their organ class by preferred term. Coded AEs will be displayed by frequency, severity, and relationship to treatment (durvalumab) in the safety population. In addition, summary tables will be generated for the following situations: 1) fatigue, diarrhea, nausea and skin rash; 2) Immune-mediated reactions of any grade; 3) other adverse events graded as 3 or more by CTCAE Version 4.03; 4) Durvalumab dose reductions; 5) discontinuations of treatment with durvalumab, with specification of reason for discontinuation; and 6) changes in the surgical treatment schedule. Toxicity grades Grade I (mild), Grade II (moderate), Grade III (severe), Grade IV (life threatening) and Grade V (fatal). Toxicities of greater than or equal to Grade III (except infusion reaction) are considered worse outcomes.","timeFrame":"At baseline (pre-treatment), during scheduled treatment and up to the 90-day follow up period after the last dose of study drug administered, with a median of 1 month and maximum of 13 months"},{"measure":"Standardized Uptake Value (SUV) as Measured by PET Scans","description":"Change in SUV activity as measured by PET scans from baseline to post-treatment not specific to HPV status.","timeFrame":"Up to 18 months"},{"measure":"Tumor Diameter Assessed Using RECIST Version 1.1 Criteria","description":"Change in tumor diameters will be compared between groups (HPV +/-) pre- and post- treatment.","timeFrame":"Up to 18 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed HNSCC of the oral cavity (OC; more than 90% patients have HPV negative cancer) or oropharynx (about 60-80% of patient have HPV positive cancer)\n* Presence of radiologically of clinically documented disease. All radiology studies must be performed within 28 days prior to registration\n* Any stage, considered candidates for surgery and planned for surgery either by robotic or by standard surgical technique\n* Documentation of HPV tested by polymerase chain reaction (PCR) (resulted or pending)\n* Willing to provide consent for an additional tissue biopsy for research purposes, to allow a part of their surgical tumor tissue to be utilized for research (in case tumor tissue has not already been saved in the tumor tissue bank), and to donate samples of blood and saliva collected weekly through the treatment\n* All patients must have provided informed consent for correlative studies\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2\n* Patients must have no prior exposure to immune-mediated therapy, including anti- cytotoxic T-lymphocyte protein 4 (CTLA-4), anti-programmed cell death 1, anti-programmed cell death 1 ligand 1 (PD-L1), or anti-programmed cell death ligand 2 antibodies, excluding therapeutic anticancer vaccines\n* At least 1 lesion, not previously irradiated, that can be accurately measured at baseline as \\> or = 10 mm in the longest diameter (except lymph nodes, which must have a short axis \\> or = 15 mm) with CT or magnetic resonance imaging (MRI) or clinical measurement and that is suitable for accurate repeated measurements as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines\n* Previous surgery is permitted provided that a minimum of 28 days (4 weeks) have elapsed between any major surgery and date of registration, and that wound healing has occurred\n* Absolute neutrophil count (ANC) \\>= 1.5 x 10\\^9/L\n* Platelet count \\>= 100 x 10\\^9/L\n* Hemoglobin \\>= 9.0 g/dL\n* Serum bilirubin =\\< 1.5 x upper limit of normal (ULN) (institutional upper limit of normal)\n* Total bilirubin is less than or equal to ULN, except the case in which the elevated total bilirubin is not a sign of liver disease, such as the Gilbert Syndrome, in which case a Total Bilirubin less than or equal to 2X ULN is acceptable.\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\\< 2.5 x ULN\n* Serum creatinine clearance (CL) \\> 40 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection for determination of creatinine clearance\n* Female subjects must either be of non-reproductive potential (ie, post-menopausal by history: \\>= 60 years old and no menses for \\>= 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry\n* In accordance with National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) policy, protocol treatment is to begin within 2 working days of patient registration\n* Written informed consent and any locally-required authorization (e.g., Health Insurance Portability and Accountability Act \\[HIPAA\\] in the United States of American \\[USA\\], European Union \\[EU\\] Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations\n* Age 18 years or older at time of study entry.\n* Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up\n\nExclusion Criteria:\n\n* Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site). Previous enrollment in the present study\n* Participation in another clinical study with an investigational product during the last 6 months (mo)\n* Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab\n* Receipt of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) within the last 6 mo (before the first dose of Durvalumab).\n* Mean QT interval corrected for heart rate (corrected QT \\[QTc\\]) \\>= 470 ms calculated from 3 electrocardiograms (ECGs) using Fridericia's correction\n* Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid\n* Any unresolved toxicity (\\> Common Terminology Criteria for Adverse Events \\[CTCAE\\] grade 2) from previous anti-cancer therapy; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)\n* Any prior grade \\>= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE \\> grade 1\n* Active or prior documented autoimmune disease within the past 2 years; NOTE: Subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded\n* Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)\n* History of primary immunodeficiency\n* History of allogeneic organ transplant\n* History of hypersensitivity to durvalumab or any excipient\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent\n* Known history of previous clinical diagnosis of tuberculosis\n* Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab\n* Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control\n* Patients with body weight \\<= 30 kg\n* Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Mercedes Porosnicu","affiliation":"Wake Forest University Health Sciences","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Comprehensive Cancer Center of Wake Forest University","city":"Winston-Salem","state":"North Carolina","zip":"27157","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Treatment (Durvalumab, Surgery) HPV Negative","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nDurvalumab: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery\n\nHPV negative"},{"id":"FG001","title":"Treatment (Durvalumab, Surgery) HPV Positive","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nDurvalumab: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery\n\nHPV positive"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Treatment (Durvalumab, Surgery) - HPV Negative","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nDurvalumab: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery\n\nHPV negative"},{"id":"BG001","title":"Treatment (Durvalumab, Surgery) - HPV Positive","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nDurvalumab: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery\n\nHPV positive"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"17"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"58.5","spread":"9.2"},{"groupId":"BG001","value":"58.0","spread":"6.5"},{"groupId":"BG002","value":"58.3","spread":"8.1"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"6"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"11"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"16"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"17"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Immune Effector Assessed in Blood by Flow Cytometry and in Tissue by Immunohistochemistry","description":"Concentration of certain immune effector will be assessed in blood pre- and post- treatment. Descriptive statistics, confidence intervals will be calculated and 2-sample t-tests will be performed. Tumor-infiltrating immune-regulator and effector cells will be quantified (0 to 3+) using standing immunofluorescence techniques. Counts and percents will be calculated for these measures overall and by HPV (+/-) groups pre- and post-treatment. Fisher exact tests will be used to compare groups at pre- and post- treatment. Stuart-Maxwell tests (generalizations of the McNemar's Test","populationDescription":"This pre-specified outcome is dependent upon 1) patients having a measurable response and 2) availability of comparable cohorts of HPV positive and negative samples. Since there was a lack of measurable clinical response in all patients and the enrolled cohorts were unbalanced, the data for this outcome was not measured/evaluated and therefore is not available for analysis.","reportingStatus":"POSTED","timeFrame":"Up to 18 months","groups":[{"id":"OG000","title":"Treatment (Durvalumab, Surgery)","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nDurvalumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nTherapeutic Conventional Surgery: Undergo surgery"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"PRIMARY","title":"Immune-regulatory miR Responses as Measured in Plasma Assessed by Quantitative Reverse Transcriptase PCR (qRT-PCR)","description":"Percent change of levels of immune-regulatory miRs assessed in plasma assessed pre-treatment and one week post-treatment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"percent change from baseline","timeFrame":"At baseline and at one week post treatment start","groups":[{"id":"OG000","title":"Treatment (Durvalumab, Surgery) - HPV Negative","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nDurvalumab: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery\n\nHPV negative"},{"id":"OG001","title":"Treatment (Durvalumab, Surgery) - HPV Positive","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nDurvalumab: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery\n\nHPV positive"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"miR 146","categories":[{"measurements":[{"groupId":"OG000","value":"27.5","lowerLimit":"-24.5","upperLimit":"124.2"},{"groupId":"OG001","value":"1251.6","lowerLimit":"116.6","upperLimit":"6039.3"}]}]},{"title":"miR 155","categories":[{"measurements":[{"groupId":"OG000","value":"19.7","lowerLimit":"-24.2","upperLimit":"364.3"},{"groupId":"OG001","value":"814","lowerLimit":"100.7","upperLimit":"2154.9"}]}]},{"title":"miR 181","categories":[{"measurements":[{"groupId":"OG000","value":"25.7","lowerLimit":"1.7","upperLimit":"189.8"},{"groupId":"OG001","value":"893.2","lowerLimit":"107.8","upperLimit":"3880.8"}]}]},{"title":"miR 20a","categories":[{"measurements":[{"groupId":"OG000","value":"-15.6","lowerLimit":"-55.2","upperLimit":"6.4"},{"groupId":"OG001","value":"520.6","lowerLimit":"43.4","upperLimit":"1226.9"}]}]},{"title":"miR 223","categories":[{"measurements":[{"groupId":"OG000","value":"13.7","lowerLimit":"-61.3","upperLimit":"51.0"},{"groupId":"OG001","value":"1031.2","lowerLimit":"43.9","upperLimit":"3034.1"}]}]},{"title":"miR 335","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"-44.9","upperLimit":"142.8"},{"groupId":"OG001","value":"1166.0","lowerLimit":"336.2","upperLimit":"2070.6"}]}]},{"title":"miR 125","categories":[{"measurements":[{"groupId":"OG000","value":"43.4","lowerLimit":"-9.2","upperLimit":"79.6"},{"groupId":"OG001","value":"194.5","lowerLimit":"4.2","upperLimit":"1789.6"}]}]}]},{"type":"PRIMARY","title":"Systemic Immune Response to HPV Assessed by Enzyme-linked Immunosorbent Assay (ELISA)","description":"Lab results will be compared between patients who are HPV+ and HPV- using 2 sample t-tests. These measures will be compared in several ways. First, baseline, pre-treatment levels will be examined using descriptive statistics (n, mean, standard deviations, range). These measures will be examined overall and by HPV (+/-) groups. For each measure, and time point, 95% confidence intervals will be estimated. Next, two sample t-tests will be performed to compare levels of the measures at baseline. Next, measures taken post-treatment will be examined in a similar manner (descriptive statistics and 2-","populationDescription":"This pre-specified outcome is dependent upon 1) patients having a measurable response and 2) availability of comparable cohorts of HPV positive and negative samples. Since there was a lack of measurable clinical response in all patients and the enrolled cohorts were unbalanced, the data for this outcome was not measured/evaluated and therefore is not available for analysis.","reportingStatus":"POSTED","timeFrame":"Up to 18 months","groups":[{"id":"OG000","title":"Treatment (Durvalumab, Surgery)","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nDurvalumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nTherapeutic Conventional Surgery: Undergo surgery"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"PRIMARY","title":"Regulatory Responses Assessed in Blood by Flow Cytometry and in Tissue by Immunohistochemistry","description":"Concentration of certain regulatory cells will be assessed in blood pre- and post- treatment. Descriptive statistics, confidence intervals will be calculated and 2-sample t-tests will be performed. Tumor-infiltrating immune-regulator and effector cells will be quantified (0 to 3+) using standing immunofluorescence techniques. Counts and percents will be calculated for these measures overall and by HPV (+/-) groups pre- and post-treatment. Fisher exact tests will be used to compare groups at pre- and post- treatment. Stuart-Maxwell tests (generalizations of the McNemar's Tes","populationDescription":"This pre-specified outcome is dependent upon 1) patients having a measurable response and 2) availability of comparable cohorts of HPV positive and negative samples. Since there was a lack of measurable clinical response in all patients and the enrolled cohorts were unbalanced, the data for this outcome was not measured/evaluated and therefore is not available for analysis.","reportingStatus":"POSTED","timeFrame":"Up to 18 months","groups":[{"id":"OG000","title":"Treatment (Durvalumab, Surgery)","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nDurvalumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nTherapeutic Conventional Surgery: Undergo surgery"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"PRIMARY","title":"Immune-regulatory miR Responses as Measured in Saliva Assessed by Quantitative Reverse Transcriptase PCR (qRT-PCR)","description":"Percent change of levels of immune-regulatory miRs assessed in saliva assessed pre-treatment and one week post-treatment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"percent change from baseline","timeFrame":"Baseline and one week post treatment start","groups":[{"id":"OG000","title":"Treatment (Durvalumab, Surgery) - HPV Negative","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nDurvalumab: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery\n\nHPV negative"},{"id":"OG001","title":"Treatment (Durvalumab, Surgery) - HPV Positive","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nDurvalumab: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery\n\nHPV positive"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"miR 146","categories":[{"measurements":[{"groupId":"OG000","value":"251.3","lowerLimit":"-12.3","upperLimit":"497.9"},{"groupId":"OG001","value":"105.3","lowerLimit":"-16.2","upperLimit":"362.7"}]}]},{"title":"miR 155","categories":[{"measurements":[{"groupId":"OG000","value":"141.2","lowerLimit":"4.6","upperLimit":"970.3"},{"groupId":"OG001","value":"255.0","lowerLimit":"0.0","upperLimit":"367.5"}]}]},{"title":"miR 181","categories":[{"measurements":[{"groupId":"OG000","value":"114.4","lowerLimit":"-35.6","upperLimit":"864.6"},{"groupId":"OG001","value":"232.5","lowerLimit":"77.8","upperLimit":"558.9"}]}]},{"title":"miR 20a","categories":[{"measurements":[{"groupId":"OG000","value":"163.9","lowerLimit":"-63.1","upperLimit":"1312.3"},{"groupId":"OG001","value":"113.1","lowerLimit":"58.6","upperLimit":"500.0"}]}]},{"title":"miR 223","categories":[{"measurements":[{"groupId":"OG000","value":"66.4","lowerLimit":"-47.0","upperLimit":"502.1"},{"groupId":"OG001","value":"199.2","lowerLimit":"0.0","upperLimit":"465.7"}]}]},{"title":"miR 335","categories":[{"measurements":[{"groupId":"OG000","value":"249.4","lowerLimit":"20.2","upperLimit":"628.5"},{"groupId":"OG001","value":"150.2","lowerLimit":"0.0","upperLimit":"397.6"}]}]},{"title":"miR 125","categories":[{"measurements":[{"groupId":"OG000","value":"351.6","lowerLimit":"-34.9","upperLimit":"471.6"},{"groupId":"OG001","value":"64.9","lowerLimit":"-10.8","upperLimit":"457.9"}]}]}]},{"type":"PRIMARY","title":"Immune-regulatory miR Responses as Measured in Tumor Tissue Assessed by Quantitative Reverse Transcriptase PCR (qRT-PCR)","description":"Levels of immune-regulatory miRs assessed in blood, saliva and tumor tissue will be assessed pre- and post- treatments. Descriptive statistics, confidence intervals will be calculated and 2-sample t-tests will be performed. In addition, correlations between the different methods will be examined (i.e., correlation between saliva and blood measures, saliva and tumor measures, and blood and tumor measures).","populationDescription":"This pre-specified outcome is dependent upon 1) patients having a measurable response and 2) availability of comparable cohorts of HPV positive and negative samples. Since there was a lack of measurable clinical response in all patients and the enrolled cohorts were unbalanced, the data for this outcome was not measured/evaluated and therefore is not available for analysis.","reportingStatus":"POSTED","timeFrame":"Up to 18 months","groups":[{"id":"OG000","title":"Treatment (Durvalumab, Surgery)","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nDurvalumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nTherapeutic Conventional Surgery: Undergo surgery"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"PRIMARY","title":"Systemic Immune Response to Tumor Associated Antigens Assessed by Enzyme-linked Immunosorbent Assay (ELISA)","description":"Lab results will be compared between patients who are HPV+ and HPV- using 2 sample t-tests. These measures will be compared in several ways. First, baseline, pre-treatment levels will be examined using descriptive statistics (n, mean, standard deviations, range). These measures will be examined overall and by HPV (+/-) groups. For each measure, and time point, 95% confidence intervals will be estimated. Next, two sample t-tests will be performed to compare levels of the measures at baseline. Next, measures taken post-treatment will be examined in a similar manner (descriptive statistics and 2-","populationDescription":"This pre-specified outcome is dependent upon 1) patients having a measurable response and 2) availability of comparable cohorts of HPV positive and negative samples. Since there was a lack of measurable clinical response in all patients and the enrolled cohorts were unbalanced, the data for this outcome was not measured/evaluated and therefore is not available for analysis.","reportingStatus":"POSTED","timeFrame":"Up to 18 months","groups":[{"id":"OG000","title":"Treatment (Durvalumab, Surgery)","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nDurvalumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nTherapeutic Conventional Surgery: Undergo surgery"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"SECONDARY","title":"Incidence of Adverse Events (AEs) as Measured by CTCAE Version 4.03","description":"AEs will be coded using the Medical Dictionary for Regulatory Activities to their organ class by preferred term. Coded AEs will be displayed by frequency, severity, and relationship to treatment (durvalumab) in the safety population. In addition, summary tables will be generated for the following situations: 1) fatigue, diarrhea, nausea and skin rash; 2) Immune-mediated reactions of any grade; 3) other adverse events graded as 3 or more by CTCAE Version 4.03; 4) Durvalumab dose reductions; 5) discontinuations of treatment with durvalumab, with specification of reason for discontinuation; and 6) changes in the surgical treatment schedule. Toxicity grades Grade I (mild), Grade II (moderate), Grade III (severe), Grade IV (life threatening) and Grade V (fatal). Toxicities of greater than or equal to Grade III (except infusion reaction) are considered worse outcomes.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"events","timeFrame":"At baseline (pre-treatment), during scheduled treatment and up to the 90-day follow up period after the last dose of study drug administered, with a median of 1 month and maximum of 13 months","groups":[{"id":"OG000","title":"HPV -","description":"HPV negative"},{"id":"OG001","title":"HPV +","description":"HPV positive"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Acute kidney injury - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Alanine aminotransferase increased - Possible to Definitely related - Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Alanine aminotransferase increased - Possible to Definitely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Alkaline phosphatase increased - Possible to Definitely related - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Alkaline phosphatase increased - Possible to Definitely related - Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Anemia - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Anorexia - Possible to Definitely relate - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Aspartate aminotransferase increased - Possible to Definitely related - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Aspartate aminotransferase increased - Possible to Definitely related - Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Aspartate aminotransferase increased - Possible to Definitely related - Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Blood bilirubin increased - Possible to Definitely related - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Blood bilirubin increased - Possible to Definitely relate - Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Bullous dermatitis - Possible to Definitely relate - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Constipation - Possible to Definitely relate - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Constipation - Possible to Definitely relate - Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Device related infection - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Diarrhea - Possible to Definitely relate - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"Diarrhea - Possible to Definitely relate - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Diarrhea - Unrelated or Unlikely related - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}]},{"title":"Fatigue - Possible to Definitely relate - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}]}]},{"title":"Fatigue - Possible to Definitely relate - Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Fatigue - Unrelated or Unlikely related - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Fatigue - Unrelated or Unlikely related - Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Head soft tissue necrosis - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hyperglycemia - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Hyperglycemia - Unrelated or Unlikely related - Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hypermagnesemia - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hypertension - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Hypoalbuminemia - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hypocalcemia - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hypocalcemia - Unrelated or Unlikely related - Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hypokalemia - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hyponatremia - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hypophosphatemia - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hypotension - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hypothyroidism - Possible to Definitely relate - Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Leukocytosis - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Lipase increased - Possible to Definitely relate - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Malaise - Possible to Definitely relate - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Nausea - Possible to Definitely relate - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Nausea - Unrelated or Unlikely related - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"Neck soft tissue necrosis - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Neutrophil count decreased - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Pruritus - Possible to Definitely relate - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Rash maculo-papular - Possible to Definitely relate - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Rash pustular - Possible to Definitely relate - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Serum amylase increased - Possible to Definitely relate - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Skin ulceration - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Skin ulceration - Unrelated or Unlikely related - Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Taste alteration (dysgeusia) - Possible to Definitely relate - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Urine output decreased - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Urticaria - Possible to Definitely relate - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Weight loss - Possible to Definitely relate - Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Wound complication - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Wound infection - Unrelated or Unlikely related - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Discontinuation of Durvalumab due to immune-related hepatitis","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Standardized Uptake Value (SUV) as Measured by PET Scans","description":"Change in SUV activity as measured by PET scans from baseline to post-treatment not specific to HPV status.","populationDescription":"This pre-specified outcome is dependent upon 1) patients having a measurable response and 2) availability of comparable cohorts of HPV positive and negative samples. Since there was a lack of measurable clinical response in all patients and the enrolled cohorts were unbalanced, the data for this outcome was not measured/evaluated for all patients.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"change in SUV","timeFrame":"Up to 18 months","groups":[{"id":"OG000","title":"Treatment (Durvalumab, Surgery) - HPV Negative","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nDurvalumab: Given IV Therapeutic Conventional Surgery: Undergo surgery HPV negative"},{"id":"OG001","title":"Treatment (Durvalumab, Surgery) - HPV Positive","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nDurvalumab: Given IV Therapeutic Conventional Surgery: Undergo surgery HPV positive"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"1.20"},{"groupId":"OG001","value":"0","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Tumor Diameter Assessed Using RECIST Version 1.1 Criteria","description":"Change in tumor diameters will be compared between groups (HPV +/-) pre- and post- treatment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"mm","timeFrame":"Up to 18 months","groups":[{"id":"OG000","title":"Treatment (Durvalumab, Surgery) - HPV Negative","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nDurvalumab: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery\n\nHPV negative"},{"id":"OG001","title":"Treatment (Durvalumab, Surgery) - HPV Positive","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nDurvalumab: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery\n\nHPV positive"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.0","upperLimit":"4.0"},{"groupId":"OG001","value":"-2.0","lowerLimit":"-2.0","upperLimit":"2.0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Adverse events and serious adverse events was recorded from time of signature of informed consent, throughout the treatment period and including the follow-up period (90 days after the last dose of durvalumab), with a median of 1 month and maximum of 13 months","eventGroups":[{"id":"EG000","title":"Treatment (Durvalumab, Surgery) - HPV Negative","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nDurvalumab: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery\n\nHPV negative","deathsNumAffected":1,"deathsNumAtRisk":11,"seriousNumAffected":5,"seriousNumAtRisk":11,"otherNumAffected":11,"otherNumAtRisk":11},{"id":"EG001","title":"Treatment (Durvalumab, Surgery) - HPV Positive","description":"Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.\n\nDurvalumab: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery\n\nHPV positive","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":6,"otherNumAtRisk":6}],"seriousEvents":[{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hyperglycemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hypocalcemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Skin ulceration","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hypotension","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]}],"otherEvents":[{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":11},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":6}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Sinus bradycardia","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":6}]},{"term":"Hearing impaired","organSystem":"Ear and labyrinth disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Corneal ulcer","organSystem":"Eye disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Floaters","organSystem":"Eye disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Colonic hemorrhage","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":11},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Mucositis oral","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Taste alteration (dysgeusia)","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Chills","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Edema face","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Fatigue","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":11},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":6}]},{"term":"Fever","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Gait disturbance","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Localized edema","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Malaise","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Neck edema","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pain","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Device related infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Lung infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Rash pustular","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Upper respiratory infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Wound infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Infections and infestations - Other: tumor infection per treating physician","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Dermatitis radiation","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Venous injury","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Wound complication","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Alkaline phosphatase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":2,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Lipase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Platelet count decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":11},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6}]},{"term":"Serum amylase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Urine output decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Weight gain","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Weight loss","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"White blood cell decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":6}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Hyperglycemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":11},{"groupId":"EG001","numEvents":12,"numAffected":5,"numAtRisk":6}]},{"term":"Hyperkalemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hypermagnesemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hypertriglyceridemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hypoalbuminemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":7,"numAtRisk":11},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":6}]},{"term":"Hypocalcemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":6,"numAtRisk":11},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":6}]},{"term":"Hypoglycemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hypokalemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":4,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hypomagnesemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":8,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hyponatremia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":7,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Hypophosphatemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":3,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Generalized muscle weakness","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Head soft tissue necrosis","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Muscle weakness upper limb","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Neck soft tissue necrosis","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Tumor pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Dizziness","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Headache","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Tremor","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Agitation","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Depression","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pelvic pain","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Allergic rhinitis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hoarseness","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Laryngeal hemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pharyngeal fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pharyngeal mucositis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pulmonary edema","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Sore throat","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Bullous dermatitis","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Erythema multiforme","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Periorbital edema","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Skin and subcutaneous tissue disorders - Other: skin irritation at G-tube site","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Surgical and medical procedures - Other: dental extraction site inflammation (dry sockets)","organSystem":"Surgical and medical procedures","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hematoma","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hot flashes","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hypertension","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6}]},{"term":"Hypotension","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Lymphedema","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Mercedes Porosnicu","organization":"Wake Forest Baptist Comprehensive Cancer Center","email":"mporosni@wakehealth.edu","phone":"336-716-8664"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2021-05-18","uploadDate":"2024-05-21T13:44","filename":"Prot_SAP_001.pdf","size":2232096},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2021-06-28","uploadDate":"2022-05-02T14:07","filename":"ICF_000.pdf","size":226893}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D030361","term":"Papillomavirus Infections"},{"id":"D000077195","term":"Squamous Cell Carcinoma of Head and Neck"}],"ancestors":[{"id":"D015229","term":"Sexually Transmitted Diseases, Viral"},{"id":"D012749","term":"Sexually Transmitted Diseases"},{"id":"D003141","term":"Communicable Diseases"},{"id":"D007239","term":"Infections"},{"id":"D004266","term":"DNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D014412","term":"Tumor Virus Infections"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"},{"id":"D002294","term":"Carcinoma, Squamous Cell"},{"id":"D002277","term":"Carcinoma"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D006258","term":"Head and Neck Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"}]},"interventionBrowseModule":{"meshes":[{"id":"C000613593","term":"durvalumab"},{"id":"D007074","term":"Immunoglobulin G"},{"id":"D004220","term":"Disulfides"}],"ancestors":[{"id":"D007132","term":"Immunoglobulin Isotypes"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D013440","term":"Sulfides"},{"id":"D000838","term":"Anions"},{"id":"D007477","term":"Ions"},{"id":"D004573","term":"Electrolytes"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D006862","term":"Hydrogen Sulfide"},{"id":"D013457","term":"Sulfur Compounds"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT03578432","orgStudyIdInfo":{"id":"PHXB-17-0072-70-15"},"secondaryIdInfos":[{"id":"NCI-2018-00492","type":"REGISTRY","domain":"CTRP (Clinical Trial Reporting Program)"},{"id":"CRAD001XUA274T"},{"id":"PHXB-17-0072-70-15","type":"OTHER","domain":"The University of Arizona Cancer Center"},{"id":"P30CA023074","type":"NIH","link":"https://reporter.nih.gov/quickSearch/P30CA023074"}],"organization":{"fullName":"University of Arizona","class":"OTHER"},"briefTitle":"Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy","officialTitle":"Clinical Evaluation of Everolimus (a Rapamycin Analog) in Restoring Salivary Gland Function to Patients Treated With Radiotherapy for Head and Neck Cancer"},"statusModule":{"statusVerifiedDate":"2019-11","overallStatus":"TERMINATED","whyStopped":"UACC-PHX is no longer able to support the study and Novartis is unable to provide drug beyond December 2019.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-05-04","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-11-15","type":"ACTUAL"},"completionDateStruct":{"date":"2019-11-15","type":"ACTUAL"},"studyFirstSubmitDate":"2018-06-15","studyFirstSubmitQcDate":"2018-07-03","studyFirstPostDateStruct":{"date":"2018-07-06","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-11-27","lastUpdatePostDateStruct":{"date":"2019-12-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"University of Arizona","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This early phase 1 trial studies the use of everolimus in restoring salivary gland function in participants with locally advanced head and neck cancer after concurrent chemoradiation or radiation therapy alone.","detailedDescription":"PRIMARY OBJECTIVES:\n\nI. To describe the recovery of salivary gland function after administration of a 5-day course of everolimus, administered two weeks after completion of radiation or chemoradiation therapy.\n\nSECONDARY OBJECTIVES:\n\nI. To describe the decrease of saliva flow rates during radiation or chemoradiation therapy.\n\nII. To describe the changes in saliva protein composition during radiation or chemoradiation therapy and following administration of a 5-day course of everolimus.\n\nOUTLINE: This is an early phase 1 proof of principal study.\n\nParticipants receive everolimus orally (PO) once daily (QD) for 5 days beginning 2 weeks after completion of radiation or chemoradiation treatment. Participants also undergo saliva output testing at baseline prior to radiation or chemoradiation treatment, after 3 weeks of RT/chemoRT, after 6 weeks of RT/chemoRT, prior to everolimus administration, at completion of the 5 day everolimus course, and at 1, 3, and 6 months after the completion of radiation or chemoradiation therapy."},"conditionsModule":{"conditions":["Salivary Gland Dysfunction","Xerostomia","Head and Neck Cancer"],"keywords":["Xerostomia","Dry Mouth","Salivary Gland Dysfunction","Head and Neck Cancer","Mouth Cancer","Everolimus","Rapamycin","Neck Cancer","Saliva"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"SUPPORTIVE_CARE","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":2,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Supportive care (everolimus, saliva output testing)","type":"EXPERIMENTAL","description":"Participants receive everolimus PO QD for 5 days beginning 2 weeks after radiation treatment. Participants also undergo saliva output testing at baseline prior to radiation or chemoradiation treatment, after 3 weeks of RT/chemoRT, after 6 weeks of RT/chemoRT, prior to everolimus administration, at completion of the 5 day everolimus course, and at 1, 3, and 6 months after the completion of radiation or chemoradiation therapy.","interventionNames":["Drug: Everolimus","Other: Laboratory Biomarker Analysis","Other: Survey Administration"]}],"interventions":[{"type":"DRUG","name":"Everolimus","description":"Given PO","armGroupLabels":["Supportive care (everolimus, saliva output testing)"],"otherNames":["42-O-(2-Hydroxy)ethyl Rapamycin","Afinitor","Certican","RAD 001","RAD001","Votubia","Zortress"]},{"type":"OTHER","name":"Laboratory Biomarker Analysis","description":"Correlative studies","armGroupLabels":["Supportive care (everolimus, saliva output testing)"]},{"type":"OTHER","name":"Survey Administration","description":"Ancillary studies","armGroupLabels":["Supportive care (everolimus, saliva output testing)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percent recovery of salivary gland function","description":"The primary end point of the analysis will be the percent recovery of salivary gland function, with pre-everolimus treatment saliva flow rate as the denominator and the saliva flow rate at 3 months after completion of radiation or chemoradiation therapy as the numerator.","timeFrame":"At 3 months after completion of radiation or chemoradiation therapy"}],"secondaryOutcomes":[{"measure":"Change of saliva flow rates","description":"This will be measured during radiotherapy treatment at 3, 6 weeks, and prior to everolimus administration and the subsequent recovery of saliva flow rates at completion of the 5 day everolimus course and 1, 3 and 6 months after radiation therapy/chemoradiation therapy completion to determine the kinetics and stability of saliva flow rate recovery. Will be explored using graphical methods.","timeFrame":"Up to 6 months after completion of radiation or chemoradiation therapy"},{"measure":"Saliva protein composition","description":"Protein composition within the saliva will be measured and will be expressed as percent decrease and recovery of amylase at all available time points. Will be explored using graphical methods.","timeFrame":"Up to 6 months after completion of radiation or chemoradiation therapy"},{"measure":"Total score obtained on Xerostomia Visual Analog Scale survey","description":"Will be explored using graphical methods. Subjective assessment of salivary dysfunction.  Scale ranges: not difficult at all - very difficult.  Not difficult at all is considered better, very difficult is considered worse. Subscales are summed. Scale ranges: 1-5 =  1 (Never), 2 (hardly ever), 3 (occasionally), 4 (fairly often), 5 (very often).  Sub scales are summed.","timeFrame":"Up to 6 months after completion of radiation or chemoradiation therapy"},{"measure":"Total score obtained on Xerostomia Inventory Survey","description":"Will be explored using graphical methods. Measures xerostomia symptoms.","timeFrame":"Up to 6 months after completion of radiation or chemoradiation therapy"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Performance status Eastern Cooperative Oncology Group (ECOG)  2\n* Absolute neutrophil count (ANC)  1.5 x 10\\^9/L\n* Platelets  100 x 10\\^9/L\n* Hemoglobin (Hgb) \\> 9 g/dL\n* Total serum bilirubin  2.0 mg/dL\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)  2.5 x upper limits of normal (ULN) ( 5 x ULN in patients with liver metastases)\n* International normalized ratio (INR)  2\n* Serum creatinine  1.5 x ULN\n* Fasting serum cholesterol  300 mg/dL or  7.75 mmol/L and fasting triglycerides  2.5 x ULN\n\n  * NOTE: in case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication\n* Signed informed consent obtained prior to any screening procedures\n* Patients with locally advanced squamous cell carcinoma of the head and neck, treated with curative intent either in the post-operative or definitive setting with high dose radiotherapy ( 50 Gy) with or without chemotherapy\n\nExclusion Criteria:\n\n* Patients currently receiving anticancer therapies or who have received anticancer therapies within 2 weeks of the start of everolimus (including chemotherapy, radiation therapy, antibody based therapy, etc.)\n* Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)\n* Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus\n* Uncontrolled diabetes mellitus as defined by glycated hemoglobin (HbA1c) \\> 8% despite adequate therapy; patients with a known history of impaired fasting glucose or diabetes mellitus (DM) may be included, however blood glucose and antidiabetic treatment must be monitored closely throughout the trial and adjusted as necessary\n* Patients who have any severe and/or uncontrolled medical conditions such as:\n\n  * Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction  6 months prior to start of everolimus, serious uncontrolled cardiac arrhythmia, or any other clinically significant cardiac disease\n  * Symptomatic congestive heart failure of New York heart Association class III or IV\n  * Active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis (i.e. quantifiable hepatitis B virus \\[HBV\\]-deoxyribonucleic acid \\[DNA\\] and/or positive hepatitis B virus surface antigen \\[HbsAg\\], quantifiable hepatitis C virus \\[HCV\\]-ribonucleic acid \\[RNA\\])\n  * Known severely impaired lung function (spirometry and carbon monoxide diffusing capacity \\[DLCO\\] 50% or less of normal and oxygen \\[O2\\] saturation 88% or less at rest on room air)\n  * Active, bleeding diathesis\n* Chronic treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowed\n* Known history of human immunodeficiency virus (HIV) seropositivity\n* Patients who have received live attenuated vaccines within 1 week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella and TY21a typhoid vaccines\n* Patients who have a history of another primary malignancy, with the exceptions of: nonmelanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast from which the patient has been disease free for  3 years\n* Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study\n* Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing\n* Pregnant or nursing (lactating) women\n* Women of child-bearing potential (WOCBP) (including female pediatric patients who are menarcheal or who become menarcheal during the treatment), defined as all women physiologically capable of becoming pregnant, must use highly effective methods of contraception during the study and 8 weeks after; women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms); highly effective contraception methods include combination of any two of the following:\n\n  * Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate \\< 1%), for example, hormone vaginal ring or transdermal hormone contraception; in case of use of oral contraception women should have been stable on the oral agent for a minimum of 3 months before taking everolimus\n  * Total abstinence\n  * Male partner sterilization; (the vasectomized male partner should be the sole partner for that subject)\n  * Female sterilization have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks prior torandomization; in the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child-bearing potential\n* Male patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Panayiotis Savvides","affiliation":"The University of Arizona Cancer Center at Dignity Health St. Joseph's Hospital and Medical Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"The University of Arizona Cancer Center","city":"Phoenix","state":"Arizona","zip":"85012","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2018-06-22","uploadDate":"2018-07-06T13:26","filename":"Prot_000.pdf","size":519598}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D014987","term":"Xerostomia"},{"id":"D006258","term":"Head and Neck Neoplasms"},{"id":"D009062","term":"Mouth Neoplasms"}],"ancestors":[{"id":"D012466","term":"Salivary Gland Diseases"},{"id":"D009059","term":"Mouth Diseases"},{"id":"D009057","term":"Stomatognathic Diseases"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068338","term":"Everolimus"}],"ancestors":[{"id":"D020123","term":"Sirolimus"},{"id":"D018942","term":"Macrolides"},{"id":"D007783","term":"Lactones"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT03459729","orgStudyIdInfo":{"id":"PRO36718"},"secondaryIdInfos":[{"id":"R01CA205633","type":"NIH","link":"https://reporter.nih.gov/quickSearch/R01CA205633"}],"organization":{"fullName":"Medical College of Wisconsin","class":"OTHER"},"briefTitle":"Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer","officialTitle":"PK Analysis of Antitumor B in Patients With Oral Cancer"},"statusModule":{"statusVerifiedDate":"2025-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-08-24","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-02-15","type":"ACTUAL"},"completionDateStruct":{"date":"2022-02-16","type":"ACTUAL"},"studyFirstSubmitDate":"2018-03-01","studyFirstSubmitQcDate":"2018-03-07","studyFirstPostDateStruct":{"date":"2018-03-09","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-03-29","resultsFirstSubmitQcDate":"2023-04-19","resultsFirstPostDateStruct":{"date":"2023-04-21","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-01-07","lastUpdatePostDateStruct":{"date":"2025-01-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Stuart Wong","investigatorTitle":"Professor","investigatorAffiliation":"Medical College of Wisconsin"},"leadSponsor":{"name":"Medical College of Wisconsin","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"A Window of Opportunity Clinical Trial. This study design permits examination of effects of an oral agent on cancer patients during the \"window\" between diagnosis of their cancer and their definitive cancer surgery. Similar to a phase 0 study, the trial design permits examination of the biologic effects of an agent; in this study pharmacokinetic properties will be examined.","detailedDescription":"Study Intervention Description:\n\nStudy participants will take the natural botanical compound ATB during a short window (7 to 28 days). Participants will provide blood samples, and saliva samples during Anti-tumor B (ATB) administration and a portion of the initial tumor biopsy."},"conditionsModule":{"conditions":["Squamous Cell Carcinoma of the Oral Cavity"],"keywords":["Anti-tumor B","ACAPHA","Pharmacokinetics"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"OTHER","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":6,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Antitumor B","type":"EXPERIMENTAL","description":"ATB will be administered on an outpatient basis.","interventionNames":["Drug: Antitumor B"]}],"interventions":[{"type":"DRUG","name":"Antitumor B","description":"Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours).","armGroupLabels":["Antitumor B"],"otherNames":["Zeng Sheng Ping","ATB","ACAPHA"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Area Under the Curve (AUC) for Matrine in Saliva","description":"The total systemic exposure to matrine as represented by the AUC will be calculated as the area bounded by the x-axis and the line drawn as straight segments through the plotted matrine concentrations at the time points: predose (0 minutes), 30 minutes, 60 minutes, 120 minutes, 180 minutes, 240 minutes, 360 minutes, 480 minutes, and 1,440 minutes. The results will be reported in (ng x hour)/ml.","timeFrame":"Day 1"},{"measure":"Area Under the Curve for Matrine in Plasma","description":"The total systemic exposure to matrine as represented by the AUC will be calculated as the area bounded by the x-axis and the line drawn as straight segments through the plotted matrine concentrations at the time points: predose (0 minutes), 30 minutes, 60 minutes, 120 minutes, 180 minutes, 240 minutes, 360 minutes, 480 minutes, and 1,440 minutes. The results will be reported in (ng x hour)/ml.","timeFrame":"Day 1"},{"measure":"Maximum Concentration (Cmax) of Matrine in Saliva","description":"This measure is the maximum concentration observed. The results will be reported in ng/ml.","timeFrame":"Day 1"},{"measure":"Maximum Concentration of Matrine in Plasma","description":"This measure is the maximum concentration observed. The results will be reported in ng/ml.","timeFrame":"Day 1"},{"measure":"Area Under the Curve (AUC) for Maackiain in Saliva","description":"The total systemic exposure to maackiain as represented by the AUC will be calculated as the area bounded by the x-axis and the line drawn as straight segments through the plotted maackiain concentrations at the time points: predose (0 minutes), 30 minutes, 60 minutes, 120 minutes, 180 minutes, 240 minutes, 360 minutes, 480 minutes, and 1,440 minutes. The results will be reported in (ng x hour)/ml.","timeFrame":"Day 1"},{"measure":"Area Under the Curve (AUC) for Maackiain in Plasma","description":"The total systemic exposure to maackiain as represented by the AUC will be calculated as the area bounded by the x-axis and the line drawn as straight segments through the plotted maackiain concentrations at the time points: predose (0 minutes), 30 minutes, 60 minutes, 120 minutes, 180 minutes, 240 minutes, 360 minutes, 480 minutes, and 1,440 minutes. The results will be reported in (ng x hour)/ml.","timeFrame":"Day 1"},{"measure":"Maximum Concentration of Maackiain in Saliva","description":"This measure is the maximum concentration observed. The results will be reported in ng/ml.","timeFrame":"Day 1"},{"measure":"Maximum Concentration of Maackiain in Plasma","description":"This measure is the maximum concentration observed. The results will be reported in ng/ml.","timeFrame":"Day 1"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of oral cavity squamous cell cancer.\n* Patient can start study agent administration but histological confirmation of squamous cell cancer (SCC) of the oral cavity (or histologic variants of SCC) by the pathologist must happen within 7 days of registration in order to continue study agent administration.\n* Clinical stage II-IVA (as defined by the American Joint Committee on Cancer, 8th Edition \\[see Amin, 2017\\]) and amenable to surgical resection\n* New diagnosis of oral SCC, new second primary, or recurrent oral SCC following a minimum remission of 6 months following previous definite surgery\n* History and physical examination by an otolaryngologist and medical oncologist within 14 calendar days of study registration\n* Study agent administration should start within 7 days of registration\n* Patient must receive administration of study agent for a minimum of 7 days\n* Zubrod Score/Eastern Cooperative Oncology Group (ECOG) Performance status \\< 2.\n* Age  18 years.\n* Complete Blood Count (CBC)/differential obtained within 14 calendar days prior to registration, with adequate bone marrow function defined as follows:\n\n  * Absolute neutrophil count (ANC)  1,500 cells/mm\\^3;\n  * Platelets  100,000 cells/mm\\^3;\n  * Hemoglobin  8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb  8.0 g/dl is acceptable.);\n* Adequate renal and hepatic function within 14 calendar days prior to registration, defined as follows:\n\n  o Serum creatinine \\< 1.5 mg/dl or creatinine clearance (CCr)  50 ml/min within 14 calendar days prior to registration, determined by 24-hour collection or estimated by Cockcroft-Gault formula: CCr male = \\[(140 - age) x (wt in kg)\\] \\[(Serum Cr mg/dl) x (72)\\] CCr female = 0.85 x (CrCl male)\n* Total bilirubin \\< 2 x the institutional upper limit of normal (ULN) within 14 calendar days prior to registration\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)  3 x the institutional ULN within 14 calendar days prior to registration\n* Magnesium, calcium, glucose, potassium, and sodium within 14 calendar days prior to registration, with the following required parameters:\n\n  * Magnesium: \\> 0.9 mg/dl or \\< 3 mg/dl;\n  * Calcium: \\> 7 mg/dl or \\< 12.5 mg/dl;\n  * Glucose: \\> 40 mg/dl or \\< 250 mg/dl;\n  * Potassium: \\> 3 mmol/L or \\< 6 mmol/L;\n  * Sodium: \\> 130 mmol/L or \\< 155 mmol/L.\n* Female patients must meet one of the following:\n\n  * Postmenopausal for at least one year before the screening visit, or\n  * Surgically sterile (e.g., undergone a hysterectomy or bilateral oophorectomy), or\n  * If the subject is of childbearing potential (defined as not satisfying either of the above two criteria), agree to practice two acceptable methods of contraception (combination methods requires use of two of the following: diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male or female condom, hormonal contraceptive) from the time of signing of the informed consent form through 90 days after the last dose of study agent, AND\n  * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \\[e.g., calendar, ovulation, symptothermal, postovulation methods\\] and withdrawal are not acceptable contraception methods.)\n* Male patients, even if surgically sterilized (e.g., status post vasectomy), must agree to one of the following:\n\n  * Practice effective barrier contraception during the entire study period and through 60 calendar days after the last dose of study agent, OR\n  * Must also adhere to the guidelines of any study-specific pregnancy prevention program, if applicable, OR\n  * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \\[e.g., calendar, ovulation, symptothermal, post ovulation methods\\] and withdrawal are not acceptable methods of contraception.)\n* Patients must be deemed able to comply with the study plan.\n* Gastric tube study agent administration is permissible.\n* Patients must provide study-specific informed consent prior to study entry.\n\nExclusion Criteria:\n\n* History of active liver disease\n* Pregnant or lactating women are ineligible due to unforeseeable risks to embryo or fetus.\n* Concurrent use of any medicinal botanical, natural, or other herbal compound/s that the study PI believes could potentially impact the results/objectives of this study\n* Planned subtotal or debulking surgery, as determined by enrolling physician determination, is not permissible.\n* Prior systemic chemotherapy for oral SCC; note that prior chemotherapy for a different cancer is allowable.\n* Prior radiotherapy for oral SCC is permissible if disease free for 1 year since prior oral cancer treatment and free of significant late radiation effects.\n* Severe active comorbidity such as uncontrolled cardiac disease, infection, severe Chronic Obstructive Pulmonary Disease (COPD).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Stuart Wong, MD","affiliation":"Medical College of Wisconsin","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Froedtert Hospital and the Medical College of Wisconsin","city":"Milwaukee","state":"Wisconsin","zip":"53226","country":"United States","geoPoint":{"lat":43.0389,"lon":-87.90647}}]},"referencesModule":{"references":[{"pmid":"28094848","type":"BACKGROUND","citation":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging. CA Cancer J Clin. 2017 Mar;67(2):93-99. doi: 10.3322/caac.21388. Epub 2017 Jan 17."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Six prospective subjects signed the Institutional Review Board-approved consent form. Two subjects did not meet eligibility criteria during screening and were excluded.","groups":[{"id":"FG000","title":"Antitumor B","description":"Antitumor B (ATB) will be administered on an outpatient basis.\n\nAntitumor B: Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"6"}]},{"type":"Received Therapy","achievements":[{"groupId":"FG000","numSubjects":"4"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"}]}],"dropWithdraws":[{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Antitumor B","description":"ATB will be administered on an outpatient basis.\n\nAntitumor B: Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"2"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"2"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"67.3","spread":"9.7"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"2"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"2"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"4"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"4"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Area Under the Curve (AUC) for Matrine in Saliva","description":"The total systemic exposure to matrine as represented by the AUC will be calculated as the area bounded by the x-axis and the line drawn as straight segments through the plotted matrine concentrations at the time points: predose (0 minutes), 30 minutes, 60 minutes, 120 minutes, 180 minutes, 240 minutes, 360 minutes, 480 minutes, and 1,440 minutes. The results will be reported in (ng x hour)/ml.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng x h/mL","timeFrame":"Day 1","groups":[{"id":"OG000","title":"Antitumor B","description":"ATB will be administered on an outpatient basis.\n\nAntitumor B: Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4007.9","spread":"2882.9"}]}]}]},{"type":"PRIMARY","title":"Area Under the Curve for Matrine in Plasma","description":"The total systemic exposure to matrine as represented by the AUC will be calculated as the area bounded by the x-axis and the line drawn as straight segments through the plotted matrine concentrations at the time points: predose (0 minutes), 30 minutes, 60 minutes, 120 minutes, 180 minutes, 240 minutes, 360 minutes, 480 minutes, and 1,440 minutes. The results will be reported in (ng x hour)/ml.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng x h/mL","timeFrame":"Day 1","groups":[{"id":"OG000","title":"Antitumor B","description":"ATB will be administered on an outpatient basis.\n\nAntitumor B: Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"783.2","spread":"283.7"}]}]}]},{"type":"PRIMARY","title":"Maximum Concentration (Cmax) of Matrine in Saliva","description":"This measure is the maximum concentration observed. The results will be reported in ng/ml.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Day 1","groups":[{"id":"OG000","title":"Antitumor B","description":"ATB will be administered on an outpatient basis.\n\nAntitumor B: Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"457.4","spread":"380.3"}]}]}]},{"type":"PRIMARY","title":"Maximum Concentration of Matrine in Plasma","description":"This measure is the maximum concentration observed. The results will be reported in ng/ml.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Day 1","groups":[{"id":"OG000","title":"Antitumor B","description":"ATB will be administered on an outpatient basis.\n\nAntitumor B: Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.5","spread":"14.7"}]}]}]},{"type":"PRIMARY","title":"Area Under the Curve (AUC) for Maackiain in Saliva","description":"The total systemic exposure to maackiain as represented by the AUC will be calculated as the area bounded by the x-axis and the line drawn as straight segments through the plotted maackiain concentrations at the time points: predose (0 minutes), 30 minutes, 60 minutes, 120 minutes, 180 minutes, 240 minutes, 360 minutes, 480 minutes, and 1,440 minutes. The results will be reported in (ng x hour)/ml.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng x h/mL","timeFrame":"Day 1","groups":[{"id":"OG000","title":"Antitumor B","description":"ATB will be administered on an outpatient basis.\n\nAntitumor B: Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.4"}]}]}]},{"type":"PRIMARY","title":"Area Under the Curve (AUC) for Maackiain in Plasma","description":"The total systemic exposure to maackiain as represented by the AUC will be calculated as the area bounded by the x-axis and the line drawn as straight segments through the plotted maackiain concentrations at the time points: predose (0 minutes), 30 minutes, 60 minutes, 120 minutes, 180 minutes, 240 minutes, 360 minutes, 480 minutes, and 1,440 minutes. The results will be reported in (ng x hour)/ml.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng x h/mL","timeFrame":"Day 1","groups":[{"id":"OG000","title":"Antitumor B","description":"ATB will be administered on an outpatient basis.\n\nAntitumor B: Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"3.2"}]}]}]},{"type":"PRIMARY","title":"Maximum Concentration of Maackiain in Saliva","description":"This measure is the maximum concentration observed. The results will be reported in ng/ml.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Day 1","groups":[{"id":"OG000","title":"Antitumor B","description":"ATB will be administered on an outpatient basis.\n\nAntitumor B: Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.1"}]}]}]},{"type":"PRIMARY","title":"Maximum Concentration of Maackiain in Plasma","description":"This measure is the maximum concentration observed. The results will be reported in ng/ml.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Day 1","groups":[{"id":"OG000","title":"Antitumor B","description":"ATB will be administered on an outpatient basis.\n\nAntitumor B: Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"1 day","eventGroups":[{"id":"EG000","title":"Antitumor B","description":"ATB will be administered on an outpatient basis.\n\nAntitumor B: Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours).","deathsNumAffected":0,"deathsNumAtRisk":4,"seriousNumAffected":0,"seriousNumAtRisk":4,"otherNumAffected":0,"otherNumAtRisk":4}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Stuart Wong, MD","organization":"Froedtert and the Medical college of Wisconsin","email":"swong@mcw.edu","phone":"414-805-4600"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2020-04-16","uploadDate":"2023-03-07T17:27","filename":"Prot_SAP_000.pdf","size":924583},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2022-01-12","uploadDate":"2023-03-07T17:27","filename":"ICF_001.pdf","size":296271}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D000077195","term":"Squamous Cell Carcinoma of Head and Neck"}],"ancestors":[{"id":"D002294","term":"Carcinoma, Squamous Cell"},{"id":"D002277","term":"Carcinoma"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D006258","term":"Head and Neck Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"}]},"interventionBrowseModule":{"meshes":[{"id":"C027128","term":"Antitumor B"},{"id":"C541947","term":"antitumor A"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT03870529","orgStudyIdInfo":{"id":"IRB00050640"},"secondaryIdInfos":[{"id":"NCI-2018-00888","type":"OTHER","domain":"Clinical Trial Reporting Program"},{"id":"WFBCCC 62218","type":"OTHER","domain":"Wake Forest Baptist Comprehensive Cancer Center"},{"id":"P30CA012197","type":"NIH","link":"https://reporter.nih.gov/quickSearch/P30CA012197"}],"organization":{"fullName":"Wake Forest University Health Sciences","class":"OTHER"},"briefTitle":"High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer","officialTitle":"A Pilot Study of Neoadjuvant High Dose Vitamin A for Resectable Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2023-12","overallStatus":"TERMINATED","whyStopped":"Slow accruals","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-08-19","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-12-09","type":"ACTUAL"},"completionDateStruct":{"date":"2022-12-09","type":"ACTUAL"},"studyFirstSubmitDate":"2019-03-08","studyFirstSubmitQcDate":"2019-03-08","studyFirstPostDateStruct":{"date":"2019-03-12","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-11-20","resultsFirstSubmitQcDate":"2023-12-19","resultsFirstPostDateStruct":{"date":"2024-01-09","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-12-19","lastUpdatePostDateStruct":{"date":"2024-01-09","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Wake Forest University Health Sciences","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This trial studies how well high dose vitamin A compound works in treating participants with non-small cell lung cancer that can be removed by surgery. Vitamin A compound may increase the number of germinal centers (immune centers that make antibodies mature) in tumor and lymph tissues which may be beneficial to patients with cancer.","detailedDescription":"PRIMARY OBJECTIVES:\n\nI. To compare the percentage of resected cancers containing germinal centers (GCs) in patients who receive neoadjuvant vitamin A compound (vitamin A) to controls.\n\nSECONDARY OBJECTIVES:\n\nI. To compare the abundance of GCs in adjacent lymph nodes in patients who receive neoadjuvant vitamin A to controls.\n\nII. To compare histopathologic responses based on tumor necrosis in lung cancer patients who receive neoadjuvant vitamin A to controls.\n\nIII. To compare overall survival of patients who receive neoadjuvant vitamin A to controls.\n\nEXPLORATORY OBJECTIVES:\n\nI. To describe immunophenotypic changes of monocytes including myeloid derived suppressor cells (MDSCs) in pre- and post-treatment blood samples.\n\nOUTLINE: Participants are randomized to 1 of 2 groups.\n\nGROUP I: Participants receive vitamin A compound orally (PO) for 7 consecutive days in the absence of disease progression or unacceptable toxicity. Within 21 days of completing treatment, participants then undergo surgical resection.\n\nGROUP II: Participants undergo surgical resection.\n\nAfter completion of study treatment, participants are followed up for 30 days."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer","Stage I Lung Cancer","Stage Ib Lung Carcinoma","Stage IA Lung Carcinoma AJCC V7","Stage IIA Lung Carcinoma","Stage IIIA Lung Carcinoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":20,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Vitamin A compound","type":"EXPERIMENTAL","description":"Participants receive vitamin A compound PO for 7 consecutive days in the absence of disease progression or unacceptable toxicity. Within 21 days of completing treatment, participants then undergo surgical resection.","interventionNames":["Drug: Vitamin A Compound"]},{"label":"Therapeutic Conventional Surgery","type":"ACTIVE_COMPARATOR","description":"Description Participants undergo surgical resection.","interventionNames":["Procedure: Therapeutic Conventional Surgery"]}],"interventions":[{"type":"DRUG","name":"Vitamin A Compound","description":"Participants randomized to this arm will receive 7 consecutive days of of Vitamin A compound without disease progression or unacceptable toxicities. Within 21 days of completion of treatment participants will undergo surgical resection","armGroupLabels":["Vitamin A compound"],"otherNames":["Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, 68-26-8, A 313, Anti-Infective Vitamin, Anti-Infective vitamin, Antixerophthalmic Vitamin, Antixerophthalmic vitamin"]},{"type":"PROCEDURE","name":"Therapeutic Conventional Surgery","description":"Participants randomized to this arm will receive surgical resection","armGroupLabels":["Therapeutic Conventional Surgery"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Presence or Absence of Germinal Centers in Resected Tissue","description":"Presence/absence of germinal centers (GCs) in resected cancer tissues from patients who receive neoadjuvant vitamin A and controls.","timeFrame":"Up to 2 years"}],"secondaryOutcomes":[{"measure":"Proportion of Germinal Centers in Lymph Nodes","description":"Measurement of GCs per unit area in adjacent lymph nodes will be assessed using semi-quantitative designation (Score of high, moderate, low, or absent) in patients who receive neoadjuvant vitamin A and controls.","timeFrame":"Up to 2 years"},{"measure":"Presence or Absence of Tumor Necrosis","description":"Pathologic response will be defined by tumor necrosis which will be dichotomized as present or absent in patients who receive neoadjuvant vitamin A and controls","timeFrame":"Up to 2 years"},{"measure":"Overall Survival","description":"Overall survival of patients receiving neoadjuvant Vitamin A and in controls.","timeFrame":"Up to 2 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient must be 18 years of age or older.\n* Patients must have either biopsy proven or radiographically suspected non-small cell lung cancer.\n* Patients must have disease in the chest that is felt to be surgically resectable.\n* ECOG performance status of 0-2.\n* Ability to understand and the willingness to sign an IRB-approved informed consent document\n\nExclusion Criteria:\n\n* Patients younger than 18 years of age\n* Women who are pregnant or breast feeding.\n* Patients may not be receiving any other investigational agents for the treatment of nonsmall cell lung cancer.\n* Patients may not be taking the following medications: high dose vitamin A supplement (multivitamin supplements prohibited only if vitamin A content is greater than 3,500 international units), bexarotene, alitretinoin, tretinoin, adapalene, isotretinoin, acitretin, doxycycline, minocycline, or demeclocycline,\n* Uncontrolled intercurrent illness including, but not limited to, pancreatitis, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Hypervitaminosis A - toxic effects of ingesting too much vitamin A.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"William J Petty, MD","affiliation":"Wake Forest University Health Sciences","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Wake Forest Baptist Comprehensive Cancer Center","city":"Winston-Salem","state":"North Carolina","zip":"27157","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Vitamin A Compound","description":"Participants receive vitamin A compound PO for 7 consecutive days in the absence of disease progression or unacceptable toxicity. Within 21 days of completing treatment, participants then undergo surgical resection.\n\nVitamin A Compound: Participants randomized to this arm will receive 7 consecutive days of of Vitamin A compound without disease progression or unacceptable toxicities. Within 21 days of completion of treatment participants will undergo surgical resection"},{"id":"FG001","title":"Therapeutic Conventional Surgery","description":"Description Participants undergo surgical resection.\n\nTherapeutic Conventional Surgery: Participants randomized to this arm will receive surgical resection"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"9"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"9"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Vitamin A Compound","description":"Participants receive vitamin A compound PO for 7 consecutive days in the absence of disease progression or unacceptable toxicity. Within 21 days of completing treatment, participants then undergo surgical resection.\n\nVitamin A Compound: Participants randomized to this arm will receive 7 consecutive days of of Vitamin A compound without disease progression or unacceptable toxicities. Within 21 days of completion of treatment participants will undergo surgical resection"},{"id":"BG001","title":"Therapeutic Conventional Surgery","description":"Description Participants undergo surgical resection.\n\nTherapeutic Conventional Surgery: Participants randomized to this arm will receive surgical resection"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"20"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"66.0","spread":"9.0"},{"groupId":"BG001","value":"69.1","spread":"10.8"},{"groupId":"BG002","value":"67.4","spread":"9.7"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"10"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"10"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"20"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"19"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"20"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Presence or Absence of Germinal Centers in Resected Tissue","description":"Presence/absence of germinal centers (GCs) in resected cancer tissues from patients who receive neoadjuvant vitamin A and controls.","populationDescription":"No samples were analyzed for outcomes and the study was stopped therefore data was not collected for outcome measures","reportingStatus":"POSTED","timeFrame":"Up to 2 years","groups":[{"id":"OG000","title":"Vitamin A Compound","description":"Participants receive vitamin A compound PO for 7 consecutive days in the absence of disease progression or unacceptable toxicity. Within 21 days of completing treatment, participants then undergo surgical resection.\n\nVitamin A Compound: Participants randomized to this arm will receive 7 consecutive days of of Vitamin A compound without disease progression or unacceptable toxicities. Within 21 days of completion of treatment participants will undergo surgical resection"},{"id":"OG001","title":"Therapeutic Conventional Surgery","description":"Description Participants undergo surgical resection.\n\nTherapeutic Conventional Surgery: Participants randomized to this arm will receive surgical resection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Proportion of Germinal Centers in Lymph Nodes","description":"Measurement of GCs per unit area in adjacent lymph nodes will be assessed using semi-quantitative designation (Score of high, moderate, low, or absent) in patients who receive neoadjuvant vitamin A and controls.","populationDescription":"No samples were analyzed for outcomes and the study was stopped therefore data was not collected for outcome measures","reportingStatus":"POSTED","timeFrame":"Up to 2 years","groups":[{"id":"OG000","title":"Vitamin A Compound","description":"Participants receive vitamin A compound PO for 7 consecutive days in the absence of disease progression or unacceptable toxicity. Within 21 days of completing treatment, participants then undergo surgical resection.\n\nVitamin A Compound: Participants randomized to this arm will receive 7 consecutive days of of Vitamin A compound without disease progression or unacceptable toxicities. Within 21 days of completion of treatment participants will undergo surgical resection"},{"id":"OG001","title":"Therapeutic Conventional Surgery","description":"Description Participants undergo surgical resection.\n\nTherapeutic Conventional Surgery: Participants randomized to this arm will receive surgical resection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Presence or Absence of Tumor Necrosis","description":"Pathologic response will be defined by tumor necrosis which will be dichotomized as present or absent in patients who receive neoadjuvant vitamin A and controls","populationDescription":"No samples were analyzed for outcomes and the study was stopped therefore data was not collected for outcome measures","reportingStatus":"POSTED","timeFrame":"Up to 2 years","groups":[{"id":"OG000","title":"Vitamin A Compound","description":"Participants receive vitamin A compound PO for 7 consecutive days in the absence of disease progression or unacceptable toxicity. Within 21 days of completing treatment, participants then undergo surgical resection.\n\nVitamin A Compound: Participants randomized to this arm will receive 7 consecutive days of of Vitamin A compound without disease progression or unacceptable toxicities. Within 21 days of completion of treatment participants will undergo surgical resection"},{"id":"OG001","title":"Therapeutic Conventional Surgery","description":"Description Participants undergo surgical resection.\n\nTherapeutic Conventional Surgery: Participants randomized to this arm will receive surgical resection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival of patients receiving neoadjuvant Vitamin A and in controls.","populationDescription":"No samples were analyzed for outcomes and the study was stopped therefore data was not collected for outcome measures","reportingStatus":"POSTED","timeFrame":"Up to 2 years","groups":[{"id":"OG000","title":"Vitamin A Compound","description":"Participants receive vitamin A compound PO for 7 consecutive days in the absence of disease progression or unacceptable toxicity. Within 21 days of completing treatment, participants then undergo surgical resection.\n\nVitamin A Compound: Participants randomized to this arm will receive 7 consecutive days of of Vitamin A compound without disease progression or unacceptable toxicities. Within 21 days of completion of treatment participants will undergo surgical resection"},{"id":"OG001","title":"Therapeutic Conventional Surgery","description":"Description Participants undergo surgical resection.\n\nTherapeutic Conventional Surgery: Participants randomized to this arm will receive surgical resection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"30 days after last dose of study drug is administered","eventGroups":[{"id":"EG000","title":"Vitamin A Compound","description":"Participants receive vitamin A compound PO for 7 consecutive days in the absence of disease progression or unacceptable toxicity. Within 21 days of completing treatment, participants then undergo surgical resection.\n\nVitamin A Compound: Participants randomized to this arm will receive 7 consecutive days of of Vitamin A compound without disease progression or unacceptable toxicities. Within 21 days of completion of treatment participants will undergo surgical resection","deathsNumAffected":0,"deathsNumAtRisk":11,"seriousNumAffected":0,"seriousNumAtRisk":11,"otherNumAffected":0,"otherNumAtRisk":11},{"id":"EG001","title":"Therapeutic Conventional Surgery","description":"Description Participants undergo surgical resection.\n\nTherapeutic Conventional Surgery: Participants randomized to this arm will receive surgical resection","deathsNumAffected":0,"deathsNumAtRisk":9,"seriousNumAffected":0,"seriousNumAtRisk":9,"otherNumAffected":0,"otherNumAtRisk":9}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Study Coordinator","organization":"Wake Forest Baptist Comprehensive Cancer Center","email":"jkettler@wakehealth.edu","phone":"336-716-4760"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2021-05-18","uploadDate":"2023-11-20T12:33","filename":"Prot_SAP_001.pdf","size":1436067},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2021-02-04","uploadDate":"2023-12-19T16:17","filename":"ICF_002.pdf","size":299302}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D008175","term":"Lung Neoplasms"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D014801","term":"Vitamin A"}],"ancestors":[{"id":"D012176","term":"Retinoids"},{"id":"D002338","term":"Carotenoids"},{"id":"D011090","term":"Polyenes"},{"id":"D000475","term":"Alkenes"},{"id":"D006839","term":"Hydrocarbons, Acyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D053138","term":"Cyclohexenes"},{"id":"D003510","term":"Cyclohexanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D013729","term":"Terpenes"},{"id":"D004224","term":"Diterpenes"},{"id":"D010860","term":"Pigments, Biological"},{"id":"D001685","term":"Biological Factors"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT02901925","orgStudyIdInfo":{"id":"D16107"},"secondaryIdInfos":[{"id":"R01CA167413","type":"NIH","link":"https://reporter.nih.gov/quickSearch/R01CA167413"}],"organization":{"fullName":"Dartmouth-Hitchcock Medical Center","class":"OTHER"},"briefTitle":"A Microdose Evaluation Study of ABY-029 in Recurrent Glioma","officialTitle":"A Phase 0 Open Label, Single-center Clinical Trial of ABY-029, an Anti-EGFR Fluorescence Imaging Agent Via Single Intravenous Injection to Subjects With Recurrent Glioma","acronym":"ABY-029"},"statusModule":{"statusVerifiedDate":"2024-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-02-13","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-06-29","type":"ACTUAL"},"completionDateStruct":{"date":"2021-06-29","type":"ACTUAL"},"studyFirstSubmitDate":"2016-09-12","studyFirstSubmitQcDate":"2016-09-14","studyFirstPostDateStruct":{"date":"2016-09-15","type":"ESTIMATED"},"resultsFirstSubmitDate":"2024-08-31","resultsFirstSubmitQcDate":"2024-11-20","resultsFirstPostDateStruct":{"date":"2024-12-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-11-20","lastUpdatePostDateStruct":{"date":"2024-12-13","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"David W. Roberts","investigatorTitle":"Principal Investigator","investigatorAffiliation":"Dartmouth-Hitchcock Medical Center"},"leadSponsor":{"name":"Dartmouth-Hitchcock Medical Center","class":"OTHER"},"collaborators":[{"name":"Dartmouth College","class":"OTHER"},{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The primary study objective is to determine if microdoses of ABY-029 lead to detectable signals in sampled tissues with an EGFR pathology score  1 based on histological staining.\n\nThe secondary study objective is to assess diagnostic accuracy of ABY-029 detection by iFI and intraoperative probe relative to histopathology diagnosis, and other indicators (e.g. proliferation, infiltration, etc.) as the gold standard, and to measure the molecular uptake and concentration of ABY-029 in resected specimens.","detailedDescription":"The investigators plan a sample size of 6-12 patients in this open label, single center, clinical trial of ABY-029. Administration will occur as a single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery.\n\nThe protocol is not a safety study since no physiological effects are expected at microdose levels of ABY-029. Rather, doses have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. No diagnostic or therapeutic intent is proposed, and administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure."},"conditionsModule":{"conditions":["Glioma"],"keywords":["ABY-029","Affibody","Molecular Fluorescence-Guided Surgery","Epidermal Growth Factor Receptor (EGFR)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","interventionModelDescription":"Pilot feasibility study","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"NONE","maskingDescription":"open label"}},"enrollmentInfo":{"count":14,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"ABY-029 1X dose group","type":"EXPERIMENTAL","description":"ABY-029 will be administered at the 1X dose level prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.","interventionNames":["Drug: ABY-029"]},{"label":"ABY-029 3X dose group","type":"EXPERIMENTAL","description":"ABY-029 will be administered at the 3X dose level prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.","interventionNames":["Drug: ABY-029"]},{"label":"ABY-029 6X dose group","type":"EXPERIMENTAL","description":"ABY-029 will be administered at the 6X dose level prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.","interventionNames":["Drug: ABY-029"]}],"interventions":[{"type":"DRUG","name":"ABY-029","description":"Using a sample size of 6-12 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.","armGroupLabels":["ABY-029 1X dose group","ABY-029 3X dose group","ABY-029 6X dose group"],"otherNames":["ABY-029 trifluoroacetate salt","IRDye 800CW Maleimide labeled Affibody peptide"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Fluorescence Signal Detection","description":"The primary study endpoint is to determine if the fluorescence signal from ABY-029, as measured by Biological Variance Ratio (BVR), can be detected in brain tissue during surgery. This will help researchers determine if ABY-029 functions well for imaging brain tumor tissue during surgery.","timeFrame":"during procedure"}],"secondaryOutcomes":[{"measure":"Mean Tumor-to-background Ratio","description":"A secondary study endpoint is to calculate the ratio of the average (mean) fluorescence intensity of ABY-029 measured in the tumor, to the average (mean) fluorescence intensity of ABY-029 measured in the surrounding tissues in the brain during surgery. This will help researchers determine how well ABY-029 works for imaging tumor tissue.","timeFrame":"during procedure"},{"measure":"Ex Vivo Fluorescence Intensity","description":"Another secondary study endpoint is to quantify the relationship between the dose of ABY-029 administered and the fluorescence intensity produced by ABY-029 in ex vivo tissue samples after they have been transferred to the pathology department. This endpoint will be measured in relative fluorescence units, and will help researchers conduct analyses on how well ABY-029 works for imaging in tissue following surgery.","timeFrame":"post surgical"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Preoperative diagnosis of recurrent high-grade glioma having EGFR positive tissue from prior surgery.\n2. Tumor judged to be suitable for open cranial resection based on preoperative imaging studies.\n3. Valid informed consent by subject.\n4. Age  18 years old.\n\nExclusion Criteria:\n\n1. Pregnant women or women who are breast feeding.\n2. Patients on any experimental anti-EGFR targeted therapies","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"David W Roberts, MD","affiliation":"Dartmouth-Hitchcock Medical Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Dartmouth-Hitchcock Medical Center","city":"Lebanon","state":"New Hampshire","zip":"03756","country":"United States","geoPoint":{"lat":43.64229,"lon":-72.25176}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Participants were recruited and enrolled at 1 academic medical center between February 2017 and June 2021. Of 14 participants enrolled (patients met the inclusion criteria and signed the consent form), a total of 12 received the study drug and started the study across the 3 dose groups: 3 patients in the 1X dose group, 3 patients in the 3X dose group, and 6 patients in the 6X dose group.","groups":[{"id":"FG000","title":"ABY-029 1X Dose Group","description":"A 1X dose of ABY-029 will be administered prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.\n\nABY-029: In 3 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure."},{"id":"FG001","title":"ABY-029 3X Dose Group","description":"A 3X dose of ABY-029 will be administered prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.\n\nABY-029: In 3 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure."},{"id":"FG002","title":"ABY-029 6X Dose Group","description":"A 6X dose of ABY-029 will be administered prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.\n\nABY-029: In 3-6 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"6"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"6"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"ABY-029 1X Dose Group","description":"A 1X dose of ABY-029 will be administered prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.\n\nABY-029: Using a sample size of 3 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure."},{"id":"BG001","title":"ABY-029 3X Dose Group","description":"A 3X dose of ABY-029 will be administered prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.\n\nABY-029: Using a sample size of 3 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure."},{"id":"BG002","title":"ABY-029 6X Dose Group","description":"A 6X dose of ABY-029 will be administered prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.\n\nABY-029: Using a sample size of 3-6 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"12"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"7"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"5"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"6"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"6"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"12"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"11"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"12"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Fluorescence Signal Detection","description":"The primary study endpoint is to determine if the fluorescence signal from ABY-029, as measured by Biological Variance Ratio (BVR), can be detected in brain tissue during surgery. This will help researchers determine if ABY-029 functions well for imaging brain tumor tissue during surgery.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Biological variance ratio","timeFrame":"during procedure","groups":[{"id":"OG000","title":"1X Dose Group","description":"Patients received 30 nanomoles or 237g of ABY-029"},{"id":"OG001","title":"3X Dose Group","description":"Patients received 90 nanomoles or 711g of ABY-029"},{"id":"OG002","title":"6X Dose Group","description":"Patients received 180 nanomoles or 1.42 mg of ABY-029"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"2.4"},{"groupId":"OG001","value":"5.0","spread":"1.2"},{"groupId":"OG002","value":"8.8","spread":"3.7"}]}]}]},{"type":"SECONDARY","title":"Mean Tumor-to-background Ratio","description":"A secondary study endpoint is to calculate the ratio of the average (mean) fluorescence intensity of ABY-029 measured in the tumor, to the average (mean) fluorescence intensity of ABY-029 measured in the surrounding tissues in the brain during surgery. This will help researchers determine how well ABY-029 works for imaging tumor tissue.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"tumor-to-background ratio","timeFrame":"during procedure","groups":[{"id":"OG000","title":"1X Dose Group","description":"Patients received 30 nanomoles or 237g of ABY-029"},{"id":"OG001","title":"3X Dose Group","description":"Patients received 90 nanomoles or 711g of ABY-029"},{"id":"OG002","title":"6X Dose Group","description":"Patients received 180 nanomoles or 1.42 mg of ABY-029"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.1"},{"groupId":"OG001","value":"2.1","spread":"0.6"},{"groupId":"OG002","value":"2.6","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Ex Vivo Fluorescence Intensity","description":"Another secondary study endpoint is to quantify the relationship between the dose of ABY-029 administered and the fluorescence intensity produced by ABY-029 in ex vivo tissue samples after they have been transferred to the pathology department. This endpoint will be measured in relative fluorescence units, and will help researchers conduct analyses on how well ABY-029 works for imaging in tissue following surgery.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"relative fluorescence units","timeFrame":"post surgical","groups":[{"id":"OG000","title":"1X Dose Group","description":"Patients received 30 nanomoles or 237g of ABY-029"},{"id":"OG001","title":"3X Dose Group","description":"Patients received 90 nanomoles or 711g of ABY-029"},{"id":"OG002","title":"6X Dose Group","description":"Patients received 180 nanomoles or 1.42 mg of ABY-029"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.4","spread":"25.1"},{"groupId":"OG001","value":"215.2","spread":"109.1"},{"groupId":"OG002","value":"884.1","spread":"475.4"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"1 month","eventGroups":[{"id":"EG000","title":"ABY-029 1X Dose Group","description":"A 1X dose of ABY-029 will be administered prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.\n\nABY-029: Using a sample size of 3 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.","deathsNumAffected":0,"deathsNumAtRisk":3,"seriousNumAffected":0,"seriousNumAtRisk":3,"otherNumAffected":0,"otherNumAtRisk":3},{"id":"EG001","title":"ABY-029 3X Dose Group","description":"A 3X dose of ABY-029 will be administered prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.\n\nABY-029: Using a sample size of 3 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.","deathsNumAffected":0,"deathsNumAtRisk":3,"seriousNumAffected":0,"seriousNumAtRisk":3,"otherNumAffected":0,"otherNumAtRisk":3},{"id":"EG002","title":"ABY-029 6X Dose Group","description":"A 6X dose of ABY-029 will be administered prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.\n\nABY-029: Using a sample size of 6 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":0,"otherNumAtRisk":6}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Dr. David Roberts","organization":"Dartmouth-Hitchcock","email":"David.W.Roberts@dartmouth.edu","phone":"603-650-"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2019-02-14","uploadDate":"2024-08-21T17:37","filename":"Prot_SAP_001.pdf","size":652832},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2021-06-17","uploadDate":"2021-07-12T10:21","filename":"ICF_000.pdf","size":196491}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D005910","term":"Glioma"}],"ancestors":[{"id":"D018302","term":"Neoplasms, Neuroepithelial"},{"id":"D017599","term":"Neuroectodermal Tumors"},{"id":"D009373","term":"Neoplasms, Germ Cell and Embryonal"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009380","term":"Neoplasms, Nerve Tissue"}]},"interventionBrowseModule":{"meshes":[{"id":"C000626949","term":"ABY-029"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT04883645","orgStudyIdInfo":{"id":"103625"},"secondaryIdInfos":[{"id":"7R21CA252441-02","type":"NIH","link":"https://reporter.nih.gov/quickSearch/7R21CA252441-02"}],"organization":{"fullName":"Medical University of South Carolina","class":"OTHER"},"briefTitle":"Neoadjuvant Imiquimod Immunotherapy for Oral Cancer","officialTitle":"Pilot Clinical Trial of Neoadjuvant Toll-like Receptor 7 Agonist (Imiquimod) Immunotherapy in Early-Stage Oral Squamous Cell Carcinoma"},"statusModule":{"statusVerifiedDate":"2025-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-04-28","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-06-30","type":"ACTUAL"},"completionDateStruct":{"date":"2024-07-31","type":"ACTUAL"},"studyFirstSubmitDate":"2021-05-06","studyFirstSubmitQcDate":"2021-05-11","studyFirstPostDateStruct":{"date":"2021-05-12","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-11-19","resultsFirstSubmitQcDate":"2025-01-08","resultsFirstPostDateStruct":{"date":"2025-01-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-01-08","lastUpdatePostDateStruct":{"date":"2025-01-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Medical University of South Carolina","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"The purpose of this research study is to find out what effects, good and/or bad, topical application of the drug Aldara will have on patients and on their oral cancer. Aldara is a drug that activates toll-like receptor (TLR) in oral cancer cells causing self-destruction of tumor cells. It also activates immune cells to attack and eliminate cancer cells. Aldara is currently approved by the Food and Drug Administration (FDA) for treatment of skin cancer and melanoma. Its use in this study is 'off-label' (use of a drug approved by FDA for skin cancer to treat oral cancer in this study).\n\nThe preliminary efficacy of topical imiquimod in a neoadjuvant setting in patients with early-stage oral squamous cell carcinoma will be determined by a reduction in tumor cellularity in post-treatment tissue compared to pre-treatment tissue. Safety and tolerability will be evaluated by CTCAE v5 criteria. The effect of imiquimod on the tumor immune microenvironment will be assessed by performing quantitative multiplex immunofluorescence.","detailedDescription":"The researchers propose an exploratory clinical trial to evaluate the efficacy of topical imiquimod, a TLR-7 agonist, in patients with early-stage oral squamous cell carcinoma. The analysis of pre- and post-treatment tumor specimen collected from patients treated on this study will be used for quantitative immunoflourescence analysis to assess the immunomodulatory activity of imiquimod in human tumor samples. The researchers hypothesize that TLR-7 stimulation will reduce the size of the tumor in patients with early-stage oral squamous cell carcinoma. The researchers anticipate that activation of immune cells will correlate with response to therapy."},"conditionsModule":{"conditions":["Oral Squamous Cell Carcinoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":16,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Experimental: Topical Aldara","type":"EXPERIMENTAL","description":"All patients receive the same treatment (there is no \"placebo\" arm). Treatment will be self-administered by the patients on an outpatient basis. All patients with untreated and biopsy confirmed oral squamous cell carcinoma (OSCC) who meet the inclusion criteria.","interventionNames":["Drug: Imiquimod 5% Cream"]}],"interventions":[{"type":"DRUG","name":"Imiquimod 5% Cream","description":"Imiquimod as a 5% cream is being used to treat several skin cancers, including malignant melanoma, basal cell carcinoma (BCC) and SCC. With respect to SCC treatment, it has been demonstrated that imiquimod stimulates tumor destruction by recruiting T cells (cells in the immune system) from blood and by inhibiting tonic anti-inflammatory signals within the tumor. The patient will be instructed to apply imiquimod cream, 7 nights a week for 4 weeks to the oral tumor at bedtime.","armGroupLabels":["Experimental: Topical Aldara"],"otherNames":["Aldera"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With 50% Reduction in Tumor Cell Count and Major Pathologic Response","description":"A minimum of 50% reduction in tumor cell count assessed by quantitative multiplex immunofluorescence (qmIF) within the tumor bed of the surgical tissue (post-treatment) compared to the biopsy tissue (pre-treatment). In addition, the major pathologic response to be assessed using Immune-Related Pathologic Response Criteria (irPCR) in the tumor bed of the post-treatment surgical tissue.","timeFrame":"Following 28 days of treatment"}],"secondaryOutcomes":[{"measure":"Safety of Imiquimod Therapy","description":"Defined as safe no life-threatening (Grade 4) adverse events assessed by CTCAE v5 criteria.","timeFrame":"2 months"}],"otherOutcomes":[{"measure":"Changes in Immune Cell Count","description":"To assess the changes in anti-tumoral immune cell counts from pre- to post-therapy by quantitative multiplex immunofluorescence (normalized cell number per mm\\^2 from 6 to 8 regions of interest).","timeFrame":"Following 28 days of treatment"},{"measure":"RFS Follow-up","description":"One-year relapse-free survival (RFS)","timeFrame":"1 year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Previously untreated and biopsy confirmed oral squamous cell carcinoma (OSCC)\n* Clinical (TNM) stage I or II\n* Age \\>= 18 years\n* Eastern Cooperative Oncology Group (ECOG) =\\< 2\n\nExclusion Criteria:\n\n* Patients associated with prior therapy requiring treatment with systemic immunosuppressive treatments with the exception of vitiligo, childhood asthma that has resolved, residual endocrinopathies requiring replacement therapy, or psoriasis that does not require systemic treatment\n* Treatment with any other investigational agents\n* Requirement for immunosuppressive intraoral topical or systemic corticosteroids prior to the study\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* HIV positive patients on combination antiretroviral therapy\n* Have evidence of any other significant oral mucosal condition, clinical disorder, physical examination finding, or laboratory finding that, as judged by the investigator, makes it undesirable for the patient to participate in the study\n* Pregnant women are excluded from this study because imiquimod may have adverse effect on the fetus (FDA pregnancy risk category C). Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with imiquimod, breastfeeding should be discontinued if the mother is receiving study treatment\n* Male patients unwilling or unable to comply with pregnancy prevention measures\n* Subjects not receiving initial surgical treatment at Medical University of South Carolina (MUSC)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Angela Yoon, DDS","affiliation":"Medical University of South Carolina","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Medical University of South Carolina","city":"Charleston","state":"South Carolina","zip":"29425","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}}]},"referencesModule":{"references":[{"pmid":"39931064","type":"DERIVED","citation":"Yoon AJ, Carvajal RD, Graboyes EM, Kaczmar JM, Albergotti WG, Kejner AE, Troob SH, Philipone E, Anoma JS, Armeson KE, Hill EG, Richardson MS, Woods TR, Chera BS, Nourollah-Zadeh F, Lee BJ, Pandruvada S, Kourtidis A, Kingsley C, O'Quinn EC, Mills S, Jordan VC, Spencer M, Fails D, McKee TD, Zaidi M, Brisendine A, Horn S, Mehrotra S, Ogretmen B, Newman JG. Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma. Front Immunol. 2025 Jan 27;16:1530262. doi: 10.3389/fimmu.2025.1530262. eCollection 2025."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Experimental: Topical Aldara","description":"All patients receive the same treatment (there is no \"placebo\" arm). Treatment will be self-administered by the patients on an outpatient basis. All patients with untreated and biopsy confirmed oral squamous cell carcinoma (OSCC) who meet the inclusion criteria.\n\nImiquimod 5% Cream: Imiquimod as a 5% cream is being used to treat several skin cancers, including malignant melanoma, basal cell carcinoma (BCC) and SCC. With respect to SCC treatment, it has been demonstrated that imiquimod stimulates tumor destruction by recruiting T cells (cells in the immune system) from blood and by inhibiting tonic anti-inflammatory signals within the tumor. The patient will be instructed to apply imiquimod cream, 7 nights a week for 4 weeks to the oral tumor at bedtime."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"16"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"15"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Early-stage oral squamous cell carcinoma","groups":[{"id":"BG000","title":"Imiquimod Treatment","description":"All patients receive the same treatment (there is no \"placebo\" arm). Treatment will be self-administered by the patients on an outpatient basis. All patients with untreated and biopsy confirmed oral squamous cell carcinoma (OSCC) who meet the inclusion criteria.\n\nImiquimod 5% Cream: Imiquimod as a 5% cream is being used to treat several skin cancers, including malignant melanoma, basal cell carcinoma (BCC) and SCC. With respect to SCC treatment, it has been demonstrated that imiquimod stimulates tumor destruction by recruiting T cells (cells in the immune system) from blood and by inhibiting tonic anti-inflammatory signals within the tumor. The patient will be instructed to apply imiquimod cream, 7 nights a week for 4 weeks to the oral tumor at bedtime."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"15"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"6"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"9"}]}]}]},{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"65","lowerLimit":"52","upperLimit":"87"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"6"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"9"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"2"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"12"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With 50% Reduction in Tumor Cell Count and Major Pathologic Response","description":"A minimum of 50% reduction in tumor cell count assessed by quantitative multiplex immunofluorescence (qmIF) within the tumor bed of the surgical tissue (post-treatment) compared to the biopsy tissue (pre-treatment). In addition, the major pathologic response to be assessed using Immune-Related Pathologic Response Criteria (irPCR) in the tumor bed of the post-treatment surgical tissue.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Following 28 days of treatment","groups":[{"id":"OG000","title":"Experimental: Imiquimod","description":"All patients receive the same treatment (there is no \"placebo\" arm). Treatment will be self-administered by the patients on an outpatient basis. All patients with untreated and biopsy confirmed oral squamous cell carcinoma (OSCC) who meet the inclusion criteria.\n\nImiquimod 5% Cream: Imiquimod as a 5% cream is being used to treat several skin cancers, including malignant melanoma, basal cell carcinoma (BCC) and SCC. With respect to SCC treatment, it has been demonstrated that imiquimod stimulates tumor destruction by recruiting T cells (cells in the immune system) from blood and by inhibiting tonic anti-inflammatory signals within the tumor. The patient will be instructed to apply imiquimod cream, 7 nights a week for 4 weeks to the oral tumor at bedtime."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"categories":[{"title":"Greater than 50% reduction and Major Pathologic Response","measurements":[{"groupId":"OG000","value":"9"}]},{"title":"Less than 50% reduction and Partial Response","measurements":[{"groupId":"OG000","value":"6"}]}]}]},{"type":"SECONDARY","title":"Safety of Imiquimod Therapy","description":"Defined as safe no life-threatening (Grade 4) adverse events assessed by CTCAE v5 criteria.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"2 months","groups":[{"id":"OG000","title":"Experimental: Imiquimod","description":"All patients receive the same treatment (there is no \"placebo\" arm). Treatment will be self-administered by the patients on an outpatient basis. All patients with untreated and biopsy confirmed oral squamous cell carcinoma (OSCC) who meet the inclusion criteria.\n\nImiquimod 5% Cream: Imiquimod as a 5% cream is being used to treat several skin cancers, including malignant melanoma, basal cell carcinoma (BCC) and SCC. With respect to SCC treatment, it has been demonstrated that imiquimod stimulates tumor destruction by recruiting T cells (cells in the immune system) from blood and by inhibiting tonic anti-inflammatory signals within the tumor. The patient will be instructed to apply imiquimod cream, 7 nights a week for 4 weeks to the oral tumor at bedtime."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"categories":[{"title":"Grade 4 AEs","measurements":[{"groupId":"OG000","value":"0"}]},{"title":"No Grade 4 AEs","measurements":[{"groupId":"OG000","value":"15"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Changes in Immune Cell Count","description":"To assess the changes in anti-tumoral immune cell counts from pre- to post-therapy by quantitative multiplex immunofluorescence (normalized cell number per mm\\^2 from 6 to 8 regions of interest).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Normalized cells/mm^2","timeFrame":"Following 28 days of treatment","groups":[{"id":"OG000","title":"Correlative: Change in Antitumor Immune Cell Count After Imiquimod Immunotherapy.","description":"All patients receive the same treatment (there is no \"placebo\" arm). Treatment will be self-administered by the patients on an outpatient basis. All patients with untreated and biopsy confirmed oral squamous cell carcinoma (OSCC) who meet the inclusion criteria."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Contribution of Increase in Functional Helper T cells in Reduction in Tumor","categories":[{"measurements":[{"groupId":"OG000","value":"0.54","lowerLimit":"0.06","upperLimit":"0.84"}]}]},{"title":"Contribution of Increase in Activated Cytotoxic T cells in Tumor Reduction","categories":[{"measurements":[{"groupId":"OG000","value":"0.55","lowerLimit":"-0.06","upperLimit":"0.97"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"RFS Follow-up","description":"One-year relapse-free survival (RFS)","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"1 year","groups":[{"id":"OG000","title":"Correlative: Shift in Antitumor Immune Profile After Imiquimod Immunotherapy.","description":"All patients receive the same treatment (there is no \"placebo\" arm). Treatment will be self-administered by the patients on an outpatient basis. All patients with untreated and biopsy confirmed oral squamous cell carcinoma (OSCC) who meet the inclusion criteria."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"categories":[{"title":"One-year RFS","measurements":[{"groupId":"OG000","value":"13"}]},{"title":"Recurrence within one-year","measurements":[{"groupId":"OG000","value":"1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Two months","description":"The secondary endpoint was treatment-related toxicity graded by CTCAE v5, defined as safe if no life-threatening (Grade 4) is reported.","eventGroups":[{"id":"EG000","title":"Imiquimod","description":"Treatment group","deathsNumAffected":1,"deathsNumAtRisk":16,"seriousNumAffected":1,"seriousNumAtRisk":16,"otherNumAffected":14,"otherNumAtRisk":16}],"seriousEvents":[{"term":"Mortality","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":16}]}],"otherEvents":[{"term":"Oral mucositis","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":16}]},{"term":"Oral pain/Sore throat","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":16}]},{"term":"Fatigue","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":16}]},{"term":"Oral hemorrhage","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":16}]},{"term":"Nausea","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":16}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Dr. Angela J. Yoon","organization":"Medical University of South Carolina","email":"yoona@musc.edu","phone":"8437924496"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2023-11-15","uploadDate":"2024-11-19T14:41","filename":"Prot_SAP_001.pdf","size":791760},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2023-05-16","uploadDate":"2024-03-05T17:05","filename":"ICF_000.pdf","size":229367}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D000077195","term":"Squamous Cell Carcinoma of Head and Neck"}],"ancestors":[{"id":"D002294","term":"Carcinoma, Squamous Cell"},{"id":"D002277","term":"Carcinoma"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D006258","term":"Head and Neck Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077271","term":"Imiquimod"}],"ancestors":[{"id":"D000634","term":"Aminoquinolines"},{"id":"D011804","term":"Quinolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT05798507","orgStudyIdInfo":{"id":"STUDY00004876"},"secondaryIdInfos":[{"id":"NCI-2023-00602","type":"REGISTRY","domain":"CTRP (Clinical Trial Reporting Program)"},{"id":"STUDY00004876","type":"OTHER","domain":"Emory University Hospital/Winship Cancer Institute"},{"id":"WINSHIP5751-22","type":"OTHER","domain":"Emory University Hospital/Winship Cancer Institute"},{"id":"P30CA138292","type":"NIH","link":"https://reporter.nih.gov/quickSearch/P30CA138292"}],"organization":{"fullName":"Emory University","class":"OTHER"},"briefTitle":"Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma","officialTitle":"A Single-Dose Study of Orally Administrated Defactinib or VS-6766 in Patients With Glioblastoma"},"statusModule":{"statusVerifiedDate":"2025-12","overallStatus":"ACTIVE_NOT_RECRUITING","startDateStruct":{"date":"2023-07-28","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12-03","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-12-03","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-03-03","studyFirstSubmitQcDate":"2023-03-22","studyFirstPostDateStruct":{"date":"2023-04-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-12-10","lastUpdatePostDateStruct":{"date":"2025-12-15","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Kimberly Bojanowski Hoang","investigatorTitle":"Principal Investigator","investigatorAffiliation":"Emory University"},"leadSponsor":{"name":"Emory University","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"},{"name":"Verastem, Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This early phase I trial tests brain concentration level and safety of defactinib or VS-6766 for the treatment of patients with glioblastoma. Recently, two new drugs that seem to work together have been shown to have promising treatment effects in tissue culture and animal models of glioblastoma. Each inhibits a different glioblastoma growth pathway and when used together may create a larger effect on tumor growth than either alone. Growth pathway describes a series of chemical reactions in which a group of molecules in a cell work together to control cell growth. It is known that glioblastoma tumor cells can grow because of lack of regulation. Both Pyk2 and the closely related kinase (FAK) proteins help regulate tumor cell invasion, unless they are produced in large amounts (over expressed). Specifically, Raf and FAK/Pyk2 regulation of cell division is activated quite a bit more in gliomas compared to normal tissues. Recently developed inhibitors of Raf (VS-6766) and FAK (defactinib) which belong to a class of medications called kinase inhibitors, are aimed to bring their activity to proper levels and may stop tumor growth.","detailedDescription":"PRIMARY OBJECTIVES:\n\nI. Estimate (or characterize) the concentration of defactinib or avutometinib (VS-6766) that accumulates in the glioblastoma (GBM) and brain around tumor.\n\nII. Assess the safety of the administration of a single oral dose of defactinib or VS-6766 in patients with glioblastoma.\n\nIII. Assess the inhibition of Pyk2/FAK or MEK, Erk signaling in tumor and brain around tumor.\n\nIV. Assess the pharmacodynamics of defactinib or VS-6766 in patients with glioblastoma.\n\nOUTLINE: This is a dose-escalation study of defactinib and avutometinib. Patients are assigned to 1 of 2 arms.\n\nARM I: Patients receive 1 dose of defactinib orally (PO) while on study, prior to planned tumor resection.\n\nARM II: Patients receive 1 dose of avutometinib PO while on study, prior to planned tumor resection.\n\nPatients undergo blood collection and donate resected tumor tissue while on study."},"conditionsModule":{"conditions":["Glioblastoma","Recurrent Glioblastoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":14,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm I (Defactinib)","type":"EXPERIMENTAL","description":"Patients receive 1 dose of defactinib PO while on study, prior to planned tumor resection. Patients undergo blood collection and donate resected tumor tissue while on study.","interventionNames":["Procedure: Biospecimen Collection","Drug: Defactinib"]},{"label":"Arm II (Avutometinib)","type":"EXPERIMENTAL","description":"Patients receive 1 dose of avutometinib PO while on study, prior to planned tumor resection. Patients undergo blood collection and donate resected tumor tissue while on study.","interventionNames":["Drug: Avutometinib","Procedure: Biospecimen Collection"]}],"interventions":[{"type":"DRUG","name":"Avutometinib","description":"Given PO","armGroupLabels":["Arm II (Avutometinib)"],"otherNames":["CH-5126766","CH5126766","CKI-27","R-7304","Raf/MEK Inhibitor VS-6766","RG 7304","RG-7304","RG7304","RO5126766","VS 6766","VS-6766","VS6766"]},{"type":"PROCEDURE","name":"Biospecimen Collection","description":"Undergo blood and tissue sample collection","armGroupLabels":["Arm I (Defactinib)","Arm II (Avutometinib)"],"otherNames":["Biological Sample Collection","Biospecimen Collected","Specimen Collection"]},{"type":"DRUG","name":"Defactinib","description":"Given PO","armGroupLabels":["Arm I (Defactinib)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Concentration of defactinib that accumulates in the glioblastoma (GBM) and brain around tumor","description":"Defactinib concentration will be measured in a sample of the glioblastoma, brain around the glioblastoma, and in a serum sample from each subject receiving Defactinib. Descriptive statistics, such as mean and standard deviation, will be generated with these results. Concentration will be compared between dose levels within study drug using two-sample t-tests or non-parametric equivalents such as Mann Whitney U tests.","timeFrame":"At time of surgery"},{"measure":"Concentration of avutometinib (VS-6766) that accumulates in the GBM and brain around tumor","description":"VS-6766 concentration will be measured in a sample of the glioblastoma, brain around the glioblastoma, and in a serum sample from each subject receiving VS-6766. Descriptive statistics, such as mean and standard deviation, will be generated with these results. Concentration will be compared between dose levels within study drug using two-sample t-tests or non-parametric equivalents such as Mann Whitney U tests.","timeFrame":"At time of surgery"},{"measure":"Incidence of adverse events associated with defactinib","description":"Will be assessed by quantification of the recognized side effects of this agent including fatigue, nausea, diarrhea, vomiting, hyperbilirubinemia, decreased appetite, peripheral edema, dizziness, and headache and by monitoring for new or undescribed adverse events. Summary statistics will include frequencies and percentages of adverse events.","timeFrame":"Up to 2 weeks post surgery"},{"measure":"Incidence of adverse events associated with VS-6766","description":"Will be assessed by quantification of the recognized side effects of this agent including rash, creatine phosphokinase elevation, visual disturbances, hypoalbuminemia, and fatigue and by monitoring for new or undescribed adverse events. Summary statistics will include frequencies and percentages of adverse events.","timeFrame":"Up to 2 weeks post surgery"}],"secondaryOutcomes":[{"measure":"Pyk2 and FAK phosphorylation in tumor, brain around tumor, and serum","description":"These results will be summarized with descriptive statistics. These results will be compared to current and historical control samples of glioblastoma (collected in our previous human GBM specimens' studies) and analyzed in parallel with study subject samples and run on one western blot membrane to reduce technique variation. The mean phosphorylation will be compared between groups using two-sample t-test or non-parametric equivalents such as Mann Whitney U tests. Dose levels will be compared to a historical control, both alone and combined.","timeFrame":"At time of surgery"},{"measure":"MEK and Erk in tumor, brain around tumor, and serum","description":"These results will be summarized with descriptive statistics. These results will be compared to current and historical control samples of glioblastoma (collected in our previous human GBM specimens' studies) and analyzed in parallel with study subject samples and run on one western blot membrane to reduce technique variation. Phosphorylation will be compared between dose levels within study drug using two-sample t-tests or non-parametric equivalents such as Mann Whitney U tests.","timeFrame":"At time of surgery"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* New or recurrent glioblastoma diagnosed by neuroimaging techniques for which surgical resection is indicated\n* Age older than 21 years\n* An Eastern Cooperative Group (ECOG) performance status =\\< 1\n* Hemoglobin (Hb) \\>= 9.0 g/dL. If a red blood cell transfusion has been administered the Hb must remain stable and \\>= 9.0 g/dL for at least 1 week prior to first dose of study therapy.\n* Platelets \\>= 100,000/mm\\^3\n* Absolute neutrophil count (ANC) \\>= 1500/mm\\^3\n* Total bilirubin =\\< 1.5  upper limit of normal (ULN) per the institution; patients with Gilbert syndrome may enroll if total bilirubin \\< 3.0 mg/dL (51 umole/L)\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\\< 2.5  ULN (or \\< 5x ULN in patients with liver metastases)\n* Creatinine clearance rate of \\>= 50 mL/min as calculated by the Cockcroft-Gault formula or serum creatinine of =\\< 1.5 x ULN\n* Albumin \\>= 3.0 g/dL (451 umole/L)\n* Creatine phosphokinase (CPK) =\\< 2.5 x ULN\n* Left ventricular ejection fraction \\>= 50% by echocardiography (ECHO) or multiple-gated acquisition (MUGA) scan\n* Baseline QTc interval \\< 460 ms for women and =\\< 450 ms for men (average of triplicate readings) (Common Terminology Criteria for Adverse Events \\[CTCAE\\] Grade 1) using Fredericia's QT correction formula. NOTE: This criterion does not apply to subjects with a right or left bundle branch block\n* Adequate recovery from toxicities related to prior treatments to at least Grade 1 by CTCAE v 5.0. Exceptions include alopecia and peripheral neuropathy grade =\\< 2\n* Male and female patients with reproductive potential agree to use highly effective method of contraceptive (per Clinical Trial Facilitation Group \\[CFTG\\] recommendations) during the trial and for 3 months following the last dose of VS-6766 for male patients, and 1 month following the last dose of VS-6766 for female patients.\n\nExclusion Criteria:\n\n* Clinically significant gastrointestinal abnormalities, requirement for systemic anticoagulation or potent CYP 2C8 inhibitors, and history of clinically significant cardiac or pulmonary disorders\n* Minors will be excluded from the investigation. Glioblastoma is the major form of brain cancer in people over 50 years old. Pediatric cases of glioblastoma are relatively rare. Besides this, there are crucial molecular differences between adult and pediatric gliomas. Our preliminary data for proposed investigation were obtained on GBM specimens and cultures developed from GBM tissues donated by adult subjects. Results of investigation of adult glioma tissue cannot simply be extrapolated to children. Therefore, our primary research focus is the investigation of GBM in adults. If appropriate, a separate, age-specific study in children will be performed\n* Pregnant women will be excluded from the study as altered hormonal and immunological status can affect the study results\n* Prisoners will be excluded from the study\n* Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy\n* History of prior malignancy, with the exception of curatively treated malignancies or malignancies with very low potential for recurrence or progression\n* Major surgery within 4 weeks (excluding placement of vascular access), minor surgery within 2 weeks, or palliative radiotherapy within 1 week of the first dose of VS-6766\n* Exposure to medications (with or without prescription), supplements, herbal remedies, or foods with potential for drug-drug interactions with VS-6766 within 14 days prior to the first dose of VS-6766 and during the course of therapy, including:\n\n  * VS-6766: strong CYP3A4, inhibitors or inducers, due to potential drug-drug interactions with VS-6766 and/or defactinib\n  * Defactinib: strong CYP3A4, CYP2C9, and P-glycoprotein (P-gp) inhibitors or inducers, due to potential drug-drug interactions with VS-6766 and/or defactinib\n* Known hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection that is active and/or requires therapy\n* Active skin disorder that has required systemic therapy within the past 1 year\n* History of rhabdomyolysis\n* Concurrent ocular disorders:\n\n  * Patients with history of glaucoma, history of retinal vein occlusion (RVO), predisposing factors for RVO, including uncontrolled hypertension, uncontrolled diabetes\n  * Patients with history of retinal pathology or evidence of visible retinal pathology that is considered a risk factor for RVO, intraocular pressure \\> 21 mm Hg as measured by tonometry, or other significant ocular pathology, such as anatomical abnormalities that increase the risk for RVO\n  * Patients with a history of corneal erosion (instability of corneal epithelium), corneal degeneration, active or recurrent keratitis, and other forms of serious ocular surface inflammatory conditions\n* Concurrent congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association \\[NYHA\\]), myocardial infarction within the last 6 months, unstable arrhythmias, unstable angina, or severe obstructive pulmonary disease\n* Patients with the inability to swallow oral medications or impaired gastrointestinal absorption due to gastrectomy or active inflammatory bowel disease\n* Patients with a history of hypersensitivity to any of the inactive ingredients (hydroxypropylmethylcellulose, mannitol, magnesium stearate) of the investigational product","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Kimberly B. Hoang, MD","affiliation":"Emory University Hospital/Winship Cancer Institute","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Emory University Hospital/Winship Cancer Institute","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}}]}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2024-08-30","uploadDate":"2025-09-08T13:34","filename":"Prot_SAP_000.pdf","size":5638290},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2024-09-04","uploadDate":"2025-09-08T13:35","filename":"ICF_001.pdf","size":2980147}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D005909","term":"Glioblastoma"}],"ancestors":[{"id":"D001254","term":"Astrocytoma"},{"id":"D005910","term":"Glioma"},{"id":"D018302","term":"Neoplasms, Neuroepithelial"},{"id":"D017599","term":"Neuroectodermal Tumors"},{"id":"D009373","term":"Neoplasms, Germ Cell and Embryonal"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009380","term":"Neoplasms, Nerve Tissue"}]},"interventionBrowseModule":{"meshes":[{"id":"C577924","term":"RO5126766"},{"id":"D013048","term":"Specimen Handling"},{"id":"C584510","term":"defactinib"}],"ancestors":[{"id":"D019411","term":"Clinical Laboratory Techniques"},{"id":"D019937","term":"Diagnostic Techniques and Procedures"},{"id":"D003933","term":"Diagnosis"},{"id":"D008919","term":"Investigative Techniques"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT03020017","orgStudyIdInfo":{"id":"NU 16C01"},"secondaryIdInfos":[{"id":"STU00203790","domain":"CTRP (Clinical Trial Reporting Program)"},{"id":"NU 16C01","type":"OTHER","domain":"Northwestern University"},{"id":"P30CA060553","type":"NIH","link":"https://reporter.nih.gov/quickSearch/P30CA060553"},{"id":"NCI-2016-02007","type":"REGISTRY","domain":"CTRP (Clinical Trial Reporting Program)"}],"organization":{"fullName":"Northwestern University","class":"OTHER"},"briefTitle":"NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery","officialTitle":"A Phase 0 First-In-Human Study Using NU-0129: A Spherical Nucleic Acid (SNA) Gold Nanoparticle Targeting BCL2L12 in Recurrent Glioblastoma Multiforme or Gliosarcoma Patients"},"statusModule":{"statusVerifiedDate":"2022-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-05-25","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-09-06","type":"ACTUAL"},"completionDateStruct":{"date":"2020-08-19","type":"ACTUAL"},"studyFirstSubmitDate":"2017-01-11","studyFirstSubmitQcDate":"2017-01-11","studyFirstPostDateStruct":{"date":"2017-01-13","type":"ESTIMATED"},"resultsFirstSubmitDate":"2022-07-11","resultsFirstSubmitQcDate":"2022-08-05","resultsFirstPostDateStruct":{"date":"2022-08-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-08-05","lastUpdatePostDateStruct":{"date":"2022-08-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Priya Kumthekar","investigatorTitle":"Priya Kumthekar, MD","investigatorAffiliation":"Northwestern University"},"leadSponsor":{"name":"Northwestern University","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this research study is to evaluate the safety of the study drug, NU-0129, based on Spherical Nucleic Acid (SNA) platform when infused in patients with recurrent glioblastoma multiforme or gliosarcoma. The SNA consists of nucleic acids arranged on the surface of a small spherical gold nanoparticle. This is a first-in-human trial to determine the safety of NU-0129. NU-0129 can cross the blood brain barrier (a filtering mechanism that carry blood to the brain). Once within the tumor, the nucleic acid component is able to target a gene called Bcl2L12 that is present in glioblastoma multiforme, and is associated with tumor growth. This gene prevents tumor cells from apoptosis, which is the process of programmed cell death, thus promoting tumor growth. Researchers think that targeting the Bcl2L12 gene with NU-0129 will help stop cancer cells from growing.","detailedDescription":"PRIMARY OBJECTIVES:\n\nI. To assess the safety of intravenous NU-0129 in patients with recurrent glioblastoma multiforme (GBM) or gliosarcoma (GS).\n\nSECONDARY OBJECTIVES:\n\nI. To analyze drug concentration in serum at specific time points after drug administration.\n\nII. To demonstrate intratumoral penetration of NU-0129. III. To assess the feasibility of giving NU-0129 as a standard treatment for recurrent GBM or GS.\n\nTERTIARY OBJECTIVES:\n\nI. To analyze tumor tissue for Bcl2L12 expression levels after NU-0129 administration.\n\nII. Preliminary response (progression free survival \\[PFS\\] and overall survival \\[OS\\] at 6 months; overall response rate \\[ORR\\]).\n\nOUTLINE:\n\nPatients receive NU-0129 intravenously (IV) over 20-50 minutes and undergo standard of care tumor resection within 8-48 hours.\n\nAfter completion of study treatment, patients are followed up at 7, 14, 21, and 28 days and then every 84 days for up to 2 years."},"conditionsModule":{"conditions":["Gliosarcoma","Recurrent Glioblastoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":8,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment (NU-0129)","type":"EXPERIMENTAL","description":"Patients receive NU-0129 IV over 20-50 minutes and undergo standard of care tumor resection within 8-48 hours.","interventionNames":["Other: Laboratory Biomarker Analysis","Other: Pharmacological Study","Drug: Targeted Molecular Therapy"]}],"interventions":[{"type":"OTHER","name":"Laboratory Biomarker Analysis","description":"Correlative studies","armGroupLabels":["Treatment (NU-0129)"]},{"type":"OTHER","name":"Pharmacological Study","description":"Correlative studies","armGroupLabels":["Treatment (NU-0129)"]},{"type":"DRUG","name":"Targeted Molecular Therapy","description":"Given NU-0129 IV","armGroupLabels":["Treatment (NU-0129)"],"otherNames":["molecularly targeted therapy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Patients With Adverse Events","description":"To evaluate the safety of intravenous NU-0129 in patients with recurrent GBM or GS, the number of adverse events will be assessed and will be graded according to the NCI's Common Terminology Criteria in Adverse Events (CTCAE) version 4.03 where the grading is as follows:\n\nGrade 1: Mild Grade 2: Moderate Grade 3: Severe Grade 4: Life-threatening Grade 5: Fatal","timeFrame":"Up to 21 days after study drug administration"}],"secondaryOutcomes":[{"measure":"NU-0129 Concentration in Blood After Drug Administration Using Maximum Concentration","description":"Blood samples will be collected post-infusion to analyze drug concentration at specific time points after drug administration. Median plasma concentrations of NU-0129 were derived from time profiles for both Seven different small interfering RNA (siRNA) and gold (Au) concentrations, with Au plasma concentration determined by inductively coupled plasma mass spectrometry (ICP-MS) and siRNA concentration assessed by liquid chromatography-high performance liquid chromatography (LC-HPLC) using an atto dye-labeled PNA probe.","timeFrame":"At 1, 3, 5, 10, 30, and 60 minutes, and 4, 8, and 24 hours post infusion"},{"measure":"Biodistribution of NU-0129 in Tumor Tissue","description":"Tissue will be collected during the scheduled surgery and assayed with Inductively Coupled Plasma Mass Spectrometry (ICP-MS) to analyze the concentration of particles in various parts of tumor tissue. To analyze spatial distribution of Au within tumor tissue, synchrotron XFM elemental maps of GBM tissue slices were acquired at micron and submicron resolution and matched to adjacent hematoxylin and eosin (H\\&E)- and Ki67-stained tumor sections. Approximate percentage of gold (Au) found in cancer cells is reported below.","timeFrame":"At time of surgery"},{"measure":"Feasibility of Giving NU-0129 as a Standard Treatment","description":"Feasibility will be calculated as the rate of successful production, delivery, and administration of the investigational product and subsequent resection.","timeFrame":"At time of infusion (8-48 hours prior to resection) and during surgery"},{"measure":"NU-0129 Concentration in Blood After Drug Administration Using Half-life","description":"Blood samples will be collected post-infusion to analyze drug concentration at specific time points after drug administration. Median plasma concentrations of NU-0129 were derived from time profiles for both Seven different small interfering RNA (siRNA) and gold (Au) concentrations, with Au plasma concentration determined by inductively coupled plasma mass spectrometry (ICP-MS) and siRNA concentration assessed by liquid chromatography-high performance liquid chromatography (LC-HPLC) using an atto dye-labeled PNA probe.","timeFrame":"At 1, 3, 5, 10, 30, and 60 minutes, and 4, 8, and 24 hours post infusion"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must have histologically proven glioblastoma multiforme (GBM) or gliosarcoma (GS)\n* Patients must have measurable disease by Response Assessment in Neuro-Oncology (RANO) 2010 criteria at the time of registration (pre-operative)\n* Patients must have failed at least one regimen of chemo or radiation therapy; NOTE: There is no limit to the number or types of prior therapy\n* The patient must be a candidate for surgical debulking (either subtotal or gross total resection); biopsy-only candidates will not be eligible\n* All patients must be capable to voluntarily sign an informed consent indicating that they are aware of the investigational nature of this study prior to registration\n* Patients must have a Karnofsky performance status of \\>= 70\n* Patients must have adequate bone marrow, liver, coagulation and renal function within 7days prior to study registration, as defined below:\n* White blood cell count (WBC) \\>= 3,000/uL\n* Absolute neutrophil count (ANC) \\>= 1,500/mm\\^3\n* Platelet count of \\>= 100,000/mm\\^3 (Note: Transfusion or growth factor may be used for eligibility outside of 7 days)\n* Hemoglobin \\>= 8 mg/dL (Note: Transfusion may be used for eligibility outside of 7 days)\n* Bilirubin =\\< 2 x upper limit of normal (ULN)\n* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\\< 2 x ULN\n* Creatinine =\\< 1.5 x ULN\n* Urine protein =\\< 3 x ULN\n* Cholesterol =\\< 300 mg/dL\n* International normalized ration (INR) =\\< 1.5 x ULN\n* Prothrombin time (PT)/partial thromboplastin time (PTT) =\\< 1.5 x ULN\n* Any patient who has had a recent surgery should have recovered from all effects of the surgery and be cleared by their surgeon\n* Patients must have confirmed availability of archival or freshly biopsied tumor tissue meeting protocol-defined specifications (10 unstained slides) prior to study enrollment\n* Females of child-bearing potential (FOCBP) and males must agree to use adequate contraception (e.g. hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 28 days following completion of therapy; should a female patient, or a male patient's partner, become pregnant or suspect she is pregnant while participating in this study, the patient should inform her or his treating physician immediately\n\n  * NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n    * Has not undergone a hysterectomy or bilateral oophorectomy\n    * Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \\> 12 months)\n* FOCBP must have a negative pregnancy test (either urine or serum) within 14 days prior to registration\n\nExclusion Criteria:\n\n* Patients must not have any significant infections or medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate NU-0129\n* Patients must not have a history of any other cancer unless they are in complete remission and off of all therapy for that disease for a minimum of 3 years\n\n  * Note: Non-melanoma skin cancer or carcinoma in-situ of the cervix are exceptions and may be permitted after discussion with study quality assurance manager (QAM)\n* Patients must not have had radiation therapy within 12 weeks prior to registration\n* Patients must not have had prior cancer therapy (including biologic, cytotoxic, and experimental therapies, nitrosoureas, and Gliadel wafers or other surgically implantable antitumor treatment) within 21 days of registration; if questions arise, please ask the principal investigator (PI)\n\n  * NOTE: Patients must not have Novocure within 24 hours\n* Hormonal tumor therapies should not be administered within 14 days of registration; exceptions may be discussed with the PI\n* Patients must not have symptomatic hypertension\n* Patients with known human immunodeficiency virus (HIV) infection or chronic or acute hepatitis B or C are not eligible; Note: Patients do not need to have HIV, hepatitis B, or hepatitis C testing at screening\n* Female patients who are pregnant or breast feeding are not eligible\n* Patients are not eligible if they are unwilling or unable to comply with the protocol","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Priya Kumthekar, MD","affiliation":"Northwestern University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Northwestern University","city":"Chicago","state":"Illinois","zip":"60611","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"NU-0129 Treatment","description":"NU-0129 will be administered inpatient at \\~ 0.04mg/kg IV 8-48 hours once prior to scheduled tumor resection. Dose corresponds to 1/50th of the no-observed-adverse-event level."}],"periods":[{"title":"NU-0129","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"8"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"8"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]}]},{"title":"Standard of Care Resection","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"8"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"8"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"NU-0129 Treatment","description":"NU-0129 will be administered inpatient at \\~ 0.04mg/kg IV 8-48 hours once prior to scheduled tumor resection. Dose corresponds to 1/50th of the no-observed-adverse-event level."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"8"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"55.5","lowerLimit":"28","upperLimit":"66"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"4"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"4"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"8"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"7"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With Adverse Events","description":"To evaluate the safety of intravenous NU-0129 in patients with recurrent GBM or GS, the number of adverse events will be assessed and will be graded according to the NCI's Common Terminology Criteria in Adverse Events (CTCAE) version 4.03 where the grading is as follows:\n\nGrade 1: Mild Grade 2: Moderate Grade 3: Severe Grade 4: Life-threatening Grade 5: Fatal","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 21 days after study drug administration","groups":[{"id":"OG000","title":"NU-0129 Treatment","description":"NU-0129 will be administered inpatient at \\~ 0.04mg/kg IV 8-48 hours once prior to scheduled tumor resection. Dose corresponds to 1/50th of the no-observed-adverse-event level."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"classes":[{"title":"Experienced any AE","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"Experienced an AE related to NU-01289","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Experienced any SAE","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Experienced an SAE related to NU-0129","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"NU-0129 Concentration in Blood After Drug Administration Using Maximum Concentration","description":"Blood samples will be collected post-infusion to analyze drug concentration at specific time points after drug administration. Median plasma concentrations of NU-0129 were derived from time profiles for both Seven different small interfering RNA (siRNA) and gold (Au) concentrations, with Au plasma concentration determined by inductively coupled plasma mass spectrometry (ICP-MS) and siRNA concentration assessed by liquid chromatography-high performance liquid chromatography (LC-HPLC) using an atto dye-labeled PNA probe.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ng/ml","timeFrame":"At 1, 3, 5, 10, 30, and 60 minutes, and 4, 8, and 24 hours post infusion","groups":[{"id":"OG000","title":"NU-0129 Treatment","description":"NU-0129 will be administered inpatient at \\~ 0.04mg/kg IV 8-48 hours once prior to scheduled tumor resection. Dose corresponds to 1/50th of the no-observed-adverse-event level."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"classes":[{"title":"siRNA maximum observed plasma concentration","categories":[{"measurements":[{"groupId":"OG000","value":"62.1","lowerLimit":"22.8","upperLimit":"123"}]}]},{"title":"Au maximum observed plasma concentration","categories":[{"measurements":[{"groupId":"OG000","value":"4290","lowerLimit":"3120","upperLimit":"7140"}]}]}]},{"type":"SECONDARY","title":"Biodistribution of NU-0129 in Tumor Tissue","description":"Tissue will be collected during the scheduled surgery and assayed with Inductively Coupled Plasma Mass Spectrometry (ICP-MS) to analyze the concentration of particles in various parts of tumor tissue. To analyze spatial distribution of Au within tumor tissue, synchrotron XFM elemental maps of GBM tissue slices were acquired at micron and submicron resolution and matched to adjacent hematoxylin and eosin (H\\&E)- and Ki67-stained tumor sections. Approximate percentage of gold (Au) found in cancer cells is reported below.","populationDescription":"2 patients tumor resections resulted in insufficient amount of viable tumor tissue for ICP-MS analysis and were not included in this analysis","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage of gold \"Au\"","timeFrame":"At time of surgery","groups":[{"id":"OG000","title":"NU-0129 Treatment","description":"NU-0129 will be administered inpatient at \\~ 0.04mg/kg IV 8-48 hours once prior to scheduled tumor resection. Dose corresponds to 1/50th of the no-observed-adverse-event level."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5","spread":"8.15"}]}]}]},{"type":"SECONDARY","title":"Feasibility of Giving NU-0129 as a Standard Treatment","description":"Feasibility will be calculated as the rate of successful production, delivery, and administration of the investigational product and subsequent resection.","populationDescription":"Patients who had drug infused and underwent subsequent resection","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At time of infusion (8-48 hours prior to resection) and during surgery","groups":[{"id":"OG000","title":"NU-0129 Treatment","description":"NU-0129 will be administered inpatient at \\~ 0.04mg/kg IV 8-48 hours once prior to scheduled tumor resection. Dose corresponds to 1/50th of the no-observed-adverse-event level."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"classes":[{"title":"Number of patients who had drug infused successfully","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"Number of patient who underwent subsequent resection","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]}]},{"type":"SECONDARY","title":"NU-0129 Concentration in Blood After Drug Administration Using Half-life","description":"Blood samples will be collected post-infusion to analyze drug concentration at specific time points after drug administration. Median plasma concentrations of NU-0129 were derived from time profiles for both Seven different small interfering RNA (siRNA) and gold (Au) concentrations, with Au plasma concentration determined by inductively coupled plasma mass spectrometry (ICP-MS) and siRNA concentration assessed by liquid chromatography-high performance liquid chromatography (LC-HPLC) using an atto dye-labeled PNA probe.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"hours","timeFrame":"At 1, 3, 5, 10, 30, and 60 minutes, and 4, 8, and 24 hours post infusion","groups":[{"id":"OG000","title":"NU-0129 Treatment","description":"NU-0129 will be administered inpatient at \\~ 0.04mg/kg IV 8-48 hours once prior to scheduled tumor resection. Dose corresponds to 1/50th of the no-observed-adverse-event level."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"classes":[{"title":"siRNA half-life","categories":[{"measurements":[{"groupId":"OG000","value":"0.06","lowerLimit":"0.02","upperLimit":"0.16"}]}]},{"title":"Au half-life","categories":[{"measurements":[{"groupId":"OG000","value":"18","lowerLimit":"12","upperLimit":"23"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Patients were monitored for adverse events from the time of NU-0129 infusion through 21 days post infusion","eventGroups":[{"id":"EG000","title":"NU-0129 Treatment","description":"NU-0129 will be administered inpatient at \\~ 0.04mg/kg IV 8-48 hours once prior to scheduled tumor resection. Dose corresponds to 1/50th of the no-observed-adverse-event level.","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":1,"seriousNumAtRisk":8,"otherNumAffected":8,"otherNumAtRisk":8}],"seriousEvents":[{"term":"Cerebrospinal fluid leakage","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8}]}],"otherEvents":[{"term":"Alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":8}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"White blood cell decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Hypophosphatemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":8}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Priya Kumthekar","organization":"Northwestern University","email":"p-kumthekar@northwestern.edu","phone":"312 908 5073"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2019-04-02","uploadDate":"2022-07-11T14:46","filename":"Prot_SAP_000.pdf","size":1282160}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D018316","term":"Gliosarcoma"},{"id":"D005909","term":"Glioblastoma"}],"ancestors":[{"id":"D005910","term":"Glioma"},{"id":"D018302","term":"Neoplasms, Neuroepithelial"},{"id":"D017599","term":"Neuroectodermal Tumors"},{"id":"D009373","term":"Neoplasms, Germ Cell and Embryonal"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009380","term":"Neoplasms, Nerve Tissue"},{"id":"D001254","term":"Astrocytoma"}]},"interventionBrowseModule":{"meshes":[{"id":"D058990","term":"Molecular Targeted Therapy"}],"ancestors":[{"id":"D004358","term":"Drug Therapy"},{"id":"D013812","term":"Therapeutics"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT04495751","orgStudyIdInfo":{"id":"IRB00067614"},"secondaryIdInfos":[{"id":"WFBCCC 98320","type":"OTHER","domain":"Wake Forest Baptist Comprehensive Cancer Center"},{"id":"UL1TR001420","type":"NIH","link":"https://reporter.nih.gov/quickSearch/UL1TR001420"},{"id":"P30CA012197","type":"NIH","link":"https://reporter.nih.gov/quickSearch/P30CA012197"}],"organization":{"fullName":"Wake Forest University Health Sciences","class":"OTHER"},"briefTitle":"Muscadine Grape Extract to Improve Fatigue","officialTitle":"FOCUS - Pilot Study of Muscadine Grape Extract to Improve Fatigue Among Older Adult Cancer Survivors"},"statusModule":{"statusVerifiedDate":"2025-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-04-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-08-26","type":"ACTUAL"},"completionDateStruct":{"date":"2024-08-26","type":"ACTUAL"},"studyFirstSubmitDate":"2020-07-28","studyFirstSubmitQcDate":"2020-07-28","studyFirstPostDateStruct":{"date":"2020-08-03","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-08-21","resultsFirstSubmitQcDate":"2025-09-29","resultsFirstPostDateStruct":{"date":"2025-10-16","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-29","lastUpdatePostDateStruct":{"date":"2025-10-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Wake Forest University Health Sciences","class":"OTHER"},"collaborators":[{"name":"National Center for Advancing Translational Sciences (NCATS)","class":"NIH"},{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"The purpose of this research is to see if muscadine grape extract improves fatigue in people age 70 and above who have a history of treated cancer and report the symptom of fatigue.","detailedDescription":"Primary Objective: To evaluate whether administration of MGE supplementation decreases PROMIS Fatigue score from baseline to 12 weeks compared to placebo.\n\nSecondary Objective(s)\n\n* To evaluate whether administration of muscadine grape extract supplementation (4 tablets twice daily) causes changes in physical function (Pepper Assessment Tool for Disability \\[PAT-D\\], Short Physical Performance Battery), physical fitness (6-minute walk), physical activity (Minnesota Leisure Questionnaire), sedentary behavior (Sedentary Behavior Questionnaire) from baseline to 12 weeks compared to placebo.\n* To compare changes in health related quality of life (PROMIS Global Health) at 12 weeks in participants randomized to muscadine grape extract group vs. placebo.\n* To compare changes in the Fried frailty index at 12 weeks in participants randomized to muscadine grape extract vs. placebo.\n\nOUTLINE: Patients are randomized to 1 of 2 arms.\n\nARM I: Patients receive muscadine grape extract orally (PO) twice daily (BID) for 12 weeks in the absence of disease progression or unacceptable toxicity.\n\nARM II: Patients receive placebo PO BID for 12 weeks in the absence of disease progression or unacceptable toxicity.\n\nAfter completion of study, patients are followed up for 30 days after the last dose of the study drug."},"conditionsModule":{"conditions":["Fatigue"],"keywords":["Older","Cancer","Survivors"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"SUPPORTIVE_CARE","maskingInfo":{"masking":"DOUBLE","maskingDescription":"This is a double blind study. Only the investigational pharmacists and the statisticians will be unblinded. The blind will be maintained until the study is complete.","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":64,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Muscadine Grape Extract Arm","type":"EXPERIMENTAL","description":"Muscadine grape extract pill (12 week supply)","interventionNames":["Dietary Supplement: Muscadine grape extract","Other: Quality of Life Assessment","Other: Questionnaires","Other: Participant Feedback"]},{"label":"Placebo Arm","type":"PLACEBO_COMPARATOR","description":"Placebo provided (12 week supply)","interventionNames":["Drug: Placebo","Other: Quality of Life Assessment","Other: Questionnaires","Other: Participant Feedback"]}],"interventions":[{"type":"DIETARY_SUPPLEMENT","name":"Muscadine grape extract","description":"Four pills twice daily","armGroupLabels":["Muscadine Grape Extract Arm"]},{"type":"DRUG","name":"Placebo","description":"Four pills twice daily.","armGroupLabels":["Placebo Arm"]},{"type":"OTHER","name":"Quality of Life Assessment","description":"Ancillary studies","armGroupLabels":["Muscadine Grape Extract Arm","Placebo Arm"]},{"type":"OTHER","name":"Questionnaires","description":"Ancillary studies","armGroupLabels":["Muscadine Grape Extract Arm","Placebo Arm"]},{"type":"OTHER","name":"Participant Feedback","description":"Ancillary studies","armGroupLabels":["Muscadine Grape Extract Arm","Placebo Arm"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Patient Reported Outcomes Measurement System (PROMIS) Fatigue 7a Questionnaire","description":"(PROMIS) Fatigue 7a will be used to assess fatigue. Using a mixed effects model with a constraint of a common baseline mean across treatment groups and an unstructured covariance matrix to model all fatigue measures over time, and use linear contrasts to estimate the difference in change and corresponding 90% confidence interval between the two groups. Item responses are rated on a five-point scale ranging from \"never\" to \"always\" and are summed for a total score and transformed to a T-score metric, which has a mean of 50 and a standard deviation of 10. Higher scores indicate more fatigue.","timeFrame":"At baseline and at 12 weeks"}],"secondaryOutcomes":[{"measure":"Pepper Assessment Tool for Disability (PAT-D) Questionnaire - Change From Baseline at 12 Weeks","description":"Pepper Assessment Tool for Disability (PAT-D) will used to assess self-reported physical function. The (PAT-D) is a 19-item survey designed to assess domains of physical function in older adults which contains subscales on mobility, instrumental activities of daily living (IADLs), and basic activities of daily living (ADLs). Participant responses will best describe their ability to perform certain activities of daily living (On a scale of 1 to 5; 1 = usually did with no difficulty to 5 = unable to do. Minimum score of 19, max score of 95. A lower score indicates less difficulty with tasks and better function. Investigators will estimate 95% confidence intervals for the differences between the two groups for the secondary outcomes at 12 weeks reported as mean and standard error scores.","timeFrame":"At 12 weeks"},{"measure":"Short Physical Performance Battery (SPPB)","description":"The Short Physical Performance Battery (SPPB) will be used to objectively assess lower extremity physical function. This validated measure comprises a short walk, repeated chair stands, and balance test.\n\nEach section is scored out of 4 points, so the highest total score for the SPPB is 12 points. Score range is 0-12. Poor (0-6), moderate 7-9) and good (10-12). Lower scores on the SPPB have been associated with increased risk of disability, hospitalization and worse survival among older adults with and without cancer.\n\nInvestigators will estimate 95% confidence intervals for the differences between the two groups for the secondary outcomes at 12 weeks.","timeFrame":"At 12 weeks"},{"measure":"Short Form Minnesota Leisure Time Activity Questionnaire (MLTA)","description":"This questionnaire will assess self-reported physical activity with participants answering yes/no questions in regards to physical activities done in the past two weeks and the frequency of those activities. Score is interpreted by calculating the total energy expenditure based on the frequency and duration of reported leisure activities, with higher scores indicating a greater level of physical activity; generally, scores are categorized as low (inactive), moderate (moderately active), and high (highly active). Investigators will estimate 95% confidence intervals for the differences between the two groups for the secondary outcomes at 12 weeks.","timeFrame":"At 12 weeks"},{"measure":"6-Minute Walk Test","description":"A 6-minute walk will be measured to assess physical fitness. The 6-minute walk is easy to administer in a clinical setting, accurately assesses submaximal exercise capacity, is an independent predictor of mortality and is correlated with peak V02 testing. The number of laps and distance walked on the final lap will be recorded. The total distance the participant walked will be entered onto the online database (1 lap = 30 meters distance). Investigators will estimate 95% confidence intervals for the differences between the two groups for the secondary outcomes at 12 weeks.","timeFrame":"At 12 weeks"},{"measure":"Longitudinal Aging Study Amsterdam (LASA) Sedentary Behavior Questionnaire","description":"The questionnaire will be used to measure sedentary behavior for time spent during a 24 hour period for weekday and weekend various activities. The questionnaire consists of 10 items. The average time per 24 hours on each sedentary activity will be recorded in hours and/or minutes. Scores represent the self-reported average time an older adult spends engaged in sedentary activities (i.e., watching TV, reading, or sitting during a typical weekday and weekend day), with higher scores indicating a greater amount of time spent sedentary. Investigators will estimate 95% confidence intervals for the differences between the two groups for the secondary outcomes at 12 weeks.","timeFrame":"At 12 weeks"},{"measure":"Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Short Form (SF) - Quality of Life","description":"The PROMIS Global Health Short Form (SF) is a 10-item questionnaire that will assess global quality of life including overall physical health, mental health, social health, pain, fatigue an overall perceived quality of life. Participants will respond to questions or statements with varied selections (excellent to poor; completely to not at all; never to always; and none to very severe).\n\nScores above 50 are considered a better than average quality of life and scores below 50 are considered below average quality of life.\n\nHigher T-scores indicate better health, so scores around 50 are average, while scores below 40 suggest poor health warranting further assessment, and scores above 60 indicate excellent health. 50 indicates the population mean with a standard deviation of 10 Investigators will estimate 95% confidence intervals for the differences between the two groups for the secondary outcomes at 12 weeks.","timeFrame":"At 12 weeks"},{"measure":"Adherence - Pill Count","description":"Adherence will be measured by pill count at study completion. Investigators will estimate 95% confidence intervals for the differences between the two groups for the secondary outcomes at 12 weeks.","timeFrame":"12 weeks"},{"measure":"Fried Frailty Index","description":"Frailty indexes will be assessed for differences between the two arms. The Fried frailty index is a scoring system that classifies people into three stages of frailty based on five criteria: weight loss, exhaustion, low physical activity, and slowness. Frailty index scores can be calculated by dividing the sum of the recoded values of the variables by the number of variables measured for a person.\n\nCorresponding scores are: Score of 0, non-frail; score of 1-2 pre-frail; score of 3-5 frail. Higher scores represent higher rates of frailty among participants.\n\nInvestigators will estimate 95% confidence intervals for the differences between the two groups for the secondary outcomes at 12 weeks.","timeFrame":"At 12 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Self-reported history of cancer diagnosed \\> 12 months prior to enrollment excluding non-melanoma skin cancer with no evidence of disease at enrollment.\n* Eligible solid tumor cancer types include Stage 1-3 breast, lung, head and neck, colorectal, anal, prostate, melanoma, bladder/ureteral, esophageal, gastric, pancreatic, kidney, liver/biliary, uterine, cervical, ovarian, sarcoma. (superficial disease and in situ disease only is excluded)\n* Eligible hematologic malignancies include lymphoma any subtype any stage in remission, multiple myeloma in remission, leukemia any subtype in remission.\n* Eligible prior cancer treatment modalities include surgery, radiation, chemotherapy, hormonal therapies, immunotherapy, biologic therapies.\n* All anti-cancer therapy completed \\> 12 months prior to enrollment\n* Age 65 years and older\n* Presence of self-reported fatigue defined by a response of \"somewhat, quite a bit or very much\" to the screening question \"During the past seven days, did you feel fatigued: Not at all, a little bit, somewhat, quite a bit, very much?\"\n* Ability to walk without requiring assistance from another individual (use of cane or walker acceptable)\n* Normal organ and marrow function as defined below:\n\n  * leukocytes \\>3,000/mcL\n  * absolute neutrophil count \\>1,500/mcL\n  * platelets \\>100,000/mcL\n  * total bilirubin within normal institutional limits\n  * AST(SGOT)/ALT(SGPT) \\<2.5 X institutional upper limit of normal\n  * creatinine clearance \\>30 mL/min\n* Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).\n\nExclusion Criteria:\n\n* Active malignancy or on-going cancer treatment including oral anti-estrogen therapy, immunotherapy, biologic therapy.\n* Men receiving androgen deprivation therapy\n* Use of Coumadin or Warfarin (other blood thinners are acceptable)\n* Symptomatic congestive heart failure\n* Lung disease requiring oxygen\n* End stage renal disease requiring dialysis\n* Inability to swallow capsules\n* Chronic nausea or diarrhea defined by a frequency of  once per week\n* Hemoglobin \\<10 g/dl\n* Diagnosis of dementia\n* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Known untreated hypothyroidism\n* Allergy to muscadine grapes or muscadine grape preparations","healthyVolunteers":false,"sex":"ALL","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Heidi Klepin, MD, MS","affiliation":"Wake Forest University Health Sciences","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Wake Forest Baptist Comprehensive Cancer Center","city":"Winston-Salem","state":"North Carolina","zip":"27157","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}}]},"referencesModule":{"references":[{"pmid":"36990930","type":"DERIVED","citation":"Klepin HD, Tooze JA, Bitting RL, Davis B, Pleasant K, Melo AC, Cook K, Soto-Pantoja DR, Tallant EA, Gallagher PE. Study design and methods for the pilot study of muscadine grape extract supplement to improve fatigue among older adult cancer survivors (FOCUS) trial. J Geriatr Oncol. 2023 May;14(4):101478. doi: 10.1016/j.jgo.2023.101478. Epub 2023 Mar 27."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Muscadine Grape Extract Arm","description":"Muscadine grape extract pill (12 week supply)\n\nMuscadine grape extract: Four pills twice daily\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"},{"id":"FG001","title":"Placebo Arm","description":"Placebo provided (12 week supply)\n\nPlacebo: Four pills twice daily.\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"32"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"32"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Muscadine Grape Extract Arm","description":"Muscadine grape extract pill (12 week supply)\n\nMuscadine grape extract: Four pills twice daily\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"},{"id":"BG001","title":"Placebo Arm","description":"Placebo provided (12 week supply)\n\nPlacebo: Four pills twice daily.\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"64"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"75.8","spread":"5.4"},{"groupId":"BG001","value":"75.8","spread":"5.7"},{"groupId":"BG002","value":"75.8","spread":"5.5"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"50"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"14"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"60"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"58"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"64"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Patient Reported Outcomes Measurement System (PROMIS) Fatigue 7a Questionnaire","description":"(PROMIS) Fatigue 7a will be used to assess fatigue. Using a mixed effects model with a constraint of a common baseline mean across treatment groups and an unstructured covariance matrix to model all fatigue measures over time, and use linear contrasts to estimate the difference in change and corresponding 90% confidence interval between the two groups. Item responses are rated on a five-point scale ranging from \"never\" to \"always\" and are summed for a total score and transformed to a T-score metric, which has a mean of 50 and a standard deviation of 10. Higher scores indicate more fatigue.","populationDescription":"Not all participants reported data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"score on a scale","timeFrame":"At baseline and at 12 weeks","groups":[{"id":"OG000","title":"Muscadine Grape Extract Arm","description":"Muscadine grape extract pill (12 week supply)\n\nMuscadine grape extract: Four pills twice daily\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"},{"id":"OG001","title":"Placebo Arm","description":"Placebo provided (12 week supply)\n\nPlacebo: Four pills twice daily.\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":"1.1"},{"groupId":"OG001","value":"-5.4","spread":"2.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"-1.2","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.5","ciUpperLimit":"1.1"}]},{"type":"SECONDARY","title":"Pepper Assessment Tool for Disability (PAT-D) Questionnaire - Change From Baseline at 12 Weeks","description":"Pepper Assessment Tool for Disability (PAT-D) will used to assess self-reported physical function. The (PAT-D) is a 19-item survey designed to assess domains of physical function in older adults which contains subscales on mobility, instrumental activities of daily living (IADLs), and basic activities of daily living (ADLs). Participant responses will best describe their ability to perform certain activities of daily living (On a scale of 1 to 5; 1 = usually did with no difficulty to 5 = unable to do. Minimum score of 19, max score of 95. A lower score indicates less difficulty with tasks and better function. Investigators will estimate 95% confidence intervals for the differences between the two groups for the secondary outcomes at 12 weeks reported as mean and standard error scores.","populationDescription":"Not all participants reported data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"mean score on a scale","timeFrame":"At 12 weeks","groups":[{"id":"OG000","title":"Muscadine Grape Extract Arm","description":"Muscadine grape extract pill (12 week supply)\n\nMuscadine grape extract: Four pills twice daily\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"},{"id":"OG001","title":"Placebo Arm","description":"Placebo provided (12 week supply)\n\nPlacebo: Four pills twice daily.\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.1"},{"groupId":"OG001","value":"1.6","spread":"0.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"-0.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.5","ciUpperLimit":"0.1"}]},{"type":"SECONDARY","title":"Short Physical Performance Battery (SPPB)","description":"The Short Physical Performance Battery (SPPB) will be used to objectively assess lower extremity physical function. This validated measure comprises a short walk, repeated chair stands, and balance test.\n\nEach section is scored out of 4 points, so the highest total score for the SPPB is 12 points. Score range is 0-12. Poor (0-6), moderate 7-9) and good (10-12). Lower scores on the SPPB have been associated with increased risk of disability, hospitalization and worse survival among older adults with and without cancer.\n\nInvestigators will estimate 95% confidence intervals for the differences between the two groups for the secondary outcomes at 12 weeks.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"points","timeFrame":"At 12 weeks","groups":[{"id":"OG000","title":"Muscadine Grape Extract Arm","description":"Muscadine grape extract pill (12 week supply)\n\nMuscadine grape extract: Four pills twice daily\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"},{"id":"OG001","title":"Placebo Arm","description":"Placebo provided (12 week supply)\n\nPlacebo: Four pills twice daily.\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":"0.5"},{"groupId":"OG001","value":"9.2","spread":"0.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"0.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.7","ciUpperLimit":"2.0"}]},{"type":"SECONDARY","title":"Short Form Minnesota Leisure Time Activity Questionnaire (MLTA)","description":"This questionnaire will assess self-reported physical activity with participants answering yes/no questions in regards to physical activities done in the past two weeks and the frequency of those activities. Score is interpreted by calculating the total energy expenditure based on the frequency and duration of reported leisure activities, with higher scores indicating a greater level of physical activity; generally, scores are categorized as low (inactive), moderate (moderately active), and high (highly active). Investigators will estimate 95% confidence intervals for the differences between the two groups for the secondary outcomes at 12 weeks.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"kcal/week","timeFrame":"At 12 weeks","groups":[{"id":"OG000","title":"Muscadine Grape Extract Arm","description":"Muscadine grape extract pill (12 week supply)\n\nMuscadine grape extract: Four pills twice daily\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"},{"id":"OG001","title":"Placebo Arm","description":"Placebo provided (12 week supply)\n\nPlacebo: Four pills twice daily.\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3218","spread":"517"},{"groupId":"OG001","value":"4192","spread":"1141"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"-973.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3500","ciUpperLimit":"1553"}]},{"type":"SECONDARY","title":"6-Minute Walk Test","description":"A 6-minute walk will be measured to assess physical fitness. The 6-minute walk is easy to administer in a clinical setting, accurately assesses submaximal exercise capacity, is an independent predictor of mortality and is correlated with peak V02 testing. The number of laps and distance walked on the final lap will be recorded. The total distance the participant walked will be entered onto the online database (1 lap = 30 meters distance). Investigators will estimate 95% confidence intervals for the differences between the two groups for the secondary outcomes at 12 weeks.","populationDescription":"Not all participants reported data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"meters","timeFrame":"At 12 weeks","groups":[{"id":"OG000","title":"Muscadine Grape Extract Arm","description":"Muscadine grape extract pill (12 week supply)\n\nMuscadine grape extract: Four pills twice daily\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"},{"id":"OG001","title":"Placebo Arm","description":"Placebo provided (12 week supply)\n\nPlacebo: Four pills twice daily.\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"29"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"369.8","spread":"22.1"},{"groupId":"OG001","value":"349.1","spread":"14.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"20.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-32.4","ciUpperLimit":"73.8"}]},{"type":"SECONDARY","title":"Longitudinal Aging Study Amsterdam (LASA) Sedentary Behavior Questionnaire","description":"The questionnaire will be used to measure sedentary behavior for time spent during a 24 hour period for weekday and weekend various activities. The questionnaire consists of 10 items. The average time per 24 hours on each sedentary activity will be recorded in hours and/or minutes. Scores represent the self-reported average time an older adult spends engaged in sedentary activities (i.e., watching TV, reading, or sitting during a typical weekday and weekend day), with higher scores indicating a greater amount of time spent sedentary. Investigators will estimate 95% confidence intervals for the differences between the two groups for the secondary outcomes at 12 weeks.","populationDescription":"Not all participants reported data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"hours","timeFrame":"At 12 weeks","groups":[{"id":"OG000","title":"Muscadine Grape Extract Arm","description":"Muscadine grape extract pill (12 week supply)\n\nMuscadine grape extract: Four pills twice daily\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"},{"id":"OG001","title":"Placebo Arm","description":"Placebo provided (12 week supply)\n\nPlacebo: Four pills twice daily.\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":"1.0"},{"groupId":"OG001","value":"12.7","spread":"0.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"0.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.2","ciUpperLimit":"3.2"}]},{"type":"SECONDARY","title":"Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Short Form (SF) - Quality of Life","description":"The PROMIS Global Health Short Form (SF) is a 10-item questionnaire that will assess global quality of life including overall physical health, mental health, social health, pain, fatigue an overall perceived quality of life. Participants will respond to questions or statements with varied selections (excellent to poor; completely to not at all; never to always; and none to very severe).\n\nScores above 50 are considered a better than average quality of life and scores below 50 are considered below average quality of life.\n\nHigher T-scores indicate better health, so scores around 50 are average, while scores below 40 suggest poor health warranting further assessment, and scores above 60 indicate excellent health. 50 indicates the population mean with a standard deviation of 10 Investigators will estimate 95% confidence intervals for the differences between the two groups for the secondary outcomes at 12 weeks.","populationDescription":"Not all participants reported data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"T score","timeFrame":"At 12 weeks","groups":[{"id":"OG000","title":"Muscadine Grape Extract Arm","description":"Muscadine grape extract pill (12 week supply)\n\nMuscadine grape extract: Four pills twice daily\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"},{"id":"OG001","title":"Placebo Arm","description":"Placebo provided (12 week supply)\n\nPlacebo: Four pills twice daily.\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"32"}]}],"classes":[{"title":"Quality of Life - Self-rate health","categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"0.1"},{"groupId":"OG001","value":"3.2","spread":"0.1"}]}]},{"title":"Quality of life - Ability to carry out social activities and roles","categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"0.2"},{"groupId":"OG001","value":"3.7","spread":"0.2"}]}]},{"title":"Physical health (t score)","categories":[{"measurements":[{"groupId":"OG000","value":"47.2","spread":"1.2"},{"groupId":"OG001","value":"46.3","spread":"1.3"}]}]},{"title":"Mental health (t score)","categories":[{"measurements":[{"groupId":"OG000","value":"50.6","spread":"1.5"},{"groupId":"OG001","value":"52.0","spread":"1.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Quality of Life - Self-rate health","nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"0.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.2","ciUpperLimit":"0.7"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Quality of life - Ability to carry out social activities and roles","paramType":"Mean Difference (Final Values)","paramValue":"0.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.3","ciUpperLimit":"0.6"},{"groupIds":["OG000","OG001"],"groupDescription":"Physical health (t score)","nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"0.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.7","ciUpperLimit":"4.5"},{"groupIds":["OG000","OG001"],"groupDescription":"Global Mental health (t score","nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"-1.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.4","ciUpperLimit":"2.5"}]},{"type":"SECONDARY","title":"Adherence - Pill Count","description":"Adherence will be measured by pill count at study completion. Investigators will estimate 95% confidence intervals for the differences between the two groups for the secondary outcomes at 12 weeks.","populationDescription":"Not all participants reported data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"number of pills","timeFrame":"12 weeks","groups":[{"id":"OG000","title":"Muscadine Grape Extract Arm","description":"Muscadine grape extract pill (12 week supply)\n\nMuscadine grape extract: Four pills twice daily\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"},{"id":"OG001","title":"Placebo Arm","description":"Placebo provided (12 week supply)\n\nPlacebo: Four pills twice daily.\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"569.1","spread":"35.4"},{"groupId":"OG001","value":"568.0","spread":"35.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"1.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-99.7","ciUpperLimit":"101.9"}]},{"type":"SECONDARY","title":"Fried Frailty Index","description":"Frailty indexes will be assessed for differences between the two arms. The Fried frailty index is a scoring system that classifies people into three stages of frailty based on five criteria: weight loss, exhaustion, low physical activity, and slowness. Frailty index scores can be calculated by dividing the sum of the recoded values of the variables by the number of variables measured for a person.\n\nCorresponding scores are: Score of 0, non-frail; score of 1-2 pre-frail; score of 3-5 frail. Higher scores represent higher rates of frailty among participants.\n\nInvestigators will estimate 95% confidence intervals for the differences between the two groups for the secondary outcomes at 12 weeks.","populationDescription":"Not all participants reported data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"score on a scale","timeFrame":"At 12 weeks","groups":[{"id":"OG000","title":"Muscadine Grape Extract Arm","description":"Muscadine grape extract pill (12 week supply)\n\nMuscadine grape extract: Four pills twice daily\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"},{"id":"OG001","title":"Placebo Arm","description":"Placebo provided (12 week supply)\n\nPlacebo: Four pills twice daily.\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"0.2"},{"groupId":"OG001","value":"0.9","spread":"0.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.5","ciUpperLimit":"0.5"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"12 weeks","eventGroups":[{"id":"EG000","title":"Muscadine Grape Extract Arm","description":"Muscadine grape extract pill (12 week supply)\n\nMuscadine grape extract: Four pills twice daily\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies","deathsNumAffected":0,"deathsNumAtRisk":32,"seriousNumAffected":0,"seriousNumAtRisk":32,"otherNumAffected":29,"otherNumAtRisk":32},{"id":"EG001","title":"Placebo Arm","description":"Placebo provided (12 week supply)\n\nPlacebo: Four pills twice daily.\n\nQuality of Life Assessment: Ancillary studies\n\nQuestionnaires: Ancillary studies\n\nParticipant Feedback: Ancillary studies","deathsNumAffected":0,"deathsNumAtRisk":32,"seriousNumAffected":1,"seriousNumAtRisk":32,"otherNumAffected":28,"otherNumAtRisk":32}],"seriousEvents":[{"term":"Hyperkalemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]}],"otherEvents":[{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":32},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":32}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":32},{"groupId":"EG001","numEvents":12,"numAffected":9,"numAtRisk":32}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":32},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":32}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":32},{"groupId":"EG001","numEvents":15,"numAffected":12,"numAtRisk":32}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":32},{"groupId":"EG001","numEvents":22,"numAffected":19,"numAtRisk":32}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":32},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":32}]},{"term":"Fatigue","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":32},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":32}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Hyperglycemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":32},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":32}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":32},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":32},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":32}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":32},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Rash maculopapular","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Hypertension","organSystem":"Vascular disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":32}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":32},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32}]},{"term":"Platelet count decreased","organSystem":"Investigations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Principal Investigator","organization":"Wake Forest Baptist Comprehensive Cancer Center","email":"hklepin@advocatehealth.org","phone":"336-713-5440"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2021-04-27","uploadDate":"2025-08-13T16:00","filename":"Prot_SAP_001.pdf","size":652241},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2024-07-31","uploadDate":"2024-09-24T15:04","filename":"ICF_000.pdf","size":238018}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D005221","term":"Fatigue"},{"id":"D009369","term":"Neoplasms"}],"ancestors":[{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"D011795","term":"Surveys and Questionnaires"}],"ancestors":[{"id":"D003625","term":"Data Collection"},{"id":"D004812","term":"Epidemiologic Methods"},{"id":"D008919","term":"Investigative Techniques"},{"id":"D017531","term":"Health Care Evaluation Mechanisms"},{"id":"D011787","term":"Quality of Health Care"},{"id":"D017530","term":"Health Care Quality, Access, and Evaluation"},{"id":"D011634","term":"Public Health"},{"id":"D004778","term":"Environment and Public Health"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT04825275","orgStudyIdInfo":{"id":"STUDY00015948"},"secondaryIdInfos":[{"id":"1R03CA255992-01","type":"NIH","link":"https://reporter.nih.gov/quickSearch/1R03CA255992-01"}],"organization":{"fullName":"Milton S. Hershey Medical Center","class":"OTHER"},"briefTitle":"Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial","officialTitle":"Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial"},"statusModule":{"statusVerifiedDate":"2025-11","overallStatus":"TERMINATED","whyStopped":"The study was stopped due to slow accrual.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-05-13","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-11-06","type":"ACTUAL"},"completionDateStruct":{"date":"2024-11-06","type":"ACTUAL"},"studyFirstSubmitDate":"2021-03-25","studyFirstSubmitQcDate":"2021-03-27","studyFirstPostDateStruct":{"date":"2021-04-01","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-11-06","resultsFirstSubmitQcDate":"2025-11-21","resultsFirstPostDateStruct":{"date":"2025-12-17","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-05","lastUpdatePostDateStruct":{"date":"2026-01-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Alireza Mansouri","investigatorTitle":"Assistant Professor, Department of Neurosurgery","investigatorAffiliation":"Penn State Health Milton S Hershey Medical Center"},"leadSponsor":{"name":"Milton S. Hershey Medical Center","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This research is being done to find out if the study drug (posaconazole) can enter brain tumors at a high enough amount to stop the tumor cells from dividing. Posaconazole is a drug which doctors already use for fungal infections and is thought to be able to effect tumor cells. As treatments for this type of brain tumor are limited, it is hoped that the results of this study will help to determine if the study drug should be studied further as a possible treatment.","detailedDescription":"Both ketoconazole and posaconazole are FDA-approved anti-fungal agents with a well-established side effect and safety profile. Ketoconazole and posaconazole have shown efficacy in reducing tumor cell proliferation in in-vitro studies. Furthermore, both have also shown efficacy, mediated at least in part through inhibition of HK2 activity, in animal models with dosing concentration and schedules that are documented as safe in humans. As a drug, posaconazole has a more predictable half-life than ketoconazole and has less off-target effects. Therefore, the proposed trial will focus on the role of posaconazole exclusively. As a first step, demonstration of adequate penetrance of study drug in brain and tumor tissue (pharmacokinetics) and biological effect (inhibition of glycolysis and subsequent tumor cell death) is necessary prior to large scale clinical studies. A total of 5 control participants will be included in this study as the investigator specifically wants to assess for pharmacodynamic differences too. The addition of a control group to this study rather to both the studies (ketoconazole study is a separate protocol) is because the investigator feels posaconazole may be a more promising drug for moving forward.\n\nPlasma drug concentration measurements are an unreliable method to assess delivery of drugs across the blood-brain barrier. In contrast, intracerebral MDC monitoring allows for approximate measurements within extracellular fluid (ECF) sampling of the brain. MDC placement within the brain is not a novel technique and has been utilized routinely in the ICU setting to measure brain metabolism by sampling of ECF of traumatic brain injury patients \\[59-61\\].\n\nMDC are now FDA-approved and are being placed routinely with intracranial pressure monitors. This method allows for continuous measurement of ECF within a tumor or normal tissue. The dialysis probe has a semipermeable membrane which is less than 1 mm in diameter into which two sections of microcatheter are fused. Previous studies have demonstrated the feasibility of keeping the catheters in place of critically injured patients for up to 2 weeks \\[62-64\\].\n\nWhen placed at the time of surgical resection, the microcatheters are stereotactically implanted, placing the probe within the desired brain and/or tumor region. Externally, the catheter is connected to a syringe pump, which delivers a low flow rate (l/min) of continuous perfusion fluid (Lactated Ringers or artificial CSF) and dialysate is collected in a microvial from the outlet tube. This sterile, single use catheter is minimally invasive and developed to achieve optimal diffusing characteristics similar to passive diffusion of a capillary blood vessel. Just as in the function of brain capillary vessel, water, inorganic ions and small organic molecules freely diffuse across the membrane of the probe, whereas proteins and protein bound compounds are impermeable. Additionally, lipophilic compounds are poorly recovered. Therefore, assessment of pharmacokinetics of drug using MDC provides valuable insight relevant to its anti-neoplastic properties."},"conditionsModule":{"conditions":["Glioblastoma","Glioblastoma Multiforme","Glioblastoma Multiforme of Brain","Glioblastoma Multiforme, Adult"],"keywords":["Glioblastoma","Glioblastoma Multiforme","GBM","Brain cancer","Posaconazole","Anti-fungal agents"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":7,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Posaconazole","type":"EXPERIMENTAL","description":"Participants will be taking 300 mg of the study drug (three 100 mg tablets) by mouth twice a day the first day and then 300 mg once a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them.","interventionNames":["Drug: Posaconazole Pill"]},{"label":"Control","type":"NO_INTERVENTION","description":"Participants will not undergo any intervention."}],"interventions":[{"type":"DRUG","name":"Posaconazole Pill","description":"300 mg (three 100 mg tablets) orally","armGroupLabels":["Posaconazole"],"otherNames":["Noxafil"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Posaconazole Concentration in Cerebrospinal Fluid Using Microdialysis Catheters","description":"Assessment of the concentration of drug in the dialysate fluid.","timeFrame":"Collected over a 24-hour period after surgery (biopsy or resection)"}],"secondaryOutcomes":[{"measure":"Number of Participants Able to Tolerate Preoperative Steady-state Dosing of Posaconazole","description":"Measured through the Grade and Frequency of adverse events, based on the CTCAE v5.0 criteria","timeFrame":"from Baseline to Visit 7 (14 days +/- 7 days post-op)"},{"measure":"Posaconazole Effect on Hexokinase 2 Concentration Within Tumor Tissue","description":"Measured using a hexokinase-2 ELISA with a range of 1.56 ng/mL - 100 ng/mL on tumor tissue.","timeFrame":"Within 24 hours after biopsy or tumor resection"},{"measure":"Posaconazole Effect on Tumor Proliferation in Tumor Tissue","description":"Measured using Ki-67 proliferation index with of a range of 0% proliferation (no proliferation) to 100% (high proliferation). Ki-67 is a marker found in actively dividing cells. A higher Ki-67 value may signify a more aggressive tumor. Ki-67 is routinely measured during pathology analysis of tumor samples.","timeFrame":"Within 24 hours after biopsy or tumor resection"},{"measure":"Posaconazole Effect on Cell Death in Tumor Tissue","description":"Measured using a BCL-2 ELISA with a range of 0.156 ng/mL to 10 ng/mL.","timeFrame":"Within 24 hours after biopsy or tumor resection"},{"measure":"Posaconazole Effect on Angiogenesis in Tumor Tissue","description":"Measured using a CD31 ELISA with a range of 31.2 pg/mL to 2000 pg/mL.","timeFrame":"Within 24 hours after biopsy or tumor resection"},{"measure":"Correlation of Neuro-pharmacokinetic Profile of Posaconazole With Lactate Concentration","description":"The concentration vs. time profile of posaconazole will be correlated with the concentration vs. time profile of lactate in the cerebrospinal fluid.","timeFrame":"Collected over a 24-hour period after surgery (biopsy or resection)"},{"measure":"Correlation of Neuro-pharmacokinetic Profile of Posaconazole With Pyruvate Concentration","description":"The concentration vs. time profile of posaconazole will be correlated with the concentration vs. time profile of pyruvate in the cerebrospinal fluid.","timeFrame":"Collected over a 24-hour period after surgery (biopsy or resection)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18 years\n* Evidence of primary or recurrent HGG that in the opinion of the treating team would require surgical resection\n* Karnofsky Performance Score (KPS)  60%\n* ECOG  2\n* Life expectancy greater than 12 weeks\n* Adequate liver function defined as ALT, AST, ALP within 1.5x institutional upper limit of normal (for study drug arm only)\n* Ability to swallow medication (for study drug arm only)\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation (for study drug arm only)\n* Ability to understand and willingness to sign a written informed consent document\n* Be able to comply with treatment plan, study procedures and follow-up examinations\n\nExclusion Criteria:\n\n* Patients may not be receiving any other investigational agents while on study\n* Patients who have known allergy to posaconazole or other azoles (for study drug arm only)\n* Patients who have previously had a severe side effect, such as agranulocytosis and neutropenia, in conjunction with previous azole class drugs for a parasitic infection (for study drug arm only)\n* Patients with a history of acute or chronic hepatitis (for study drug arm only)\n* Patients with liver enzymes (ALT, AST, ALP) \\>1.5x above normal range for the laboratory performing the test (for study drug arm only)\n* Patients who are taking metronidazole and cannot be safely moved to a different antibiotic greater than 7 days prior to starting posaconazole therapy (for study drug arm only)\n* Patients who are taking any anti-convulsant medication that interferes with the cytochrome P450 pathway (e.g. phenytoin, phenobarbital, carbamazepine, etc.) and who cannot be switched to alternative medications such as keppra (levetiracetam) (for study drug arm only)\n* Uncontrolled intercurrent illness such as chronic hepatitis, acute hepatitis, or psychiatric illness/social situation that would limit compliance with study requirements (for study drug arm only)\n* Patients with a history of Addison's disease or other forms of adrenal insufficiency (for study drug arm only)\n* Patient with little or no stomach acid production (achlorhydria) (for study drug arm only)\n* Pregnant and breast feeding women)\n* Patients with a history of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risks associated with the study participation or investigational product administration or may interfere with the interpretation of the results.\n* Patients who are not available for follow-up assessments or unable to comply with study requirements.\n* Patients who are currently taking medications that induce the metabolism of posaconazole, such as isoniazid, nevirapine, rifamycins (such as rifabutin, rifampin), or St. John's wort and cannot be safely discontinued off of them for the duration of the trial (for study drug arm only).\n* Patients who are currently taking medications for which the metabolism may be affected by posaconazole, which include but are not limited to: benzodiazepines (such as alprazolam, midazolam, triazolam), domperidone, eletriptan, eplerenone, ergot drugs (such as ergotamine), nisoldipine, drugs used to treat erectile dysfunction-ED or pulmonary hypertension (such as sildenafil, tadalafil), some drugs used to treat seizures (such as carbamazepine, phenytoin), some statin drugs (such as atorvastatin, lovastatin, simvastatin) (for study drug arm only).\n* Patients who are non-English speakers\n* Patients who are not capable of understanding the consent form and would need a legally authorized representative.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Alireza Mansouri, MD","affiliation":"Milton S. Hershey Medical Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Penn State Milton S Hershey Medical Center","city":"Hershey","state":"Pennsylvania","zip":"17033","country":"United States","geoPoint":{"lat":40.28592,"lon":-76.65025}}]},"referencesModule":{"references":[{"pmid":"35861778","type":"DERIVED","citation":"Bhanja D, Neighbors J, Connor J, Zadeh G, Mansouri A. Neuropharmacological Study of Posaconazole for Glioblastoma: A Phase 0 Clinical Trial Protocol. Neurosurgery. 2022 Oct 1;91(4):658-665. doi: 10.1227/neu.0000000000002071. Epub 2022 Jul 25."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Participants were assigned to the Control Arm if their tumor resection surgery was scheduled more than 7-10 days after informed consent was obtained.","recruitmentDetails":"Seven participants gave informed consent to participate in the clinical trial. One participant withdrew consent prior to beginning dosing posaconazole.","groups":[{"id":"FG000","title":"Posaconazole","description":"Participants will be taking 300 mg of the study drug (three 100 mg tablets) by mouth twice a day the first day and then 300 mg once a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them."},{"id":"FG001","title":"Control","description":"Participants will not undergo any intervention."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Posaconazole","description":"Participants will be taking 300 mg of the study drug (three 100 mg tablets) by mouth twice a day the first day and then 300 mg once a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them."},{"id":"BG001","title":"Control","description":"Participants will not undergo any intervention."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}]}],"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}]}],"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}]}],"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Neuro-pharmacokinetic Profile of Posaconazole Prior to Dosing","description":"Although it was impossible to obtain CSF to test the neuro-pharmacokinetic profile prior to implantation of the microdialysis catheter during tumor resection surgery (at which point participants were already dosed with posaconazole), participants taking azole drugs outside of the study prior to surgery were not included. So, the baseline neuro-pharmacokinetic profile of posaconazole is not applicable.","populationDescription":"Since CSF was not collected prior to tumor resection surgery (or posaconazole dosing), the baseline neuro-pharmacokinetic profile of posaconazole is not applicable.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"ng/mL","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Posaconazole Concentration in Cerebrospinal Fluid Using Microdialysis Catheters","description":"Assessment of the concentration of drug in the dialysate fluid.","populationDescription":"The fourth control participant's samples were unavailable for analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Collected over a 24-hour period after surgery (biopsy or resection)","groups":[{"id":"OG000","title":"Posaconazole","description":"Participants will be taking 300 mg of the study drug (three 100 mg tablets) by mouth twice a day the first day and then 300 mg once a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them."},{"id":"OG001","title":"Control","description":"Participants will not undergo any intervention."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"Results were less than the limit of detection."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Results were less than the limit of detection."}]}]}]},{"type":"SECONDARY","title":"Number of Participants Able to Tolerate Preoperative Steady-state Dosing of Posaconazole","description":"Measured through the Grade and Frequency of adverse events, based on the CTCAE v5.0 criteria","populationDescription":"Control participants did not take the study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants Who Tolerated Dosing","timeFrame":"from Baseline to Visit 7 (14 days +/- 7 days post-op)","groups":[{"id":"OG000","title":"Posaconazole","description":"Participants will be taking 300 mg of the study drug (three 100 mg tablets) by mouth twice a day the first day and then 300 mg once a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them."},{"id":"OG001","title":"Control","description":"Participants will not undergo any intervention."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}]},{"type":"SECONDARY","title":"Posaconazole Effect on Hexokinase 2 Concentration Within Tumor Tissue","description":"Measured using a hexokinase-2 ELISA with a range of 1.56 ng/mL - 100 ng/mL on tumor tissue.","populationDescription":"The fourth control participant's samples were unavailable for analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mg","timeFrame":"Within 24 hours after biopsy or tumor resection","groups":[{"id":"OG000","title":"Posaconazole","description":"Participants will be taking 300 mg of the study drug (three 100 mg tablets) by mouth twice a day the first day and then 300 mg once a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them."},{"id":"OG001","title":"Control","description":"Participants will not undergo any intervention."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"Results were all less than the limit of detection."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Results were all less than the limit of detection."}]}]}]},{"type":"SECONDARY","title":"Posaconazole Effect on Tumor Proliferation in Tumor Tissue","description":"Measured using Ki-67 proliferation index with of a range of 0% proliferation (no proliferation) to 100% (high proliferation). Ki-67 is a marker found in actively dividing cells. A higher Ki-67 value may signify a more aggressive tumor. Ki-67 is routinely measured during pathology analysis of tumor samples.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"% cells actively dividing","timeFrame":"Within 24 hours after biopsy or tumor resection","groups":[{"id":"OG000","title":"Posaconazole","description":"Participants will be taking 300 mg of the study drug (three 100 mg tablets) by mouth twice a day the first day and then 300 mg once a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them."},{"id":"OG001","title":"Control","description":"Participants will not undergo any intervention."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":"0.05"},{"groupId":"OG001","value":"39","spread":"0.134"}]}]}]},{"type":"SECONDARY","title":"Posaconazole Effect on Cell Death in Tumor Tissue","description":"Measured using a BCL-2 ELISA with a range of 0.156 ng/mL to 10 ng/mL.","populationDescription":"The fourth control participant's samples were unavailable for analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Within 24 hours after biopsy or tumor resection","groups":[{"id":"OG000","title":"Posaconazole","description":"Participants will be taking 300 mg of the study drug (three 100 mg tablets) by mouth twice a day the first day and then 300 mg once a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them."},{"id":"OG001","title":"Control","description":"Participants will not undergo any intervention."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3078","spread":"0.2418"},{"groupId":"OG001","value":"0.5363","spread":"0.2908"}]}]}]},{"type":"SECONDARY","title":"Posaconazole Effect on Angiogenesis in Tumor Tissue","description":"Measured using a CD31 ELISA with a range of 31.2 pg/mL to 2000 pg/mL.","populationDescription":"The fourth control participant's samples were unavailable for analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"Within 24 hours after biopsy or tumor resection","groups":[{"id":"OG000","title":"Posaconazole","description":"Participants will be taking 300 mg of the study drug (three 100 mg tablets) by mouth twice a day the first day and then 300 mg once a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them."},{"id":"OG001","title":"Control","description":"Participants will not undergo any intervention."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2130","spread":"1500"},{"groupId":"OG001","value":"2240","spread":"499.8"}]}]}]},{"type":"SECONDARY","title":"Correlation of Neuro-pharmacokinetic Profile of Posaconazole With Lactate Concentration","description":"The concentration vs. time profile of posaconazole will be correlated with the concentration vs. time profile of lactate in the cerebrospinal fluid.","populationDescription":"The entirety of the cerebrospinal fluid collected from the microdialysis catheters was consumed during the posaconazole concentration analysis. Since the catheters yielded a low volume of sample, none was available to test lactate concentration, thus, correlation of posaconazole profile to lactate concentration could not be analyzed for any of the participants.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Correlation Coefficient","timeFrame":"Collected over a 24-hour period after surgery (biopsy or resection)","groups":[{"id":"OG000","title":"Posaconazole","description":"Participants will be taking 300 mg of the study drug (three 100 mg tablets) by mouth twice a day the first day and then 300 mg once a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them."},{"id":"OG001","title":"Control","description":"Participants will not undergo any intervention."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Correlation of Neuro-pharmacokinetic Profile of Posaconazole With Pyruvate Concentration","description":"The concentration vs. time profile of posaconazole will be correlated with the concentration vs. time profile of pyruvate in the cerebrospinal fluid.","populationDescription":"The entirety of the cerebrospinal fluid collected from the microdialysis catheters was consumed during the posaconazole concentration analysis. Since the catheters yielded a low volume of sample, none was available to test pyruvate concentration, thus, correlation of posaconazole profile to pyruvate concentration could not be analyzed for any of the participants.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Correlation Coefficient","timeFrame":"Collected over a 24-hour period after surgery (biopsy or resection)","groups":[{"id":"OG000","title":"Posaconazole","description":"Participants will be taking 300 mg of the study drug (three 100 mg tablets) by mouth twice a day the first day and then 300 mg once a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them."},{"id":"OG001","title":"Control","description":"Participants will not undergo any intervention."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse event data were collected from the Baseline visit through Visit 7 (14+/-7 days Post-Op).","eventGroups":[{"id":"EG000","title":"Posaconazole","description":"Participants will be taking 300 mg of the study drug (three 100 mg tablets) by mouth twice a day the first day and then 300 mg once a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them.","deathsNumAffected":0,"deathsNumAtRisk":2,"seriousNumAffected":0,"seriousNumAtRisk":2,"otherNumAffected":2,"otherNumAtRisk":2},{"id":"EG001","title":"Control","description":"Participants will not undergo any intervention.","deathsNumAffected":0,"deathsNumAtRisk":4,"seriousNumAffected":2,"seriousNumAtRisk":4,"otherNumAffected":4,"otherNumAtRisk":4}],"seriousEvents":[{"term":"Wound Complication","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Hypertension","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Hypertensive Emergency","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":4}]}],"otherEvents":[{"term":"Hyperphosphatemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":2},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Low HCT","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Low RBC","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Increased RDW","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Hypoalbuminemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":2},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Hyperglycemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":2},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":4}]},{"term":"Platelet Count Decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":2},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Agitation","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Confusion","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Delirium","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Alanine Aminotransferase Increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Creatinine Increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Hyperkalemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Hyponatremia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Lymphocyte Count Decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Renal Disorder - BUN Increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Asymptomatic Stroke","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Fatigue","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Urinary Retention","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":4}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"A limitation in data analysis is failure to meet the enrollment goal. Enrollment was difficult due to the rare nature of the disease and the 7-10 day dosing window. Some patients were eligible, but immediate surgical intervention was necessary, so they could not reach steady-state posaconazole.\n\nTwo planned outcome measures, correlation of neuro-pharmacokinetic profile with concentration of lactate and pyruvate, were not analyzed due to limited volume of cerebrospinal fluid from microdialysis."},"certainAgreement":{"piSponsorEmployee":true,"restrictiveAgreement":false},"pointOfContact":{"title":"Alireza Mansouri, MD","organization":"Penn State College of Medicine","email":"connect@mansourimd.com","phone":"717-763-2559"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2025-08-13","uploadDate":"2025-11-03T12:19","filename":"Prot_SAP_000.pdf","size":1689993},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2025-08-13","uploadDate":"2025-11-03T12:20","filename":"ICF_001.pdf","size":517409}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D005909","term":"Glioblastoma"},{"id":"D001932","term":"Brain Neoplasms"}],"ancestors":[{"id":"D001254","term":"Astrocytoma"},{"id":"D005910","term":"Glioma"},{"id":"D018302","term":"Neoplasms, Neuroepithelial"},{"id":"D017599","term":"Neuroectodermal Tumors"},{"id":"D009373","term":"Neoplasms, Germ Cell and Embryonal"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009380","term":"Neoplasms, Nerve Tissue"},{"id":"D016543","term":"Central Nervous System Neoplasms"},{"id":"D009423","term":"Nervous System Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D001927","term":"Brain Diseases"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C101425","term":"posaconazole"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT05245682","orgStudyIdInfo":{"id":"STUDY00002992"},"secondaryIdInfos":[{"id":"P30CA138292","type":"NIH","link":"https://reporter.nih.gov/quickSearch/P30CA138292"},{"id":"WINSHIP5380-21","type":"OTHER","domain":"Emory University"},{"id":"NCI-2021-09678","type":"REGISTRY","domain":"CTRP"}],"organization":{"fullName":"Emory University","class":"OTHER"},"briefTitle":"Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer","officialTitle":"Early-Phase Open-label Study of Tolinapant and Radiation in Cisplatin-Ineligible Patients With Previously Untreated, Locally Advanced Head and Neck Cancer"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"ACTIVE_NOT_RECRUITING","startDateStruct":{"date":"2022-02-17","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-01-15","type":"ACTUAL"},"completionDateStruct":{"date":"2026-07-21","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-01-11","studyFirstSubmitQcDate":"2022-02-08","studyFirstPostDateStruct":{"date":"2022-02-18","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-02-27","resultsFirstSubmitQcDate":"2025-02-27","resultsFirstPostDateStruct":{"date":"2025-03-17","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-06","lastUpdatePostDateStruct":{"date":"2026-01-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Nicole Schmitt","investigatorTitle":"Principal Investigator","investigatorAffiliation":"Emory University"},"leadSponsor":{"name":"Emory University","class":"OTHER"},"collaborators":[{"name":"Astex Pharmaceuticals, Inc.","class":"INDUSTRY"},{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This early-phase trial tests the safety and side effects of a tolinapant given together with radiation therapy in treating patients with head and neck cancer for which the patient has not received treatment in the past (previously untreated), has spread to nearby tissue or lymph nodes (locally advanced) and cannot receive cisplatin (cisplatin-ineligible). Tolinapant may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving tolinapant and radiation therapy may kill more tumor cells.","detailedDescription":"Primary Objective:\n\nTo evaluate the safety and tolerability of the recommended phase 2 dose (RP2D) of tolinapant when given in combination with radiation.\n\nSecondary Objectives:\n\nTo assess preliminary efficacy of the combination of tolinapant and radiation in cisplatin ineligible patients with head and neck cancer as determined by locoregional control, two year progression-free survival (PFS), and two-year overall survival (OS).\n\nExploratory Objective:\n\nTo compare immune cell infiltrates following the first cycle of tolinapant + radiation, compared with baseline biopsy tissue and peripheral blood.\n\nTERTIARY/EXPLORATORY OBJECTIVES:\n\nI. To assess the effects of the combination of tolinapant + radiation on immune cells in blood and tumor.\n\nII. To assess the association between immune responses and FADD expression in tumors.\n\nOUTLINE:\n\nPatients undergo standard of care radiation therapy for a total of 35 fractions over 6-7 weeks and receive tolinapant orally (PO) daily for 7 days during weeks 1, 3, 5, and 7 of radiation therapy in the absence of disease progression or unacceptable toxicity.\n\nAfter completion of study treatment, patients are followed up 1, 3, 6, 12, and 24 months."},"conditionsModule":{"conditions":["Head and Neck Carcinoma of Unknown Primary","Locally Advanced Head and Neck Squamous Cell Carcinoma","Locally Advanced Hypopharyngeal Squamous Cell Carcinoma","Locally Advanced Laryngeal Squamous Cell Carcinoma","Locally Advanced Nasopharyngeal Squamous Cell Carcinoma","Locally Advanced Oropharyngeal Squamous Cell Carcinoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":10,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment (tolinapant, radiation therapy)","type":"EXPERIMENTAL","description":"Patients undergo standard of care radiation therapy for a total of 35 fractions over 7 weeks and receive tolinapant PO daily for 7 days during weeks 1, 3, 5, and 7 of radiation therapy in the absence of disease progression or unacceptable toxicity.","interventionNames":["Drug: Tolinapant","Radiation: Radiation Therapy"]}],"interventions":[{"type":"DRUG","name":"Tolinapant","description":"Given PO","armGroupLabels":["Treatment (tolinapant, radiation therapy)"],"otherNames":["ASTX660","1799328-86-1","XIAP/cIAP1 Antagonist ASTX660"]},{"type":"RADIATION","name":"Radiation Therapy","description":"Undergo radiation therapy","armGroupLabels":["Treatment (tolinapant, radiation therapy)"],"otherNames":["Cancer Radiotherapy","Radiation","Radiation Therapy, NOS","Radiotherapeutics","Radiotherapy","RT Therapy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Safety of Tolinapant + Radiation (Number of Patients With Adverse Events Per CTCAE v5.0)","description":"Safety will be assessed on clinical examination and measurement of laboratory parameters. All safety assessments including adverse events, clinical laboratory evaluations, and vital signs will be summarized with descriptive statistics, where appropriate, and listed in the data listings using MedDRA terms.","timeFrame":"Up to 60 days post-treatment"},{"measure":"Feasibility of Tolinapant + Radiation (Number of Patients Able to Complete Treatment)","description":"Feasibility is defined as completion of treatment, which will be reported as a percentage, with a 95% exact confidence interval using the Clopper-Pearson method.","timeFrame":"Upon completion of treatment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or Female.\n2. Age 18 years.\n3. ECOG performance status 1 (see Appendix A).\n4. Patients with histologically or cytologically confirmed diagnosis of HNSCC, previously untreated and locally advanced, for whom definitive or adjuvant radiation is planned but cisplatin chemotherapy is contraindicated.\n\n   For the purposes of trial eligibility, anatomic subsites of HNSCC may include the larynx, oropharynx, hypopharynx, nasopharynx, or unknown primary site presenting with neck lymph nodal disease.\n\n   Patients must have a contraindication to cisplatin as defined below. The scores must be recorded on a CRF:\n\n   Age  70 with moderate to severe comorbidity, defined as having one or more of the following conditions within 30 days prior to registration:\n   * Modified Charlson Comorbidity Index  1\n   * ACE-27 Index  1\n   * G-8 score  14\n   * CARG Toxicity Score  30%\n   * CIRS-G Score  4 -OR-\n\n   Age  18 with an absolute or relative contraindication to cisplatin, defined as one or more of the following criterion within 30 days prior to registration:\n   * Pre-existing peripheral neuropathy grade  1;\n   * History of hearing loss, defined as either an existing need of a hearing aid OR moderate hearing loss as defined by the American Speech and Hearing Association (pretreatment audiogram showing 40-55 db HL hearing loss)\n   * Creatinine clearance (CrCl) must be \\> 30 and \\< 50 mL/min. For this calculation, use the Cockroft-Gault formula: CrCl = 0.85 (if female)\\* ((140-Age) / (Serum Creatinine)) \\* (Weight in kg / 72).\n5. Acceptable organ function, as evidenced by the following laboratory data:\n\n   * Absolute neutrophil count \\[ANC\\]  1,500 cells/l; hemoglobin  9 g/dl, platelets  100,000/l.\n   * Serum creatinine  1.5 mg/dl, or calculated creatinine clearance  60 ml/min.\n   * Bilirubin  upper limit normal \\[ULN\\], alanine aminotransferase \\[ALT\\]  1.5 x ULN and/or aspartate aminotransferase \\[AST\\]  1.5 x ULN, alkaline phosphatase  2.5 x ULN.\n   * Prothrombin time (PT)/international normalized ratio (INR)  1.5 x ULN.\n   * Activated partial thromboplastin (aPTT) time  1.5 x ULN. Amylase and lipase  ULN.\n6. The effects of tolinapant on the developing human fetus are unknown. For this reason and because tolinapant as well as other therapeutic agents used in this trial are known to be teratogenic, females of child-bearing potential (FCBP) must have a negative serum pregnancy test prior to starting therapy.\n7. Female patients of childbearing potential and men must agree to use adequate contraception (at least one highly effective method and one additional method of birth control at the same time or complete abstinence) prior to study entry, for the duration of study participation and for at least 6 months following study drug discontinuation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. A female of childbearing potential (FCBP) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (if age \\> 55 years); if the female subject is \\< 55 years and she has been naturally postmenopausal for \\> 1 year her reproductive status has to be verified by additional lab tests (\\< 20 estradiol OR estradiol \\< 40 with FSH \\> 40 in women not on estrogen replacement therapy).\n8. Willingness and ability of the subject to comply with scheduled visits, drug administration plan, protocol specified laboratory tests, other study procedures, and study restrictions.\n9. Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.\n\nExclusion Criteria:\n\n1. Patients who have had prior radiotherapy to the head and neck region\n2. Patients who are receiving any other investigational agents or an investigational device within 21 days before administration of first dose of study drugs.\n3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to tolinapant.\n4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n5. Significant cardiovascular disease (e.g., myocardial infarction, arterial thromboembolism, cerebrovascular thromboembolism) within 3 months prior to start of study therapy; angina requiring therapy; symptomatic peripheral vascular disease; New York Heart Association Class 3 or 4 congestive heart failure (or ejection fraction \\<50%); or uncontrolled Grade 3 hypertension (diastolic blood pressure 100 mmHg or systolic blood pressure 160 mmHg) despite antihypertensive therapy.\n6. Contraindications to radiotherapy (e.g. uncontrolled connective tissue disorder).\n7. Women who are pregnant or breast feeding.\n8. Vulnerable populations including prisoners and adults who are unable to consent.\n9. Known history of human immunodeficiency virus (HIV) infection, or seropositive results consistent with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection.\n10. Grade 3 or greater neuropathy.\n11. Known distant metastases (i.e., outside of the neck).\n12. Known significant mental illness or other conditions such as active alcohol or other substance abuse that, in the opinion of the investigator, predisposes the subject to high risk of noncompliance with the protocol treatment or assessments.\n13. Concurrent second malignancy requiring active therapy.\n14. Patients with a history of allogenic transplant must not have Grade 3 graft-versus-host disease (GVHD) or any clinically significant GVHD requiring systemic immunosuppression.\n15. Systemic corticosteroids \\>20 mg daily prednisone equivalent (unless patient has been taking a continuous dose for \\>3 weeks prior to study entry).\n16. Medications known to cause QT prolongation including some antipsychotics (chlorpromazine, haloperidol, droperidol, quetiapine, olanzapine, amisulpride, thioridazine), antiarrhythmics (quinidine, procainamide, disopyramide, flecanide, encainide, sotalol, amiodarone), antidipressants (amitriptyline, doxepin, imipramine, nortriptyline, desipramine), mianserin, citalopram, escitalopram, venlafaxine, bupropion, moclobemide), and antihistamines (diphenhydramine, astemizole, loratadine, terfenadine), macrolide antibiotics (erythromycin, clarithromycin), and antimalarials (chloroquine, hydroxychloroquine, quinine), unless the use of these drugs cannot be avoided.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Nicole C Schmitt, MD","affiliation":"Emory University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Emory University/Winship Cancer Institute","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Treatment (Tolinapant, Radiation Therapy)","description":"Patients undergo standard of care radiation therapy for a total of 35 fractions over 7 weeks and receive tolinapant PO daily for 7 days during weeks 1, 3, 5, and 7 of radiation therapy in the absence of disease progression or unacceptable toxicity.\n\nTolinapant: Given PO\n\nRadiation Therapy: Undergo radiation therapy"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"10"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"10"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Treatment (Tolinapant, Radiation Therapy)","description":"Patients undergo standard of care radiation therapy for a total of 35 fractions over 7 weeks and receive tolinapant PO daily for 7 days during weeks 1, 3, 5, and 7 of radiation therapy in the absence of disease progression or unacceptable toxicity.\n\nTolinapant: Given PO\n\nRadiation Therapy: Undergo radiation therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"10"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"3"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"7"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"68.6","spread":"9.75"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"2"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"8"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"10"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"8"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Safety of Tolinapant + Radiation (Number of Patients With Adverse Events Per CTCAE v5.0)","description":"Safety will be assessed on clinical examination and measurement of laboratory parameters. All safety assessments including adverse events, clinical laboratory evaluations, and vital signs will be summarized with descriptive statistics, where appropriate, and listed in the data listings using MedDRA terms.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 60 days post-treatment","groups":[{"id":"OG000","title":"Treatment (Tolinapant, Radiation Therapy)","description":"Patients undergo standard of care radiation therapy for a total of 35 fractions over 7 weeks and receive tolinapant PO daily for 7 days during weeks 1, 3, 5, and 7 of radiation therapy in the absence of disease progression or unacceptable toxicity.\n\nTolinapant: Given PO\n\nRadiation Therapy: Undergo radiation therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}]},{"type":"PRIMARY","title":"Feasibility of Tolinapant + Radiation (Number of Patients Able to Complete Treatment)","description":"Feasibility is defined as completion of treatment, which will be reported as a percentage, with a 95% exact confidence interval using the Clopper-Pearson method.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Upon completion of treatment","groups":[{"id":"OG000","title":"Treatment (Tolinapant, Radiation Therapy)","description":"Patients undergo standard of care radiation therapy for a total of 35 fractions over 7 weeks and receive tolinapant PO daily for 7 days during weeks 1, 3, 5, and 7 of radiation therapy in the absence of disease progression or unacceptable toxicity.\n\nTolinapant: Given PO\n\nRadiation Therapy: Undergo radiation therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"2 years post treatment","eventGroups":[{"id":"EG000","title":"Treatment (Tolinapant, Radiation Therapy)","description":"Patients undergo standard of care radiation therapy for a total of 35 fractions over 7 weeks and receive tolinapant PO daily for 7 days during weeks 1, 3, 5, and 7 of radiation therapy in the absence of disease progression or unacceptable toxicity.\n\nTolinapant: Given PO\n\nRadiation Therapy: Undergo radiation therapy","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":10,"otherNumAtRisk":10}],"otherEvents":[{"term":"Radiation Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":10}]},{"term":"Fatigue","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":10}]},{"term":"Anorexia","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":10}]},{"term":"Throat/Tumor Pain","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":10}]},{"term":"Dysphagia","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":10}]},{"term":"Dysgeusia","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":10}]},{"term":"Nausea","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":10}]},{"term":"Dry Mouth","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":10}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Nicole Schmitt","organization":"Emory University","email":"nicole.cherie.schmitt@emory.edu","phone":"404-778-0278"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2024-09-06","uploadDate":"2025-02-21T16:19","filename":"Prot_SAP_000.pdf","size":476706}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"interventionBrowseModule":{"meshes":[{"id":"C000710345","term":"ASTX-660"},{"id":"D011878","term":"Radiotherapy"},{"id":"D011827","term":"Radiation"}],"ancestors":[{"id":"D013812","term":"Therapeutics"},{"id":"D055585","term":"Physical Phenomena"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT03018249","orgStudyIdInfo":{"id":"NCI-2017-00058"},"secondaryIdInfos":[{"id":"NCI-2017-00058","type":"REGISTRY","domain":"CTRP (Clinical Trial Reporting Program)"},{"id":"NRG-GY011"},{"id":"NRG-GY011","type":"OTHER","domain":"NRG Oncology"},{"id":"NRG-GY011","type":"OTHER","domain":"CTEP"},{"id":"U10CA180868","type":"NIH","link":"https://reporter.nih.gov/quickSearch/U10CA180868"}],"organization":{"fullName":"National Cancer Institute (NCI)","class":"NIH"},"briefTitle":"Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer","officialTitle":"A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus"},"statusModule":{"statusVerifiedDate":"2021-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-10-11","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-04-18","type":"ACTUAL"},"completionDateStruct":{"date":"2021-03-12","type":"ACTUAL"},"studyFirstSubmitDate":"2017-01-11","studyFirstSubmitQcDate":"2017-01-11","studyFirstPostDateStruct":{"date":"2017-01-12","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-03-03","resultsFirstSubmitQcDate":"2021-05-05","resultsFirstPostDateStruct":{"date":"2021-06-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-11-15","lastUpdatePostDateStruct":{"date":"2021-11-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"National Cancer Institute (NCI)","class":"NIH"},"collaborators":[{"name":"NRG Oncology","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This randomized surgical window trial evaluates the effect of adding entinostat to medroxyprogesterone acetate before surgery works on progesterone receptors on endometrioid endometrial tumors. Medroxyprogesterone acetate is a progesterone, a hormone produced by body normally. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving medroxyprogesterone acetate with or without entinostat may effect tumors from endometrioid endometrial cancer.","detailedDescription":"PRIMARY OBJECTIVES:\n\nI. To determine whether the addition of the histone deacetylase inhibitor, entinostat, in combination with medroxyprogesterone acetate in the pre-operative setting results in up-regulation of activated progesterone receptors (PR) compared to medroxyprogesterone acetate alone.\n\nSECONDARY OBJECTIVES:\n\nI. To assess the response rate (as measured by cellular morphology and proliferation) and change in activated receptor levels with the addition of entinostat at the time of hysterectomy.\n\nOUTLINE: Two arms were randomly allocated to eligible patients with equal probability.\n\nARM I: Patients receive medroxyprogesterone acetate intramuscularly (IM) on day 1 and undergo hysterectomy between days 21-24.\n\nARM II: Patients receive medroxyprogesterone acetate IM on day 1 and entinostat orally (PO) on days 1, 8, and 15. Patients undergo hysterectomy between days 21-24."},"conditionsModule":{"conditions":["FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma","FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma","FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":50,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm I (medroxyprogesterone acetate, hysterectomy)","type":"ACTIVE_COMPARATOR","description":"Patients receive medroxyprogesterone acetate IM on day 1 and undergo hysterectomy between days 21-24.","interventionNames":["Procedure: Hysterectomy","Other: Laboratory Biomarker Analysis","Drug: Medroxyprogesterone Acetate"]},{"label":"Arm II (medroxyprogesterone acetate, entinostat, hysterectomy)","type":"EXPERIMENTAL","description":"Patients receive medroxyprogesterone acetate IM on day 1 and entinostat PO on days 1, 8, and 15. Patients undergo hysterectomy between days 21-24.","interventionNames":["Drug: Entinostat","Procedure: Hysterectomy","Other: Laboratory Biomarker Analysis","Drug: Medroxyprogesterone Acetate"]}],"interventions":[{"type":"DRUG","name":"Entinostat","description":"Given PO","armGroupLabels":["Arm II (medroxyprogesterone acetate, entinostat, hysterectomy)"],"otherNames":["HDAC inhibitor SNDX-275","MS 27-275","MS-275","SNDX-275"]},{"type":"PROCEDURE","name":"Hysterectomy","description":"Undergo hysterectomy","armGroupLabels":["Arm I (medroxyprogesterone acetate, hysterectomy)","Arm II (medroxyprogesterone acetate, entinostat, hysterectomy)"],"otherNames":["Hysterectomy NOS"]},{"type":"OTHER","name":"Laboratory Biomarker Analysis","description":"Correlative studies","armGroupLabels":["Arm I (medroxyprogesterone acetate, hysterectomy)","Arm II (medroxyprogesterone acetate, entinostat, hysterectomy)"]},{"type":"DRUG","name":"Medroxyprogesterone Acetate","description":"Given IM","armGroupLabels":["Arm I (medroxyprogesterone acetate, hysterectomy)","Arm II (medroxyprogesterone acetate, entinostat, hysterectomy)"],"otherNames":["Amen","Aragest","Ciclotal","Clinofem","Clinovir","Cycrin","Depo-Clinovir","Depo-Provera","Depot-Medroxyprogestereone Acetate","Farlutal","G-Farlutal","Gestapuran","Hysron","Lutoral","Medroxyprogesterone 17-Acetate","Medroxyprogesteroni Acetas","Methylacetoxyprogesterone","Metipregnone","MPA","Nadigest","Nadigest (vet)","Nidaxin","Nidaxin (vet)","Oragest","Perlutex","Prodasone","Provera","Sodelut G","Veramix"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Mean Post-treatment Tumor Progesterone Receptor H-score (Histology Score)","description":"The H-score is defined as the percent cells staining positive (0-100) multiplied by the staining intensity (0, 1, 2 or 3) measured in the tumor by immunohistochemistry and averaged over 3 reviewers. This score can range from 0 to 300. In general, PRs are expected to decrease in response to medroxyprogesterone acetate. It was hypothesized that entinostat would mitigate the decrease in PR relative to the medroxyprogesterone acetate only arm post treatment. Higher PR H-scores post treatment in the arm with entinostat relative to the medroxyprogesterone alone arm would be consistent with this hypothesis. Arm II was thought to result in higher scores which was expected to have a more favorable outcome when treated with MPA therapy.","timeFrame":"Specimens were collected at hysterectomy on day 21-24 and analyzed in batch."}],"secondaryOutcomes":[{"measure":"Percentage of Participants With a Histologic Response","description":"Pre- and post-treatment slides for each patient were evaluated in pairs for complete or partial histologic response by one reviewer. Pre- and post-treatment slides for each patient were evaluated in pairs for complete or partial histologic response by one reviewer. A histologic response was defined as either the absence of identifiable adenocarcinoma in the hysterectomy specimen section (complete) or, subjectively, as the presence of a complex proliferation of glands that retain the architectural characteristics of adenocarcinoma, but with features of secretion, decreased nuclear stratification, or the presence of eosinophilic, squamous or mucinous metaplasia, when this was absent in the initial sample (partial).","timeFrame":"Specimens were collected at initial diagnostic biopsy and at hysterectomy on day 21-24 and analyzed in batch."},{"measure":"Percent of Participants With a Ki67 Response","description":"A response was defined as a decrease in Ki-67 protein expression in tumor from pre- to post-treatment.","timeFrame":"Specimens were collected at initial diagnostic biopsy and at hysterectomy on day 21-24 and analyzed in batch."},{"measure":"The Frequency and Severity of CTCAE Version 4.0 Graded Adverse Events (AE)","description":"Maximum grade of physician assessed adverse events reported during treatment and up to 45 days after surgery. Grades start with 1 which is considered mild through grade 5 which is death. Participants on this study had adverse event grades up to grade 3 which is considered moderately severe.","timeFrame":"Up to 45 days after surgery"}],"otherOutcomes":[{"measure":"Mean Post-treatment Tumor Estrogen Receptor Score","timeFrame":"Up to 3 years"},{"measure":"Co-expression of PR, Ki67, and p21","description":"Will be compared between the arms.","timeFrame":"Up to 3 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must have a histologically proven diagnosis of endometrioid endometrial adenocarcinoma by endometrial curettage or biopsy within 8 weeks prior to registration; central pathology review will be required as part of the study but not for registration purposes\n* History/physical examination within 42 +/- 5 days of planned surgical procedure (18-21 days from day 1); further protocol-specific assessments\n* The trial is open only to women with primary endometrioid adenocarcinoma of the uterine corpus (all histologic grades and stages) who are planned and appropriate for primary surgical treatment to include removal of the uterine corpus via any surgical modality; the patient must be considered a suitable surgical candidate\n* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2, or 3 within 28 days prior to registration\n* Formalin-fixed, paraffin-embedded tumor tissue from the biopsy or curettage must be submitted along with the corresponding pathology report\n* Platelets \\>= 100,000/ul\n* Granulocytes (ANC) \\>= 1,500/ul\n* Creatinine =\\< 1.6 mg/dl\n* Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \\[ALT\\]) =\\< 3 x upper limits of normal\n* Bilirubin within institutional normal limits\n* The patient must provide study-specific informed consent and authorization permitting release of personal health information prior to study entry\n* Any patients of childbearing potential must have a negative pregnancy test\n\nExclusion Criteria:\n\n* Patients with any non-endometrioid histology (such as serous, clear cell, or carcinosarcoma)\n* Patients who have received prior progestin or anti-estrogen therapy during the 3 months before the diagnosis of endometrioid adenocarcinoma of the uterine corpus is established; estrogen therapy alone is allowed\n* Patients with ECOG performance grade of 4\n* Patients with history of thrombophlebitis within the past 2 years or ongoing thromboembolic disorders\n* Patients who have previously received systemic, radiation or other treatment for uterine cancer\n* Patients for whom formalin-fixed, paraffin-embedded tumor tissue from the biopsy or curettage is unavailable\n* Patients must not have previously received a non Food and Drug Administration (FDA) approved histone deacetylase (HDAC) inhibitor in a clinical trial setting (entinostat, belinostat)\n* Patients must not be currently taking or have ever taken vorinostat (Zolinza, Merck), panobinostat (Farydak, Novartis) or romidepsin (Istodax, Gloucester Pharmaceuticals)","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Linda R Duska","affiliation":"NRG Oncology","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"CHI Saint Vincent Cancer Center Hot Springs","city":"Hot Springs","state":"Arkansas","zip":"71913","country":"United States","geoPoint":{"lat":34.5037,"lon":-93.05518}},{"facility":"John Muir Medical Center-Concord Campus","city":"Concord","state":"California","zip":"94520","country":"United States","geoPoint":{"lat":37.97798,"lon":-122.03107}},{"facility":"John Muir Medical Center-Walnut Creek","city":"Walnut Creek","state":"California","zip":"94598","country":"United States","geoPoint":{"lat":37.90631,"lon":-122.06496}},{"facility":"Rocky Mountain Cancer Centers-Aurora","city":"Aurora","state":"Colorado","zip":"80012","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"University of Colorado Hospital","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"Boulder Community Hospital","city":"Boulder","state":"Colorado","zip":"80301","country":"United States","geoPoint":{"lat":40.01499,"lon":-105.27055}},{"facility":"Rocky Mountain Cancer Centers-Boulder","city":"Boulder","state":"Colorado","zip":"80304","country":"United States","geoPoint":{"lat":40.01499,"lon":-105.27055}},{"facility":"Penrose-Saint Francis Healthcare","city":"Colorado Springs","state":"Colorado","zip":"80907","country":"United States","geoPoint":{"lat":38.83388,"lon":-104.82136}},{"facility":"Rocky Mountain Cancer Centers-Penrose","city":"Colorado Springs","state":"Colorado","zip":"80907","country":"United States","geoPoint":{"lat":38.83388,"lon":-104.82136}},{"facility":"Denver Health Medical Center","city":"Denver","state":"Colorado","zip":"80204","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"National Jewish Health-Main Campus","city":"Denver","state":"Colorado","zip":"80206","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"The Women's Imaging Center","city":"Denver","state":"Colorado","zip":"80209","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"Porter Adventist Hospital","city":"Denver","state":"Colorado","zip":"80210","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"Colorado Blood Cancer Institute","city":"Denver","state":"Colorado","zip":"80218","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"Presbyterian - Saint Lukes Medical Center - Health One","city":"Denver","state":"Colorado","zip":"80218","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"Rocky Mountain Cancer Centers-Midtown","city":"Denver","state":"Colorado","zip":"80218","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"SCL Health Saint Joseph Hospital","city":"Denver","state":"Colorado","zip":"80218","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"Rocky Mountain Cancer Centers-Rose","city":"Denver","state":"Colorado","zip":"80220","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"Rose Medical Center","city":"Denver","state":"Colorado","zip":"80220","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"Mercy Medical Center","city":"Durango","state":"Colorado","zip":"81301","country":"United States","geoPoint":{"lat":37.27528,"lon":-107.88007}},{"facility":"Southwest Oncology PC","city":"Durango","state":"Colorado","zip":"81301","country":"United States","geoPoint":{"lat":37.27528,"lon":-107.88007}},{"facility":"Mountain Blue Cancer Care Center - Swedish","city":"Englewood","state":"Colorado","zip":"80113","country":"United States","geoPoint":{"lat":39.64777,"lon":-104.98776}},{"facility":"Swedish Medical Center","city":"Englewood","state":"Colorado","zip":"80113","country":"United States","geoPoint":{"lat":39.64777,"lon":-104.98776}},{"facility":"Mountain Blue Cancer Care Center","city":"Golden","state":"Colorado","zip":"80401","country":"United States","geoPoint":{"lat":39.75554,"lon":-105.2211}},{"facility":"National Jewish Health-Western Hematology Oncology","city":"Golden","state":"Colorado","zip":"80401","country":"United States","geoPoint":{"lat":39.75554,"lon":-105.2211}},{"facility":"North Colorado Medical Center","city":"Greeley","state":"Colorado","zip":"80631","country":"United States","geoPoint":{"lat":40.42331,"lon":-104.70913}},{"facility":"Rocky Mountain Cancer Centers-Lakewood","city":"Lakewood","state":"Colorado","zip":"80228","country":"United States","geoPoint":{"lat":39.70471,"lon":-105.08137}},{"facility":"Saint Anthony Hospital","city":"Lakewood","state":"Colorado","zip":"80228","country":"United States","geoPoint":{"lat":39.70471,"lon":-105.08137}},{"facility":"Rocky Mountain Cancer Centers-Littleton","city":"Littleton","state":"Colorado","zip":"80120","country":"United States","geoPoint":{"lat":39.61332,"lon":-105.01665}},{"facility":"Littleton Adventist Hospital","city":"Littleton","state":"Colorado","zip":"80122","country":"United States","geoPoint":{"lat":39.61332,"lon":-105.01665}},{"facility":"Rocky Mountain Cancer Centers-Sky Ridge","city":"Lone Tree","state":"Colorado","zip":"80124","country":"United States","geoPoint":{"lat":39.55171,"lon":-104.8863}},{"facility":"Longmont United Hospital","city":"Longmont","state":"Colorado","zip":"80501","country":"United States","geoPoint":{"lat":40.16721,"lon":-105.10193}},{"facility":"Rocky Mountain Cancer Centers-Longmont","city":"Longmont","state":"Colorado","zip":"80501","country":"United States","geoPoint":{"lat":40.16721,"lon":-105.10193}},{"facility":"McKee Medical Center","city":"Loveland","state":"Colorado","zip":"80539","country":"United States","geoPoint":{"lat":40.39776,"lon":-105.07498}},{"facility":"Parker Adventist Hospital","city":"Parker","state":"Colorado","zip":"80138","country":"United States","geoPoint":{"lat":39.5186,"lon":-104.76136}},{"facility":"Rocky Mountain Cancer Centers-Parker","city":"Parker","state":"Colorado","zip":"80138","country":"United States","geoPoint":{"lat":39.5186,"lon":-104.76136}},{"facility":"Saint Mary Corwin Medical Center","city":"Pueblo","state":"Colorado","zip":"81004","country":"United States","geoPoint":{"lat":38.25445,"lon":-104.60914}},{"facility":"Rocky Mountain Cancer Centers - Pueblo","city":"Pueblo","state":"Colorado","zip":"81008","country":"United States","geoPoint":{"lat":38.25445,"lon":-104.60914}},{"facility":"National Jewish Health-Northern Hematology Oncology","city":"Thornton","state":"Colorado","zip":"80260","country":"United States","geoPoint":{"lat":39.86804,"lon":-104.97192}},{"facility":"Rocky Mountain Cancer Centers-Thornton","city":"Thornton","state":"Colorado","zip":"80260","country":"United States","geoPoint":{"lat":39.86804,"lon":-104.97192}},{"facility":"SCL Health Lutheran Medical Center","city":"Wheat Ridge","state":"Colorado","zip":"80033","country":"United States","geoPoint":{"lat":39.7661,"lon":-105.07721}},{"facility":"Beebe Medical Center","city":"Lewes","state":"Delaware","zip":"19958","country":"United States","geoPoint":{"lat":38.77456,"lon":-75.13935}},{"facility":"Delaware Clinical and Laboratory Physicians PA","city":"Newark","state":"Delaware","zip":"19713","country":"United States","geoPoint":{"lat":39.68372,"lon":-75.74966}},{"facility":"Helen F Graham Cancer Center","city":"Newark","state":"Delaware","zip":"19713","country":"United States","geoPoint":{"lat":39.68372,"lon":-75.74966}},{"facility":"Medical Oncology Hematology Consultants PA","city":"Newark","state":"Delaware","zip":"19713","country":"United States","geoPoint":{"lat":39.68372,"lon":-75.74966}},{"facility":"Christiana Care Health System-Christiana Hospital","city":"Newark","state":"Delaware","zip":"19718","country":"United States","geoPoint":{"lat":39.68372,"lon":-75.74966}},{"facility":"Beebe Health Campus","city":"Rehoboth Beach","state":"Delaware","zip":"19971","country":"United States","geoPoint":{"lat":38.72095,"lon":-75.07601}},{"facility":"TidalHealth Nanticoke / Allen Cancer Center","city":"Seaford","state":"Delaware","zip":"19973","country":"United States","geoPoint":{"lat":38.64123,"lon":-75.61104}},{"facility":"Christiana Care Health System-Wilmington Hospital","city":"Wilmington","state":"Delaware","zip":"19801","country":"United States","geoPoint":{"lat":39.74595,"lon":-75.54659}},{"facility":"Sacred Heart Hospital","city":"Pensacola","state":"Florida","zip":"32504","country":"United States","geoPoint":{"lat":30.42131,"lon":-87.21691}},{"facility":"Kootenai Medical Center","city":"Coeur d'Alene","state":"Idaho","zip":"83814","country":"United States","geoPoint":{"lat":47.67768,"lon":-116.78047}},{"facility":"Kootenai Cancer Center","city":"Post Falls","state":"Idaho","zip":"83854","country":"United States","geoPoint":{"lat":47.71796,"lon":-116.95159}},{"facility":"Kootenai Cancer Clinic","city":"Sandpoint","state":"Idaho","zip":"83864","country":"United States","geoPoint":{"lat":48.27659,"lon":-116.55325}},{"facility":"Northwestern University","city":"Chicago","state":"Illinois","zip":"60611","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"University of Chicago Comprehensive Cancer Center","city":"Chicago","state":"Illinois","zip":"60637","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Northwestern Medicine Lake Forest Hospital","city":"Lake Forest","state":"Illinois","zip":"60045","country":"United States","geoPoint":{"lat":42.25863,"lon":-87.84063}},{"facility":"Good Samaritan Regional Health Center","city":"Mount Vernon","state":"Illinois","zip":"62864","country":"United States","geoPoint":{"lat":38.31727,"lon":-88.90312}},{"facility":"UC Comprehensive Cancer Center at Silver Cross","city":"New Lenox","state":"Illinois","zip":"60451","country":"United States","geoPoint":{"lat":41.51198,"lon":-87.96561}},{"facility":"University of Chicago Medicine-Orland Park","city":"Orland Park","state":"Illinois","zip":"60462","country":"United States","geoPoint":{"lat":41.63031,"lon":-87.85394}},{"facility":"Parkview Hospital Randallia","city":"Fort Wayne","state":"Indiana","zip":"46805","country":"United States","geoPoint":{"lat":41.1306,"lon":-85.12886}},{"facility":"Medical Oncology and Hematology Associates-West Des Moines","city":"Clive","state":"Iowa","zip":"50325","country":"United States","geoPoint":{"lat":41.60304,"lon":-93.72411}},{"facility":"Mercy Cancer Center-West Lakes","city":"Clive","state":"Iowa","zip":"50325","country":"United States","geoPoint":{"lat":41.60304,"lon":-93.72411}},{"facility":"Alegent Health Mercy Hospital","city":"Council Bluffs","state":"Iowa","zip":"51503","country":"United States","geoPoint":{"lat":41.26194,"lon":-95.86083}},{"facility":"Greater Regional Medical Center","city":"Creston","state":"Iowa","zip":"50801","country":"United States","geoPoint":{"lat":41.0586,"lon":-94.36135}},{"facility":"Medical Oncology and Hematology Associates-Laurel","city":"Des Moines","state":"Iowa","zip":"50314","country":"United States","geoPoint":{"lat":41.60054,"lon":-93.60911}},{"facility":"Mercy Medical Center - Des Moines","city":"Des Moines","state":"Iowa","zip":"50314","country":"United States","geoPoint":{"lat":41.60054,"lon":-93.60911}},{"facility":"University of Iowa/Holden Comprehensive Cancer Center","city":"Iowa City","state":"Iowa","zip":"52242","country":"United States","geoPoint":{"lat":41.66113,"lon":-91.53017}},{"facility":"Mercy Medical Center-West Lakes","city":"West Des Moines","state":"Iowa","zip":"50266","country":"United States","geoPoint":{"lat":41.57721,"lon":-93.71133}},{"facility":"University of Kansas Cancer Center","city":"Kansas City","state":"Kansas","zip":"66160","country":"United States","geoPoint":{"lat":39.11417,"lon":-94.62746}},{"facility":"University of Kansas Hospital-Westwood Cancer Center","city":"Westwood","state":"Kansas","zip":"66205","country":"United States","geoPoint":{"lat":39.04056,"lon":-94.6169}},{"facility":"Flaget Memorial Hospital","city":"Bardstown","state":"Kentucky","zip":"40004","country":"United States","geoPoint":{"lat":37.80923,"lon":-85.4669}},{"facility":"Commonwealth Cancer Center-Corbin","city":"Corbin","state":"Kentucky","zip":"40701","country":"United States","geoPoint":{"lat":36.9487,"lon":-84.09688}},{"facility":"Saint Joseph Radiation Oncology Resource Center","city":"Lexington","state":"Kentucky","zip":"40504","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Saint Joseph Hospital East","city":"Lexington","state":"Kentucky","zip":"40509","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Saint Joseph London","city":"London","state":"Kentucky","zip":"40741","country":"United States","geoPoint":{"lat":37.12898,"lon":-84.08326}},{"facility":"Jewish Hospital","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Saints Mary and Elizabeth Hospital","city":"Louisville","state":"Kentucky","zip":"40215","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Jewish Hospital Medical Center Northeast","city":"Louisville","state":"Kentucky","zip":"40245","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Jewish Hospital Medical Center South","city":"Shepherdsville","state":"Kentucky","zip":"40165","country":"United States","geoPoint":{"lat":37.9884,"lon":-85.71579}},{"facility":"Louisiana State University Health Science Center","city":"New Orleans","state":"Louisiana","zip":"70112","country":"United States","geoPoint":{"lat":29.95465,"lon":-90.07507}},{"facility":"Ochsner Medical Center Jefferson","city":"New Orleans","state":"Louisiana","zip":"70121","country":"United States","geoPoint":{"lat":29.95465,"lon":-90.07507}},{"facility":"Willis-Knighton Medical and Cancer Center","city":"Shreveport","state":"Louisiana","zip":"71103","country":"United States","geoPoint":{"lat":32.52515,"lon":-93.75018}},{"facility":"Greater Baltimore Medical Center","city":"Baltimore","state":"Maryland","zip":"21204","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Fairview Ridges Hospital","city":"Burnsville","state":"Minnesota","zip":"55337","country":"United States","geoPoint":{"lat":44.76774,"lon":-93.27772}},{"facility":"Mercy Hospital","city":"Coon Rapids","state":"Minnesota","zip":"55433","country":"United States","geoPoint":{"lat":45.11997,"lon":-93.28773}},{"facility":"Fairview Southdale Hospital","city":"Edina","state":"Minnesota","zip":"55435","country":"United States","geoPoint":{"lat":44.88969,"lon":-93.34995}},{"facility":"Unity Hospital","city":"Fridley","state":"Minnesota","zip":"55432","country":"United States","geoPoint":{"lat":45.08608,"lon":-93.26328}},{"facility":"Fairview Clinics and Surgery Center Maple Grove","city":"Maple Grove","state":"Minnesota","zip":"55369","country":"United States","geoPoint":{"lat":45.07246,"lon":-93.45579}},{"facility":"Minnesota Oncology Hematology PA-Maplewood","city":"Maplewood","state":"Minnesota","zip":"55109","country":"United States","geoPoint":{"lat":44.95302,"lon":-92.99522}},{"facility":"Saint John's Hospital - Healtheast","city":"Maplewood","state":"Minnesota","zip":"55109","country":"United States","geoPoint":{"lat":44.95302,"lon":-92.99522}},{"facility":"Abbott-Northwestern Hospital","city":"Minneapolis","state":"Minnesota","zip":"55407","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"Hennepin County Medical Center","city":"Minneapolis","state":"Minnesota","zip":"55415","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"Health Partners Inc","city":"Minneapolis","state":"Minnesota","zip":"55454","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"New Ulm Medical Center","city":"New Ulm","state":"Minnesota","zip":"56073","country":"United States","geoPoint":{"lat":44.31246,"lon":-94.46053}},{"facility":"North Memorial Medical Health Center","city":"Robbinsdale","state":"Minnesota","zip":"55422","country":"United States","geoPoint":{"lat":45.03219,"lon":-93.33856}},{"facility":"Park Nicollet Clinic - Saint Louis Park","city":"Saint Louis Park","state":"Minnesota","zip":"55416","country":"United States","geoPoint":{"lat":44.9483,"lon":-93.34801}},{"facility":"Regions Hospital","city":"Saint Paul","state":"Minnesota","zip":"55101","country":"United States","geoPoint":{"lat":44.94441,"lon":-93.09327}},{"facility":"United Hospital","city":"Saint Paul","state":"Minnesota","zip":"55102","country":"United States","geoPoint":{"lat":44.94441,"lon":-93.09327}},{"facility":"Saint Francis Regional Medical Center","city":"Shakopee","state":"Minnesota","zip":"55379","country":"United States","geoPoint":{"lat":44.79802,"lon":-93.5269}},{"facility":"Lakeview Hospital","city":"Stillwater","state":"Minnesota","zip":"55082","country":"United States","geoPoint":{"lat":45.05636,"lon":-92.80604}},{"facility":"Ridgeview Medical Center","city":"Waconia","state":"Minnesota","zip":"55387","country":"United States","geoPoint":{"lat":44.8508,"lon":-93.78691}},{"facility":"Rice Memorial Hospital","city":"Willmar","state":"Minnesota","zip":"56201","country":"United States","geoPoint":{"lat":45.12191,"lon":-95.04334}},{"facility":"Minnesota Oncology Hematology PA-Woodbury","city":"Woodbury","state":"Minnesota","zip":"55125","country":"United States","geoPoint":{"lat":44.92386,"lon":-92.95938}},{"facility":"Fairview Lakes Medical Center","city":"Wyoming","state":"Minnesota","zip":"55092","country":"United States","geoPoint":{"lat":45.33636,"lon":-92.99716}},{"facility":"Saint Louis Cancer and Breast Institute-Ballwin","city":"Ballwin","state":"Missouri","zip":"63011","country":"United States","geoPoint":{"lat":38.59505,"lon":-90.54623}},{"facility":"Central Care Cancer Center - Bolivar","city":"Bolivar","state":"Missouri","zip":"65613","country":"United States","geoPoint":{"lat":37.61448,"lon":-93.41047}},{"facility":"Cox Cancer Center Branson","city":"Branson","state":"Missouri","zip":"65616","country":"United States","geoPoint":{"lat":36.64367,"lon":-93.21851}},{"facility":"Freeman Health System","city":"Joplin","state":"Missouri","zip":"64804","country":"United States","geoPoint":{"lat":37.08423,"lon":-94.51328}},{"facility":"Mercy Hospital Joplin","city":"Joplin","state":"Missouri","zip":"64804","country":"United States","geoPoint":{"lat":37.08423,"lon":-94.51328}},{"facility":"Delbert Day Cancer Institute at PCRMC","city":"Rolla","state":"Missouri","zip":"65401","country":"United States","geoPoint":{"lat":37.95143,"lon":-91.77127}},{"facility":"Mercy Clinic-Rolla-Cancer and Hematology","city":"Rolla","state":"Missouri","zip":"65401","country":"United States","geoPoint":{"lat":37.95143,"lon":-91.77127}},{"facility":"Heartland Regional Medical Center","city":"Saint Joseph","state":"Missouri","zip":"64506","country":"United States","geoPoint":{"lat":39.76861,"lon":-94.84663}},{"facility":"Mercy Hospital Springfield","city":"Springfield","state":"Missouri","zip":"65804","country":"United States","geoPoint":{"lat":37.21533,"lon":-93.29824}},{"facility":"CoxHealth South Hospital","city":"Springfield","state":"Missouri","zip":"65807","country":"United States","geoPoint":{"lat":37.21533,"lon":-93.29824}},{"facility":"Saint Louis Cancer and Breast Institute-South City","city":"St Louis","state":"Missouri","zip":"63109","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Mercy Hospital Saint Louis","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Mercy Hospital Washington","city":"Washington","state":"Missouri","zip":"63090","country":"United States","geoPoint":{"lat":38.55811,"lon":-91.01209}},{"facility":"Community Hospital of Anaconda","city":"Anaconda","state":"Montana","zip":"59711","country":"United States","geoPoint":{"lat":46.12854,"lon":-112.94226}},{"facility":"Billings Clinic Cancer Center","city":"Billings","state":"Montana","zip":"59101","country":"United States","geoPoint":{"lat":45.78329,"lon":-108.50069}},{"facility":"Bozeman Deaconess Hospital","city":"Bozeman","state":"Montana","zip":"59715","country":"United States","geoPoint":{"lat":45.67965,"lon":-111.03856}},{"facility":"Benefis Healthcare- Sletten Cancer Institute","city":"Great Falls","state":"Montana","zip":"59405","country":"United States","geoPoint":{"lat":47.50024,"lon":-111.30081}},{"facility":"Great Falls Clinic","city":"Great Falls","state":"Montana","zip":"59405","country":"United States","geoPoint":{"lat":47.50024,"lon":-111.30081}},{"facility":"Saint Peter's Community Hospital","city":"Helena","state":"Montana","zip":"59601","country":"United States","geoPoint":{"lat":46.59271,"lon":-112.03611}},{"facility":"Kalispell Regional Medical Center","city":"Kalispell","state":"Montana","zip":"59901","country":"United States","geoPoint":{"lat":48.19579,"lon":-114.31291}},{"facility":"Community Medical Hospital","city":"Missoula","state":"Montana","zip":"59804","country":"United States","geoPoint":{"lat":46.87215,"lon":-113.994}},{"facility":"CHI Health Saint Francis","city":"Grand Island","state":"Nebraska","zip":"68803","country":"United States","geoPoint":{"lat":40.92501,"lon":-98.34201}},{"facility":"Heartland Hematology and Oncology","city":"Kearney","state":"Nebraska","zip":"68845","country":"United States","geoPoint":{"lat":40.69946,"lon":-99.08148}},{"facility":"CHI Health Good Samaritan","city":"Kearney","state":"Nebraska","zip":"68847","country":"United States","geoPoint":{"lat":40.69946,"lon":-99.08148}},{"facility":"Saint Elizabeth Regional Medical Center","city":"Lincoln","state":"Nebraska","zip":"68510","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}},{"facility":"Alegent Health Immanuel Medical Center","city":"Omaha","state":"Nebraska","zip":"68122","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Hematology and Oncology Consultants PC","city":"Omaha","state":"Nebraska","zip":"68122","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Alegent Health Bergan Mercy Medical Center","city":"Omaha","state":"Nebraska","zip":"68124","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Alegent Health Lakeside Hospital","city":"Omaha","state":"Nebraska","zip":"68130","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Creighton University Medical Center","city":"Omaha","state":"Nebraska","zip":"68131","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Midlands Community Hospital","city":"Papillion","state":"Nebraska","zip":"68046","country":"United States","geoPoint":{"lat":41.15444,"lon":-96.04224}},{"facility":"Women's Cancer Center of Nevada","city":"Las Vegas","state":"Nevada","zip":"89169","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Dartmouth Hitchcock Medical Center","city":"Lebanon","state":"New Hampshire","zip":"03756","country":"United States","geoPoint":{"lat":43.64229,"lon":-72.25176}},{"facility":"University of New Mexico Cancer Center","city":"Albuquerque","state":"New Mexico","zip":"87102","country":"United States","geoPoint":{"lat":35.08449,"lon":-106.65114}},{"facility":"Women's Cancer Care Associates LLC","city":"Albany","state":"New York","zip":"12208","country":"United States","geoPoint":{"lat":42.65258,"lon":-73.75623}},{"facility":"State University of New York Downstate Medical Center","city":"Brooklyn","state":"New York","zip":"11203","country":"United States","geoPoint":{"lat":40.6501,"lon":-73.94958}},{"facility":"Roswell Park Cancer Institute","city":"Buffalo","state":"New York","zip":"14263","country":"United States","geoPoint":{"lat":42.88645,"lon":-78.87837}},{"facility":"University of Rochester","city":"Rochester","state":"New York","zip":"14642","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"Duke University Medical Center","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Wake Forest University Health Sciences","city":"Winston-Salem","state":"North Carolina","zip":"27157","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"Strecker Cancer Center-Belpre","city":"Belpre","state":"Ohio","zip":"45714","country":"United States","geoPoint":{"lat":39.27396,"lon":-81.5729}},{"facility":"Adena Regional Medical Center","city":"Chillicothe","state":"Ohio","zip":"45601","country":"United States","geoPoint":{"lat":39.33312,"lon":-82.9824}},{"facility":"Good Samaritan Hospital - Cincinnati","city":"Cincinnati","state":"Ohio","zip":"45220","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Bethesda North Hospital","city":"Cincinnati","state":"Ohio","zip":"45242","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"TriHealth Cancer Institute-Westside","city":"Cincinnati","state":"Ohio","zip":"45247","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"TriHealth Cancer Institute-Anderson","city":"Cincinnati","state":"Ohio","zip":"45255","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Ohio State University Comprehensive Cancer Center","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Mount Carmel East Hospital","city":"Columbus","state":"Ohio","zip":"43213","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Columbus Oncology and Hematology Associates Inc","city":"Columbus","state":"Ohio","zip":"43214","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Riverside Methodist Hospital","city":"Columbus","state":"Ohio","zip":"43214","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Grant Medical Center","city":"Columbus","state":"Ohio","zip":"43215","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"The Mark H Zangmeister Center","city":"Columbus","state":"Ohio","zip":"43219","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Mount Carmel Health Center West","city":"Columbus","state":"Ohio","zip":"43222","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Doctors Hospital","city":"Columbus","state":"Ohio","zip":"43228","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Delaware Health Center-Grady Cancer Center","city":"Delaware","state":"Ohio","zip":"43015","country":"United States","geoPoint":{"lat":40.29867,"lon":-83.06797}},{"facility":"Delaware Radiation Oncology","city":"Delaware","state":"Ohio","zip":"43015","country":"United States","geoPoint":{"lat":40.29867,"lon":-83.06797}},{"facility":"Grady Memorial Hospital","city":"Delaware","state":"Ohio","zip":"43015","country":"United States","geoPoint":{"lat":40.29867,"lon":-83.06797}},{"facility":"Fairfield Medical Center","city":"Lancaster","state":"Ohio","zip":"43130","country":"United States","geoPoint":{"lat":39.71368,"lon":-82.59933}},{"facility":"OhioHealth Mansfield Hospital","city":"Mansfield","state":"Ohio","zip":"44903","country":"United States","geoPoint":{"lat":40.75839,"lon":-82.51545}},{"facility":"Marietta Memorial Hospital","city":"Marietta","state":"Ohio","zip":"45750","country":"United States","geoPoint":{"lat":39.41535,"lon":-81.45484}},{"facility":"OhioHealth Marion General Hospital","city":"Marion","state":"Ohio","zip":"43302","country":"United States","geoPoint":{"lat":40.58867,"lon":-83.12852}},{"facility":"Knox Community Hospital","city":"Mount Vernon","state":"Ohio","zip":"43050","country":"United States","geoPoint":{"lat":40.3934,"lon":-82.48572}},{"facility":"Licking Memorial Hospital","city":"Newark","state":"Ohio","zip":"43055","country":"United States","geoPoint":{"lat":40.05812,"lon":-82.40126}},{"facility":"Newark Radiation Oncology","city":"Newark","state":"Ohio","zip":"43055","country":"United States","geoPoint":{"lat":40.05812,"lon":-82.40126}},{"facility":"Southern Ohio Medical Center","city":"Portsmouth","state":"Ohio","zip":"45662","country":"United States","geoPoint":{"lat":38.73174,"lon":-82.99767}},{"facility":"Saint Ann's Hospital","city":"Westerville","state":"Ohio","zip":"43081","country":"United States","geoPoint":{"lat":40.12617,"lon":-82.92907}},{"facility":"Genesis Healthcare System Cancer Care Center","city":"Zanesville","state":"Ohio","zip":"43701","country":"United States","geoPoint":{"lat":39.94035,"lon":-82.01319}},{"facility":"University of Oklahoma Health Sciences Center","city":"Oklahoma City","state":"Oklahoma","zip":"73104","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Mercy Hospital Oklahoma City","city":"Oklahoma City","state":"Oklahoma","zip":"73120","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Oklahoma Cancer Specialists and Research Institute-Tulsa","city":"Tulsa","state":"Oklahoma","zip":"74146","country":"United States","geoPoint":{"lat":36.15398,"lon":-95.99277}},{"facility":"Abington Memorial Hospital","city":"Abington","state":"Pennsylvania","zip":"19001","country":"United States","geoPoint":{"lat":40.12067,"lon":-75.11795}},{"facility":"UPMC-Heritage Valley Health System Beaver","city":"Beaver","state":"Pennsylvania","zip":"15009","country":"United States","geoPoint":{"lat":40.69534,"lon":-80.30478}},{"facility":"Christiana Care Health System-Concord Health Center","city":"Chadds Ford","state":"Pennsylvania","zip":"19317","country":"United States","geoPoint":{"lat":39.87178,"lon":-75.59132}},{"facility":"Geisinger Medical Center","city":"Danville","state":"Pennsylvania","zip":"17822","country":"United States","geoPoint":{"lat":40.96342,"lon":-76.61273}},{"facility":"UPMC Cancer Centers - Arnold Palmer Pavilion","city":"Greensburg","state":"Pennsylvania","zip":"15601","country":"United States","geoPoint":{"lat":40.30146,"lon":-79.53893}},{"facility":"Geisinger Medical Center-Cancer Center Hazleton","city":"Hazleton","state":"Pennsylvania","zip":"18201","country":"United States","geoPoint":{"lat":40.95842,"lon":-75.97465}},{"facility":"UPMC-Johnstown/John P. Murtha Regional Cancer Center","city":"Johnstown","state":"Pennsylvania","zip":"15901","country":"United States","geoPoint":{"lat":40.32674,"lon":-78.92197}},{"facility":"Geisinger Medical Oncology-Lewisburg","city":"Lewisburg","state":"Pennsylvania","zip":"17837","country":"United States","geoPoint":{"lat":40.96453,"lon":-76.88441}},{"facility":"Lewistown Hospital","city":"Lewistown","state":"Pennsylvania","zip":"17044","country":"United States","geoPoint":{"lat":40.59924,"lon":-77.57138}},{"facility":"UPMC Cancer Center at UPMC McKeesport","city":"McKeesport","state":"Pennsylvania","zip":"15132","country":"United States","geoPoint":{"lat":40.34785,"lon":-79.86422}},{"facility":"UPMC-Coraopolis/Heritage Valley Radiation Oncology","city":"Moon Township","state":"Pennsylvania","zip":"15108","country":"United States","geoPoint":{"lat":40.50896,"lon":-80.23923}},{"facility":"UPMC-Magee Womens Hospital","city":"Pittsburgh","state":"Pennsylvania","zip":"15213","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"UPMC-Presbyterian Hospital","city":"Pittsburgh","state":"Pennsylvania","zip":"15213","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"UPMC-Saint Margaret","city":"Pittsburgh","state":"Pennsylvania","zip":"15215","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"University of Pittsburgh Cancer Institute (UPCI)","city":"Pittsburgh","state":"Pennsylvania","zip":"15232","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"UPMC-Shadyside Hospital","city":"Pittsburgh","state":"Pennsylvania","zip":"15232","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"UPMC-Passavant Hospital","city":"Pittsburgh","state":"Pennsylvania","zip":"15237","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"UPMC-Saint Clair Hospital Cancer Center","city":"Pittsburgh","state":"Pennsylvania","zip":"15243","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Geisinger Cancer Services-Pottsville","city":"Pottsville","state":"Pennsylvania","zip":"17901","country":"United States","geoPoint":{"lat":40.68565,"lon":-76.1955}},{"facility":"Community Medical Center","city":"Scranton","state":"Pennsylvania","zip":"18510","country":"United States","geoPoint":{"lat":41.40916,"lon":-75.6649}},{"facility":"Geisinger Medical Oncology-Selinsgrove","city":"Selinsgrove","state":"Pennsylvania","zip":"17870","country":"United States","geoPoint":{"lat":40.79897,"lon":-76.86219}},{"facility":"UPMC Cancer Center at UPMC Northwest","city":"Seneca","state":"Pennsylvania","zip":"16346","country":"United States","geoPoint":{"lat":41.37867,"lon":-79.70394}},{"facility":"Geisinger Medical Group","city":"State College","state":"Pennsylvania","zip":"16801","country":"United States","geoPoint":{"lat":40.79339,"lon":-77.86}},{"facility":"UPMC Uniontown Hospital Radiation Oncology","city":"Uniontown","state":"Pennsylvania","zip":"15401","country":"United States","geoPoint":{"lat":39.90008,"lon":-79.71643}},{"facility":"UPMC Washington Hospital Radiation Oncology","city":"Washington","state":"Pennsylvania","zip":"15301","country":"United States","geoPoint":{"lat":40.17396,"lon":-80.24617}},{"facility":"Geisinger Wyoming Valley/Henry Cancer Center","city":"Wilkes-Barre","state":"Pennsylvania","zip":"18711","country":"United States","geoPoint":{"lat":41.24591,"lon":-75.88131}},{"facility":"Women and Infants Hospital","city":"Providence","state":"Rhode Island","zip":"02905","country":"United States","geoPoint":{"lat":41.82399,"lon":-71.41283}},{"facility":"Prisma Health Cancer Institute - Laurens","city":"Clinton","state":"South Carolina","zip":"29325","country":"United States","geoPoint":{"lat":34.47263,"lon":-81.88066}},{"facility":"Prisma Health Cancer Institute - Easley","city":"Easley","state":"South Carolina","zip":"29640","country":"United States","geoPoint":{"lat":34.82984,"lon":-82.60152}},{"facility":"Prisma Health Cancer Institute - Butternut","city":"Greenville","state":"South Carolina","zip":"29605","country":"United States","geoPoint":{"lat":34.85262,"lon":-82.39401}},{"facility":"Prisma Health Cancer Institute - Faris","city":"Greenville","state":"South Carolina","zip":"29605","country":"United States","geoPoint":{"lat":34.85262,"lon":-82.39401}},{"facility":"Prisma Health Greenville Memorial Hospital","city":"Greenville","state":"South Carolina","zip":"29605","country":"United States","geoPoint":{"lat":34.85262,"lon":-82.39401}},{"facility":"Prisma Health Cancer Institute - Eastside","city":"Greenville","state":"South Carolina","zip":"29615","country":"United States","geoPoint":{"lat":34.85262,"lon":-82.39401}},{"facility":"Prisma Health Cancer Institute - Greer","city":"Greer","state":"South Carolina","zip":"29650","country":"United States","geoPoint":{"lat":34.93873,"lon":-82.22706}},{"facility":"Prisma Health Cancer Institute - Seneca","city":"Seneca","state":"South Carolina","zip":"29672","country":"United States","geoPoint":{"lat":34.68566,"lon":-82.9532}},{"facility":"Prisma Health Cancer Institute - Spartanburg","city":"Spartanburg","state":"South Carolina","zip":"29307","country":"United States","geoPoint":{"lat":34.94957,"lon":-81.93205}},{"facility":"Memorial Hospital","city":"Chattanooga","state":"Tennessee","zip":"37404","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"facility":"Vanderbilt-Ingram Cancer Center Cool Springs","city":"Franklin","state":"Tennessee","zip":"37067","country":"United States","geoPoint":{"lat":35.92506,"lon":-86.86889}},{"facility":"Pulmonary Medicine Center of Chattanooga-Hixson","city":"Hixson","state":"Tennessee","zip":"37343","country":"United States","geoPoint":{"lat":35.14063,"lon":-85.23273}},{"facility":"Vanderbilt Breast Center at One Hundred Oaks","city":"Nashville","state":"Tennessee","zip":"37204","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Vanderbilt University/Ingram Cancer Center","city":"Nashville","state":"Tennessee","zip":"37232","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Memorial GYN Plus","city":"Ooltewah","state":"Tennessee","zip":"37363","country":"United States","geoPoint":{"lat":35.07507,"lon":-85.06217}},{"facility":"Saint Joseph Regional Cancer Center","city":"Bryan","state":"Texas","zip":"77802","country":"United States","geoPoint":{"lat":30.67436,"lon":-96.36996}},{"facility":"University of Virginia Cancer Center","city":"Charlottesville","state":"Virginia","zip":"22908","country":"United States","geoPoint":{"lat":38.02931,"lon":-78.47668}},{"facility":"Harrison HealthPartners Hematology and Oncology-Bremerton","city":"Bremerton","state":"Washington","zip":"98310","country":"United States","geoPoint":{"lat":47.56732,"lon":-122.63264}},{"facility":"Harrison Medical Center","city":"Bremerton","state":"Washington","zip":"98310","country":"United States","geoPoint":{"lat":47.56732,"lon":-122.63264}},{"facility":"Highline Medical Center-Main Campus","city":"Burien","state":"Washington","zip":"98166","country":"United States","geoPoint":{"lat":47.47038,"lon":-122.34679}},{"facility":"Saint Elizabeth Hospital","city":"Enumclaw","state":"Washington","zip":"98022","country":"United States","geoPoint":{"lat":47.20427,"lon":-121.9915}},{"facility":"Saint Francis Hospital","city":"Federal Way","state":"Washington","zip":"98003","country":"United States","geoPoint":{"lat":47.32232,"lon":-122.31262}},{"facility":"Saint Clare Hospital","city":"Lakewood","state":"Washington","zip":"98499","country":"United States","geoPoint":{"lat":47.17176,"lon":-122.51846}},{"facility":"Harrison HealthPartners Hematology and Oncology-Poulsbo","city":"Poulsbo","state":"Washington","zip":"98370","country":"United States","geoPoint":{"lat":47.73593,"lon":-122.64654}},{"facility":"Fred Hutchinson Cancer Research Center","city":"Seattle","state":"Washington","zip":"98109","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Seattle Cancer Care Alliance","city":"Seattle","state":"Washington","zip":"98109","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"University of Washington Medical Center","city":"Seattle","state":"Washington","zip":"98195","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Franciscan Research Center-Northwest Medical Plaza","city":"Tacoma","state":"Washington","zip":"98405","country":"United States","geoPoint":{"lat":47.25288,"lon":-122.44429}},{"facility":"Northwest Medical Specialties PLLC","city":"Tacoma","state":"Washington","zip":"98405","country":"United States","geoPoint":{"lat":47.25288,"lon":-122.44429}},{"facility":"Cancer Center of Western Wisconsin","city":"New Richmond","state":"Wisconsin","zip":"54017","country":"United States","geoPoint":{"lat":45.12302,"lon":-92.53659}},{"facility":"Cheyenne Regional Medical Center-West","city":"Cheyenne","state":"Wyoming","zip":"82001","country":"United States","geoPoint":{"lat":41.13998,"lon":-104.82025}},{"facility":"Billings Clinic-Cody","city":"Cody","state":"Wyoming","zip":"82414","country":"United States","geoPoint":{"lat":44.52634,"lon":-109.05653}},{"facility":"Welch Cancer Center","city":"Sheridan","state":"Wyoming","zip":"82801","country":"United States","geoPoint":{"lat":44.79719,"lon":-106.95618}}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"The study was open to accrual on 8/17/2017. The first patient was enrolled on October 11, 2017. The study closed to accrual 4 months later on 2/9/2018 after 50 patients were enrolled across 13 unique sites.","groups":[{"id":"FG000","title":"Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA","description":"Patients receive medroxyprogesterone acetate IM on day 1 and undergo hysterectomy between days 21-24."},{"id":"FG001","title":"Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat","description":"Medroxyprogesterone acetate IM on day 1 and entinostat PO on days 1, 8, and 15. Followed by hysterectomy between days 21-24."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"25"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"23"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Eligible patients","groups":[{"id":"BG000","title":"Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA","description":"Patients receive medroxyprogesterone acetate IM on day 1 and undergo hysterectomy between days 21-24."},{"id":"BG001","title":"Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat","description":"Medroxyprogesterone acetate IM on day 1 and entinostat PO on days 1, 8, and 15. Followed by hysterectomy between days 21-24."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"50"}]}],"measures":[{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"30-49 years","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]}]},{"title":"50-59 years","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"14"}]}]},{"title":"60-69 years","categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"26"}]}]},{"title":"70-99 years","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"50"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"49"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"45"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Participants with Endometrioid Cell Type Cancer","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"50"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Post-treatment Tumor Progesterone Receptor H-score (Histology Score)","description":"The H-score is defined as the percent cells staining positive (0-100) multiplied by the staining intensity (0, 1, 2 or 3) measured in the tumor by immunohistochemistry and averaged over 3 reviewers. This score can range from 0 to 300. In general, PRs are expected to decrease in response to medroxyprogesterone acetate. It was hypothesized that entinostat would mitigate the decrease in PR relative to the medroxyprogesterone acetate only arm post treatment. Higher PR H-scores post treatment in the arm with entinostat relative to the medroxyprogesterone alone arm would be consistent with this hypothesis. Arm II was thought to result in higher scores which was expected to have a more favorable outcome when treated with MPA therapy.","populationDescription":"Randomized, treated, evaluable specimen. There were 2 participants in each reporting group who withdrew consent prior to treatment; no specimens were submitted for these patients. There were two additional patients with insufficient tumor post-treatment and no slides were submitted; one in each reporting group. There was one additional patient with no specimens submitted in reporting group 2.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Specimens were collected at hysterectomy on day 21-24 and analyzed in batch.","groups":[{"id":"OG000","title":"Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA","description":"Patients receive medroxyprogesterone acetate IM on day 1 and undergo hysterectomy between days 21-24."},{"id":"OG001","title":"Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat","description":"Medroxyprogesterone acetate IM on day 1 and entinostat PO on days 1, 8, and 15. Followed by hysterectomy between days 21-24."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.6","spread":"64.8"},{"groupId":"OG001","value":"42.7","spread":"49.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.87","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"SECONDARY","title":"Percentage of Participants With a Histologic Response","description":"Pre- and post-treatment slides for each patient were evaluated in pairs for complete or partial histologic response by one reviewer. Pre- and post-treatment slides for each patient were evaluated in pairs for complete or partial histologic response by one reviewer. A histologic response was defined as either the absence of identifiable adenocarcinoma in the hysterectomy specimen section (complete) or, subjectively, as the presence of a complex proliferation of glands that retain the architectural characteristics of adenocarcinoma, but with features of secretion, decreased nuclear stratification, or the presence of eosinophilic, squamous or mucinous metaplasia, when this was absent in the initial sample (partial).","populationDescription":"Randomized, treated, evaluable pre and post treatment specimen available. There were 2 participants in each reporting group who withdrew consent prior to treatment; no specimens were submitted for these patients. There was one participant with an inevaluable pre-treatment slide. There were two additional patients with insufficient tumor post-treatment and no slides were submitted; one in each reporting group. There was one additional patient with no specimens submitted in reporting group 2.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Specimens were collected at initial diagnostic biopsy and at hysterectomy on day 21-24 and analyzed in batch.","groups":[{"id":"OG000","title":"Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA","description":"Patients receive medroxyprogesterone acetate IM on day 1 and undergo hysterectomy between days 21-24."},{"id":"OG001","title":"Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat","description":"Medroxyprogesterone acetate IM on day 1 and entinostat PO on days 1, 8, and 15. Followed by hysterectomy between days 21-24."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"14"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"2.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-25","ciUpperLimit":"30"}]},{"type":"SECONDARY","title":"Percent of Participants With a Ki67 Response","description":"A response was defined as a decrease in Ki-67 protein expression in tumor from pre- to post-treatment.","populationDescription":"Randomized, treated, evaluable pre and post treatment specimens available. There were 2 participants in each reporting group who withdrew consent prior to treatment; no specimens were submitted for these patients. There was one participant with an inevaluable pre-treatment slide. There were two additional patients with insufficient tumor post-treatment and no slides were submitted; one in each reporting group. There was one additional patient with no specimens submitted in reporting group","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Specimens were collected at initial diagnostic biopsy and at hysterectomy on day 21-24 and analyzed in batch.","groups":[{"id":"OG000","title":"Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA","description":"Patients receive medroxyprogesterone acetate IM on day 1 and undergo hysterectomy between days 21-24."},{"id":"OG001","title":"Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat","description":"Medroxyprogesterone acetate IM on day 1 and entinostat PO on days 1, 8, and 15. Followed by hysterectomy between days 21-24."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"18"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"21.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-16.7","ciUpperLimit":"45.3"}]},{"type":"SECONDARY","title":"The Frequency and Severity of CTCAE Version 4.0 Graded Adverse Events (AE)","description":"Maximum grade of physician assessed adverse events reported during treatment and up to 45 days after surgery. Grades start with 1 which is considered mild through grade 5 which is death. Participants on this study had adverse event grades up to grade 3 which is considered moderately severe.","populationDescription":"Eligible and Treated Patients","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Up to 45 days after surgery","groups":[{"id":"OG000","title":"Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA","description":"Patients receive medroxyprogesterone acetate IM on day 1 and undergo hysterectomy between days 21-24."},{"id":"OG001","title":"Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat","description":"Medroxyprogesterone acetate IM on day 1 and entinostat PO on days 1, 8, and 15. Followed by hysterectomy between days 21-24."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"23"}]}],"classes":[{"title":"Grade 1 AE","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"}]}]},{"title":"Grade 2 AE","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"}]}]},{"title":"Grade 3 AE","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Grade 4 AE","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 5 AE","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Post-treatment Tumor Estrogen Receptor Score","reportingStatus":"NOT_POSTED","timeFrame":"Up to 3 years","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"Co-expression of PR, Ki67, and p21","description":"Will be compared between the arms.","reportingStatus":"NOT_POSTED","timeFrame":"Up to 3 years","denomUnitsSelected":"Participants"}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From initiation of treatment up to 45 days post-surgery","description":"There were 2 participants in each reporting group who withdrew consent prior to treatment; no specimens were submitted for these patients. No AEs were reported.","eventGroups":[{"id":"EG000","title":"Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA","description":"Patients receive medroxyprogesterone acetate IM on day 1 and undergo hysterectomy between days 21-24.","deathsNumAffected":0,"deathsNumAtRisk":23,"seriousNumAffected":1,"seriousNumAtRisk":23,"otherNumAffected":14,"otherNumAtRisk":23},{"id":"EG001","title":"Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat","description":"Medroxyprogesterone acetate IM on day 1 and entinostat PO on days 1, 8, and 15. Followed by hysterectomy between days 21-24.","deathsNumAffected":0,"deathsNumAtRisk":23,"seriousNumAffected":1,"seriousNumAtRisk":23,"otherNumAffected":16,"otherNumAtRisk":23}],"seriousEvents":[{"term":"Thromboembolic Event","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23}]},{"term":"Skin infection","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23}]}],"otherEvents":[{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":23},{"groupId":"EG001","numAffected":3,"numAtRisk":23}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":23},{"groupId":"EG001","numAffected":8,"numAtRisk":23}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":23},{"groupId":"EG001","numAffected":4,"numAtRisk":23}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":23},{"groupId":"EG001","numAffected":4,"numAtRisk":23}]},{"term":"Dry Mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":23},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":23},{"groupId":"EG001","numAffected":4,"numAtRisk":23}]},{"term":"Edema Limbs","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":23},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":23},{"groupId":"EG001","numAffected":8,"numAtRisk":23}]},{"term":"Injection Site Reaction","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":23},{"groupId":"EG001","numAffected":5,"numAtRisk":23}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":23},{"groupId":"EG001","numAffected":4,"numAtRisk":23}]},{"term":"Neutrophil Count Decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":23},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Platelet Count Decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":23},{"groupId":"EG001","numAffected":3,"numAtRisk":23}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":23},{"groupId":"EG001","numAffected":3,"numAtRisk":23}]},{"term":"Hypocalcemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":23},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":23},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":23},{"groupId":"EG001","numAffected":3,"numAtRisk":23}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":23},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":23},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":23},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Urinary Incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":23},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Pelvic Pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":23},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Vaginal Discharge","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":23},{"groupId":"EG001","numAffected":4,"numAtRisk":23}]},{"term":"Vaginal Hemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":23},{"groupId":"EG001","numAffected":4,"numAtRisk":23}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":23},{"groupId":"EG001","numAffected":5,"numAtRisk":23}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":23},{"groupId":"EG001","numAffected":5,"numAtRisk":23}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":23},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":23},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"pointOfContact":{"title":"Linda Gedeon for Virginia Filiaci, PhD","organization":"NRG Oncology","email":"linda.gedeon@roswellpark.org","phone":"716-845-1169"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2018-11-20","uploadDate":"2020-12-08T10:03","filename":"Prot_SAP_000.pdf","size":1059471}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"interventionBrowseModule":{"meshes":[{"id":"C118739","term":"entinostat"},{"id":"D007044","term":"Hysterectomy"},{"id":"D017258","term":"Medroxyprogesterone Acetate"}],"ancestors":[{"id":"D013509","term":"Gynecologic Surgical Procedures"},{"id":"D013519","term":"Urogenital Surgical Procedures"},{"id":"D013514","term":"Surgical Procedures, Operative"},{"id":"D008525","term":"Medroxyprogesterone"},{"id":"D006908","term":"Hydroxyprogesterones"},{"id":"D011374","term":"Progesterone"},{"id":"D011282","term":"Pregnenediones"},{"id":"D011283","term":"Pregnenes"},{"id":"D011278","term":"Pregnanes"},{"id":"D013256","term":"Steroids"},{"id":"D000072473","term":"Fused-Ring Compounds"},{"id":"D011083","term":"Polycyclic Compounds"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT03382574","orgStudyIdInfo":{"id":"NCI-2017-02314"},"secondaryIdInfos":[{"id":"NCI-2017-02314","type":"REGISTRY","domain":"CTRP (Clinical Trial Reporting Program)"},{"id":"AAAR6281"},{"id":"N01-CN-2012-00034"},{"id":"AAAR6281","type":"OTHER","domain":"M D Anderson Cancer Center"},{"id":"MDA2017-09-03","type":"OTHER","domain":"DCP"},{"id":"N01CN00034","type":"NIH","link":"https://reporter.nih.gov/quickSearch/N01CN00034"},{"id":"P30CA016672","type":"NIH","link":"https://reporter.nih.gov/quickSearch/P30CA016672"},{"id":"2018-0478","type":"OTHER","domain":"MD Anderson Cancer Center ID"}],"organization":{"fullName":"National Cancer Institute (NCI)","class":"NIH"},"briefTitle":"Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy","officialTitle":"Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy"},"statusModule":{"statusVerifiedDate":"2022-05","overallStatus":"TERMINATED","whyStopped":"it was decided that due to lack of accrual on the trial, and low potential for accruing over the near future, the trial will be shut down.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-03-14","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-10-22","type":"ACTUAL"},"completionDateStruct":{"date":"2021-10-22","type":"ACTUAL"},"studyFirstSubmitDate":"2017-12-22","studyFirstSubmitQcDate":"2017-12-22","studyFirstPostDateStruct":{"date":"2017-12-26","type":"ACTUAL"},"resultsFirstSubmitDate":"2022-05-23","resultsFirstSubmitQcDate":"2022-05-23","resultsFirstPostDateStruct":{"date":"2022-06-14","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-05-23","lastUpdatePostDateStruct":{"date":"2022-06-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"National Cancer Institute (NCI)","class":"NIH"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This randomized pilot early phase I trial studies how well denosumab works in BRCA1/2 mutations carriers scheduled for risk-reducing salpingo-oophorectomy. Denosumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.","detailedDescription":"PRIMARY OBJECTIVE:\n\nI. To compare the effect of denosumab 120 mg subcutaneously every 4 weeks for 1-2 doses to no treatment in the pre-surgical setting on Ki67 proliferation index by immunohistochemistry (IHC) in the fimbrial end of the fallopian tube of premenopausal BRCA1/2 mutation carriers undergoing risk-reducing salpingo-oophorectomy, with or without hysterectomy.\n\nSECONDARY OBJECTIVES:\n\nI. To assess Ki67 proliferation index by immunohistochemistry (IHC) in ovarian surface epithelium and endometrium (if also undergoing a hysterectomy, \\~20% of participants) after exposure to denosumab compared to no treatment.\n\nII. To investigate other tissue-based biomarkers in the fimbrial end of the fallopian tube, ovarian surface epithelium, and endometrium (if also undergoing hysterectomy) after exposure to denosumab compared to no treatment, including:\n\nIIa. Apoptosis with cleaved caspase-3 by IHC. IIb. Receptor activator of NF-KB (RANK) and RANK ligand (RANKL) expression by IHC.\n\nIIc. Estrogen receptor (ER) and progesterone receptor (PR) expression by IHC. IId. CD44 and p53 expression by IHC. IIe. Signal transducer and activator of transcription 3 (STAT3) and phosphorylated-STAT3 (pSTAT3) expression by IHC.\n\nIII. To analyze gene expression profiling in the fimbrial end of the fallopian tube and ovarian surface epithelium after exposure to denosumab compared to no treatment.\n\nIV. To investigate serum biomarkers at baseline (pre-treatment) and time of surgery (post-treatment) with denosumab compared to no treatment, including:\n\nIVa. Progesterone. IVb. Estradiol. IVc. Denosumab drug levels. V. To investigate serial serum C-terminal telopeptide (CTX) levels from baseline (pre-treatment) to time of surgery to 9 months and 12 months after start of intervention with denosumab compared to no treatment.\n\nVI. To monitor safety and adverse effects of denosumab compared to no treatment.\n\nOUTLINE: Patients are randomized 1 of 2 arms.\n\nARM I: Beginning within 3 days of menstrual cycle, patients receive denosumab subcutaneously (SC) every 4 weeks for 1-2 doses and undergo risk-reducing salpingo-oophorectomy 14-28 days after last dose.\n\nARM II: Patients receive no treatment for 2-8 weeks and then undergo risk-reducing salpingo-oophorectomy.\n\nAfter completion of study treatment, patients are followed up at 6, 9, and 12 months."},"conditionsModule":{"conditions":["Ovarian Carcinoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":2,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm I (denosumab, risk-reducing salpingo-oophorectomy)","type":"EXPERIMENTAL","description":"Beginning within 3 days of menstrual cycle, patients receive denosumab SC every 4 weeks for 1-2 doses and undergo risk-reducing salpingo-oophorectomy 14-28 days after last dose.","interventionNames":["Biological: Denosumab","Procedure: Salpingo-Oophorectomy"]},{"label":"Arm II (risk-reducing salpingo-oophorectomy)","type":"ACTIVE_COMPARATOR","description":"Patients receive no treatment for 2-8 weeks and then undergo risk-reducing salpingo-oophorectomy.","interventionNames":["Procedure: Salpingo-Oophorectomy"]}],"interventions":[{"type":"BIOLOGICAL","name":"Denosumab","description":"Given SC","armGroupLabels":["Arm I (denosumab, risk-reducing salpingo-oophorectomy)"],"otherNames":["AMG 162","AMG-162","Denosumab Biosimilar MW032","Denosumab Biosimilar QL1206","Denosumab Biosimilar TK-006","Prolia","TK-006","Xgeva"]},{"type":"PROCEDURE","name":"Salpingo-Oophorectomy","description":"Undergo risk-reducing salpingo-oophorectomy","armGroupLabels":["Arm I (denosumab, risk-reducing salpingo-oophorectomy)","Arm II (risk-reducing salpingo-oophorectomy)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Ki67 Proliferation Index Fallopian Tube Fimbrial Epithelial Cells","description":"Will be assessed using immunohistochemistry (IHC). Quantitative measures of the expression of Ki67 based upon percentage of positive cells will be scored by a pathologist blinded to treatment assignment. In order to evaluate the difference of Ki67 expression between the two arms, 2-sample t-test will be considered.","timeFrame":"Up to 12 months"}],"secondaryOutcomes":[{"measure":"Ki67 Proliferation Index in Ovarian Surface Epithelium and Endometrium","description":"Will be assessed using IHC. In order to evaluate the difference of Ki67 expression between the two arms, 2-sample t-test will be considered.","timeFrame":"Up to 12 months"},{"measure":"Other Tissue-based Biomarkers in the Fimbrial End of the Fallopian Tube, Ovarian Surface Epithelium, and Endometrium","description":"Will be assessed using IHC. Including: apoptosis with cleaved caspase-3 (IHC), RANK/RANKL (IHC), estrogen receptor (ER)/progesterone receptor (PR) (IHC), CD44 and p53 (IHC), and STAT3 and pSTAT3 (IHC). Values of tissue-based biomarkers measurements such as tissue Ki67 proliferation index, serum progesterone, etc., which are continuous variables, will be summarized by descriptive statistics including mean, standard deviation, median and range. For tissue biomarkers, linear regression models will be employed to investigate the association of treatment while adjusting for possible confounders (i.e., age, race, etc.). Normality, homoscedasticity, independence of errors, and lack of multicollinearity in the covariates will be evaluated; if needed, proper transformation will be considered.","timeFrame":"Up to 12 months"},{"measure":"Gene Expression Profiling of RANK, Cell Proliferation, Cell Cycle Progression, and Inflammation Pathways","description":"For gene expression profiling analysis, nSolver Analysis Software (nanoString Technologies, Washington \\[WA\\]) will be used. Geometric mean is used for calculation of normalization factors. Student's t test is used to calculate differential expression.","timeFrame":"Up to 12 months"},{"measure":"Serum Biomarkers Including Progesterone, Estradiol, and Denosumab Drug Levels","description":"Values of serum biomarkers measurements such as tissue Ki67 proliferation index, serum progesterone, etc., which are continuous variables, will be summarized by descriptive statistics including mean, standard deviation, median and range.","timeFrame":"Up to time of surgery"},{"measure":"Change in Serial Serum C-terminal Telopeptide Levels","description":"2-sample t-test may be applied to evaluate any change in serum biomarkers from baseline to after intervention. To investigate the overall changes in serum biomarkers, a linear mixed model that accommodates intra-participant correlation due to repeated measurements will be utilized adjusting for any potential covariates.","timeFrame":"Baseline up to 12 months after start of intervention"},{"measure":"Toxicity Profile and Frequency of Adverse Effects in Premenopausal BRCA1/2 Mutation Carriers","description":"Categorical variables, such as adverse events, will be summarized by frequency and proportion.","timeFrame":"Up to 12 months after start of treatment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants must be premenopausal (defined as \\< 3 months since last menstrual period OR serum follicle-stimulating hormone \\[FSH\\] \\< 20 mIU/mL)\n* Documented germline pathogenic or likely pathogenic variant in the BRCA1 or BRCA2 genes\n* Participants must be scheduled for or in the process of scheduling a risk-reducing salpingo-oophorectomy with or without hysterectomy - either bilateral or unilateral (if prior unilateral oophorectomy or salpingectomy for benign condition)\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\< 1 (Karnofsky \\>= 70%)\n* Leukocytes \\>= 3,000/microliter\n* Absolute neutrophil count \\>= 1,500/microliter\n* Platelets \\>= 100,000/microliter\n* Total bilirubin =\\< 2 x institutional upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\])) =\\< 1.5 x institutional ULN\n* Creatinine clearance \\>= 30 mL/min\n* Serum calcium or albumin adjusted \\>= 8.0 mg/dL and =\\< 11.5 mg/dL\n* Participant must have a negative urine or serum pregnancy test 14 days prior to randomization or drug administration; the effects of denosumab on the developing human fetus at the recommended therapeutic dose may cause fetal harm when administered to pregnant women; women of childbearing potential must agree to use adequate contraception from time of drug administration to time of surgery; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately\n* Women currently on hormonal contraception (i.e., oral contraceptives, Mirena intrauterine device \\[IUD\\]) are eligible to participate if they have been on a stable dose for at least 3 months; women who have undergone bilateral tubal ligation are also eligible to participate in this study; there will be stratification for hormonal contraceptive use within 3 months prior to registration\n* Participants must be willing to take supplemental oral calcium 1000 mg (two 500 mg tablets) and vitamin D3 1000 IU daily for six months (which will be supplied by the research study) after receiving denosumab treatment or no treatment\n* Ability to understand and the willingness to sign a written informed consent document in English or Spanish or Hebrew\n* Participants must have a dental examination =\\< 6 months of study registration\n* Willing to not undergo any other elective surgery procedure with general anesthesia or conscious sedation during the treatment period; the treatment period is completed after the last injection of denosumab is administered\n\nExclusion Criteria:\n\n* History of ovarian cancer; history of breast cancer or any other malignancy is permitted if last chemotherapy treatment was greater than 6 months prior to registration and participant is not using endocrine therapy\n* Previous treatment with denosumab (including Prolia for osteoporosis or Xgeva for bone metastases) or use of bisphosphonate within 3 months of registration to the study\n* Participants receiving any other investigational agents\n* History of allergic reactions or hypersensitivity attributed to denosumab or any components of denosumab or compounds of similar chemical or biologic composition to denosumab, such as other RANKL inhibitors\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Pregnant and breastfeeding women are excluded from this study because denosumab is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with denosumab, breastfeeding should be discontinued if the mother is treated with denosumab; there is no minimum amount of time since pregnancy/breastfeeding required before enrolling into the study; however, the date of delivery, pregnancy termination, or weaning from breastfeeding will be documented on case report forms; female subjects of child bearing potential and not willing to use, in combination with her partner, highly effective contraception during treatment will be excluded\n* Use of endocrine therapy (selective estrogen receptor modulator, aromatase inhibitor, gonadotrophin releasing hormone \\[GnRH\\] agonist) within 6 months of registration to the study\n* Prior history or current evidence of osteonecrosis or osteomyelitis of the jaw, evidence of untreated local gum or oral infection, or non-healed dental or oral surgery\n* Active dental or jaw conditions which require oral surgery/dental procedures, including tooth extraction within 6 months of registration to the study; dental fillings are permitted within 6 months of study registration\n* Other risk factors for the development of osteonecrosis of the jaw (ONJ) including poor oral hygiene, use of a dental appliance, immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, or gingival infections\n* Known sensitivity to any of the products to be administered during the study (e.g., calcium or vitamin D)\n* Known serious infections, including a history of active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV); screening for these infections is not required for study enrollment\n* Hypocalcemia (serum calcium or albumin adjusted calcium \\< 8.0 mg/dL) or renal dysfunction (creatinine clearance \\< 30 mL/min)\n* Women with known osteoporosis or history of osteoporotic (fragility) fracture of the spine","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Powel Brown","affiliation":"M.D. Anderson Cancer Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Dana-Farber Cancer Institute","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"NYP/Weill Cornell Medical Center","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"M D Anderson Cancer Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Tel Aviv Sourasky Medical Center","city":"Tel Aviv","zip":"64239","country":"Israel","geoPoint":{"lat":32.08088,"lon":34.78057}},{"facility":"Chaim Sheba Medical Center","city":"Tel Litwinsky","zip":"52621","country":"Israel","geoPoint":{"lat":32.05096,"lon":34.84588}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page","url":"https://grants.nih.gov/policy/sharing.htm"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"2 participants consented at Tel Aviv Sourasky Medical Center, no participants randomized nor received trial intervention (Participant 1 was deemed ineligible due to elevated FSH level and Participant 2 did not start intervention due to COVID-19 lockdown restrictions).","recruitmentDetails":"This multicenter protocol will be conducted at the following five sites: Columbia University Irving Medical Center (CUIMC), New York, NY; Weill-Cornell Medical Center, New York, NY; the Dana Farber Cancer Institute (DFCI), Boston, MA; and Tel Aviv Sourasky Medical Center and Chaim Sheba Medical Center, Tel Aviv, Israel.","groups":[{"id":"FG000","title":"Arm I (Denosumab, Risk-reducing Salpingo-oophorectomy)/Arm II (Risk-reducing Salpingo-oophorectomy)","description":"Beginning within 3 days of menstrual cycle, patients receive denosumab SC every 4 weeks for 1-2 doses and undergo risk-reducing salpingo-oophorectomy 14-28 days after last dose.\n\nDenosumab: Given SC\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy\n\nArm II Patients receive no treatment for 2-8 weeks and then undergo risk-reducing salpingo-oophorectomy.\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"2 participants consented at Tel Aviv Sourasky Medical Center, no participants randomized nor received trial intervention combined arms due to the participants were not randomized.","groups":[{"id":"BG000","title":"Arm I (Denosumab, Risk-reducing Salpingo-oophorectomy)/ Arm II (Risk-reducing Salpingo-oophorectomy)","description":"Beginning within 3 days of menstrual cycle, patients receive denosumab SC every 4 weeks for 1-2 doses and undergo risk-reducing salpingo-oophorectomy 14-28 days after last dose.\n\nDenosumab: Given SC\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy\n\nArm II Patients receive no treatment for 2-8 weeks and then undergo risk-reducing salpingo-oophorectomy.\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"0"}]}],"measures":[{"title":"Age, Categorical","classes":[{"categories":[{"title":"<=18 years"},{"title":"Between 18 and 65 years"},{"title":">=65 years"}]}]},{"title":"Sex: Female, Male","classes":[{"categories":[{"title":"Female"},{"title":"Male"}]}]},{"title":"Race and Ethnicity Not Collected","populationDescription":"Race and Ethnicity were not collected from any participant."},{"title":"Region of Enrollment","unitOfMeasure":"participants","classes":[{"title":"Israel"}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Ki67 Proliferation Index Fallopian Tube Fimbrial Epithelial Cells","description":"Will be assessed using immunohistochemistry (IHC). Quantitative measures of the expression of Ki67 based upon percentage of positive cells will be scored by a pathologist blinded to treatment assignment. In order to evaluate the difference of Ki67 expression between the two arms, 2-sample t-test will be considered.","populationDescription":"No participants were randomized, therefore no data collected.","reportingStatus":"POSTED","timeFrame":"Up to 12 months","groups":[{"id":"OG000","title":"Arm I (Denosumab, Risk-reducing Salpingo-oophorectomy)","description":"Beginning within 3 days of menstrual cycle, patients receive denosumab SC every 4 weeks for 1-2 doses and undergo risk-reducing salpingo-oophorectomy 14-28 days after last dose.\n\nDenosumab: Given SC\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy"},{"id":"OG001","title":"Arm II (Risk-reducing Salpingo-oophorectomy)","description":"Patients receive no treatment for 2-8 weeks and then undergo risk-reducing salpingo-oophorectomy.\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Ki67 Proliferation Index in Ovarian Surface Epithelium and Endometrium","description":"Will be assessed using IHC. In order to evaluate the difference of Ki67 expression between the two arms, 2-sample t-test will be considered.","populationDescription":"No participants were randomized, therefore no data collected.","reportingStatus":"POSTED","timeFrame":"Up to 12 months","groups":[{"id":"OG000","title":"Arm I (Denosumab, Risk-reducing Salpingo-oophorectomy)","description":"Beginning within 3 days of menstrual cycle, patients receive denosumab SC every 4 weeks for 1-2 doses and undergo risk-reducing salpingo-oophorectomy 14-28 days after last dose.\n\nDenosumab: Given SC\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy"},{"id":"OG001","title":"Arm II (Risk-reducing Salpingo-oophorectomy)","description":"Patients receive no treatment for 2-8 weeks and then undergo risk-reducing salpingo-oophorectomy.\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Other Tissue-based Biomarkers in the Fimbrial End of the Fallopian Tube, Ovarian Surface Epithelium, and Endometrium","description":"Will be assessed using IHC. Including: apoptosis with cleaved caspase-3 (IHC), RANK/RANKL (IHC), estrogen receptor (ER)/progesterone receptor (PR) (IHC), CD44 and p53 (IHC), and STAT3 and pSTAT3 (IHC). Values of tissue-based biomarkers measurements such as tissue Ki67 proliferation index, serum progesterone, etc., which are continuous variables, will be summarized by descriptive statistics including mean, standard deviation, median and range. For tissue biomarkers, linear regression models will be employed to investigate the association of treatment while adjusting for possible confounders (i.e., age, race, etc.). Normality, homoscedasticity, independence of errors, and lack of multicollinearity in the covariates will be evaluated; if needed, proper transformation will be considered.","populationDescription":"No participants were randomized, therefore no data collected.","reportingStatus":"POSTED","timeFrame":"Up to 12 months","groups":[{"id":"OG000","title":"Arm I (Denosumab, Risk-reducing Salpingo-oophorectomy)","description":"Beginning within 3 days of menstrual cycle, patients receive denosumab SC every 4 weeks for 1-2 doses and undergo risk-reducing salpingo-oophorectomy 14-28 days after last dose.\n\nDenosumab: Given SC\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy"},{"id":"OG001","title":"Arm II (Risk-reducing Salpingo-oophorectomy)","description":"Patients receive no treatment for 2-8 weeks and then undergo risk-reducing salpingo-oophorectomy.\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Gene Expression Profiling of RANK, Cell Proliferation, Cell Cycle Progression, and Inflammation Pathways","description":"For gene expression profiling analysis, nSolver Analysis Software (nanoString Technologies, Washington \\[WA\\]) will be used. Geometric mean is used for calculation of normalization factors. Student's t test is used to calculate differential expression.","populationDescription":"No participants were randomized, therefore no data collected.","reportingStatus":"POSTED","timeFrame":"Up to 12 months","groups":[{"id":"OG000","title":"Arm I (Denosumab, Risk-reducing Salpingo-oophorectomy)","description":"Beginning within 3 days of menstrual cycle, patients receive denosumab SC every 4 weeks for 1-2 doses and undergo risk-reducing salpingo-oophorectomy 14-28 days after last dose.\n\nDenosumab: Given SC\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy"},{"id":"OG001","title":"Arm II (Risk-reducing Salpingo-oophorectomy)","description":"Patients receive no treatment for 2-8 weeks and then undergo risk-reducing salpingo-oophorectomy.\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Serum Biomarkers Including Progesterone, Estradiol, and Denosumab Drug Levels","description":"Values of serum biomarkers measurements such as tissue Ki67 proliferation index, serum progesterone, etc., which are continuous variables, will be summarized by descriptive statistics including mean, standard deviation, median and range.","populationDescription":"No participants were randomized, therefore no data collected.","reportingStatus":"POSTED","timeFrame":"Up to time of surgery","groups":[{"id":"OG000","title":"Arm I (Denosumab, Risk-reducing Salpingo-oophorectomy)","description":"Beginning within 3 days of menstrual cycle, patients receive denosumab SC every 4 weeks for 1-2 doses and undergo risk-reducing salpingo-oophorectomy 14-28 days after last dose.\n\nDenosumab: Given SC\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy"},{"id":"OG001","title":"Arm II (Risk-reducing Salpingo-oophorectomy)","description":"Patients receive no treatment for 2-8 weeks and then undergo risk-reducing salpingo-oophorectomy.\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Change in Serial Serum C-terminal Telopeptide Levels","description":"2-sample t-test may be applied to evaluate any change in serum biomarkers from baseline to after intervention. To investigate the overall changes in serum biomarkers, a linear mixed model that accommodates intra-participant correlation due to repeated measurements will be utilized adjusting for any potential covariates.","populationDescription":"No participants were randomized, therefore no data collected.","reportingStatus":"POSTED","timeFrame":"Baseline up to 12 months after start of intervention","groups":[{"id":"OG000","title":"Arm I (Denosumab, Risk-reducing Salpingo-oophorectomy)","description":"Beginning within 3 days of menstrual cycle, patients receive denosumab SC every 4 weeks for 1-2 doses and undergo risk-reducing salpingo-oophorectomy 14-28 days after last dose.\n\nDenosumab: Given SC\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy"},{"id":"OG001","title":"Arm II (Risk-reducing Salpingo-oophorectomy)","description":"Patients receive no treatment for 2-8 weeks and then undergo risk-reducing salpingo-oophorectomy.\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Toxicity Profile and Frequency of Adverse Effects in Premenopausal BRCA1/2 Mutation Carriers","description":"Categorical variables, such as adverse events, will be summarized by frequency and proportion.","populationDescription":"No participants were randomized, therefore no data collected.","reportingStatus":"POSTED","timeFrame":"Up to 12 months after start of treatment","groups":[{"id":"OG000","title":"Arm I (Denosumab, Risk-reducing Salpingo-oophorectomy)","description":"Beginning within 3 days of menstrual cycle, patients receive denosumab SC every 4 weeks for 1-2 doses and undergo risk-reducing salpingo-oophorectomy 14-28 days after last dose.\n\nDenosumab: Given SC\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy"},{"id":"OG001","title":"Arm II (Risk-reducing Salpingo-oophorectomy)","description":"Patients receive no treatment for 2-8 weeks and then undergo risk-reducing salpingo-oophorectomy.\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"1","timeFrame":"at baseline","description":"There were no adverse events because neither consented participant were randomized, so they never received trial intervention.","eventGroups":[{"id":"EG000","title":"Arm I (Denosumab, Risk-reducing Salpingo-oophorectomy)","description":"Beginning within 3 days of menstrual cycle, patients receive denosumab SC every 4 weeks for 1-2 doses and undergo risk-reducing salpingo-oophorectomy 14-28 days after last dose.\n\nDenosumab: Given SC\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy","deathsNumAffected":0,"deathsNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"otherNumAffected":0,"otherNumAtRisk":0},{"id":"EG001","title":"Arm II (Risk-reducing Salpingo-oophorectomy)","description":"Patients receive no treatment for 2-8 weeks and then undergo risk-reducing salpingo-oophorectomy.\n\nSalpingo-Oophorectomy: Undergo risk-reducing salpingo-oophorectomy","deathsNumAffected":0,"deathsNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"otherNumAffected":0,"otherNumAtRisk":0}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Dr. Powel Brown, Chair, Clinical Cancer Prevention","organization":"UT MD Anderson Cancer Center","email":"phbrown@mdanderson.org","phone":"(713) 745-3672"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2020-07-24","uploadDate":"2022-01-11T12:48","filename":"Prot_SAP_000.pdf","size":1658916}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D010051","term":"Ovarian Neoplasms"}],"ancestors":[{"id":"D004701","term":"Endocrine Gland Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D010049","term":"Ovarian Diseases"},{"id":"D000291","term":"Adnexal Diseases"},{"id":"D005831","term":"Genital Diseases, Female"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D005833","term":"Genital Neoplasms, Female"},{"id":"D014565","term":"Urogenital Neoplasms"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D006058","term":"Gonadal Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069448","term":"Denosumab"},{"id":"C000729682","term":"QL1206"},{"id":"D000074868","term":"Salpingo-oophorectomy"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D010052","term":"Ovariectomy"},{"id":"D002369","term":"Castration"},{"id":"D013507","term":"Endocrine Surgical Procedures"},{"id":"D013514","term":"Surgical Procedures, Operative"},{"id":"D013519","term":"Urogenital Surgical Procedures"},{"id":"D013509","term":"Gynecologic Surgical Procedures"},{"id":"D058994","term":"Salpingectomy"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT04890236","orgStudyIdInfo":{"id":"STUDY00001001"},"secondaryIdInfos":[{"id":"NCI-2020-06380","type":"REGISTRY","domain":"CTRP (Clinical Trial Reporting Program)"},{"id":"Winship5085-20","type":"OTHER","domain":"Emory University"},{"id":"P30CA138292","type":"NIH","link":"https://reporter.nih.gov/quickSearch/P30CA138292"}],"organization":{"fullName":"Emory University","class":"OTHER"},"briefTitle":"Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study","officialTitle":"Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Diffuse Large B Cell Lymphoma (DEEP T CELLS)"},"statusModule":{"statusVerifiedDate":"2025-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-01-13","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-03-20","type":"ACTUAL"},"completionDateStruct":{"date":"2024-09-04","type":"ACTUAL"},"studyFirstSubmitDate":"2021-05-13","studyFirstSubmitQcDate":"2021-05-13","studyFirstPostDateStruct":{"date":"2021-05-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-01-16","lastUpdatePostDateStruct":{"date":"2025-01-20","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Edmund Waller","investigatorTitle":"Principal Investigator","investigatorAffiliation":"Emory University"},"leadSponsor":{"name":"Emory University","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"},{"name":"Secura Bio, Inc.","class":"INDUSTRY"},{"name":"Novartis","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This early phase I trial investigates how well duvelisib exposure before CAR-T cell manufacturing works to enhance immune profiles of T cells in patients with diffuse large B-cell lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Duvelisib, an oral phosphoinositide 3-kinase (PI3K) inhibitor, may favorably change a patient's T cells to make them more efficient and have a longer duration for manufacturing of CAR-T cells.","detailedDescription":"PRIMARY OBJECTIVE:\n\nI. To assess the increase in CD27+/CD28+ T cells, after 8 to 15 day exposure duvelisib prior to collection of mononuclear cells for chimeric antigen receptor T-cell (CART cell) manufacturing.\n\nSECONDARY OBJECTIVES:\n\nI. To evaluate patient compliance with duvelisib. II. To evaluate the time required for manufacturing CAR-T using mononuclear cells from duvelisib-treated patients.\n\nIII. To describe the frequencies of CD27/28 double positive T cells and CD4/8 double negative T cells.\n\nIV. To evaluate expansion and persistence of CAR-T cells V. To evaluate overall response rates following CAR-T cell therapy VI.To evaluate survival rates following CAR-T cell therapy VII. To describe the frequency of CRS and neurotoxicity requiring ICU transfer (for CRS or neurotoxicity) and/or treatment VIII. Describe the safety and tolerability profile of duvelisib\n\nOUTLINE:\n\nPatients receive duvelisib orally (PO) twice daily (BID) for 2 weeks prior to collection of CAR-T cells in the absence of disease progression or unacceptable toxicity. Patients then receive tisagenlecleucel via infusion.\n\nPatients are followed up 100 days after CAR-T infusion."},"conditionsModule":{"conditions":["Recurrent Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":4,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment (duvelisib)","type":"EXPERIMENTAL","description":"Patients receive duvelisib PO BID for 2 weeks prior to collection of CAR-T cells in the absence of disease progression or unacceptable toxicity. Patients then receive tisagenlecleucel via infusion.","interventionNames":["Drug: Duvelisib","Biological: Tisagenlecleucel"]}],"interventions":[{"type":"DRUG","name":"Duvelisib","description":"Given PO","armGroupLabels":["Treatment (duvelisib)"],"otherNames":["8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one","Copiktra","INK-1197","IPI-145"]},{"type":"BIOLOGICAL","name":"Tisagenlecleucel","description":"Given via infusion","armGroupLabels":["Treatment (duvelisib)"],"otherNames":["CART-19","CART19","CTL019","CTL019 T-cells","Kymriah","Tisagenlecleucel-T"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Fold-change increase in CD27/CD28 double positive T cells","description":"Will estimate fold-change increase in CD27/CD28 double positive T cells following in vivo exposure to duvelisib using multiparametric flow cytometry.","timeFrame":"From Baseline up to day 15"}],"secondaryOutcomes":[{"measure":"Proportion of patients that completed at least 75% of duvelisib doses","description":"Descriptive statistics will be used to calculate the proportion of patients that completed at least 75% of duvelisib doses as documented by the patient pill diaries. The proportion along with an exact 95% confidence interval will be reported.","timeFrame":"Up to day 15"},{"measure":"Manufacturing time of CAR-T 19 cells","description":"Descriptive statistics will be used to calculate the median manufacturing time from the 10 patients that completed at least 75% of duvelisib doses. The median will be reported along with the minimum and maximum manufacturing times.","timeFrame":"Up to day 15"},{"measure":"Change in proportion of CD27/28 double positive T cells and CD4/8 double negative T cells","description":"A Wilcoxon signed-rank test will evaluate the change in proportion of CD27+/CD28+ and CD4-/CD8- T cells using multiparametric flow cytometry.","timeFrame":"At baseline and at day 15"},{"measure":"Overall response rate (ORR)","description":"The ORR (complete response or partial response) will be summarized along with an exact 95% confidence interval. Disease response will be based on the Response Evaluation Criteria in Solid Tumors criteria (version 1.1).","timeFrame":"At 3 months following CAR-T cell infusion"},{"measure":"Frequency of intensive care unit (ICU) transfers due to cytokine release syndrome (CRS) and/or neurotoxicity","description":"Descriptive statistics will be used to calculate the frequency of ICU transfers due to CRS and/or neurotoxicity. Descriptive statistics will also be used to calculate the frequency of administration of tocilizumab and/or corticosteroids use for CRS and/or neurotoxicity.","timeFrame":"Up to day 90 post CAR-T cell infusion"},{"measure":"Incidence of grade III-IV adverse events","description":"Grade III-IV toxicities (as defined by Common Terminology Criteria for Adverse Events version 5.0) during duvelisib administration or for two weeks after the last dose of duvelisib.","timeFrame":"Up to 2 weeks after last dose of duvelisib"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must have a biopsy proven diagnosis of relapsed/refractory diffuse large B-cell lymphoma (DLBCL)\n* Eastern Cooperative Oncology Group (ECOG) \\< 2\n* Serum creatinine (Cr) \\< 2.0 mg/dL\n* Alanine aminotransferase (AST)/aspartate aminotransferase (ALT) \\< 2 x upper limit of normal (ULN)\n* Total bilirubin \\< 2.0 mg/dL\n* Hemoglobin \\> 8 g/dL\n* Platelet count \\> 50 K/mcl\n* An absolute neutrophil count (ANC) \\> 1,000/mm\\^3\n* An absolute lymphocyte count (ALC) \\> 300/mm\\^3\n* Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or investigational therapy) for the treatment of their DLBCL \\>= 2 weeks before the start of duvelisib. There is no limit on how many previous lines of treatment a patient may have received\n* The effects of duvelisib on the developing human fetus are unknown. For this reason, women of child-bearing potential (WOCBP) must have a negative serum or urine pregnancy test prior to starting therapy. WOCBP and men must agree to use highly effective contraception (hormonal or barrier method of birth control; abstinence) from enrollment into this study until at least 12 months after tisagenlecleucel infusion and until CAR-T cells are no longer present by quantitative polymerase chain reaction (qPCR) on two consecutive tests (qPCR tests will be available upon request). A woman of childbearing potential (WOCBP) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use highly effective contraception prior to the study, for the duration of study participation, and 3 months after completion of duvelisib administration. WOCBP must have a negative pregnancy test within 24 hours of leukapheresis, lymphodepletion (if performed) and tisagenlecleucel infusion (if lymphodepletion not performed)\n* The patient must be willing to comply with fertility requirements as below:\n* Total abstinence (when this is in line with the usual practice and lifestyle of the patient). Periodic abstinence (i.e, calendar, ovulation, post-ovulation methods) and withdrawals are not acceptable forms of contraception\n* Female sterilization (have had surgical bilateral oophorectomy with or without a hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone assessment\n* Male sterilization (at least 6 months prior to screening). For female patients on the study, the vasectomized male partner should be the sole partner\n* Use of oral (estrogen and progesterone), injected or implanted hormonal methods of contraception, or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of contraception that comparable efficacy (failure rate \\< 1%). In case of oral contraception, the woman should be stable on the same pill for a minimum of 3 months prior to enrollment on the study\n* Sexually active males must use a condom during intercourse from enrollment into this study until at least 12 months after tisagenlecleucel infusion and until CAR-T cells are no longer present by qPCR on two consecutive tests (qPCR tests will be available upon request). A condom is required of all sexually active male patients to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to their partner\n* Female patients must be either postmenopausal, free from menses \\>= 2 years (yrs), surgically sterilized, willing to use two adequate barrier methods of contraception to prevent pregnancy or agree to abstain from heterosexual activity starting with screening and for 5 months after last treatment in all patients\n* Patients must agree not to donate blood, sperm/ova or any other organs while taking protocol therapy and for at least 12 months after stopping treatment\n* Willingness and ability of the patient to comply with scheduled visits, drug administration plan, protocol specified laboratory tests, other study procedures and study restrictions\n* Evidence of personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed on the procedures to be followed, the experimental nature of the therapy, alternative, potential risks and discomforts, potential benefits and other pertinent aspects of study participation\n\nExclusion Criteria:\n\n* Primary central nervous system lymphoma\n* Patients with central nervous system (CNS) involvement of lymphoma\n* History of autoimmune disease, including but not limited to:\n\n  * Inflammatory bowel diseases (Crohn's disease, ulcerative colitis, celiac disease)\n  * Systemic lupus erythematosus\n  * Grave's disease\n  * Myasthenia gravis\n  * Rheumatoid arthritis\n  * Wegner's syndrome\n* Patients with history of drug reaction and eosinophilia systemic syndrome (DRESS) or toxic epidermal necrolysis (TEN)\n* History of human immunodeficiency virus (HIV), active Hepatitis C Infection or active Hepatitis B infection as defined by:\n\n  * Patients with a positive hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV Ab) will be excluded\n  * Patients with a positive hepatitis B core antibody (HBcAb) must have negative hepatitis B virus (HBV) deoxyribonucleic acid (DNA) to be eligible and must be periodically monitored for HBV reactivation by institutional guidelines\n* Patients with known active cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection (i.e., subjects with detectable viral load)\n* Patients with ongoing treatment for systemic bacterial, fungal or viral infection\n* Patients with history of immune or drug mediated colitis, hepatitis or pneumonitis\n* Patients with previous treatment with a PI3K inhibitor\n* Patients currently on immunosuppressive therapy, including steroids\n* Previous CD 19 directed therapy\n* Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier (i.e., have residual toxicities \\> grade 1)\n* Patients receiving any other investigational drugs\n* Pregnant women are excluded from this study because duvelisib is agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with duvelisib, breastfeeding should be discontinued if the mother is treated with duvelisib and breastfeeding should not be resumed until at least 1 month after last dose of duvelisib\n* Patients with history of chronic liver disease or veno-occlusive disease\n* Patients that are unable to receive prophylactic treatment for pneumocystis, herpes simplex virus (HSV), or herpes zoster \"(VZV) at screening\n* Patients with history of tuberculosis treatment within the 2 years prior to randomization\n* Patients with prior surgery or gastrointestinal dysfunction that may affect drug absorption (e.g., gastric bypass surgery, gastrectomy). Subjects with clinically significant medical condition of malabsorption, inflammatory bowel disease, chronic conditions which manifest with diarrhea, refractory nausea, vomiting or any other condition that will interfere significantly with drug absorption\n* Concurrent administration of medications or foods that are strong inhibitors or inducers of cytochrome P450 3A (CYP3A). No prior use within 2 weeks before the start of study intervention\n* Administration of a live or live attenuated vaccine within 6 weeks of randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Edmund K Waller, MD, PhD","affiliation":"Emory University Hospital/Winship Cancer Institute","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Emory University Hospital/Winship Cancer Institute","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"University of Chicago Comprehensive Cancer Center","city":"Chicago","state":"Illinois","zip":"60637","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}}]}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2023-04-25","uploadDate":"2024-11-25T14:37","filename":"Prot_SAP_000.pdf","size":682301},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2023-05-03","uploadDate":"2024-11-25T14:36","filename":"ICF_001.pdf","size":284635}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D016403","term":"Lymphoma, Large B-Cell, Diffuse"}],"ancestors":[{"id":"D016393","term":"Lymphoma, B-Cell"},{"id":"D008228","term":"Lymphoma, Non-Hodgkin"},{"id":"D008223","term":"Lymphoma"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D008232","term":"Lymphoproliferative Disorders"},{"id":"D008206","term":"Lymphatic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D007160","term":"Immunoproliferative Disorders"},{"id":"D007154","term":"Immune System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C586691","term":"duvelisib"},{"id":"C000626284","term":"tisagenlecleucel"},{"id":"C000598123","term":"CTL019 chimeric antigen receptor"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT02603887","orgStudyIdInfo":{"id":"2015-0371"},"secondaryIdInfos":[{"id":"NCI-2015-02135","type":"REGISTRY","domain":"CTRP (Clinical Trial Reporting Program)"},{"id":"2015-0371","type":"OTHER","domain":"M D Anderson Cancer Center"}],"organization":{"fullName":"M.D. Anderson Cancer Center","class":"OTHER"},"briefTitle":"Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma","officialTitle":"Pilot Single Arm, Single Center, Open Label Trial of Pembrolizumab in Patients With Intermediate and High Risk Smoldering Multiple Myeloma"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-07-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-12-30","type":"ACTUAL"},"completionDateStruct":{"date":"2027-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2015-11-11","studyFirstSubmitQcDate":"2015-11-12","studyFirstPostDateStruct":{"date":"2015-11-13","type":"ESTIMATED"},"resultsFirstSubmitDate":"2020-02-07","resultsFirstSubmitQcDate":"2020-03-06","resultsFirstPostDateStruct":{"date":"2020-03-20","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-13","lastUpdatePostDateStruct":{"date":"2026-01-29","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"M.D. Anderson Cancer Center","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This pilot early phase I trial studies pembrolizumab in treating patients with slow growing (smoldering) multiple myeloma with intermediate or high-risk of spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.","detailedDescription":"PRIMARY OBJECTIVE:\n\nI. To determine the overall response rate after 8 cycles of treatment according to the International Myeloma Working Group Criteria (IMWG).\n\nSECONDARY OBJECTIVES:\n\nI. To determine time to progression to multiple myeloma (TTP) at 30 months from study entry.\n\nII. To determine overall survival (OS). III. To determine duration of response (DOR). IV. To determine the clinical benefit rate (CBR) after 8 cycles of treatment according to the modified IMWG Criteria for multiple myeloma (MM).\n\nV. To evaluate safety and tolerability of single agent treatment in this population.\n\nEXPLORATORY OBJECTIVES:\n\nI. Rate of minimal residual disease (MRD) negativity at complete remission (CR).\n\nII. Molecular profiling (including whole exome sequencing and gene expression profiling) and cellular (including flow cytometry) profiling at baseline and/or at progression using bone marrow aspirate samples and peripheral blood.\n\nIII. Immunophenotypic characterization of dendritic, T-, B-, natural killer (NK)- and natural killer T (NKT)-cells, and inhibitory/activation markers on tumor cells at baseline and at completion of 8 cycles of therapy in bone marrow aspirate samples and/or peripheral blood.\n\nIV. Evaluation of changes in PD-L1 and PD-1 expression at baseline/end of 8 cycles of treatment and correlate with clinical response.\n\nOUTLINE:\n\nPatients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\nAfter completion of study treatment, patients are followed up every 6-12 months."},"conditionsModule":{"conditions":["Smoldering Plasma Cell Myeloma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":20,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment (pembrolizumab)","type":"EXPERIMENTAL","description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.","interventionNames":["Other: Laboratory Biomarker Analysis","Biological: Pembrolizumab"]}],"interventions":[{"type":"OTHER","name":"Laboratory Biomarker Analysis","description":"Correlative studies","armGroupLabels":["Treatment (pembrolizumab)"]},{"type":"BIOLOGICAL","name":"Pembrolizumab","description":"Given IV","armGroupLabels":["Treatment (pembrolizumab)"],"otherNames":["Keytruda","Lambrolizumab","MK-3475","SCH 900475"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Response Rate (ORR)","description":"Overall response rate is defined as patients who have achieved partial response or higher as described per IMWG criteria for multiple myeloma after 8 cycles of therapy with pembrolizumab. Will be measured according to International Myeloma Working Group Criteria (IMWG) criteria. Response rate will be estimated accordingly. Each cycle has a duration of 21 days.","timeFrame":"From cycle 1 to cycle 8, up to 168 days"}],"secondaryOutcomes":[{"measure":"Number of Participants That Had Progression to Multiple Myeloma","description":"Progressive disease assessed by IMWG criteria for multiple myeloma after 8 cycles of therapy with pembrolizumab.","timeFrame":"At 30 months from study entry"},{"measure":"Clinical Benefit Rate","description":"Minor response or better assessed by IMWG criteria for multiple myeloma after 8 cycles of therapy with pembrolizumab","timeFrame":"From cycle 1 to cycle 8, up to 168 days"},{"measure":"Overall Survival","description":"Participants in a study or treatment group who are still alive for a certain period of time after they were diagnosed with or started treatment for a disease","timeFrame":"Time of start of treatment to death from any cause up to 2 years and 6 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult patients with intermediate or high-risk smoldering multiple myeloma (SMM) are eligible; patients need to have clonal bone marrow plasma cells \\>= 10% and/or monoclonal spike in blood of \\>= 3 g/dL and/or monoclonal urine component (Bence jones proteinuria) \\>= 500 mg/24 hours and need to meet subject inclusion criteria and exclusion criteria as per below\n* Patients must have histologically confirmed SMM based on the following criteria:\n\n  * (A) Mayo clinic criteria (patient must have at least 2 risk factors present):\n\n    * 1\\. Bone marrow core biopsy plasma cell involvement by cluster of differentiation (CD)138 immunohistochemistry \\>= 10%\n    * 2\\. Monoclonal spike \\>= 3 g/dL\n    * 3\\. Free light chain ratio in serum \\< 0.125 or \\> 8; \\*2 of 3 risk factors: intermediate risk for progression at a rate of 51% at 5 years, \\*3 of 3 risk factors: high risk for progression at a rate of 76% at 5 years\n  * OR (B) Programa para el Tratamiento de Hemopatias Malignas (PETHEMA) criteria (patient must have at least 1 risk factor present)\n\n    * 1\\. \\>= 95% abnormal plasma cells/total plasma cells in bone marrow compartment\n    * 2\\. Immunoparesis \\*1 of 2 risk factors: intermediate risk for progression at a rate of 46% at 5 years, \\*2 of 2 risk factors: high risk for progression at a rate of 72% at 5 years\n  * OR (C) Southwestern Oncology Group (SWOG) criteria (patient must have 2 risk factors present or one risk factor if this risk factor is a 70-gene signature (GEP70) score of \\> 37.2)\n\n    * 1\\. Monoclonal spike \\>= 3 g/dL\n    * 2\\. Involved free light chain \\>= 25 mg/dL\n    * 3\\. GEP70 risk score \\> 37.2 \\*\\>= 2 risk factors: high risk of progression at a rate of 70% at 2 years\\*; we would also include patients with 1 risk factor as long as this risk factor is GEP70 risk score \\> 37.2 since patients with this risk factor have an intermediate risk of progression at a rate of 50% at 2 years\n* Creatinine clearance \\>= 50 ml/min; creatinine clearance (CrCl) will be calculated by Cockcroft-Gault method\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Absolute neutrophil count (ANC) \\>= 1.0 x 10\\^9 /L\n* Hemoglobin \\>= 10 g/dL\n* Platelet count \\>= 50 x 10\\^9/L\n* Bilirubin \\< 1.5 x the upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\< 3.0 x ULN\n* Subjects must be able to give informed consent\n* Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \\> 1 year\n* Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy\n\nExclusion Criteria:\n\n* Evidence of myeloma defining events or biomarkers of malignancy due to underlying plasma cell proliferative disorder meeting at least one of the following\n\n  * 1\\) Hypercalcemia: serum calcium \\> 0.25 mmol/L (\\> 1 mg/dL) higher than the upper limit of normal or \\> 2.75 mmol/L (\\> 11 mg/dL)\n  * 2\\) Renal insufficiency: creatinine clearance \\< 40 ml/min or serum creatinine \\> 2 mg/dL\n  * 3\\) Anemia: hemoglobin value \\< 10 g/dL or 2 g/dL \\< normal reference\n  * 4\\) Bone lesions: one or more osteolytic lesions on skeletal radiography, computerized tomography (CT) or 2-deoxy-2\\[F-18\\] fluoro-D-glucose positron emission tomography CT (PET-CT)\n  * 5\\) Clonal bone marrow plasma cell percentage \\>= 60%\n  * 6\\) Involved: uninvolved serum free light chain ratio \\>= 100 measured by Freelite assay (The Binding Site Group, Birmingham, United Kingdom \\[UK\\])\n  * 7\\) \\> 1 focal lesions on magnetic resonance imaging (MRI) studies (each focal lesion must be 5 mm or more in size), if clinically indicated\n* Prior or concurrent systemic treatment for SMM; a) bisphosphonates are permitted; b) treatment with corticosteroids is not permitted; c) radiotherapy is not permitted; d) prior treatment for smoldering multiple myeloma with chemotherapy agents approved for the treatment of multiple myeloma is not permitted\n* Plasma cell leukemia\n* Pregnant or lactating females; breastfeeding should be discontinued if the mother is treated with pembrolizumab\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment\n* Has a known history of active TB (bacillus tuberculosis)\n* Hypersensitivity to pembrolizumab or any of its excipients\n* Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =\\< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier\n* Has a known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment\n* Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis\n* Has an active infection requiring systemic therapy\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-programmed death ligand 2 (PD-L2) agent\n* Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)\n* Has known active hepatitis B (e.g., hepatitis B surface antigen \\[HBsAg\\] reactive) or hepatitis C (e.g., hepatitis C virus \\[HCV\\] ribonucleic acid \\[RNA\\] \\[qualitative\\] is detected)\n* Has received a live vaccine within 30 days of planned start of study therapy; Note: seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed\n* Evidence of interstitial lung disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Neeraj Saini, MD","affiliation":"M.D. Anderson Cancer Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"M D Anderson Cancer Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}}]},"referencesModule":{"references":[{"pmid":"31405950","type":"DERIVED","citation":"Manasanch EE, Han G, Mathur R, Qing Y, Zhang Z, Lee H, Weber DM, Amini B, Berkova Z, Eterovic K, Zhang S, Zhang J, Song X, Mao X, Morgan M, Feng L, Baladandayuthapani V, Futreal A, Wang L, Neelapu SS, Orlowski RZ. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv. 2019 Aug 13;3(15):2400-2408. doi: 10.1182/bloodadvances.2019000300."}],"seeAlsoLinks":[{"label":"MD Anderson Cancer Center","url":"http://www.mdanderson.org"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"20 participants were consented. 13 participants were treated at MD Anderson Cancer Center. An additional participant started stage 2 that did not participate in Stage 1\"","recruitmentDetails":"Enrollment period was between July 2016 and August 2017","groups":[{"id":"FG000","title":"Treatment (Pembrolizumab)","description":"Pembrolizumab 200 mg, 30 minute IV infusion every 21 days up to 24 cycles if equal or higher than minor response and without serious adverse events after 8 cycles"}],"periods":[{"title":"Stage 1","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"12"}]},{"type":"Cycle 1","achievements":[{"groupId":"FG000","numSubjects":"12"}]},{"type":"Cycle 8","achievements":[{"groupId":"FG000","numSubjects":"7"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"7"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"4"}]},{"type":"Disease progression","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]},{"title":"Stage 2","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Cycle 1","achievements":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Cycle 8","achievements":[{"groupId":"FG000","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"}]}],"dropWithdraws":[{"type":"FDA guidance","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Treatment (Pembrolizumab)","description":"Pembrolizumab 200 mg, 30 minute IV infusion every 21 days up to 24 cycles if equal or higher than minor response and without serious adverse events after 8 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"13"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"5"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"8"}]}]}]},{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"INTER_QUARTILE_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"68","lowerLimit":"59","upperLimit":"71"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"5"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"8"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"13"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"12"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}]}]},{"title":"Myeloma related labs","description":"Measure Description: Laboratory exams including hemoglobin, calcium, creatinine, serum paraprotein, bence jones urine protein, kappa and lambda free light chain, free light chain ratio, involved:uninvolved ratio, B2 microglobulin, LDH and bone marrow biopsy plasma cell percentage, needed to assess properly a patient with plasma cell dyscrasia","paramType":"MEDIAN","dispersionType":"INTER_QUARTILE_RANGE","unitOfMeasure":"gm/dL","classes":[{"title":"Hemoglobin","categories":[{"measurements":[{"groupId":"BG000","value":"12.4","lowerLimit":"11.95","upperLimit":"13.95"}]}]},{"title":"Serum paraprotein","categories":[{"measurements":[{"groupId":"BG000","value":"1.9","lowerLimit":"0.8","upperLimit":"3.15"}]}]}]},{"title":"Myeloma related labs","description":"Measure Description: Laboratory exams including hemoglobin, calcium, creatinine, serum paraprotein, bence jones urine protein, kappa and lambda free light chain, free light chain ratio, involved:uninvolved ratio, B2 microglobulin, LDH and bone marrow biopsy plasma cell percentage, needed to assess properly a patient with plasma cell dyscrasia","paramType":"MEDIAN","dispersionType":"INTER_QUARTILE_RANGE","unitOfMeasure":"mg/dL","classes":[{"title":"Calcium","categories":[{"measurements":[{"groupId":"BG000","value":"9.3","lowerLimit":"8.7","upperLimit":"9.55"}]}]},{"title":"Creatinine","categories":[{"measurements":[{"groupId":"BG000","value":".88","lowerLimit":"0.79","upperLimit":"1.04"}]}]}]},{"title":"Myeloma related labs","description":"Measure Description: Laboratory exams including hemoglobin, calcium, creatinine, serum paraprotein, bence jones urine protein, kappa and lambda free light chain, free light chain ratio, involved:uninvolved ratio, B2 microglobulin, LDH and bone marrow biopsy plasma cell percentage, needed to assess properly a patient with plasma cell dyscrasia","paramType":"MEDIAN","dispersionType":"INTER_QUARTILE_RANGE","unitOfMeasure":"mg/L","classes":[{"title":"B2 microglobulin","categories":[{"measurements":[{"groupId":"BG000","value":"1.9","lowerLimit":"1.75","upperLimit":"2.3"}]}]},{"title":"Kappa free light chain","categories":[{"measurements":[{"groupId":"BG000","value":"127.04","lowerLimit":"18.18","upperLimit":"277.48"}]}]},{"title":"Lambda free light chain","categories":[{"measurements":[{"groupId":"BG000","value":"8.08","lowerLimit":"6.74","upperLimit":"14.59"}]}]}]},{"title":"Myeloma related lab Lactate dehydrogenase","paramType":"MEDIAN","dispersionType":"INTER_QUARTILE_RANGE","unitOfMeasure":"u/L","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"439","lowerLimit":"349.5","upperLimit":"488"}]}]}]},{"title":"Myeloma related lab Bone marrow biopsy plasma cells","paramType":"MEDIAN","dispersionType":"INTER_QUARTILE_RANGE","unitOfMeasure":"percentage of plasma cells","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"30","lowerLimit":"17.5","upperLimit":"45"}]}]}]},{"title":"Myeloma related lab Bence Jones urine protein","paramType":"MEDIAN","dispersionType":"INTER_QUARTILE_RANGE","unitOfMeasure":"mg/day","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6","lowerLimit":"0","upperLimit":"30.5"}]}]}]},{"title":"Myeloma related labs","description":"Measure Description: Measure Description: Laboratory exams including hemoglobin, calcium, creatinine, serum paraprotein, bence jones urine protein, kappa and lambda free light chain, free light chain ratio, involved:uninvolved ratio, B2 microglobulin, LDH and bone marrow biopsy plasma cell percentage, needed to assess properly a patient with plasma cell dyscrasia","paramType":"MEDIAN","dispersionType":"INTER_QUARTILE_RANGE","unitOfMeasure":"ratio","classes":[{"title":"Free Light Chains (FLCs) ratio","categories":[{"measurements":[{"groupId":"BG000","value":"12.27","lowerLimit":"2.44","upperLimit":"38.25"}]}]},{"title":"Involved:Uninvolved ratio","categories":[{"measurements":[{"groupId":"BG000","value":"17.95","lowerLimit":"6.44","upperLimit":"38.25"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Response Rate (ORR)","description":"Overall response rate is defined as patients who have achieved partial response or higher as described per IMWG criteria for multiple myeloma after 8 cycles of therapy with pembrolizumab. Will be measured according to International Myeloma Working Group Criteria (IMWG) criteria. Response rate will be estimated accordingly. Each cycle has a duration of 21 days.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From cycle 1 to cycle 8, up to 168 days","groups":[{"id":"OG000","title":"Treatment (Pembrolizumab)","description":"Pembrolizumab 200 mg, 30 minute IV infusion every 21 days up to 24 cycles if equal or higher than minor response and without serious adverse events after 8 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants That Had Progression to Multiple Myeloma","description":"Progressive disease assessed by IMWG criteria for multiple myeloma after 8 cycles of therapy with pembrolizumab.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At 30 months from study entry","groups":[{"id":"OG000","title":"Treatment (Pembrolizumab)","description":"Pembrolizumab 200 mg, 30 minute IV infusion every 21 days up to 24 cycles if equal or higher than minor response and without serious adverse events after 8 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]}]},{"type":"SECONDARY","title":"Clinical Benefit Rate","description":"Minor response or better assessed by IMWG criteria for multiple myeloma after 8 cycles of therapy with pembrolizumab","populationDescription":"Clinical benefit rate is described as minor response or better assessed by IMWG criteria for multiple myeloma after 8 cycles of therapy with pembrolizumab. 1 participant of 13 achieved sCR","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From cycle 1 to cycle 8, up to 168 days","groups":[{"id":"OG000","title":"Treatment (Pembrolizumab)","description":"Pembrolizumab 200 mg, 30 minute IV infusion every 21 days up to 24 cycles if equal or higher than minor response and without serious adverse events after 8 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Participants in a study or treatment group who are still alive for a certain period of time after they were diagnosed with or started treatment for a disease","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time of start of treatment to death from any cause up to 2 years and 6 months","groups":[{"id":"OG000","title":"Treatment (Pembrolizumab)","description":"Pembrolizumab 200 mg, 30 minute IV infusion every 21 days up to 24 cycles if equal or higher than minor response and without serious adverse events after 8 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"From time the consent form is signed through 90 days following cessation of treatment and at each examination on the Adverse Event case report/forms/worksheet, up to 2 years and 6 months","description":"All adverse events were recorded on the adverse event case report/worksheet by the principal investigator and/or research team, as well as evaluated by a qualified physician","eventGroups":[{"id":"EG000","title":"Single Arm, Intermediate-high Risk SMM Participants","description":"Pembrolizumab 200 mg, 30 minute IV infusion every 21 days up to 24 cycles if equal or higher than minor response and without serious adverse events after 8 cycles","deathsNumAffected":1,"deathsNumAtRisk":13,"seriousNumAffected":3,"seriousNumAtRisk":13,"otherNumAffected":13,"otherNumAtRisk":13}],"seriousEvents":[{"term":"Transaminitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"All adverse events were recorded on the adverse event case report/worksheet by the principal investigator and/or research team, as well as evaluated by a qualified physician","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]}],"otherEvents":[{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Alanine aminotranferase increased","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}]},{"term":"Allergic rhinitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":13}]},{"term":"Anorexia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Aspartate aminotransferase increased","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Autoimmune disorder","organSystem":"Immune system disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Blurred vision","organSystem":"Eye disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Bronchial infection","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":13}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Creatinine increased","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":13}]},{"term":"Dizziness","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Edema limbs","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":13}]},{"term":"Endocrine disorders - Other, specify","organSystem":"Endocrine disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}]},{"term":"Epistaxis","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Eye disorders - Other, specify","organSystem":"Eye disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Eye pain","organSystem":"Eye disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":13}]},{"term":"Fever","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Gastrointestinal disorders - Other, specify","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"General disorders and administration site conditions - Other, specify","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Generalized muscle weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Headache","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Hematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Hemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Hepatobiliary disorders - Other, specify","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Hot flashes","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Hypercalcemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Hyperglycemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":13}]},{"term":"Hyperuricemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Hypocalcemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Hypomagnesemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":13}]},{"term":"Hyponatremia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Hypophosphatemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Insomnia","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Lipase increased","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}]},{"term":"Memory impairment","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Metabolism and nutrition - Other, specify","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":13}]},{"term":"Mucositis oral","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Muscoloeskeletal and connective tissue disorder - Other, specify","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":13}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Neck edema","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Neoplasm benign, malignant and unspecified (incl cyst and polyps) - Other, specify","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Neutrophil count decreased","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":13}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Photophobia","organSystem":"Eye disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Platelet count decreased","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Prostate infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":13}]},{"term":"Psychiatric disorders - Other, specify","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":13}]},{"term":"Renal and urinary disorders - Other, specify","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}]},{"term":"Respiratory, thoracic and mediastinal disorders - Other, specify","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Serum amylase increased","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}]},{"term":"Skin and subcutaneous tissue disorders - Other, specify","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}]},{"term":"Tinnutis","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Transaminitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Upper respiratory infection","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}]},{"term":"Urinary frequency","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Urinary tract infection","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Urinary tract pain","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Urinary urgency","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]},{"term":"Weight loss","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE version 4.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Dr. Elisabet Manasanch/ Assistant Professor, Lymphoma-Myeloma","organization":"UT MD Anderson Cancer Center","email":"eemanasanch@mdanderson.org","phone":"713-745-8092"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2016-04-08","uploadDate":"2020-02-07T10:11","filename":"Prot_SAP_000.pdf","size":997751}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D000075122","term":"Smoldering Multiple Myeloma"}],"ancestors":[{"id":"D011230","term":"Precancerous Conditions"},{"id":"D009369","term":"Neoplasms"},{"id":"D006942","term":"Hypergammaglobulinemia"},{"id":"D001796","term":"Blood Protein Disorders"},{"id":"D006402","term":"Hematologic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D010265","term":"Paraproteinemias"},{"id":"D007160","term":"Immunoproliferative Disorders"},{"id":"D007154","term":"Immune System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C582435","term":"pembrolizumab"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT04327934","orgStudyIdInfo":{"id":"2000020950"},"secondaryIdInfos":[{"id":"R01HL135089-01A1","type":"NIH","link":"https://reporter.nih.gov/quickSearch/R01HL135089-01A1"}],"organization":{"fullName":"Yale University","class":"OTHER"},"briefTitle":"Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome","officialTitle":"Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome"},"statusModule":{"statusVerifiedDate":"2024-01","overallStatus":"TERMINATED","whyStopped":"Unble to complete all arms of the planned study due to Covid stoppage and difficulty with recruiting and getting enrolled participants to return post Covid.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-12-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-06-30","type":"ACTUAL"},"completionDateStruct":{"date":"2022-06-30","type":"ACTUAL"},"studyFirstSubmitDate":"2018-10-17","studyFirstSubmitQcDate":"2020-03-27","studyFirstPostDateStruct":{"date":"2020-03-31","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-02-24","resultsFirstSubmitQcDate":"2024-01-04","resultsFirstPostDateStruct":{"date":"2024-02-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-01-04","lastUpdatePostDateStruct":{"date":"2024-02-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Yale University","class":"OTHER"},"collaborators":[{"name":"National Heart, Lung, and Blood Institute (NHLBI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"Women with androgen excess polycystic ovary syndrome (AE-PCOS) leads to hypertension.","detailedDescription":"Our scientific premise is that in AE-PCOS women, the androgen-dominant hormonal milieu causes BP increases via sympathetic activation, vasoconstriction and renal sympathetic nervous system activation. Moreover, this androgen-dominant milieu increases BP via activation of the renin-angiotensin system."},"conditionsModule":{"conditions":["Polycystic Ovary Syndrome","Hypertension"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":28,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Healthy Control","type":"ACTIVE_COMPARATOR","description":"Healthy control participants.","interventionNames":["Drug: GnRH antagonist","Drug: GnRH antagonist + MethylTESTOSTERone 5 MG"]},{"label":"AE-PCOS","type":"EXPERIMENTAL","description":"Participants with AE-PCOS.","interventionNames":["Drug: GnRH antagonist","Drug: GnRH antagonist + MethylTESTOSTERone 5 MG"]}],"interventions":[{"type":"DRUG","name":"GnRH antagonist","description":"GnRH antagonist up to 16 days.","armGroupLabels":["AE-PCOS","Healthy Control"],"otherNames":["Antagon"]},{"type":"DRUG","name":"GnRH antagonist + MethylTESTOSTERone 5 MG","description":"GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.","armGroupLabels":["AE-PCOS","Healthy Control"],"otherNames":["Antagon + MethylTESTOSTERone"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Baroreflex Response to LBNP","description":"forearm blood flow (ultrasound)/mean arterial pressure as a linear function of lower body negative pressure. This is an important measure of autonomic control of blood pressure. Indicating the the sensitivity of changes in vessel diameter in response to blood pooling (induced by lower body negative pressure).","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone"},{"measure":"Free Plasma Testosterone Levels","description":"Concentration of testosterone in blood.","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone"},{"measure":"Renal Response to LBNP","description":"POST Lower body negative pressure Plasma renin activity","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone"},{"measure":"Renal Responses to LBNP","description":"PRE lower body negative pressure Plasma renin activity","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone"},{"measure":"Resting Systolic Blood Pressure","description":"Blood pressure prior to lower body negative pressure","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone"},{"measure":"Final Systolic Blood Pressure","description":"SBP at the end of lower body negative pressure","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone"},{"measure":"Resting Sympathetic Activity","description":"Total sympathetic nerve activity","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone"},{"measure":"Sympathetic Baroreflex","description":"microneurography, diastolic blood pressure (finipres) This is an important measure of autonomic control of blood pressure. Indicating the the sensitivity of changes in muscle sympathetic nerve activity in response to small changes in blood pressure induced by drug perfusion (modified Oxford).","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone"}],"secondaryOutcomes":[{"measure":"Aldosterone","description":"Plasma aldosterone concentration","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone"},{"measure":"Renal Responses","description":"P\\[ACE\\], angiotensin-converting enzyme","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical Diagnosis of Polycystic Ovary Syndrome\n* Able to inject study drug\n* Able to swallow pills\n\nControls:\n\n-Diagnosis of Insulin resistance\n\nExclusion Criteria:\n\n* Any woman that does not fit the inclusion criteria\n* Males","healthyVolunteers":true,"sex":"FEMALE","genderBased":true,"genderDescription":"Obese Insulin Resistant (IR) women","minimumAge":"18 Years","maximumAge":"35 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Nina Stachenfeld, PhD","affiliation":"Yale University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"The John B Pierce Laboratory","city":"New Haven","state":"Connecticut","zip":"06519","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"We will recruit subjects using flyers, our clinics, and social media. Dates 12/01/2017 - 04/29/2022; We were not able to reach recruit goals because our laboratory closed during Covid. When we reopened, we lost a one interested subject, and found greater challenges to recruit subjects.","groups":[{"id":"FG000","title":"Healthy Control","description":"Healthy control participants.\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."},{"id":"FG001","title":"AE-PCOS","description":"Participants with AE-PCOS.\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"14"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"9"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"5"}]}],"dropWithdraws":[{"type":"Did not qualify","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Baseline characteristics are presented for people that completed the study- which is defined as those that were allocated, began and completed the study.","groups":[{"id":"BG000","title":"Healthy Control","description":"Healthy control participants.\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."},{"id":"BG001","title":"AE-PCOS","description":"Participants with AE-PCOS.\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"16"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"16"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28","spread":"6"},{"groupId":"BG001","value":"24","spread":"5"},{"groupId":"BG002","value":"26","spread":"6"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"16"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"13"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"9"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"16"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Baroreflex Response to LBNP","description":"forearm blood flow (ultrasound)/mean arterial pressure as a linear function of lower body negative pressure. This is an important measure of autonomic control of blood pressure. Indicating the the sensitivity of changes in vessel diameter in response to blood pooling (induced by lower body negative pressure).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Arbitrary Units/Beat/mmHg","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone","groups":[{"id":"OG000","title":"Healthy Control","description":"Healthy Control\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."},{"id":"OG001","title":"AE-PCOS","description":"Participants with AE-PCOS.\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"1.35"},{"groupId":"OG001","value":"1.36","spread":"0.96"}]}]},{"title":"GnRH antagonist","categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"3.0"},{"groupId":"OG001","value":"4.28","spread":"6.51"}]}]},{"title":"GnRH antagonist with GnRH + Testosterone","categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":"0.65"},{"groupId":"OG001","value":"1.46","spread":"0.76"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"We compared groups across treatments","pValue":"0.018","statisticalMethod":"ANOVA"}]},{"type":"PRIMARY","title":"Free Plasma Testosterone Levels","description":"Concentration of testosterone in blood.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mg/dL","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone","groups":[{"id":"OG000","title":"Healthy Control","description":"Healthy Control\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."},{"id":"OG001","title":"AE-PCOS","description":"Participants with AE-PCOS.\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":"0.57"},{"groupId":"OG001","value":"2.72","spread":"1.13"}]}]},{"title":"GnRH","categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.39"},{"groupId":"OG001","value":"1.06","spread":"0.31"}]}]},{"title":"GnRH + Testosterone","categories":[{"measurements":[{"groupId":"OG000","value":"1.34","spread":"0.23"},{"groupId":"OG001","value":"2.19","spread":"0.19"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"We compared across groups and within groups over time.","pValue":"<0.016","statisticalMethod":"ANOVA"},{"groupIds":["OG000"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"We compared across groups and within groups over time.","pValue":"0.08","statisticalMethod":"ANOVA"}]},{"type":"PRIMARY","title":"Renal Response to LBNP","description":"POST Lower body negative pressure Plasma renin activity","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL ANG/hour","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone","groups":[{"id":"OG000","title":"Healthy Control","description":"Healthy Control\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."},{"id":"OG001","title":"AE-PCOS","description":"Participants with AE-PCOS.\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":"0.82"},{"groupId":"OG001","value":"1.10","spread":"0.46"}]}]},{"title":"GnRH","categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":"0.33"},{"groupId":"OG001","value":"1.14","spread":"1.31"}]}]},{"title":"GnRH+Testosterone","categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.71"},{"groupId":"OG001","value":"1.36","spread":"1.51"}]}]}]},{"type":"PRIMARY","title":"Renal Responses to LBNP","description":"PRE lower body negative pressure Plasma renin activity","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL ANG/hour","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone","groups":[{"id":"OG000","title":"Healthy Control","description":"Healthy Control\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."},{"id":"OG001","title":"AE-PCOS","description":"Participants with AE-PCOS.\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":"0.48"},{"groupId":"OG001","value":"0.85","spread":"0.97"}]}]},{"title":"GnRH","categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":"0.21"},{"groupId":"OG001","value":"0.79","spread":"1.24"}]}]},{"title":"GnRH + Testosterone","categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"0.43"},{"groupId":"OG001","value":"0.76","spread":"0.75"}]}]}]},{"type":"PRIMARY","title":"Resting Systolic Blood Pressure","description":"Blood pressure prior to lower body negative pressure","populationDescription":"Systolic Blood Pressure","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mm Hg","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone","groups":[{"id":"OG000","title":"AE-PCOS","description":"Participants with AE-PCOS.\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."},{"id":"OG001","title":"Healthy Control","description":"Healthy control participants.\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":"15"},{"groupId":"OG001","value":"123","spread":"13"}]}]},{"title":"GnRH","categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":"10"},{"groupId":"OG001","value":"124","spread":"16"}]}]},{"title":"GnRH +Testosterone","categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":"12"},{"groupId":"OG001","value":"121","spread":"16"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.05","pValueComment":"Friedman's tests to compare slopes","statisticalMethod":"Friedman's test"}]},{"type":"PRIMARY","title":"Final Systolic Blood Pressure","description":"SBP at the end of lower body negative pressure","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mm Hg","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone","groups":[{"id":"OG000","title":"Healthy Control","description":"Healthy Control\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."},{"id":"OG001","title":"AE-PCOS","description":"Participants with AE-PCOS.\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":"21"},{"groupId":"OG001","value":"99","spread":"23"}]}]},{"title":"GnRH","categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":"16"},{"groupId":"OG001","value":"113","spread":"12"}]}]},{"title":"GnRH + Testosterone","categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":"16"},{"groupId":"OG001","value":"121","spread":"10"}]}]}]},{"type":"PRIMARY","title":"Resting Sympathetic Activity","description":"Total sympathetic nerve activity","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"burst/100 heart beats","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone","groups":[{"id":"OG000","title":"Healthy Control","description":"Healthy Control\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."},{"id":"OG001","title":"AE-PCOS","description":"Participants with AE-PCOS.\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":"4.4"},{"groupId":"OG001","value":"10.3","spread":"2.0"}]}]},{"title":"GnRH","categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":"0.8"},{"groupId":"OG001","value":"6.9","spread":"1.5"}]}]},{"title":"GnRH + Testosterone","categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":"3.6"},{"groupId":"OG001","value":"14.5","spread":"5.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.023","statisticalMethod":"t-test, 2 sided"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.04","statisticalMethod":"ANOVA"}]},{"type":"PRIMARY","title":"Sympathetic Baroreflex","description":"microneurography, diastolic blood pressure (finipres) This is an important measure of autonomic control of blood pressure. Indicating the the sensitivity of changes in muscle sympathetic nerve activity in response to small changes in blood pressure induced by drug perfusion (modified Oxford).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Gain (bursts/100 heart beats/ mm Hg)","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone","groups":[{"id":"OG000","title":"Healthy Control","description":"Healthy Control\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."},{"id":"OG001","title":"AE-PCOS","description":"Participants with AE-PCOS.\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"-0.479","spread":"0.085"},{"groupId":"OG001","value":"-0.496","spread":"0.142"}]}]},{"title":"GnRH","categories":[{"measurements":[{"groupId":"OG000","value":"-0.468","spread":"0.101"},{"groupId":"OG001","value":"-0.640","spread":"0.171"}]}]},{"title":"GnRH+Testosterone","categories":[{"measurements":[{"groupId":"OG000","value":"-0.445","spread":"0.087"},{"groupId":"OG001","value":"-0.487","spread":"0.124"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"We compared groups across treatments","pValue":"0.0023","statisticalMethod":"ANOVA"}]},{"type":"SECONDARY","title":"Aldosterone","description":"Plasma aldosterone concentration","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone","groups":[{"id":"OG000","title":"Healthy Control","description":"Healthy Control\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."},{"id":"OG001","title":"AE-PCOS","description":"Participants with AE-PCOS.\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":"41.4"},{"groupId":"OG001","value":"136.5","spread":"60.1"}]}]},{"title":"GnRH","categories":[{"measurements":[{"groupId":"OG000","value":"44.0","spread":"37.0"},{"groupId":"OG001","value":"127.8","spread":"70.5"}]}]},{"title":"GnRH+testosterone","categories":[{"measurements":[{"groupId":"OG000","value":"46.1","spread":"28.6"},{"groupId":"OG001","value":"98.7","spread":"46.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.04","statisticalMethod":"ANOVA"}]},{"type":"SECONDARY","title":"Renal Responses","description":"P\\[ACE\\], angiotensin-converting enzyme","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"g/L","timeFrame":"Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone","groups":[{"id":"OG000","title":"Healthy Control","description":"Healthy Control\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."},{"id":"OG001","title":"AE-PCOS","description":"Participants with AE-PCOS.\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"38.2","spread":"14.7"},{"groupId":"OG001","value":"101.9","spread":"93.4"}]}]},{"title":"GnRH","categories":[{"measurements":[{"groupId":"OG000","value":"43.4","spread":"27.3"},{"groupId":"OG001","value":"77.7","spread":"76.5"}]}]},{"title":"GnRH + Testosterone","categories":[{"measurements":[{"groupId":"OG000","value":"40.6","spread":"14.1"},{"groupId":"OG001","value":"44.2","spread":"43.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.04","statisticalMethod":"ANOVA"}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Six to eight weeks","description":"One subject experienced mild back pain during LBNP. Another experienced an incident of lupus on an experimental day, not due to our studies. However this was reported to our IRB.","eventGroups":[{"id":"EG000","title":"Healthy Control","description":"Healthy control participants.\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.","deathsNumAffected":0,"deathsNumAtRisk":14,"seriousNumAffected":0,"seriousNumAtRisk":14,"otherNumAffected":1,"otherNumAtRisk":14},{"id":"EG001","title":"AE-PCOS","description":"Participants with AE-PCOS.\n\nGnRH antagonist: GnRH antagonist up to 16 days.\n\nGnRH antagonist + MethylTESTOSTERone 5 MG: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.","deathsNumAffected":0,"deathsNumAtRisk":14,"seriousNumAffected":0,"seriousNumAtRisk":14,"otherNumAffected":1,"otherNumAtRisk":14}],"otherEvents":[{"term":"non serious adverse event","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":14}]},{"term":"non serious adverse event","organSystem":"Immune system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"lupus flair unrelated to study","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numAffected":1,"numAtRisk":14}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Our primary limitation was stoppage due to Covid (our laboratory was forced to close). We also had a very challenging time recruiting subjects when we reopened after the three-month closure under new rules. Subjects who had been enrolled did not return, and new subjects were difficult to recruit. Thus, we were not able to complete all arms of the planned study. We were able to answer our primary questions regarding autonomic function in women with PCOS."},"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Nina Stachenfeld","organization":"John B. Pierce Laboratory/Yale School of Medicine","email":"nina.stachenfeld@yale.edu","phone":"203 562 9901","phoneExt":"219"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2022-01-13","uploadDate":"2023-02-24T16:02","filename":"Prot_SAP_000.pdf","size":1493931},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2021-04-14","uploadDate":"2023-02-24T16:02","filename":"ICF_001.pdf","size":274539}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-11"},"conditionBrowseModule":{"meshes":[{"id":"D011085","term":"Polycystic Ovary Syndrome"},{"id":"D006973","term":"Hypertension"}],"ancestors":[{"id":"D010048","term":"Ovarian Cysts"},{"id":"D003560","term":"Cysts"},{"id":"D009369","term":"Neoplasms"},{"id":"D010049","term":"Ovarian Diseases"},{"id":"D000291","term":"Adnexal Diseases"},{"id":"D005831","term":"Genital Diseases, Female"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D006058","term":"Gonadal Disorders"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D014652","term":"Vascular Diseases"},{"id":"D002318","term":"Cardiovascular Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C092464","term":"LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)-"},{"id":"C061018","term":"ganirelix"},{"id":"D008777","term":"Methyltestosterone"}],"ancestors":[{"id":"D013739","term":"Testosterone"},{"id":"D000737","term":"Androstenols"},{"id":"D000736","term":"Androstenes"},{"id":"D000731","term":"Androstanes"},{"id":"D013256","term":"Steroids"},{"id":"D000072473","term":"Fused-Ring Compounds"},{"id":"D011083","term":"Polycyclic Compounds"}]}},"hasResults":true}
]